{"results": [[0, "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.", [" PARAMETER: []\n\nThe following format was not followed in the given text. There are no cited entities or described entities mentioned in the text that can be parsed as parameters.", {}]], [1, "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.", [" \"PATIENT\": [\"patient\"],\n\"DISEASE\": [\"liposarcoma\"],\n\"TREATMENT\": [\"trabectedin\"],\n\"TOXICITY\": [\"heavy toxicity\"],\n\"ADVERSE\\_EVENT\": [\"rhabdomyolysis\"],\n\"COURSE\": [\"fourth course\"],\n\"ALTERNATIVE\\_MEDICINE\": [\"herbal medicine\"]", {"Pathology": ["rhabdomyolysis", "retroperitoneal liposarcoma", "adverse event"], "Drug": ["trabectedin"]}]], [2, "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.", [" \"Abdominal mass\": [\"mass\"]\n\"Surgical removal\": []\n\"Complete margin negative (R0) resection\": [\"R0 resection\"]", {}]], [3, "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.", [" \"LESION\": [\"16 \u00d7 10 cm\", \"pre-aortic seat\", \"retro-peritoneum space\"]\n\"CHEMOTHERAPY\": []", {}]], [4, "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.", [" \"PATIENT\": [\"the patient\"],\n\"DRUG\": [\"trabectedin\"],\n\"TREATMENT\": [\"treatment with trabectedin\"],\n\"CO-MORBIDITY\": [\"due to the absence of co-morbidity\"]", {"Drug": ["trabectedin"]}]], [5, "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].", [" \"Cancer patients\": [],\n\"Likely to experience drug interactions\": [],\n\"Increased number and types of chemotherapeutic drugs\": [],\n\"Oncology practice\": [],\n\"Narrow therapeutic index\": [],\n\"Prolonged life expectancy\": [],\n\"Broad range of ancillary medications\": [],\n\"Cancer-related syndromes\": [],\n\"Treatment-induced toxicity\": []", {"Pathology": ["cancer", "cancer-related syndromes", "treatment-induced toxicity"]}]], [6, "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.", [" \"COMMERCIAL PREPARATION OF CHOKEBERRY JUICE\": []\n\"PATIENT\": []\n\"INTERACTIONS\": [\"inhibition of transport mechanisms\", \"activation of the death receptor\", \"other unknown mechanisms\"]\n\"TRANSPORT MECHANISMS\": []\n\"DEATH RECEPTOR\": []", {"Extraction process": ["chokeberry juice"]}]], [7, "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.", [" \"Medicinal cannabis\": []\n\"Health risks\": [\"Health risks\", \"risks\"]\n\nThis case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use. A 35-year-old man with a history of schizophrenia presented to the emergency department with acute psychosis and agitation. He reported using medicinal cannabis daily for the past year for symptomatic relief of anxiety and insomnia.\n\n\"Schizophrenia\": [\"schizophrenia\"]\n\"Anxiety\": [\"anxiety\"]\n\"Insomnia\": [\"insomnia\"]\n\nUpon arrival, the patient was agitated, disoriented, and hallucinating. His vital signs were stable, but laboratory tests revealed an elevated creatinine level, indicating renal dysfunction. The patient reported recent use of medicinal cannabis and denied use of any other substances.\n\n\"Agitation\": [\"agitation\"]\n\"Disoriented\": [\"disoriented\"]\n\"Hallucinating\": [\"hallucinating\"]\n\"Vital signs\": [\"vital signs\"]\n\"Laboratory tests\": [\"laboratory tests\"]\n\"Renal dysfunction\": [\"renal dysfunction\"]\n\"Creatinine\": [\"creatinine\"]\n\nThe patient was admitted to the hospital for further evaluation and management of his psychosis and renal dysfunction. He was treated with antipsychotic medications and intravenous fluids to address his acute symptoms and prevent complications.\n\n\"Hospital\": []\n\"Admitted\": [\"admitted\"]\n\"Further evaluation\": [\"further evaluation\"]\n\"Management\": [\"management\"]\n\"Antipsychotic medications\": [\"antipsychotic medications\"]\n\"Intravenous fluids\": [\"intravenous fluids\"]\n\nThe patient's renal function improved over the next few days, and he was discharged from the hospital with a plan for ongoing treatment of his schizophrenia and addiction to medicinal cannabis.\n\n\"Improved\": [\"improved\"]\n\"Discharged\": [\"discharged\"]\n\"Ongoing treatment\": [\"ongoing treatment\"]\n\nThis case highlights the importance of caution when using medicinal cannabis, particularly in individuals with preexisting medical conditions or a history of mental illness", {"Herb name": ["cannabis"]}]], [8, "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.", [" \"PATIENT\": [\"patient\"],\n\"CHRONIC BACK PAIN\": [\"chronic back pain\"],\n\"CANNABIS\": [\"cannabis\"],\n\"PGx TEST\": [\"PGx test\"],\n\"COMT\": [\"COMT gene\"],\n\"HTR2A\": [\"HTR2A gene\"]", {"Herb name": ["cannabis"], "Pathology": ["chronic back pain"]}]], [9, "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].", [" \"Neuronal death\": [\"death of neurons\"],\n\"this region\": [],\n\"results\": [],\n\"in low dopamine concentrations\": [\"low concentrations of dopamine\"],\n\"therefore\": [],\n\"treatment strategies\": [],\n\"for PD\": [\"Parkinson's Disease\"],\n\"often involve\": [],\n\"initiating medications\": [],\n\"e.g., carbidopa-levodopa, ropinirole, entacapone\": [\"carbidopa-levodopa\", \"ropinirole\", \"entacapone\"],\n\"that result in increased concentrations of dopamine\": [\"increased concentrations of dopamine\"],\n\"to improve movement control\": [\"improve movement control\"]", {"Pathology": ["PD"], "Drug": ["carbidopa-levodopa", "ropinirole", "entacapone"]}]], [10, "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.", [" \"CANNABIS\": [\"marijuana\", \"cannabis and an individual\u2019s\", \"pharmacokinetic and pharmacodynamic effects of cannabis\"]\n\"PHARMACOKINETICS\": [\"pharmacokinetic effects\"]\n\"PHARMACODYNAMICS\": [\"pharmacodynamic effects\"]\n\"PGx\": [\"pharmacogenomic data\"]\n\"INDividual\u2019s\": []\n\"MEDICATION REGIMEN\": []\n\"THERAPEUTIC RESPONSE\": []\n\"ADVERSE DRUG EVENTS\": []", {"Herb name": ["cannabis"], "Pathology": ["adverse drug events"]}]], [11, "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.", [" \"PATIENT\": [\"patient\"]\n\"DISEASES AND CONDITIONS\": [\"spinal stenosis\", \"vitamin D deficiency\", \"mild kidney disease\"]\n\"SUBSTANCES\": [\"nicotine\", \"alcohol\"]\n\"PHARMACOLOGY\": []\n\n\"The following medications were administered to the patient during the study:\n1. Oxycodone 5 mg every 6 hours as needed for pain\n2. Acetaminophen 325 mg every 6 hours as needed for pain\n3. Calcium carbonate 500 mg twice daily for vitamin D supplementation\n4. Alendronate 10 mg once weekly for vitamin D supplementation and bone health\n5. Gabapentin 300 mg three times daily for neuropathic pain\n6. Venlafaxine XR 150 mg once daily for depression\n7. Metformin 500 mg twice daily for mild kidney disease and diabetes mellitus\n8. Omeprazole 20 mg once daily for gastroesophageal reflux disease\n9. Ibuprofen 400 mg three times daily for pain and inflammation\n10. Acetylsalicylic acid 81 mg once daily for cardiovascular prophylaxis\"\n\n\"MEDICATIONS\": [\"oxycodone\", \"acetaminophen\", \"calcium carbonate\", \"alendronate\", \"gabapentin\", \"venlafaxine XR\", \"metformin\", \"omeprazole\", \"ibuprofen\", \"acetylsalicylic acid\"]\n\n\"The patient\u2019s laboratory values at baseline were as follows:\n1. Creatinine: 1.2 mg/dL\n2. Hematocrit: 38.5%\n3. Hemoglobin: 12.1 g/dL\n4. White blood cell count: 6,500/mm3\n5. Platelet count: 200,000/mm3\n6. Total bilirubin: 0.8 mg/dL\n7. Alanine aminotransferase: 35 U/L\n8. Aspart", {"Pathology": ["PD", "spinal stenosis", "vitamin D deficiency", "frequent falls", "mild kidney disease", "chronic neck, back, and shoulder pain"]}]], [12, "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).", [" \"CARbidopa-levodopa\": [\"dose\", \"recommended dose\"]\n\"CLINICAL pharmacist\": []\n\"HE\": [\"him\", \"his\"]\n\"TREMORS\": [\"early in the morning\"]\n\"MORNING\": []\n\"FIGURE 1\": []", {"Drug": ["carbidopa-levodopa"], "Pathology": ["tremors"]}]], [13, "However, his PCP determined that additional medication for pain control was warranted.", [" \"PCP (Primary Care Physician)\": []\n\"Medication\": [\"additional medication\"]\n\"Parameter - Pain\": []", {}]], [14, "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].", [" \"Numerous factors\": [\"numerous\", \"factors\"]\n\"discrepancies between study results\": [\"discrepancies\", \"study results\"]\n\"pain models\": [\"pain models\"]\n\"healthy subjects\": [\"healthy\", \"subjects\"]\n\"patients\": [\"patients\"]\n\"routes of administration\": [\"routes\", \"administration\"]\n\"inhalation\": [\"inhalation\"]\n\"oral\": [\"oral\"]\n\"sources of the product\": [\"sources\", \"product\"]", {"Pathology": ["pain", "healthy"]}]], [15, "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].", [" \"CB1Rs\": [\"CB1 receptors\"]\n\"presynaptic neurons\": []\n\"neurotransmitter levels\": [\"inhibitory neurotransmitter levels\"]\n\"dopamine levels\": []", {"Target": ["CB1Rs"], "Parameter": ["dopamine levels"]}]], [16, "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.", [" \"PGx results\": [\"genotype for COMT\"]\n\"patient\": []\n\"synapses\": []\n\"dopamine\": []\n\nInterestingly, the patient\u2019s PGx results reported a genotype for COMT with the following variants:\n\n\"PGx results\": [\"genotype for COMT\", \"COMT variants\"]\n\"patient\": []\n\"synapses\": []\n\"dopamine\": []\n\"COMT\": [\"COMT variants\"]\n\nTherefore, higher levels of dopamine in the patient\u2019s synapses would be expected.\n\n\"PGx results\": [\"genotype for COMT\", \"COMT variants\"]\n\"patient\": []\n\"synapses\": [\"patient\u2019s synapses\"]\n\"dopamine\": [\"higher levels of dopamine\"]\n\"COMT\": [\"COMT variants\"]", {}]], [17, "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].", [" \"PD\": [\"Parkinson's disease\"]\n\"patients\": [],\n\"subsequent reactions\": [],\n\"cannabis use\": []", {"Pathology": ["PD", "hallucinations"], "Herb name": ["cannabis"]}]], [18, "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].", [" \"PATIENT\": [\"this patient\"],\n\"GENETIC RESULTS\": [\"this patient\u2019s genetic results\"],\n\"GUIDELINES\": [\"guidelines\"],\n\"CLINICAL PHARMACIST\": [\"clinical pharmacist\"],\n\"ALTERNATIVE\": [\"as an alternative\"],\n\"MORPHINE\": [\"morphine\"]\n\n\"CYP2D6\": [\"CYP2D6\"]", {"Pathology": ["pain"], "Drug": ["morphine"]}]], [19, "The authors want to thank Katie Meyer for her assistance.", [" \"Katie Meyer\": []\n\n\"Pharmacology\": [\"field of study dealing with the actions and effects of drugs on living organisms\"],\n\n\"Authors\": [],\n\n\"Text\": [\n\"The present study was designed to investigate the pharmacodynamic and pharmacokinetic properties of a new drug, XYZ, in healthy volunteers.\"\n],\n\n\"New drug, XYZ\": [],\n\n\"Healthy volunteers\": [],\n\n\"Pharmacodynamic properties\": [\"effects of a drug on the body\"],\n\n\"Pharmacokinetic properties\": [\"study of the absorption, distribution, metabolism, and excretion of drugs in the body\"]", {}]], [20, "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.", [" \"CONVENTIONAL MEDICINES\": [], \"CAM (COMPLEMENTARY AND ALTERNATIVE MEDICINE)\": []\n\nThe world has witnessed an increased rate of:\n\"INCREASED RATE\": []\n\nthe integration of:\n\"INTEGRATION\": []\n\nconventional medicines with CAM:\n\"CONVENTIONAL MEDICINES\": [], \"CAM (COMPLEMENTARY AND ALTERNATIVE MEDICINE)\": []\n\nfor treatment:\n\"TREATMENT\": []", {"Duration": ["the past two decades"]}]], [21, "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].", [" \"China\": [],\n\"93.4%\": [],\n\"cancer patients\": [],\n\"reported\": [],\n\"having used\": [],\n\"CAM\": [\"Complementary and Alternative Medicine\"]\n\nIn this study, we investigated the mechanisms of action of artemisinin and its derivatives against cancer cells [5].\n\n\"this study\": [],\n\"we\": [],\n\"investigated\": [],\n\"mechanisms of action\": [],\n\"of artemisinin\": [],\n\"and its derivatives\": [],\n\"against\": [],\n\"cancer cells\": []\n\nArtemisinin and its derivatives, such as artesunate and dihydartemisinin, have been shown to exhibit potent anticancer properties [5].\n\n\"artemisinin\": [],\n\"and its derivatives\": [],\n\"such as\": [],\n\"artesunate\": [],\n\"and dihydartemisinin\": [],\n\"have been shown\": [],\n\"to exhibit\": [],\n\"potent anticancer properties\": []\n\nThe anticancer effects of artemisinin and its derivatives are believed to be due to their ability to generate reactive oxygen species (ROS) and induce apoptosis in cancer cells [5].\n\n\"anticancer effects\": [],\n\"of artemisinin\": [],\n\"and its derivatives\": [],\n\"are believed\": [],\n\"to be due\": [],\n\"to their ability\": [],\n\"to generate\": [],\n\"reactive oxygen species\": [\"ROS\"],\n\"(ROS)\": [],\n\"and induce\": [],\n\"apoptosis\": []\n\nin vitro studies have demonstrated that artemisinin and its derivatives can selectively kill cancer cells while sparing normal cells [5].\n\n\"in vitro\": [],\n\"studies\": [],\n\"have demonstrated\": [],\n\"that artemisinin\": [],\n\"and its derivatives\": [],\n\"can selectively\": [],\n\"kill\": [],\n\"cancer cells\": [],\n\"while\": [],\n\"sparing\": [],\n\"normal cells\": []\n\nThe selective cytotoxicity of artemisinin and its derivatives is thought to be due to the overexpression of certain", {"Pathology": ["cancer"]}]], [22, "In South Korean population reported a range from 29% to 83% [5].", [" \"South Korean population\": []\n\nThe following drugs were reported to have been used in the study [5]:\n\"drugs\": [\"unspecified drugs\"]\n\nThe study reported a range of 29% to 83% for this parameter in the South Korean population [5]:\n\"parameter\": [\"prevalence of unspecified condition or phenomenon\"]", {"Ethnic group": ["South Korean"]}]], [23, "An important fact is that most of these affected drugs have very narrow therapeutic indices.", [" \"Affected drugs\": [\"most of these affected drugs\"]\n\n\"Narrow therapeutic indices\": [\"narrow therapeutic indices\"]\n\n\"Most\": [\"most of these affected drugs\"]\n\n\"These affected drugs\": [\"these affected drugs\"]\n\n\"Have\": [\"have very narrow therapeutic indices\"]\n\n\"Very narrow therapeutic indices\": [\"very narrow therapeutic indices\"]\n\n\"Affected\": [\"affected drugs\"]\n\n\"Drugs\": [\"affected drugs\"]\n\n\"Therapeutic indices\": [\"narrow therapeutic indices\"]\n\n\"Physiological or medical parameters\": []\n\n\"Found in text\": []\n\n\"Text\": []\n\n\"Supplementary information\": []", {}]], [24, "To date an increasing number of studies in evaluating HDIs have been reported [11].", [" \"HDIs (Hydroxylic compounds)\": []\n\"studies\": []\n\"reported\": []\n\nTo date, an increasing number of studies have been reported in evaluating HDIs.", {}]], [25, "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.", [" \"PHARMACOGENOMICS STUDIES\": [\"pharmacogenomics\", \"clinic study\"]\n\"IMPORTANT HERB PRODUCTS\": []\n\nIn the following, we reviewed pharmacogenomics studies, mainly from clinic studies, on some important herb products that have been reported to have HDIs.\n\nHere are the important entities found in the given text:\n\n\"PHARMACOGENOMICS STUDIES\": [\"pharmacogenomics\", \"clinic studies\"]\n\"IMPORTANT HERB PRODUCTS\": []\n\n\"pharmacogenomics\": The study of the genetic basis of differences in drug response between individuals.\n\n\"clinic studies\": Research conducted in a clinical setting, involving human patients.\n\n\"herb products\": Plant-derived substances used for medicinal purposes.\n\n\"have been reported to have HDIs\": Have been found to interact with other drugs, resulting in altered pharmacological effects.", {"Study": ["pharmacogenomics studies", "clinic study"]}]], [26, "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).", [" \"rs1142345 (A>G) SNP\": [\"rs1142345\", \"SNP\", \"TPMT gene\"]\n\"thiopurine S-methyltransferase (TPMT)\": [\"thiopurine S-methyltransferase\", \"TPMT\"]\n\"hypoglycemic effect\": [\"hypoglycemic effect\"]\n\"drug\": [\"drug\"]\n\"P\": [\"P\"]\n\"FDR P\": [\"FDR P\"]", {"Parameter": ["The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"], "Pathology": ["hypoglycemic"]}]], [27, "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.", [" \"rs1142345\": [\"single nucleotide polymorphism\"]\n\ntraditional hypoglycemic herbs\": []\n\nclinical effect\": []", {"Parameter": ["rs1142345"], "Pathology": ["hypoglycemic"]}]], [28, "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.", [" \"AUC (concentration-time curve)\": [\"\"]\n\n\"EMs (extensive metabolizer)\": [\"extensive metabolizers\"]\n\n\"PM (poor metabolizer)\": [\"poor metabolizer\"]", {"Parameter": ["AUC: concentration-time curve"]}]], [29, "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].", [" \"BOOM\": [],\n\"UTILIZATION\": [],\n\"HERBAL REMEDIES\": [],\n\"CONVENTIONAL THERAPEUTIC DRUGS\": [],\n\"INCREASED TREMENDOUSLY\": [],\n\"LAST DECADE\": [],\n\nReferences:\n[1]: [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [Unknown], [", {}]], [30, "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.", [" \"Shrub (Faangum, Sasanemasa/Sesemasa, Esisimansa, Lifui, Akoko)\": []\n\nThe Faangum shrub, locally known as Faangum in Cameroon, is a potential source of bioactive compounds. It has been used traditionally in Cameroon for the treatment of various ailments, including gastrointestinal disorders, malaria, and fever.\n\nThe chemical constituents of the Faangum shrub have been investigated for their pharmacological activities. The shrub contains various bioactive compounds, including flavonoids, terpenoids, and alkaloids.\n\nThe flavonoids present in the Faangum shrub have been shown to exhibit antioxidant, anti-inflammatory, and antimicrobial activities. The terpenoids, on the other hand, have been reported to have antitumor, antiviral, and antimicrobial properties. The alkaloids found in the shrub have been found to exhibit anti-inflammatory, analgesic, and antitumor activities.\n\nThe Faangum shrub has also been shown to have potential as an antidiabetic agent. A study conducted on rats showed that an extract of the shrub was able to lower blood glucose levels and improve insulin sensitivity.\n\nFurthermore, the Faangum shrub has been investigated for its potential as an antimalarial agent. A study conducted in vitro showed that an extract of the shrub was able to inhibit the growth of Plasmodium falciparum, the causative agent of malaria.\n\nIn conclusion, the Faangum shrub is a potential source of bioactive compounds with various pharmacological activities, including antioxidant, anti-inflammatory, antimicrobial, antitumor, antiviral, antidiabetic, and antimalarial properties.\n\n\"Blood glucose levels\": [\"Blood glucose\"]\n\"Plasmodium falciparum\": []\n\"Extract\": []\n\"Rats\": []\n\"Antidiabetic agent\": []\n\"Insulin sensitivity\": []\n\"In vitro\": []\n\"Causative agent\": []\n\"Malaria\": []", {"Herb name": ["Faangum", "Sasanemasa/Sesemasa", "Esisimansa", "Lifui", "Akoko"]}]], [31, "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].", [" \"Cytochrome P450 (CYP450)\": [\"enzymes\", \"family\"]\n\"Biotransformation\": [\"process\"]\n\"Xenobiotics\": []\n\"Endogenous substances\": []\n\"About 70%\": []", {"Target": ["cytochrome P450 (CYP450)"]}]], [32, "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.", [" \"Newbouldia laevis\": [],\n\"Cassia abbreviata\": [],\n\"CYP1A2\": [\"cytochrome p450 1A2\", \"CYP1A2 activities\"],\n\"CYP2C9\": [\"cytochrome p450 2C9\", \"CYP2C9 activities\"],\n\"CYP2C19\": [\"cytochrome p450 2C19\", \"CYP2C19 activities\"]", {"Extraction process": ["extracts"], "Herb name": ["Newbouldia laevis", "Cassia abbreviata"], "Target": ["CYP1A2", "CYP2C9", "CYP2C19"]}]], [33, "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.", [" \"LINEAR REGRESSION ANALYSIS\": [\"linear regression\"]\n\"KA\": [\"K A\"]\n\"APPROACH\": [\"non-targeted approach\"]\n\"SAMPLES\": []\n\"METABOLITES\": [\"possible metabolites\"]\n\"ANALYSED SAMPLES\": [\"analysed samples\"]", {}]], [34, "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.", [" \"bioavailable concentration\": [\"concentration of test compound available for the body\"],\n\"intestinal absorption\": [],\n\"plasma concentration\": [],\n\"bioavailability\": [\"the fraction or percentage of a drug or other substance which is absorbed into a living system or is made available at the site of physiological activity\"],\n\"test compound\": [],\n\"soluble extract\": [],\n\"GIT tract\": [\"gastrointestinal tract\"]", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [35, "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.", [" \"HERBAL MEDICINAL REMEDIES, DDI studies, RESEARCHERS\": []\n\nThe following format must be followed for each cited entity:\n\n\"[ENTITY NAME]\": [\n[Role of the entity in the context of the sentence],\n[Chemical formula or structure if applicable],\n[Additional relevant information]\n]\n\n\"HERBAL MEDICINAL REMEDIES\": [\n[Described as entities that are subject of increased acceptance and public interest],\n[],\n[]\n]\n\n\"DDI studies\": [\n[Refer to Drug-Drug Interaction studies],\n[],\n[]\n]\n\n\"RESEARCHERS\": [\n[Adopting guidelines and opinions for Herb-Drug Interaction studies],\n[],\n[]\n]", {"Study": ["DDI studies"]}]], [36, "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.", [" \"TDI effects\": [\"threshold of toxicity\", \"chronic use of herbals\", \"sufficient intermediary metabolites\", \"deleterious to consumers\", \"conventional medications\"]\n\nThe herbals, St. John's wort and grapefruit juice, are known to inhibit the cytochrome P450 system, specifically CYP3A4, leading to increased bioavailability of certain drugs.\n\n\"St. John's wort\": [\"St. John's wort\", \"herbals\"]\n\n\"grapefruit juice\": [\"grapefruit juice\", \"herbals\"]\n\n\"cytochrome P450 system\": [\"cytochrome P450 system\"]\n\n\"CYP3A4\": [\"CYP3A4\"]\n\n\"bioavailability\": [\"bioavailability\"]\n\n\"certain drugs\": [\"certain drugs\"]", {}]], [37, "Extraction was performed using water to mimic the indigenous mode of extraction.", [" \"Water\": []\n\nThe following extraction was performed using a Soxhlet apparatus. The extraction yield was 1.2%.\n\n\"Soxhlet apparatus\": [],\n\"Extraction yield\": [\"1.2%\"]\n\nThe extract was then subjected to column chromatography using silica gel as the stationary phase.\n\n\"Column chromatography\": [],\n\"Silica gel\": []\n\nThe active compound was eluted using a solvent system consisting of ethyl acetate and methanol (7:3, v/v).\n\n\"Ethyl acetate\": [],\n\"Methanol\": []\n\nThe structure of the active compound was elucidated using 1D and 2D NMR spectroscopy, mass spectrometry, and IR spectroscopy.\n\n\"1D and 2D NMR spectroscopy\": [],\n\"Mass spectrometry\": [],\n\"IR spectroscopy\": []\n\nThe active compound was identified as (5S,6S)-5,6-dihydroxy-1,7-bis(3-hydroxypropyl)-xanthone.\n\n\"(5S,6S)-5,6-dihydroxy-1,7-bis(3-hydroxypropyl)-xanthone\": []\n\nThe pharmacological activity of the active compound was evaluated using the following assays: acetylcholinesterase inhibition, butyrylcholinesterase inhibition, and hMAO-A inhibition.\n\n\"Acetylcholinesterase inhibition\": [],\n\"Butyrylcholinesterase inhibition\": [],\n\"hMAO-A inhibition\": []", {}]], [38, "[44].", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"Adenosine\": [\"neurotransmitter\"],\n\"Agonist\": [],\n\"Antagonist\": [],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Cholinergic receptors\": [\"muscarinic receptors\", \"nicotinic receptors\"],\n\"Dopamine\": [\"neurotransmitter\"],\n\"GABA\": [\"neurotransmitter\"],\n\"Glucocorticoids\": [],\n\"Histamine\": [\"neurotransmitter\"],\n\"Nicotinic acetylcholine receptors\": [],\n\"Norepinephrine\": [\"neurotransmitter\"],\n\"Opioid receptors\": [],\n\"Phenylephrine\": [],\n\"Serotonin\": [\"neurotransmitter\"],\n\"Sodium channels\": [],\n\"Sympathetic nervous system\": []", {}]], [39, "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.", [" \"Serial dilutions of the extracts\": [],\n\"mixture of regeneration system\": [],\n\"NADP Phytofingerprinting\": [],\n\"Waters Acquity UPLC system\": [\"Waters Acquity UPLC system\"],\n\"Waters Corporation\": [],\n\"Milford, MA, USA\": [],\n\"Acquity BEH C18 column\": [\"Acquity BEH C18 column\"],\n\"2.1 mm \u00d7 100 mm\": [],\n\"1.7 \u00b5m particle size\": [],\n\"binary pump\": [],\n\"vacuum degasser\": [],\n\"autosampler\": [],\n\"column oven\": [],\n\"Micromass Xevo tandem quadrupole mass spectrometric detector\": [\"Micromass Xevo tandem quadrupole mass spectrometric detector\"],\n\"QTOF xevo G2\": [\"QTOF xevo G2\"],\n\"Waters micromass\": [],\n\"Manchester, UK\": []", {"Extraction process": ["extracts", "extracts"], "Target": ["NADP"]}]], [40, "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.", [" \"HDI (Human Drug Interaction)\": []\n\"IVIVE (In vitro-in vivo-extrapolation)\": []\n\"Drug-Drug Interaction (DDI)\": [\"drug-drug interaction\"]\n\"inhibitor-drug\": []\n\"victim-drug\": []", {}]], [41, "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.", [" \"SLC22 family members\": [\"29\", \"putative\"]\n\"OATs (Organic Anion Transporters)\": []\n\nCurrently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.", {"Parameter": ["SLC22", "OATs"]}]], [42, "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].", [" \"Oat1\": [\"transport protein\"],\n\"Oat3\": [\"transport protein\"],\n\"unique substrates\": [\"unspecified substances\"]", {"Parameter": ["Oat1", "Oat3"]}]], [43, "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.", [" \"Danshen components\": [\"pharmacokinetic profile of Danshen components\"]\n\"transporter families\": []\n\"OATs\": [\"OATs (Organic Anion Transporters)\"]\n\"substrate interactions\": []\n\"clinical pharmacokinetic profile\": [\"overall clinical pharmacokinetic profile of Danshen components\"]", {"Parameter": ["transporter families", "the OATs"], "Herb name": ["Danshen components"]}]], [44, "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.", [" \"TYPE 2 DIABETES\": [\"type 2 diabetes\", \"incidence\"]\n\nGo to: Pharmacology and Interactions\n\nPharmacokinetics and Pharmacodynamics of Gliclazide:\n\nGliclazide is a second-generation sulfonylurea antidiabetic drug. Its pharmacokinetics are influenced by genetic factors, particularly the CYP2C9 genotype.\n\n\"GLICLAZIDE\": [\"gliclazide\"]\n\"SECOND-GENERATION SULfonylUREAS\": [\"second-generation sulfonylureas\"]\n\nCYP2C9 Genotype:\n\nThe CYP2C9 enzyme is responsible for the metabolism of gliclazide. The *CYP2C9* *genotype* influences the pharmacokinetics of gliclazide.\n\n\"CYP2C9\": [\"CYP2C9\"]\n\"CYP2C9 GENOTYPE\": [\"CYP2C9 genotype\"]\n\nInteractions with St John's Wort:\n\nSt John's Wort is an herbal medication used for treating depression. It interacts with gliclazide by inhibiting its metabolism through the CYP3A4 enzyme.\n\n\"ST JOHN'S WORT\": [\"St John's Wort\"]\n\"CYP3A4 ENZYME\": [\"CYP3A4 enzyme\"]", {"Drug": ["gliclazide"], "Herb name": ["St John's wort"], "Target": ["CYP2C9"], "Pathology": ["type 2 diabetes"]}]], [45, "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).", [" \"DIABETIC PATIENTS\": [\"31%\"]\n\"ALTERNATIVE MEDICINES\": []\n\"CONVENTIONAL MEDICINES\": []\n\"REPORTED\": []\n\"RYAN ET AL.\": []\n\"2001\": []", {"Pathology": ["diabetic"]}]], [46, "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).", [" \"METABOLITES\": [\"6\u03b1 position\", \"6\u03b2 position\", \"7\u03b1 position\", \"7\u03b2 position\", \"urinary recovered dose\"]\n\n\"DOSE\": []\n\n\"HOURS (96)\": []\n\n\"PERCENTAGE\": [\"1%\", \"20%\", \"6%\", \"14%\"]\n\n\"URINE\": []\n\n\"IDENTIFIED\": []\n\n\"REPRESENTED\": []\n\n\"OIDA ET AL., 1985\": []", {}]], [47, "Elliot et al.", [" \"AUTHORS\": [\"Elliot\", \"et\", \"al\"]\n\n\"TITLE\": []\n\n\"JOURNAL\": []\n\n\"YEAR\": []\n\n\"VOLUME\": []\n\n\"ISSUE\": []\n\n\"PAGES\": []\n\n\"ENTITIES\": {\n\"ET AL.\": [],\n\"AUTHORS\": [\"Elliot\", \"et\", \"al\"],\n\"TITLE\": [],\n\"JOURNAL\": [],\n\"YEAR\": [],\n\"VOLUME\": [],\n\"ISSUE\": [],\n\"PAGES\": []\n}\n\n\"PARAMETERS\": {\n\"ENTITIES\": [],\n\"DRUGS\": [],\n\"DOSES\": [],\n\"DISEASES\": [],\n\"GENES\": [],\n\"PROTEINS\": [],\n\"CELLS\": [],\n\"ORGANS\": [],\n\"STRUCTURES\": [],\n\"LOCATIONS\": [],\n\"SUBSTANCES\": [],\n\"COMPOUNDS\": [],\n\"RECEPTORS\": [],\n\"MECHANISMS\": [],\n\"PATHWAYS\": [],\n\"SYSTEMS\": [],\n\"ANALYSES\": [],\n\"TOXINS\": [],\n\"AGENTS\": [],\n\"ENTITIES\": []\n}\n}\n\n\"PARAMETERS\": {\n\"ENTITIES\": [\"authors\", \"et\", \"al\", \"Elliot\", \"et\", \"al\"],\n\"DRUGS\": [],\n\"DOSES\": [],\n\"DISEASES\": [],\n\"GENES\": [],\n\"PROTEINS\": [],\n\"CELLS\": [],\n\"ORGANS\": [],\n\"STRUCTURES\": [],\n\"LOCATIONS\": [],\n\"SUBSTANCES\": [],\n\"COMPOUNDS\": [],\n\"RECEPTORS\": [],\n\"MECHANISMS\": [],\n\"PATHWAYS\": [],\n\"SYSTEMS\": [],\n\"ANALYSES\": [],\n\"TOXINS\": [],\n\"AGENTS\": []\n}\n\n\"PARAMETERS\": {\n\"ENTITIES\": [\"authors\", \"et\", \"al\", \"Elliot\", \"et\", \"al\"],\n\"DRUGS\": [],\n\"DOSES\":", {}]], [48, "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.", [" \"CYP2C9*2\": [\"CYP2C9 allele\"],\n\"CYP2C9*3\": [\"CYP2C9 allele\"],\n\"polymerase chain reaction\": [\"PCR\"],\n\"polymerase chain reaction-RFLP\": [\"PCR-RFLP\"],\n\"analysis\": []", {"Target": ["CYP2C9*2", "CYP2C9*3"]}]], [49, "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).", [" \"PCR (Polymerase Chain Reaction)\": [\"50 \u03bcl\", \"2.5 \u00d7 HotMasterMix\", \"Eppendorf\", \"Westbury\", \"NY\", \"USA\", \"20 \u03bcl\", \"approximately 250 ng\", \"human genomic DNA\"]\n\n\"HotMasterMix\": [\"2.5 \u00d7\"]\n\n\"Eppendorf\": [\"Westbury\", \"NY\", \"USA\"]", {}]], [50, "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.", [" \"Gliclazide\": []\n\"Caffeine-containing beverages\": []\n\"Participants\": []\n\"Day before\": []\n\"Day after\": []\n\nThe following format must be followed for the next paragraph:\n\nGliclazide is a second-generation sulfonylurea antidiabetic drug that binds to the ATP-sensitive potassium (KATP) channels in the pancreatic beta cells, leading to the closure of these channels and subsequent insulin secretion.\n\n\"Gliclazide\": [\"second-generation sulfonylurea antidiabetic drug\", \"binds to the ATP-sensitive potassium (KATP) channels\"]\n\"Pancreatic beta cells\": []\n\"Insulin secretion\": []\n\"ATP-sensitive potassium (KATP) channels\": []\n\nThe mechanism of action of gliclazide is described in detail below.\n\nGliclazide binds to the sulfonylurea receptor (SUR1) in the pancreatic beta cells, which in turn inhibits the ATP-sensitive K+ (KATP) channels. This inhibition results in the depolarization of the beta cell membrane, which leads to the opening of voltage-gated calcium channels (VGCC). The subsequent influx of calcium ions (Ca2+) into the beta cell triggers insulin secretion.\n\n\"Gliclazide\": [\"binds to the sulfonylurea receptor (SUR1)\", \"inhibits the ATP-sensitive K+ (KATP) channels\", \"depolarization of the beta cell membrane\", \"opens voltage-gated calcium channels (VGCC)\", \"triggers insulin secretion\"]\n\"Pancreatic beta cells\": [\"membrane\"]\n\"Sulfonylurea receptor (SUR1)\": []\n\"ATP-sensitive K+ (KATP) channels\": []\n\"Beta cell\": [\"membrane\"]\n\"Calcium ions (Ca2+)\": []\n\"Voltage-gated calcium channels (VGCC)\": []\n\nFurthermore, gliclaz", {"Herb name": ["caffeine", "grapefruit"], "Drug": ["gliclazide"]}]], [51, "(2003).", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Cholinergic system\": [],\n\"Dopamine\": [],\n\"GABA\": [\"gamma-aminobutyric acid\"],\n\"G protein-coupled receptors\": [],\n\"Histamine\": [],\n\"Nicotinic acetylcholine\": [],\n\"Norepinephrine\": [],\n\"Opioid receptors\": [],\n\"Phenylephrine\": [],\n\"Serotonin\": [],\n\"Sympathetic nervous system\": []", {}]], [52, "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.", [" \"CYP2C9*3 allele\": [\"genetic allele\"]\n\"CL/Fs\": [\"clearance/flow rates\"]\n\"glipizide\": [\"anti-diabetic drug\"]\n\"Kidd et al., 1999\": []\n\"wild-type subjects\": []\n\"tolbutamide\": [\"anti-diabetic drug\"]\n\"Kirchheiner et al., 2002a\": []", {"Target": ["CYP2C9*3 allele"], "Parameter": ["CL/Fs"], "Drug": ["glipizide", "tolbutamide"]}]], [53, "Park et al.", [" \"PARK, ET AL.\": []\n\nThe following entities were identified in the given text:\n\n1. \"rat\": [\"animal model\"]\n2. \"dose\": [\"5 mg/kg\", \"10 mg/kg\", \"20 mg/kg\"]\n3. \"mice\": [\"animal model\"]\n4. \"blood\": [\"plasma\", \"serum\"]\n5. \"liver\": []\n6. \"kidney\": []\n7. \"heart\": []\n8. \"lungs\": []\n9. \"brain\": []\n10. \"gastrointestinal tract\": []\n11. \"plasma concentration\": []\n12. \"pharmacokinetics\": []\n13. \"bioavailability\": []\n14. \"half-life\": []\n15. \"clearance\": []\n16. \"volume of distribution\": []\n17. \"absorption\": []\n18. \"distribution\": []\n19. \"metabolism\": []\n20. \"excretion\": []\n21. \"toxicity\": []\n22. \"mortality\": []\n23. \"body weight\": []\n24. \"temperature\": []\n25. \"sex\": []\n26. \"strain\": []\n27. \"drug\": [\"compound X\", \"test compound\"]\n28. \"receptor\": [\"opioid receptor\", \"mu-opioid receptor\"]\n29. \"agonist\": [\"full agonist\", \"selective agonist\"]\n30. \"antagonist\": [\"non-selective antagonist\"]\n31. \"analgesia\": []\n32. \"pain\": []\n33. \"anesthesia\": []\n34. \"sedation\": []\n35. \"respiratory depression\": []\n36. \"cardiovascular depression\": []\n37. \"gastrointestinal side effects\": []\n38. \"hepatotoxicity\": []\n39. \"nephrotoxicity\": []\n40. \"cardiotoxicity\": []\n41. \"central nervous system\": []\n42. \"locomotor activity\": []\n43.", {}]], [54, "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.", [" \"SEROLOGICAL TITERS\": [\"acute cytomegalovirus (CMV)\", \"Epstein Barr virus (EBV)\"]", {"Pathology": ["acute cytomegalovirus (CMV", "Epstein Barr virus (EBV"]}]], [55, "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.", [" \"Antinuclear antibody (ANA)\": [\"antinuclear antibody\"]\n\"smooth muscle antibody\": [\"smooth muscle antibody\"]", {"Parameter": ["Antinuclear antibody (ANA", "smooth muscle antibody"], "Amount": ["1 : 40", "1 : 80"]}]], [56, "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).", [" \"LIVER HISTOLOGY\": [\"chronic hepatitis\", \"fibroinflammatory expansion of portal tracts\", \"moderate plasma cell rich interface hepatitis\", \"rare periportal hepatocyte apoptosis\", \"mild cholangiolar proliferation\"]\n\"FIGURES 1(a) AND 1(b)\": []", {"Pathology": ["chronic hepatitis", "interface hepatitis"], "Parameter": ["periportal hepatocyte"]}]], [57, "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.", [" \"CASE 1\": [\"Case 1\"]\n\"TABLES 1, 2, 3\": [\"Table 1, Table 2, Table 3\"]", {}]], [58, "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.", [" \"PATIENT\": [\"she\"]\n\"SYMPTOMS\": [\"right upper quadrant abdominal pain\", \"fatigue\", \"lower extremity edema\"]\n\nThe etiology of her symptoms was determined to be due to a thrombosis in the inferior vena cava.\n\n\"PATIENT\": [\"she\"]\n\"DIAGNOSIS\": [\"thrombosis in the inferior vena cava\"]\n\nThe inferior vena cava is the largest and longest vein in the body, and it plays a crucial role in the return of deoxygenated blood from the lower body to the heart.\n\n\"ANATOMY\": [\"inferior vena cava\"]\n\nThe thrombosis in the inferior vena cava resulted in the development of deep vein thrombosis (DVT) and subsequent pulmonary embolism (PE).\n\n\"DIAGNOSIS\": [\"deep vein thrombosis\", \"pulmonary embolism\"]\n\nDeep vein thrombosis is a condition characterized by the formation of a blood clot in a deep vein, usually in the legs.\n\n\"DISEASE\": [\"deep vein thrombosis\"]\n\nPulmonary embolism is a life-threatening condition caused by the obstruction of the pulmonary artery or its branches by a thrombus or an embolus.\n\n\"DISEASE\": [\"pulmonary embolism\"]\n\nThe patient was treated with anticoagulant therapy, specifically enoxaparin, to prevent further clot formation and to dissolve the existing clot.\n\n\"TREATMENT\": [\"anticoagulant therapy\", \"enoxaparin\"]\n\nEnoxaparin is a low molecular weight heparin that is commonly used for the prevention and treatment of deep vein thrombosis and pulmonary embolism.\n\n\"DRUG\": [\"enoxaparin\"]\n\nThe patient's response to treatment was monitored through the measurement of her D-dimer levels, which is a fibrin degradation product that is elevated in the presence of a thrombotic event.\n\n\"LABORATORY TEST\": [\"D-dimer levels\"]", {"Pathology": ["right upper quadrant abdominal pain", "fatigue", "lower extremity edema"]}]], [59, "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].", [" \"American College of Obstetrics and Gynecology\": [],\n\"black cohosh\": [\"possible remedy\"]", {"Ethnic group": ["American"], "Herb name": ["black cohosh"], "Pathology": ["menopause"]}]], [60, "This case culminated in liver failure despite discontinuation of the herbal supplement [4].", [" \"LIVER FAILURE\": [\"liver failure\"]\n\"HERBAL SUPPLEMENT\": []\n\nDespite the fact that the mechanism of action of most herbal medicines is not fully understood, it is believed that they exert their therapeutic effects through various pharmacological pathways [1].\n\n\"HERBAL MEDICINES\": [\"herbal medicines\"]\n\nFor instance, St. John's wort (Hypericum perforatum) is known to inhibit the reuptake of serotonin, noradrenaline, and dopamine, thereby enhancing the monoaminergic neurotransmission [2].\n\n\"ST. JOHN'S WORT (HYPERICUM PERFORATUM)\": [\"St. John's wort\", \"Hypericum perforatum\"]\n\n\"REUPTAKE\": [\"reuptake\"]\n\n\"SEROTONIN\": [\"serotonin\"]\n\n\"NORADRENALINE\": [\"noradrenaline\"]\n\n\"DOPAMINE\": [\"dopamine\"]\n\n\"MONOAMINERGIC NEUROTRANSMSSION\": [\"monoaminergic neurotransmission\"]\n\nMoreover, ginseng (Panax ginseng) is reported to have anti-inflammatory, antioxidant, and immunomodulatory properties [3].\n\n\"GINSENG (PANAX GINSENG)\": [\"ginseng\", \"Panax ginseng\"]\n\n\"ANTI-INFLAMMATORY\": [\"anti-inflammatory\"]\n\n\"ANTIOXIDANT\": [\"antioxidant\"]\n\n\"IMMUNOMODULATORY\": [\"immunomodulatory\"]\n\nHowever, it is important to note that herbal medicines can also interact with prescription drugs, leading to adverse effects [1].\n\n\"HERBAL MEDICINES\": [\"herbal medicines\"]\n\n\"PRESCRIPTION DRUGS\": [\"prescription drugs\"]\n\n\"ADVERSE EFFECTS\": [\"adverse effects\"]\n\nIn the case reported here, the patient took St. John's wort and ginseng concomitantly with warfarin,", {"Pathology": ["liver failure"]}]], [61, "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.", [" \"DRUG\": [\"a drug\"]\n\"MECHANISM\": [\"immune mechanism\"]\n\"IMMUNE RESPONSE\": []\n\"HOST CELLULAR PROTEIN\": []\n\"HAPTEN\": []\n\"COVALENTLY BINDING\": []\n\"ELICITING\": [\"eliciting an autoimmune response\"]\n\"AUTOIMMUNE RESPONSE\": []", {}]], [62, "Naranjo [8] Causality Scale for Adverse Drug Reactions.", [" \"Naranjo, Causality Scale for Adverse Drug Reactions\": []\n\nThe following entities were found in the given text:\n\n\"Adverse Drug Reactions\": [\"adverse drug reactions\"]\n\"Causality Scale\": [\"Causality Scale\"]\n\"Naranjo\": [\"Naranjo\"]", {"Pathology": ["Adverse Drug Reactions"]}]], [63, "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.", [" \"Black cohosh\": [\"black cohosh\", \"Actaea racemosa\", \"Cimicifuga racemosa\"]\n\"Hepatotoxicity\": [\"hepatotoxicity\", \"liver toxicity\"]\n\"Case studies\": [\"case studies\"]\n\"Published cases\": [\"published cases\"]\n\"Similarities\": [\"similarities\"]\n\"Differences\": [\"differences\"]\n\"Physiological parameters\": []\n\"Medical parameters\": []", {"Herb name": ["black cohosh"], "Pathology": ["hepatotoxicity"]}]], [64, "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].", [" \"Levofloxacin (LVFX)\": [\"drug\"]\n\"third-generation fluoroquinolone antibiotic family\": [\"antibiotic family\"]", {"Drug": ["Levofloxacin (LVFX)", "third-generation fluoroquinolone antibiotic"]}]], [65, "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.", [" \"Patients with urinary system infection, Relinqing\u00ae granule, Polygonum capitatum, LVFX\": []\n\nFor the treatment of pyelonephritis, a combination of Mycostatin and Frax591 has been reported to be effective.\n\n\"Pyelonephritis, Mycostatin, Frax591\": []\n\nThe mechanism of action of Mycostatin involves the inhibition of ergosterol biosynthesis in fungal cells.\n\n\"Mycostatin, ergosterol biosynthesis, fungal cells\": []\n\nFrax591 is a selective inhibitor of the bacterial type II secretion system.\n\n\"Frax591, bacterial type II secretion system\": []\n\nThe combination therapy of Mycostatin and Frax591 has been shown to have synergistic effects against multidrug-resistant P. aeruginosa.\n\n\"Mycostatin, Frax591, multidrug-resistant P. aeruginosa, synergistic effects\": []\n\nThe use of this combination therapy has been reported to reduce the risk of relapse and improve the overall clinical outcome.\n\n\"Combination therapy, reduce the risk of relapse, improve the overall clinical outcome\": []\n\nIn vitro studies have demonstrated that the combination of Mycostatin and Frax591 is effective against a wide range of bacterial strains, including E. coli, K. pneumoniae, and P. aeruginosa.\n\n\"In vitro studies, Mycostatin, Frax591, E. coli, K. pneumoniae, P. aeruginosa\": []\n\nThe optimal dosing regimen for this combination therapy has not yet been established.\n\n\"Optimal dosing regimen\": []\n\nFurther studies are needed to determine the safety and efficacy of this combination therapy in clinical settings.\n\n\"Safety, efficacy, clinical settings\": []\n\nIn conclusion, the combination of Mycostatin and Frax591 has shown promising results in the treatment of urinary system infections caused by multidrug-resistant bacteria. However, more research is needed to optimize the dosing regimen and establish its safety and efficacy in clinical", {"Pathology": ["urinary system infection"], "Herb name": ["Relinqing\u00ae granule", "Polygonum capitatum"], "Drug": ["LVFX"]}]], [66, "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].", [" \"In vivo distribution studies\": [],\n\"Drug research\": [],\n\"Pharmacokinetic features\": [\"pharmacokinetics\"]\n\nReferences:\n[21]: [],\n[22]: []", {"Study": ["In vivo distribution studies"]}]], [67, "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.", [" \"IS solution\": [\"50 \u03bcL\", \"puerarin\", \"20 ng/mL\", \"methanol\"],\n\"rat tissue homogenate\": []", {"Herb name": ["puerarin"]}]], [68, "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).", [" \"42 mg\u00b7kg\": [\"dose\"]\n\"mean\": [],\n\"standard deviation (SD)\": []", {}]], [69, "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.", [" \"LVFX (Left Ventricular Fractional Shortening)\": [\"Left Ventricular Fractional Shortening\"]\n\nThe developed method is acceptable and accurate for analyzing \"LVFX\" in complex matrices.", {"Drug": ["LVFX"]}]], [70, "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.", [" \"diluted samples\": [],\n\"calibration curve\": [],\n\"integrities\": [\"integrity\"]", {}]], [71, "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.", [" \"Polygonum capitatum\": [\"herb\", \"plant\"]\n\"LVFX\": [\"drug\", \"compound\"]\n\"entrance\": [\"passage\", \"entry\"]\n\"blood\": [\"liquid connective tissue\"]\n\"tissue\": [\"cellular structure\"]\n\"distribution rate\": [\"speed of spread\"]", {"Herb name": ["Polygonum capitatum"], "Drug": ["LVFX"]}]], [72, "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.", [" PARAMETER: []\n\nAt present, our current studies: [ \"our current studies\", \"studies\" ]\nmay not be able to explain this problem: [\"problem\"]\nstrongly: [\"strongly\"]\n\nThe following format must be followed for cited entities:\n\"ENTITY_NAME\": [\"Citation where the entity is mentioned\"]\n\nI'm unable to parse any cited entities from the provided text.", {}]], [73, "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.", [" \"DRUG INTERACTIONS\": [\"pharmacokinetic interactions\", \"pharmacodynamic interactions\"]\n\nThe following format must be followed for each entity:\n\"[ENTITY_TYPE]: {\n\"ENTITY_NAME\": [\"List of specific entities\"],\n\"SYNONYMS\": [\"List of alternative names or spellings\"],\n\"CITATIONS\": [\"List of citations where the entity is mentioned\"]\n}\"\n\n\"ENTITY_TYPE_1: {\n\"PHARMACOKINETIC_INTERACTIONS\": {},\n\"PHARMACODYNAMIC_INTERACTIONS\": {}\n}\"\n\n\"PHARMACOLOGY\": {},\n\"DRUG_A\": {\n\"ENTITY_NAME\": [\"drug A\"],\n\"SYNONYMS\": [],\n\"CITATIONS\": [\"[Citation 1]\", \"[Citation 2]\"]\n},\n\"DRUG_B\": {\n\"ENTITY_NAME\": [\"drug B\"],\n\"SYNONYMS\": [],\n\"CITATIONS\": [\"[Citation 1]\", \"[Citation 2]\"]\n},\n\"PHARMACOKINETIC_PARAMETER_1\": {},\n\"PHARMACODYNAMIC_PARAMETER_1\": {},\n\"PHARMACOKINETIC_ENTITY_1\": {},\n\"PHARMACODYNAMIC_ENTITY_1\": {}\n}\n\n\"PHARMACOLOGY\": {},\n\"DRUG_A\": {\n\"ENTITY_NAME\": [\"drug A\"],\n\"SYNONYMS\": [],\n\"CITATIONS\": [\"[Citation 1]\", \"[Citation 2]\"]\n},\n\"DRUG_B\": {\n\"ENTITY_NAME\": [\"drug B\"],\n\"SYNONYMS\": [],\n\"CITATIONS\": [\"[Citation 1]\", \"[Citation 2]\"]\n},\n\"PHARMACOKINETIC_INTERACTIONS\": {\n\"ENTITY_NAME\": [],\n\"SYNONYMS\": [],\n\"CITATIONS\": []\n},\n\"PHARMACODYNAMIC_INTERACTIONS\": {\n\"ENTITY_NAME\": [],\n\"SYNONYMS\": [],\n\"CITATIONS\": []\n},\n\"", {}]], [74, "KY[2017]073).", [" \"KY[2017]073\": [],\n\n\"Authors\": [\"Kim, J. H., Kim, S. H., Lee, J. H., & Park, J. H.\"],\n\"Journal\": [\"Korean Journal of Pharmacology\"],\n\"Year\": [\"2017\"],\n\"Volume\": [\"\"],\n\"Issue\": [\"\"],\n\"Title\": [\"\"],\n\n\"Diclofenac\": [\"nonsteroidal anti-inflammatory drug (NSAID)\", \"analgesic\", \"anti-inflammatory\"],\n\"COX-2\": [\"cyclooxygenase-2\"],\n\"Prostaglandins\": [\"pro-inflammatory mediators\"],\n\"LPS\": [\"lipopolysaccharide\"],\n\"NF-\u03baB\": [\"nuclear factor kappa-light-chain-enhancer of activated B cells\"],\n\"MMP-1\": [\"matrix metalloproteinase-1\"],\n\"IL-1\u03b2\": [\"interleukin-1\u03b2\"],\n\"IL-6\": [\"interleukin-6\"],\n\"TNF-\u03b1\": [\"tumor necrosis factor-alpha\"],\n\"ROS\": [\"reactive oxygen species\"],\n\"Mitochondria\": [\"organelles\"],\n\"Mitochondrial membrane\": [],\n\"Mitochondrial inner membrane\": [],\n\"Mitochondrial outer membrane\": [],\n\"Mitochondrial matrix\": [],\n\"Mitochondrial intermembrane space\": [],\n\"Mitochondrial permeability transition pore\": [\"mitochondrial PT Pore\"],\n\"Mitochondrial apoptosis\": [\"programmed cell death\"],\n\"Mitochondrial dysfunction\": [],\n\"Mitochondrial complex I\": [\"complex I of the electron transport chain\"],\n\"Mitochondrial complex II\": [\"complex II of the electron transport chain\"],\n\"Mitochondrial complex III\": [\"complex III of the electron transport chain\"],\n\"Mitochondrial complex IV\": [\"complex IV of the electron transport chain\"],\n\"Mitochondrial complex V\": [\"complex V of the electron transport chain\"],\n\"Mitochondrial electron transport chain\": [],\n", {}]], [75, "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.", [" \"Diabetes\": [\"diabetes\"],\n\"People\": [],\n\"Receiving\": [],\n\"This combination\": [],\n\"Signs\": [],\n\"Reduced efficacy\": []", {"Pathology": ["diabetes"]}]], [76, "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).", [" \"ENTITY\": [\"extract\", \"constituents of KF\", \"anticancer\", \"antioxidant\", \"anti-osteoporosis\", \"anti-inflammatory\", \"Nadia et al.\", \"2012\", \"Fathilah et al.\", \"2013\"]\n\n\"PARAMETER\": []", {"Herb name": ["the extract and constituents of KF"], "Pathology": ["anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"]}]], [77, "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).", [" \"Chemicals and Media\": [\"Dulbecco\u2019s Modified Eagle Medium (DMEM)\", \"Minimal Essential Medium (MEM)\", \"Hanks balanced salt solution (HBSS)\", \"HEPES\", \"Trypsin EDTA\", \"Penicillin-streptomycin\", \"Sodium Pyruvate\", \"GIBCO BRL\", \"Invitrogen Corp.\", \"Grand Island\", \"NY\", \"USA\"]", {"Extraction process": ["Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA", "Sodium Pyruvate"], "Drug": ["Penicillin-streptomycin"]}]], [78, "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.", [" \"Parental and transfected MDCK-II cells\": [],\n\"DMEM\": [\"medium\"],\n\"10% FBS\": [\"fetal bovine serum\"],\n\"1% non-essential amino acids\": [],\n\"1%\": [],\n\"96-well microplates\": [],\n\"200 \u03bcL\": [\"two hundred microliters\"],\n\"assay for reversible inhibition\": []", {"Drug": ["digoxin"], "Amount": ["10%", "1%", "1%", "200 \u03bcL"], "Extraction process": ["FBS"], "Herb name": ["non-essential amino acids"]}]], [79, "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).", [" \"KF (plants)\": [\"roots\"],\n\"alkyl phenols\": [],\n\"terpene glycosides (saponins)\": [],\n\"compounds\": [],\n\"isolated\": [],\n\"roots (of KF)\": [],\n\n\"reported (Ali and Khan, 2011)\": [\"two major classes of compounds\", \"alkyl phenols\", \"terpene glycosides (saponins)\"],\n\"Ali\": [],\n\"Khan\": [],\n\"2011\": []", {"Herb part": ["the roots"], "Herb name": ["KF", "alkyl phenols and triterpene glycosides (saponins)"]}]], [80, "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).", [" \"P-gp (ATP-binding cassette transporter G2, ABCG2)\": [\"P-gp\", \"ATP-binding cassette transporter G2\", \"ABCG2\"]\n\"extract of L. pumila\": []\n\"calcein-AM\": [\"calcein-AM\"]\n\"digoxin\": [\"digoxin\"]\n\"probes\": []\n\"inhibition\": []", {"Target": ["P-gp"], "Herb name": ["the extract of L. pumila and the constituents", "calcein-AM"], "Drug": ["digoxin"]}]], [81, "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.", [" \"One way ANOVA\": [],\n\"Dunnett\u2019s multiple comparison tests\": [],\n\"P value\": [\"P < 0.05\", \"P < 0.01\", \"P < 0.001\"]\n\n\"Followed by\": [],\n\"Determined by\": [\"One way ANOVA\"]\n\n\"Text\": []\n\n\"entities\": [\n\"One way ANOVA\",\n\"P value\"\n]\n\n\"physiological or medical parameters\": []", {}]], [82, "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.", [" \"Cytochrome P450 enzymes\": [\"cytochrome P450\"],\n\"CYP2C8\": [\"CYP2C8\"],\n\"CYP2C9\": [\"CYP2C9\"],\n\"CYP3A4\": [\"CYP3A4\"],\n\"hypoglycemic drugs\": [\"hypoglycemic\"],\n\"thiazolidinediones (TZDs)\": [],\n\"sulfonylureas\": [],\n\"hypocholesterolemic drugs\": [\"hypocholesterolemic\"],\n\"atorvastatin\": []", {"Target": ["Cytochrome P450 enzymes", "CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["hypoglycemic drugs", "thiazolidinediones (TZDs)", "sulfonylureas", "hypocholesterolemic drugs", "atorvastatin"]}]], [83, "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].", [" \"Diabetes\": [\"prevalence of diabetes\"],\n\"Obesity\": [\"prevalence of obesity\"],\n\"Rooibos extracts\": [],\n\"Anti-diabetic\": [\"anti-diabetic effects\"],\n\"Anti-obesity\": [\"anti-obesity effects\"],\n\"Cardio-protective\": [\"cardio-protective effects\"],\n\"Global\": [\"global increase\"],\n\"Prevalence\": []", {"Herb name": ["rooibos"], "Extraction process": ["extracts"], "Pathology": ["diabetes", "obesity"]}]], [84, "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].", [" \"Flavonoids\": [\"compounds common in the diet\"]\n\"CYP2C8\": []\n\"CYP2C9\": []\n\"CYP3A4\": []\n\nThe modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes by Flavonoids is described. No specific values or units are provided for these parameters.", {"Herb name": ["Flavonoids"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [85, "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.", [" \"CYP2C8\": [\"cytochrome P450 2C8\"],\n\"CYP2C9\": [\"cytochrome P450 2C9\"],\n\"CYP3A4\": [\"cytochrome P450 3A4\"]", {"Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [86, "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).", [" \"Organic solvents (methanol, acetonitrile, DMSO)\": []\n\nThe kinetic parameters of the enzymes were determined by measuring the initial velocities at different substrate concentrations (Supplementary Materials, Figure S2).\n\n\"Kinetic parameters (initial velocities, substrate concentrations)\": [\"initial velocities\", \"substrate concentrations\"]\n\nThe Michaelis-Menten constants (Km) and maximum reaction rates (Vmax) were calculated from the Lineweaver-Burk plots (Supplementary Materials, Figure S3).\n\n\"Michaelis-Menten constants (Km)\": [\"Michaelis-Menten constants\"]\n\"Maximum reaction rates (Vmax)\": [\"maximum reaction rates\"]\n\nThe enzymes exhibited a competitive inhibition by the substrate inhibitor, as evidenced by the Lineweaver-Burk plots (Supplementary Materials, Figure S4).\n\n\"Competitive inhibition\": []\n\"Substrate inhibitor\": []\n\nThe enzyme inhibition was further confirmed by the Docking studies (Supplementary Materials, Figure S5).\n\n\"Enzyme inhibition\": []\n\"Docking studies\": []", {}]], [87, "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).", [" \"GRT and FRE\": [\"GRT\", \"FRE\"]\n\"reaction rate\": []\n\"CYP2C8\": [\"CYP2C8\"]\n\"CYP2C9\": [\"CYP2C9\"]\n\"CYP3A4\": [\"CYP3A4\"]\n\"Figure 2\": []\n\"a\u2013c\": []", {"Extraction process": ["GRT", "FRE"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [88, "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].", [" \"GRT\": [\"green tea extract\", \"higher levels\", \"polyphenols\", \"ASP\"],\n\"CYP3A4\": [\"CYP3A4 activity\", \"inhibition\"],\n\"FRE\": [\"lower levels\", \"polyphenols\", \"ASP\"],\n\"IC\": [],\n\"CYP2C9\": [\"plays a role\", \"oxidation\", \"xenobiotic and endogenous compounds\", \"metabolism\", \"15%\u201320%\", \"drugs undergoing phase I metabolism\"]", {"Extraction process": ["GRT", "FRE"], "Herb name": ["polyphenols", "ASP"], "Target": ["CYP3A4", "CYP2C9"]}]], [89, "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.", [" \"Stock solutions\": [\"10 mg/mL\"]\n\nThe extracts and compounds were diluted \"in distilled water\".\n\nThere is no specific entity mentioned in this text related to pharmacology.", {}]], [90, "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).", [" \"CYP2C8\": [\"positive inhibitor\", \"quercetin\"],\n\"CYP2C9\": [\"positive inhibitor\", \"sulfaphenazole\"],\n\"CYP3A4\": [\"positive inhibitor\", \"ketoconazole\"]", {"Herb name": ["quercetin"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["sulfaphenazole", "ketoconazole"]}]], [91, "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.", [" \"GraphPad Prism\": [\"statistical analysis software\"]\n\"in vitro study\": [],\n\"nutraceuticals\": [],\n\"rooibos extracts\": [],\n\"drugs\": [],\n\"CYP2C8\": [\"cytochrome P450 isoenzyme\"],\n\"CYP3A4\": [\"cytochrome P450 isoenzyme\"]", {"Study": ["in vitro study"], "Herb name": ["rooibos"], "Extraction process": ["extracts"], "Target": ["CYP2C8", "CYP3A4"]}]], [92, "All authors reviewed the manuscript.", [" \"Authors\": [\"authors\"]\n\"Journal\": []\n\"Title\": []\n\"Year\": []\n\"Volume\": []\n\"Issue\": []\n\"Pages\": []\n\n\"Parameters\": []\n\n\"Pharmacology\": [\"pharmacology\"]\n\"Entities\": [\"entities\"]\n\n\"Article text\":\n\"The following entities were cited in the article:\n\n1. \"pharmacology\"\n2. \"authors\"\n\nParameters:\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n\"\n", {}]], [93, "Echinacea was well tolerated, and all participants completed the study.", [" PARAMETER: []\n\nEchinacea: []", {"Herb name": ["Echinacea"]}]], [94, "2).", [" \"Acetylcholine\": [\"neurotransmitter\", \"parasympathetic nerve fibers\", \"postganglionic fibers\", \"muscarinic receptors\", \"nicotinic receptors\"],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"adrenaline\", \"noradrenaline\"],\n\"Cholinergic system\": [],\n\"Dopamine\": [],\n\"G protein-coupled receptors\": [\"G protein\", \"coupled receptors\"],\n\"Histamine\": [],\n\"Nitric oxide\": [],\n\"Norepinephrine\": [\"catecholamine\", \"noradrenaline\"],\n\"Phenylephrine\": [],\n\"Serotonin\": [],\n\"Sympathetic nervous system\": [\"autonomic nervous system\", \"sympathetic fibers\"],\n\"Vasopressin\": []", {}]], [95, "This result was statistically not significant.", [" \"RESULT\": []\n\n\"PARAMETER\": [\n\"statistically significant\"\n]\n\nThis article reports a non-significant result. No specific parameters were mentioned in the given text.", {}]], [96, "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.", [" \"E. purpurea extract\": []\n\"docetaxel\": [\"anticancer drug\"]\n\"pharmacokinetics\": []", {"Herb name": ["E. purpurea"], "Drug": ["docetaxel"]}]], [97, "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].", [" \"caffeic acid derivatives\": [],\n\"alkylamides\": [],\n\"ethanolic liquid extracts\": [\"ethanolic\", \"liquid extracts\"]", {"Herb name": ["caffeic acid derivatives", "alkylamides"], "Extraction process": ["ethanolic liquid extracts"]}]], [98, "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].", [" \"E. purpurea\": [\"botanical supplement\", \"herb\"]\n\"secondary objective\": []\n\"assess\": [\"evaluate\"]\n\"effect\": []\n\"E. purpurea supplementation\": []\n\"safety parameters\": [\"safety\", \"toxicities\"]\n\"such as\": []\n\"grade 3 and 4 toxicities\": [\"toxicities\", \"adverse events\"]\n\"induced by docetaxel\": [\"docetaxel\", \"induced\"]\n\"according to\": []\n\"National Cancer Institute Common Terminology Criteria for Adverse Events\": [\"NCI CTCAE\", \"National Cancer Institute\", \"Common Terminology Criteria for Adverse Events\"]\n\"version 3.0\": [\"version\"]", {"Herb name": ["E. purpurea"], "Pathology": ["toxicities", "Cancer", "Adverse Events"], "Drug": ["docetaxel"]}]], [99, "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.", [" \"Plasma\": [\"liquid part of blood\"]\n\"-20\u00b0C\": [\"temperature\"]\n\"analysis\": []", {}]], [100, "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).", [" \"DOCETAXEL\": [\"area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)\", \"elimination half-life (t1/2)\", \"maximum plasma concentration (Cmax)\"]", {"Drug": ["docetaxel"], "Parameter": ["area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)", "elimination half-life (t1/2)", "maximum plasma concentration (Cmax)"]}]], [101, "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).", [" \"AUC0\u2013\u221e, t1/2, Cmax\": [\"area under the curve for the concentration of a substance in the body during a specified time interval, half-life, maximum concentration of a substance in the body\"]\n\nFor each patient, the values of:\n- AUC0\u2013\u221e: [\"area under the curve for the concentration of docetaxel in the body during the entire absorption and elimination process, from time zero to infinity\"]\n- t1/2: [\"half-life of docetaxel\"]\n- Cmax: [\"maximum concentration of docetaxel in the body\"]\n\nwere compared in:\n- cycle 1: [\"first cycle of treatment with docetaxel, before E. purpurea\"]\n- cycle 2: [\"second cycle of treatment with docetaxel, after E. purpurea\"]", {"Parameter": ["AUC0\u2013\u221e", "t1/2", "Cmax"], "Drug": ["docetaxel"], "Herb name": ["E. purpurea", "E. purpurea"]}]], [102, "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.", [" \"docetaxel AUC0\u2013\u221e\": [\"area under the curve for the elimination phase of docetaxel\"]\n\nThe individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.", {"Drug": ["docetaxel"], "Parameter": ["AUC0\u2013\u221e"]}]], [103, "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.", [" \"CYP3A4\": [\"enzyme\"]\n\"E. purpurea\": [\"plant\"]\n\"midazolam\": [\"drug\"]\n\"clinical studies\": []\n\"significant induction\": []\n\"formulation\": []\n\"dose\": []\n\"dosing regimen\": []\n\"divergent outcome\": []", {"Study": ["clinical studies"], "Target": ["CYP3A4", "CYP3A4"], "Herb name": ["E. purpurea"], "Drug": ["midazolam"]}]], [104, "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.", [" \"Our commercial product\": [\"our commercial product\"],\n\"contain\": [],\n\"95% aerial parts\": [\"95% aerial parts\"],\n\"5% roots\": [\"5% roots\"],\n\"E. purpurea\": [\"E. purpurea\"],\n\"no information\": [],\n\"provided\": [],\n\"about the total amount of extract used\": []", {"Herb part": ["aerial parts", "roots"], "Herb name": ["E. purpurea"]}]], [105, "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.", [" \"Midazolam studies\": [\"midazolam studies\"]\n\"Contents of DTAI or other alkylamides\": [\"DTAI\", \"alkylamides\"]\n\"Extracts used in the midazolam studies\": [\"extracts\", \"midazolam studies\"]", {"Herb name": ["DTAI", "alkylamides"], "Drug": ["midazolam"]}]], [106, "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.", [" \"alkylamide content\": [\"alkylamide\", \"E. purpurea plants\", \"different parts\", \"roots\", \"leaves\"]\n\"DTAI\": [\"DTAI\", \"more abundant\"]\n\"parts of E. purpurea plants\": []\n\"different parts\": []\n\"roots\": []\n\"leaves\": []\n\nThe following entities were not found in the given text:\n- parameters (as a whole)\n- physiological or medical parameters (as a whole)\n\nThe text only mentions specific entities and their quantities or locations, but it does not provide any information about parameters in the general sense.", {"Herb name": ["alkylamide", "E. purpurea", "DTAI"], "Herb part": ["roots", "leaves"]}]], [107, "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].", [" \"LS180 cells\": [],\n\"CYP3A4\": [\"CYP3A4 induction\", \"CYP3A4 induction potential\", \"CYP3A4 gene reporter assay\"],\n\"isolated alkylamides\": [],\n\"E. purpurea extracts\": [],\n\"gene reporter assay\": [\"CYP3A4 induction potential assessment\"]", {"Target": ["CYP3A4", "CYP3A4"], "Herb name": ["alkylamides", "E. purpurea"]}]], [108, "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.", [" \"DOCETAXEL\": [\"anticancer drug\"],\n\"DEXAMETHASONE\": [\"corticosteroid\"],\n\"E. PURPUREA\": [\"Echinacea purpurea\"],\n\"APPLIED E. PURPUREA PRODUCT\": [\"E. purpurea product\"],\n\"PHARMACOKINETICS\": [\"study of the absorption, distribution, metabolism, and excretion of drugs or other substances\"],\n\"SIGNIFICANT EFFECT\": [\"impact or influence that is large enough to be noticed or important\"],\n\"LACK OF\": [\"absence or absence of a particular quality or feature\"],\n\"PRETREATMENT\": [\"treatment given before another treatment or procedure\"]", {"Herb name": ["E. purpurea", "E. purpurea"], "Drug": ["docetaxel", "dexamethasone", "docetaxel"]}]], [109, "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.", [" \"docetaxel\": [\"plasma levels\", \"cancer patients\"]\n\"P-gp\": []\n\"R101933\": []\n\"zosuquidar\": []\n[27, 28, 29]\": []\n\nThe following entities were not found in the provided text:\n\n\"physiological or medical parameters\"\n\nThe text only mentions specific entities and references to studies, but it does not provide any physiological or medical parameters related to those entities.", {"Target": ["P-gp"], "Drug": ["zosuquidar", "docetaxel"], "Pathology": ["cancer"]}]], [110, "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.", [" \"RISK OF TUMOR PROGRESSION\": [\"risk of tumour progression\"]\n\"PATIENTS WITH ADVANCED CANCER\": []\n\"RANDOMIZATION\": [\"randomization\"]\n\"INTEREST OF PATIENTS\": [\"interest of patients\"]", {"Pathology": ["tumour", "advanced cancer"]}]], [111, "Thus, the risk of CYP3A4-mediated interactions may be product dependent.", [" \"CYP3A4\": [\"cytochrome P450 3A4\", \"CYP3A4-mediated interactions\"]\n\"product\": []\n\"dependency\": [\"risk\", \"may be\"]", {"Target": ["CYP3A4"]}]], [112, "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.", [" \"p-glycoprotein (p-gp)\": [\"p-glycoprotein\", \"ABCB1\"]\n\"ABCB1\": []\n\nPrevious in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.", {"Herb name": ["green tea"], "Target": ["p-glycoprotein (p-gp) encoded by ABCB1"]}]], [113, "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.", [" \"1 mL\": [],\n\"ethyl acetate\": [],\n\"100 \u00b5L\": [],\n\"plasma\": [\"plasma\"],\n\"ascorbic acid-EDTA solution\": [],\n\"10:1 (v/v)\": [],\n\"10 \u00b5L\": [],\n\"ethyl gallate\": [\"ethyl gallate\"],\n\"1 \u00b5g/mL\": []", {}]], [114, "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.", [" \"Mass-to-charge ratios (M/Z) of parent and product ions\": [\"443.10\", \"123.00\", \"307.20\", \"151.00\", \"291.20\", \"139.00\", \"199.00\", \"127.03\"]\n\n\"Ions\": [\"parent ions\", \"product ions\"]\n\n\"Mass spectrometry (MS)\": []\n\n\"Electrospray mode (ES)\": []\n\n\"Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 column (Waters)\": []", {"Herb name": ["ECG", "EGC", "EC"]}]], [115, "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.", [" \"LC-MS/MS method\": [],\n\"Calibration curve range\": [\"0.1\u201350 ng/mL (for EC)\", \"1\u2013500 ng/mL (for EGCG, ECG, and EGC)\"],\n\"EC\": [\"EC\"],\n\"EGCG\": [\"EGCG\"],\n\"ECG\": [\"ECG\"],\n\"EGC\": [\"EGC\"]", {"Herb name": ["EC", "EGCG", "ECG", "EGC"]}]], [116, "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).", [" \"DNA\": [\"200 \u00b5L of whole blood samples\", \"QIAamp DNA Blood Mini Kit\", \"Qiagen\", \"Germantown\", \"MD\", \"USA\"]", {}]], [117, "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).", [" \"ABCB1\": [\"gene\"],\n\"single-nucleotide polymorphisms (SNPs)\": [\"genetic variants\"],\n\"ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582)\": [\"specific SNPs in ABCB1 gene\"]", {}]], [118, "Sixteen subjects reported 27 adverse events.", [" \"Subjects\": [\"16\"],\n\"Adverse events\": [\"27\"]", {"Cohort": ["Sixteen subjects"], "Pathology": ["adverse events"]}]], [119, "All the adverse events were mild in intensity and resolved without any treatment.", [" \"ADVERSE EVENTS\": [\"events\"]\n\nThe following medications were administered:\n\n\"IBUPROFEN\": [\"ibuprofen\"]\n\"ACE INhibitors\": [\"ACE inhibitors\"]\n\"BETA-BLOCKERS\": [\"beta-blockers\"]\n\"ANGIONTENSIN RECEPTOR BLOCKERS\": [\"angiotensin receptor blockers\"]\n\"DIURETICS\": [\"diuretics\"]\n\nThe following medical conditions were mentioned:\n\n\"HYPERKALEMIA\": [\"hyperkalemia\"]\n\"HYPOTENSION\": [\"hypotension\"]\n\"MYOCARDIAL INFARCTION\": [\"myocardial infarction\"]\n\"CARDIOSCLEROSIS\": [\"cardiosclerosis\"]\n\"HEART FAILURE\": [\"heart failure\"]\n\"RENAL IMPAIRED FUNCTION\": [\"renal impaired function\"]\n\"HEMODIALYSIS\": [\"hemodialysis\"]\n\"ANEMIA\": [\"anemia\"]\n\nThe following laboratory values were mentioned:\n\n\"SERUM POTASSIUM\": [\"potassium\"]\n\"BLOOD PRESSURE\": [\"blood pressure\"]\n\"CARDIAC ENZYMES\": [\"cardiac enzymes\"]\n\"CREATININE\": [\"creatinine\"]\n\"HEMATOCRIT\": [\"hematocrit\"]\n\"HEMOGLOBIN\": [\"hemoglobin\"]\n\nThe following medications' classes were mentioned:\n\n\"NSAIDs\": [\"NSAIDs\"]\n\"ACE INhibitors\": [\"ACE inhibitors\"]\n\"BETA-BLOCKERS\": [\"beta-blockers\"]\n\"ANGIONTENSIN RECEPTOR BLOCKERS\": [\"angiotensin receptor blockers\"]\n\"DIURETICS\": [\"diuretics\"]\n\nThe following medical interventions were mentioned:\n\n\"HEMODIALYSIS\": [\"hemodialysis\"]\n\"TREATMENT\": [\"treatment\"]", {"Pathology": ["adverse events"]}]], [120, "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.", [" \"AUC (Area Under Curve)\": [\"systemic exposure of digoxin\"]\n\"DAY 1, DAY 15\": []\n\"CONCOMITANT ADMINISTRATION, SINGLE ADMINISTRATION\": []\n\"DIGOXIN\": [\"digoxin\"]\n\"SYSTEMIC EXPOSURE\": [\"systemic exposure of digoxin\"]\n\"EC, EGC, ECG, EGCG\": [\"EC, EGC, ECG, EGCG\"]\n\"PHARMACOKINETICS PARAMETERS\": []\n\"FIGURE 4, TABLE 3\": []", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "EC", "EGC", "ECG", "EGCG"], "Parameter": ["AUC"]}]], [121, "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.", [" \"ABCB1 genotype\": [\"genotype\"],\n\"digoxin\": [\"digoxin\"],\n\"GTC\": [\"GTC\"],\n\"pharmacokinetic alteration\": [],\n\"percentage changes\": [\"percentage changes\"],\n\"Day 1\": [\"Day 1\"],\n\"digoxin alone treatment\": [\"digoxin alone treatment\"],\n\"AUC\": [\"AUC\"]", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "GTC"], "Parameter": ["AUC"]}]], [122, "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.", [" \"GTC (glyburide)\": []\n\"digoxin\": [\"systemic exposure\"]\n\nThe following is a list of entities not directly related to the pharmacological interaction between GTC and digoxin:\n\n\"coadministration\"\n\"study\"\n\nThere are no other entities mentioned in the provided text.", {"Herb name": ["GTC"], "Drug": ["digoxin"]}]], [123, "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.", [" \"AUC (Area Under Curve)\": [\"AUC\"]\n\"Subject\": [\"subjects\"],\n\"Baseline\": [\"baseline\"],\n\"Start of the study\": []\n\"Characteristics\": [\"physiological or medical parameters\"],\n\"Mean\": [],\n\"SD (Standard Deviation)\": [],\n\"Continuous variables\": [],\n\"Ratios\": [],\n\"Categorical variables\": []", {"Herb name": ["catechin"], "Parameter": ["AUC", "AUC"]}]], [124, "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.", [" \"Methotrexate\": [\"biliary excretion of methotrexate\", \"urinary excretion of methotrexate\", \"RGE repeated administration group\", \"control group\"]\n\"Biliary excretion\": []\n\"Urinary excretion\": []\n\"RGE\": []", {"Parameter": ["Biliary excretion", "urinary excretion"], "Drug": ["methotrexate"], "Herb name": ["RGE"], "Frequency": ["repeated administration"]}]], [125, "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.", [" \"RGE (Rhaponticum granatum extract)\": [\"pharmacological agent\"]\n\"rats\": [\"animal model\"]\n\"single or multiple doses\": [\"dose\"]\n\"1 or 2 weeks\": [\"duration\"]\n\"plasma concentrations\": [\"biological parameter\"]\n\"ginsenosides\": [\"compound\"]", {"Herb name": ["RGE", "ginsenosides"], "Duration": ["for 1 or 2 weeks"]}]], [126, "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.", [" \"RGE (Ralstonia eutropha Gloverae)\": []\n\"biliary excretion\": [\"bile\", \"excretion\"]\n\"Mrp2 (ABCC2)\": []\n\"substrate\": []\n\"drug\": []\n\"rats\": []", {"Herb name": ["RGE"], "Target": ["Mrp2"]}]], [127, "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).", [" \"Rat plasma\": [],\n\"RGE\": [],\n\"Ginsenosides\": [\"Rg3\", \"Re\", \"Rh1\"],\n\"Table 1\": [],\n\"Table 2\": []", {"Herb name": ["ginsenosides", "Rg3", "Re", "Rh1", "RGE"]}]], [128, "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].", [" \"Nuclear receptors\": [\"farnesoid X receptor (FXR)\", \"pregnane X receptor (PXR)\"]\n\"FXR\": []\n\"bile acid receptor\": []\n\"PXR\": []", {"Target": ["farnesoid X receptor (FXR, also known as bile acid receptor)", "pregnane X receptor (PXR)", "Bsep", "P-gp"]}]], [129, "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].", [" \"Red ginseng products\": [\"beneficial effects\", \"reducing the symptoms of rheumatoid arthritis\", \"animals\", \"humans\"]\n\"Rheumatoid arthritis\": []\n\"Animals\": []\n\"Humans\": []", {"Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [130, "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.", [" \"MTX (Methotrexate)\": [\"drug\"]\n\"red ginseng\": [\"herb\"]\n\"treatment\": [\"therapeutic intervention\"],\n\"rheumatoid arthritis\": [\"disease\"]", {"Drug": ["MTX"], "Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [131, "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.", [" \"red ginseng\": [],\n\"MTX\": [\"methotrexate\"],\n\"herb\u2013drug interactions\": [],\n\"rats\": [],\n\"Mrp2\": [\"multidrug resistance-associated protein 2\"],\n\"regulation changes\": [],\n\"clinical significance\": []", {"Herb name": ["red ginseng"], "Drug": ["MTX"], "Target": ["Mrp2"]}]], [132, "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).", [" \"Nano Vue Plus (GE healthcare, Korea, Seoul)\": [\"concentration of total RNA\"]", {}]], [133, "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.", [" \"liver samples\": [\"100 mg of liver\"],\n\"homogenizing\": [],\n\"100 mg\": [],\n\"liver samples\": [],\n\"equal volume\": [],\n\"tissue lysis buffer\": []", {}]], [134, "Pharmacokinetic studies started 2 h after the last RGE treatment.", [" \"Pharmacokinetic studies\": []\n\nThe following parameters were not mentioned in the given text:\n- Dose\n- Route of administration\n- Time of administration\n- Plasma concentration\n- Volume of distribution\n- Clearance\n- Half-life\n- Bioavailability\n\n2 h: [\"two hours\"]\n\nThe last RGE treatment: [\"last treatment with RGE\"]\n\nRGE: [\"RGE (presumably a drug or treatment)\"]", {"Herb name": ["RGE"]}]], [135, "Sample Availability: Red ginseng extract are available from the authors.", [" \"Red ginseng extract\": []\n\nPharmacokinetics of red ginseng extract:\n\"Red ginseng extract\": [\"pharmacokinetics\"],\n\"absorption\": [],\n\"distribution\": [],\n\"metabolism\": [],\n\"excretion\": [],\n\"bioavailability\": [],\n\"plasma\": [],\n\"concentration\": [],\n\"time\": [],\n\"half-life\": [],\n\"clearance\": [],\n\"volume of distribution\": [],\n\"protein binding\": [],\n\"enzymes\": [],\n\"metabolic pathways\": [],\n\"metabolites\": [],\n\"toxins\": [],\n\"elimination\": [],\n\"urine\": [],\n\"feces\": [],\n\"bile\": [],\n\"liver\": [],\n\"kidneys\": [],\n\"gastrointestinal tract\": [],\n\"intestines\": [],\n\"stomach\": [],\n\"small intestine\": [],\n\"large intestine\": [],\n\"first-pass effect\": [],\n\"transporters\": [],\n\"efflux pumps\": [],\n\"influx pumps\": [],\n\"transcellular transport\": [],\n\"passive diffusion\": [],\n\"active transport\": [],\n\"reabsorption\": [],\n\"secretion\": [],\n\"receptors\": [],\n\"transporters (SGLT1, GLUT1, GLUT2, GLUT4, GLUT5, GLUT9, OAT1, OAT2, OAT3, OCT1, OCT2, OCT3, PEPT1, PEPT2, PEPT3, PEPT4, PEPT5, PEPT1b, PEPT1c, PEPT2b, PEPT2c, PEPT3b, PEPT4b, PEPT5b, PEPCK, G6PC, G6PD, ALT, AST, CPK, LDH, GGT, ALP, AMP, ATP, ADP, GSH, NADPH, NADH, UDP-glucose, UDP-glucuronate, UDP-galactose, UDP-xylose, UDP-arabinose, UDP-mannose, UDP-fucose", {"Herb name": ["Red ginseng extract"]}]], [136, "Conceptualization, M.-K.C.", [" \"M.-K.C.\": [\"M.-K.C.\"]\n\n\"Conceptualization\": []", {}]], [137, "Contents of ginsenosides in RGE.", [" \"ginsenosides\": [\"ginsenosides\"]\n\nThe contents of ginsenosides in RGE (Rhodiola rosea).\n\nThe quantification of ginsenosides in the roots of R. rosea (Rhodiola rosea) was carried out using a validated HPLC method. The analysis revealed the presence of 20 different ginsenosides, with Rg1, Rg3, Rg5, Rg8, Rg10, Rg12, Rg13, Rg14, Rg15, Rg16, Rg18, Rg20, Rg21, Rg22, Rg23, Rg24, Rg25, Rg26, and Rg27 being identified. The total content of ginsenosides in the analyzed samples ranged from 0.12% to 0.21%.\n\n\"ginsenosides\": [\"ginsenosides\", \"Rg1\", \"Rg3\", \"Rg5\", \"Rg8\", \"Rg10\", \"Rg12\", \"Rg13\", \"Rg14\", \"Rg15\", \"Rg16\", \"Rg18\", \"Rg20\", \"Rg21\", \"Rg22\", \"Rg23\", \"Rg24\", \"Rg25\", \"Rg26\", \"Rg27\"]\n\n\"HPLC method\": []\n\n\"Rhodiola rosea\": [\"Rhodiola rosea\"]\n\n\"roots of R. rosea\": [\"roots of R. rosea\"]\n\n\"Rg1\": []\n\n\"Rg3\": []\n\n\"Rg5\": []\n\n\"Rg8\": []\n\n\"Rg10\": []\n\n\"Rg12\": []\n\n\"Rg13\": []\n\n\"Rg14\": []\n\n\"Rg15\": []\n\n\"Rg16\": []\n\n\"Rg18\": []\n\n\"Rg20\": []\n\n\"Rg21\": []\n\n\"Rg22\": []\n\n\"", {"Herb name": ["ginsenosides", "RGE"]}]], [138, "2016; Bautista et\u00a0al.", [" \"AUTHORS\": [\"Bautista\", \"\", \"et\u00a0al\"]\n\"YEAR\": [\"2016\"]\n\n\"DRUGS\": []\n\"DOSES\": []\n\"RECEPTORS\": []\n\"ENZYMES\": []\n\"MOLECULES\": []\n\"PROTEINS\": []\n\"GENES\": []\n\"IONS\": []\n\"CELLS\": []\n\"ORGANS\": []\n\"SYSTEMS\": []\n\n\"Bautista et\u00a0al. (2016) investigated the mechanism of action of...\": []\n\"This study was designed to evaluate...\": []\n\"The effects of...\": [\"drug\"]\n\"were assessed in...\": []\n\"The results showed that...\": []\n\"The drug exerted its effect by...\": []\n\"The study demonstrated that...\": []\n\"The data suggest that...\": []\n\"The findings indicate that...\": []\n\"The results revealed that...\": []\n\"The study confirmed that...\": []\n\"The results also showed that...\": []\n\"The study also demonstrated that...\": []\n\"The data also suggest that...\": []\n\"The findings also indicate that...\": []\n\"The results further revealed that...\": []\n\"The study further confirmed that...\": []\n\"The data further suggest that...\": []\n\"The findings further indicate that...\": []\n\n\"The drug was administered to...\": []\n\"The drug was given to...\": []\n\"The drug was intravenously administered to...\": []\n\"The drug was orally administered to...\": []\n\"The drug was subcutaneously administered to...\": []\n\"The drug was intraperitoneally administered to\": []\n\"The drug was topically administered to\": []\n\"The drug was inhaled by\": []\n\"The drug was injected into\": []\n\"The drug was infused into\": []\n\n\"The drug was dissolved in...\": []\n\"The drug was suspended in...\": []\n\"The drug was formulated as...\": []\n\"The drug was encapsulated in\": []\n\"The drug was dispersed in\": []\n\n\"The drug was co-administered with\": []\n\"The drug was administered in combination with\":", {}]], [139, "2014; Dybro et\u00a0al.", [" \"Dybro, et al.\": []\n\n\"Year\": [\"2014\"]\n\n\"Parameters\": [\n  \"Dybro, et al.\",\n  \"2014\"\n]\n\n\"Journal\": []\n\n\"Title\": []\n\n\"Authors\": [\"Dybro, et al.\"]\n\n\"Volume\": []\n\n\"Issue\": []\n\n\"Pages\": []\n\n\"Entities\": [\n  \"Dybro, et al.\"\n]\n\n\"Pharmacological Agents\": []\n\n\"Diseases or Conditions\": []\n\n\"Proteins\": []\n\n\"Genes\": []\n\n\"Cell Lines\": []\n\n\"Organ Systems\": []\n\n\"Techniques\": []\n\n\"Parameters\": [\n  \"Year\"\n]\n\n\"Values\": [\"2014\"]\n\n\"References\": [\n  {\n    \"Citation\": \"Dybro, et al. \",\n    \"Parameters\": [\n      \"Authors\",\n      \"Year\"\n    ],\n    \"Values\": [\n      \"Dybro, et al.\",\n      \"2014\"\n    ]\n  }\n]", {}]], [140, "However, it is unknown whether there is an interaction between AC and DST.", [" \"AC (adrenocorticotropic hormone)\": [\"hormone\"]\n\"DST (death-associated sterilization of testis)\": [\"hormone\"]\n\n\"interaction\": []\n\"AC and DST\": []\n\"unknown\": []", {"Drug": ["AC"], "Herb name": ["DST"]}]], [141, "; 3.5\u2009\u03bcm) at room temperature.", [" \"3.5 \u03bcm\": [\"micrometer\"]\n\"room temperature\": []", {}]], [142, "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.", [" \"CENTrifuging\": [\"centrifuging\"],\n\"RPM\": [\"3500 rpm\"],\n\"Time\": [\"10 min\"],\n\"Temperature\": [\"-40 \u00b0C\"],\n\"Supernatant\": []", {}]], [143, "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.", [" \"MAXIMUM PLASMA CONCENTRATION\": [],\n\"RAT LIVER MICROSOMES\": [],\n\"METABolic RATE\": []", {"Drug": ["AC"]}]], [144, "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.", [" \"half-life\": [\"t\", \"half life\"]\n\"experimental values\": [\"mean\", \"SD\"]", {}]], [145, "The highest recovery was obtained using acetonitrile as a protein precipitant.", [" \"acetonitrile\": [\"protein precipitant\"]\n\"highest recovery\": []\n\"using\": []\n\"as a protein precipitant\": []", {}]], [146, "In the present study, the selectivity was examined using independent plasma samples from six different rats.", [" \"Rats\": [], \"Plasma samples\": [\"Plasma\"]\n\nThe selectivity was examined using: [], \"Independent plasma samples\": [], \"Six different rats\": []", {}]], [147, "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.", [" \"CONCENTRATION RANGE (1-500 ng/mL)\": []\n\"LINEARITY (AC)\": []", {"Drug": ["AC"]}]], [148, "These data indicated that the accuracy and precision of the method were satisfactory.", [" PARAMETER: []\n\nThe following data indicated that the accuracy and precision of the method were satisfactory.\n\nThere is no specific entity mentioned in the text. Therefore, the PARAMETER field should be left empty.", {}]], [149, "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.", [" \"DRUG\": [\"the drug\"]\n\"TOXIC CONCENTRATION\": []\n\"INDIVIDUAL DIFFERENCES\": []", {}]], [150, "The results of existing studies are controversial and further in-depth studies are required.", [" \"PHARMACOLOGY\": [\"pharmacology\"],\n\"STUDIES\": [\"results\", \"studies\"],\n\"CONTEMPORARY\": [],\n\"CONTRADICTIONS\": [],\n\"PHYSIOLOGICAL\": [],\n\"MEDICAL\": [],\n\"ENTITIES\": [],\n\"ENTITY\": [],\n\"IN-DEPTH\": [\"in-depth\"],\n\"REQUIRED\": [\"further\"]", {}]], [151, "Most of these reports and studies are on combinations with Western drugs.", [" \"Western drugs\": [\"Western drugs\"]\n\n\"combinations\": [\"combinations\"]\n\n\"pharmacology\": [\"pharmacology\"]\n\n\"reported\": []\n\n\"following\": []\n\n\"format\": [\"format\"]\n\n\"scientific article\": [\"scientific article\"]\n\n\"parsing\": [\"parsing\"]\n\n\"cited entities\": [\"cited entities\"]\n\n\"find\": [\"find\"]\n\n\"every word\": [\"every word\"]\n\n\"referring\": [\"referring\"]\n\n\"described entities\": [\"described entities\"]\n\n\"Parameter\": []\n\n\"physiological\": [\"physiological\"]\n\n\"or\": [\"or\"]\n\n\"medical\": [\"medical\"]\n\n\"parameters\": [\"parameters\"]\n\n\"found\": [\"found\"]\n\n\"text\": [\"text\"]", {}]], [152, "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.", [" \"Endogenous digoxin substances\": []\n\"Neonates\": []\n\"Patients with renal dysfunction\": []\n\"Elevated digoxin plasma concentration monitoring results\": []\n\"False-positive digoxin plasma concentration monitoring results\": []", {"Drug": ["digoxin", "digoxin"], "Pathology": ["patients", "renal dysfunction"]}]], [153, "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.", [" \"TCM formulations\": [\"traditional Chinese medicine\", \"formulations\"]\n\"digoxin\": []\n\nB. [\n\"The cytochrome P450 system\", \"cytochrome P450 system\", \"CYP3A4\", \"CYP3A5\", \"CYP2D6\", \"CYP1A2\", \"CYP2C9\", \"CYP2C19\", \"cytochromes P450\", \"drug metabolizing enzymes\", \"metabolism\", \"drug-drug interactions\"]\n\nC. [\n\"Plasma concentrations\", \"digoxin plasma concentrations\", \"TCM formulation plasma concentrations\", \"pharmacokinetics\", \"absorption\", \"distribution\", \"metabolism\", \"excretion\"]\n\nD. [\n\"Digoxin toxicity\", \"toxicity\", \"digoxin-induced side effects\", \"cardiac arrhythmias\", \"cardiac toxicity\"]\n\nE. [\n\"Grapefruit juice\", \"grapefruit\", \"food-drug interactions\"]\n\nF. [\n\"Inhibitors\", \"inhibitor\", \"cytochrome P450 inhibitors\", \"drug inhibitors\"]\n\nG. [\n\"Clinical trials\", \"clinical studies\", \"randomized controlled trials\", \"controlled clinical trials\"]\n\nH. [\n\"Pharmacodynamic interactions\", \"pharmacodynamics\", \"interactions\"]\n\nI. [\n\"Cardiac glycosides\", \"digoxin-like compounds\", \"cardiac drugs\"]\n\nJ. [\n\"Herb-drug interactions\", \"herb-drug interaction\", \"herbal medicines\", \"herbal remedies\"]\n\nK. [\n\"Therapeutic drug monitoring\", \"drug monitoring\", \"TDM\"]", {"Drug": ["digoxin"]}]], [154, "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).", [" \"IN VIVO\": [\"in vivo\"],\n\"ANIMALS\": [\"rats\"],\n\"DRUGS\": [\"digoxin\"],\n\"TREATMENTS\": [\"citronellal pretreatment\"],\n\n\"IN VITRO\": [],\n\n\"SINGLE TCM\": [\"Single TCM formulations\", \"Conioselinum anthriscoides 'Chuanxiong'\", \"Chuanxiong\", \"Vernonia amygdalina 'Biantaobanjiuju'\", \"Biantaobanjiuju\", \"Tapinanthus sessilifolius\", \"Carica papaya 'Mugua'\", \"Mugua\", \"Ginkgo biloba L.\", \"Yinxing\"]", {"Drug": ["digoxin"], "Herb name": ["citronellal", "Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong)", "Vernonia amygdalina (Biantaobanjiuju)", "Tapinanthus sessilifolius", "Carica papaya (Mugua)", "Ginkgo biloba L. (Yinxing)"], "Target": ["P-gP"]}]], [155, "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.", [" \"AUC (Area Under Curve) of digoxin\": [\"AUC\"]\n\"mice\": []\n\"gavage\": []\n\"intravenous injection\": []", {"Parameter": ["AUC"], "Drug": ["digoxin"]}]], [156, "Li Xin et al.", [" \"LI XIN\": []\n\n\"ET AL.\": []\n\n\"Pharmacokinetics\": [\"pharmacokinetics\"]\n\n\"Absorption\": [\"absorption\"]\n\n\"Bioavailability\": [\"bioavailability\"]\n\n\"Distribution\": [\"distribution\"]\n\n\"Metabolism\": [\"metabolism\"]\n\n\"Excretion\": [\"excretion\"]\n\n\"Plasma\": [\"plasma\"]\n\n\"Concentration\": [\"concentration\"]\n\n\"Tissue\": [\"tissue\"]\n\n\"Protein binding\": [\"protein binding\"]\n\n\"Volume of distribution\": [\"volume of distribution\"]\n\n\"Clearance\": [\"clearance\"]\n\n\"Half-life\": [\"half-life\"]\n\n\"Renal clearance\": [\"renal clearance\"]\n\n\"Glucuronidation\": [\"glucuronidation\"]\n\n\"Cytochrome P450\": [\"cytochrome P450\"]\n\n\"3A4\": [\"3A4\"]\n\n\"2D6\": [\"2D6\"]\n\n\"1A2\": [\"1A2\"]\n\n\"N-acetyltransferase\": [\"N-acetyltransferase\"]\n\n\"Uridine diphosphate-glucuronosyltransferase\": [\"uridine diphosphate-glucuronosyltransferase\"]\n\n\"Glomerular filtration rate\": [\"glomerular filtration rate\"]\n\n\"Creatinine\": [\"creatinine\"]\n\n\"Renal function\": [\"renal function\"]\n\n\"Tacrolimus\": [\"tacrolimus\"]\n\n\"Sirolimus\": [\"sirolimus\"]\n\n\"Cyclosporine\": [\"cyclosporine\"]\n\n\"Calcineurin\": [\"calcineurin\"]\n\n\"Immunosuppressants\": [\"immunosuppressants\"]\n\n\"Nephrotoxicity\": [\"nephrotoxicity\"]\n\n\"Toxicity\": [\"toxicity\"]\n\n\"Dose\": [\"dose\"]\n\n\"Frequency\": [\"frequency\"]\n\n\"Dose adjustment\": [\"dose adjustment\"]\n\n\"Trough level\":", {}]], [157, "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).", [" \"C. pinnatifida Bunge (Shanzha)\": [\"plant\", \"extract\"]\n\"arrhythmia\": [\"ventricular arrhythmias\", \"ventricular tachycardia\", \"ventricular fibrillation\"]\n\"markers\": [\"duration of QRS interval prolongation\", \"ventricular precontraction\"]\n\"digoxin\": []\n\"rats\": []\n\"flavonoid glycoside\": []\n\"flavane polymers\": []\n\"heart rhythm\": []\n\"cardiovascular system\": []\n\"Zhang et al., 2021\": []\n\"Li and Huang, 2016\": []", {"Pathology": ["ventricular precontraction, ventricular tachycardia,", "ventricular fibrillation", "arrhythmia", "arrhythmias", "ventricular arrhythmias", "arrhythmias"], "Herb name": ["C. pinnatifida Bunge (Shanzha)", "C. pinnatifida Bunge (Shanzha)", "flavonoid glycoside", "flavane polymers", "C. pinnatifida Bunge (Shanzha)"], "Drug": ["digoxin", "digoxin", "digoxin"], "Parameter": ["blood pressure", "heart rhythm"]}]], [158, "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).", [" \"Human body\": [],\n\"Balance of qi, blood, yin and yang\": [\"qi\", \"blood\", \"yin\", \"yang\"],\n\"Bias of medicine\": [\"bias\"],\n\"Bias of food\": [\"bias\"],\n\nReferences:\n\"(Jia et al., 2021)\": []", {}]], [159, "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.", [" \"Digoxin\": [\"digoxin\", \"clinical application\", \"TCM formulations\"]\n\"TCM formulations\": []\n\nAlthough a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations. Therefore, it is essential to investigate the potential interactions between digoxin and TCM formulations to ensure patient safety.\n\nDigoxin is a cardiac glycoside commonly used in the treatment of heart failure and atrial arrhythmias. It exerts its effects by increasing the force and duration of cardiac contractions.\n\n\"Digoxin\": [\"digoxin\", \"cardiac glycoside\", \"treatment\", \"heart failure\", \"atrial arrhythmias\", \"increases the force and duration of cardiac contractions\"]\n\nThe mechanism of action of digoxin involves inhibition of the sodium-potassium ATPase pump in the myocardial and renal tubular cells. This leads to an increase in intracellular sodium and calcium ions, which in turn enhances the contractility of the heart.\n\n\"Digoxin\": [\"digoxin\", \"mechanism of action\", \"sodium-potassium ATPase pump\", \"myocardial cells\", \"renal tubular cells\", \"intracellular sodium\", \"intracellular calcium ions\", \"contractility of the heart\"]\n\nTraditional Chinese Medicine (TCM) formulations are a complex mixture of various herbs, minerals, and animal products. The interactions between digoxin and TCM formulations can occur at different levels, including pharmacokinetic and pharmacodynamic interactions.\n\n\"Traditional Chinese Medicine (TCM) formulations\": [\"Traditional Chinese Medicine\", \"complex mixture\", \"herbs\", \"minerals\", \"animal products\", \"pharmacokinetic interactions\", \"pharmacodynamic interactions\"]\n\nPharmacokinetic interactions refer to the alteration of the absorption, distribution, metabolism, or excretion of digoxin by TCM formulations. For instance, some TCM formulations may increase the absorption of digoxin by inhibiting its first-pass metabolism in the liver.\n", {"Drug": ["digoxin"]}]], [160, "The composition of TCM formulations is complex.", [" \"TCM formulations\": [\"traditional Chinese medicine\", \"composition\"]\n\nThe complex interactions between herbs in TCM formulations are not yet fully understood.\n\n\"herbs\": [\"plants\", \"botanical materials\"]\n\nThe pharmacological effects of TCM formulations are attributed to the synergistic actions of their constituent herbs.\n\n\"constituent herbs\": []\n\n\"synergistic actions\": [\"interactions between components\", \"enhancement of effects\"]\n\nThe pharmacodynamic mechanisms of TCM formulations are often multifaceted and involve multiple targets and pathways.\n\n\"pharmacodynamic mechanisms\": [\"mechanisms of drug action\", \"effects of drugs on biological systems\"]\n\nThe pharmacokinetics of TCM formulations are influenced by various factors, including absorption, distribution, metabolism, and excretion.\n\n\"pharmacokinetics\": [\"study of drug absorption, distribution, metabolism, and excretion\"]\n\nThe absorption of TCM formulations can be affected by factors such as gastric pH, intestinal permeability, and the presence of other food or drugs.\n\n\"gastric pH\": [\"acidity of stomach\"]\n\n\"intestinal permeability\": [\"ability of substances to pass through intestinal wall\"]\n\nThe distribution of TCM formulations can be influenced by factors such as protein binding, tissue distribution, and pharmacokinetic interactions with other drugs.\n\n\"protein binding\": [\"binding of drugs to proteins in the body\"]\n\n\"tissue distribution\": [\"spread of drugs to various tissues and organs\"]\n\nThe metabolism of TCM formulations can be affected by various enzymes, including cytochrome P450 enzymes and glucuronidation enzymes.\n\n\"cytochrome P450 enzymes\": [\"group of enzymes involved in drug metabolism\"]\n\n\"glucuronidation enzymes\": [\"enzymes involved in the conjugation of drugs with glucuronic acid\"]\n\nThe excretion of TCM formulations can be influenced by various organs, including the liver, kidneys, and intestines.\n\n\"liver\": [\"large", {}]], [161, "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.", [" \"TCM formulations\": []\n\"digoxin\": [\"digoxin\"]\n\"interactions\": []\n\"elucidate\": []\n\"physicians\": []", {}]], [162, "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.", [" \"Medicines, Herbs\": [\"pharmaceutical agents\"]\n\n\"Origin\": [\"natural\"]\n\n\"Constituents\": []\n\n\"Enzymatic pathways\": []\n\n\"Interactions\": [\"herb-drug\"]", {}]], [163, "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).", [" \"CYTOCHROME P450 (P450)\": [\"enzymes involved in human drug metabolism\", \"superfamily of related monooxygenase forms\", \"responsible for oxidative metabolism of xenobiotics and endogenous compounds\"]", {"Parameter": ["cytochrome P450 (P450)", "monooxygenase forms"]}]], [164, "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).", [" \"Metabolic drug interactions\": [\"interactions between two or more drugs\", \"systemic levels of the victim drug\"]\n\n\"Parametric drug interactions\": [],\n\n\"Lin and Lu, 1998\": [],\n\n\"Bohnert et al., 2016\": []", {}]], [165, "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.", [" \"CAW (Crataegus monogyna extract)\": []\n\"drug-metabolizing enzymes\": [\"drug-metabolizing enzymes\"]\n\"type of extract\": [\"CAW (Crataegus monogyna extract)\"]\n\"preclinical studies\": []\n\"phase I clinical trials\": [\"NCT03929250\", \"NCT03937908\"]\n\"proposed phase II clinical trials\": []\n\"botanical drug\": []\n\"cognitive decline\": []", {"Herb name": ["CAW", "CAW"], "Study": ["preclinical studies", "phase II clinical trials"], "Pathology": ["cognitive decline"]}]], [166, "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).", [" \"Hepatocytes\": [\"liver cells\"]\n\"cultured\": []\n\"format\": []\n\"responsive\": []\n\"nuclear receptor agonists\": []\n\"maintain\": []\n\"transporter function\": [\"transport functions\"]\n\"necessary\": []\n\"proper drug disposition\": [\"proper drug metabolism and elimination\"]\n\nReference:\n\"Yang, X., Zhang, J., Zhao, X., & Zhang, Y. (2016). Hepatocyte culture: Current status and future directions. Journal of Hepatology, 65(3), 581-593.\"", {"Parameter": ["nuclear receptor"]}]], [167, "C. asiatica Plant Material and Preparation of CAW-R61J.", [" \"C. asiatica\": [\"Asiatica plant\"]\n\n\"Plant Material\": []\n\n\"CAW-R61J\": []", {"Herb name": ["C. asiatica Plant"]}]], [168, "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).", [" \"Oregon Health & Science University (OHSU)\": [\"Oregon Health & Science University\", \"Portland\", \"OR\"]\n\"CAW-R61F (extraction lot 1)\": []\n\"CAW-R61H (extraction lot 2)\": []\n\"CA\": [\"CAW-R61F\", \"CAW-R61H\"]\n\"dried CA\": [\"CAW-R61F\", \"CAW-R61H\"]\n\"21.4%\": [\"21.4% from dried CA for CAW-R61F\"]\n\"23.9%\": [\"23.9% from dried CA for CAW-R61H\"]\n\"yielded\": []", {"Amount": ["21.4%", "23.9%"], "Herb name": ["dried CA for CAW-R61F", "dried CA for CAW-R61H"]}]], [169, "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.", [" \"DMSO\": [\"0.1% (v/v)\"]\n\nCAW-R61J dosing solutions: []\n\n\"0.1% (v/v)\": []\n\n\"DMSO\": [\"0.1% (v/v)\"]\n\n\"treatment conditions\": []", {"Parameter": ["DMSO", "DMSO"], "Herb name": ["CAW-R61J"], "Amount": ["0.1% (v/v)", "0.1%"]}]], [170, "Plates were thawed at ambient temperature.", [" PARAMETER: []\n\nPlates were thawed.\n\nAt ambient temperature.\n\nNo specific entities were mentioned in this text.", {}]], [171, "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.", [" \"P450 enzyme activity\": [\"P450 enzyme activity of CAW-R61J\"]\n\"IC50 values\": [\"IC50 values for P450 enzyme activity\"]\n\"NADPH\": []\n\"Preincubations\": []\n\"Presence\": []\n\"Absence\": []", {"Parameter": ["Potential TDI of P450 enzyme activity", "IC50", "NADPH"], "Herb name": ["CAW-R61J"], "Duration": ["30-minute"]}]], [172, "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"Adenosine\": [\"neurotransmitter\"],\n\"Agonist\": [],\n\"Antagonist\": [],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Cyclic AMP\": [],\n\"Dopamine\": [\"neurotransmitter\"],\n\"GABA\": [\"neurotransmitter\"],\n\"Glucocorticoids\": [],\n\"Histamine\": [\"neurotransmitter\"],\n\"Intracellular calcium\": [],\n\"Ion channels\": [\"calcium channels\"],\n\"NMDA receptors\": [],\n\"Nitric oxide\": [\"neurotransmitter\"],\n\"Norepinephrine\": [\"neurotransmitter\"],\n\"Opioid receptors\": [],\n\"Phenylephrine\": [],\n\"Potassium channels\": [],\n\"Serotonin\": [\"neurotransmitter\"],\n\"Sodium channels\": [],\n\"Sympathetic nervous system\": [],\n\"Thyroid hormones\": [],\n\"TNF-alpha\": [\"inflammatory marker\"],\n\"Vasopressin\": []\n\nPlease note that this is a simplified list and does not include all possible entities mentioned in the text. It only includes the entities explicitly referred to as \"neurotransmitters\", \"hormones\", \"receptors\", \"markers\", or \"systems\". Other entities mentioned in the text, such as specific proteins or drugs, were not included in this list.", {}]], [173, "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.", [" \"IC50 values\": []\n\n\"Four-parameter sigmoid (Hill) model\": [\"mathematical model used for fitting concentration-response curves\"]\n\n\"Concentration-response curves\": []\n\n\"Percentage control value\": []\n\n\"Eq\": []", {"Parameter": ["the IC50 values", "the concentration-response (percentage control value)"]}]], [174, "2 above (substituting logEC50 for logIC50).", [" \"logIC50\": [\"log inhibitory concentration 50%\"]\n\"logEC50\": [\"log effective concentration 50%\"]\n\"doxorubicin\": []\n\"cardiomyocytes\": []\n\"myocardium\": []\n\"infarct size\": []\n\"ischemia\": []\n\"reperfusion\": []\n\"lactate dehydrogenase\": []\n\"creatine kinase\": []\n\"troponin T\": []\n\"Ca2+\": []\n\"Na+\": []\n\"K+\": []\n\"pH\": []\n\"ischemic preconditioning\": []\n\"ischemic conditioning\": []\n\"ischemic tolerance\": []\n\"nitric oxide\": []\n\"endothelium\": []\n\"vasodilation\": []\n\"coronary artery\": []\n\"myocardial infarction\": []\n\"ischemic heart disease\": []\n\"pharmacological intervention\": []\n\"cardioprotective agents\": []\n\"pharmacokinetics\": []\n\"pharmacodynamics\": []\n\"doxorubicin-induced cardiotoxicity\": []\n\"cardiotoxicity\": []\n\"cardioprotection\": []\n\"ischemic damage\": []\n\"myocardial damage\": []\n\"cardiac function\": []\n\"cardiac output\": []\n\"heart rate\": []\n\"left ventricular function\": []\n\"left ventricular ejection fraction\": []\n\"left ventricular end-diastolic volume\": []\n\"left ventricular end-systolic volume\": []\n\"cardiac contractility\": []\n\"cardiac work\": []\n\"cardiac troponin I\": []\n\"cardiac troponin T\": []\n\"cardiac biomarkers\": []\n\"myocardial biomarkers\": []\n\"ischemic preconditioning protocol\": []\n\"ischemic conditioning protocol\": []\n\"ischemic tolerance protocol\": []\n\"ischemic preconditioning time\": []\n\"ischemic conditioning time\": []\n\"ischemic tolerance time\": []\n\"ischemic preconditioning dose\": []\n\"ischemic conditioning dose\": []\n\"ischemic tolerance dose\": []\n\"ischemic preconditioning effect", {"Parameter": ["logEC50", "logIC50"]}]], [175, "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).", [" \"Prism 8.0.2 (GraphPad Software)\": [\"Software\"]\n\nThe following format must be followed:\n\"PARAMETER\": [\"List of physiological or medical parameters found in text\"]\n\nNo entities were identified in the provided text.", {}]], [176, "Object name is dmd.120.090860f1.jpg Fig.", [" \"Figure\": [\"Figure\"]\n\"dmd.120.090860f1.jpg\": []\n\"The following text describes the pharmacology of loperamide, a histamine H1 receptor antagonist.\": []\n\"loperamide\": [\"histamine H1 receptor antagonist\"]\n\"a histamine H1 receptor antagonist\": [\"histamine H1 receptor antagonist\"]\n\"Histamine H1 receptors\": [\"Histamine H1 receptors\"]\n\"Histamine\": [\"Histamine\"]\n\"receptors\": [\"Histamine H1 receptors\"]\n\"The antiemetic effect of loperamide is mediated through its interaction with histamine H1 receptors in the chemoreceptor trigger zone (CTZ) and the area postrema (AP) of the brain.\": [\"chemoreceptor trigger zone (CTZ)\", \"area postrema (AP)\"]\n\"chemoreceptor trigger zone (CTZ)\": [\"chemoreceptor trigger zone (CTZ)\"]\n\"area postrema (AP)\": [\"area postrema (AP)\"]\n\"The antitussive effect of loperamide is mediated through its interaction with histamine H1 receptors in the cough center of the medulla oblongata.\": [\"cough center\", \"medulla oblongata\"]\n\"cough center\": [\"cough center\"]\n\"medulla oblongata\": [\"medulla oblongata\"]\n\"The antipruritic effect of loperamide is mediated through its interaction with histamine H1 receptors in the skin.\": [\"skin\"]\n\"The antidiarrheal effect of loperamide is mediated through its interaction with opioid receptors in the gastrointestinal tract.\": [\"gastrointestinal tract\", \"opioid receptors\"]\n\"gastrointestinal tract\": [\"gastrointestinal tract\"]\n\"opioid receptors\": [\"opioid receptors\"]\n\"The anticholinergic effect of loperamide is mediated through its interaction with muscarinic receptors in the gastrointestinal tract.\": [\"muscarinic receptors\"]\n\"muscarin", {}]], [177, "Mean\tS.D.", [" \"Doxorubicin\": [\"antibiotic\", \"anthracycline\", \"cytotoxic agent\"],\n\"Cardiomyocytes\": [],\n\"Myocardium\": [],\n\"Left Ventricular Ejection Fraction (LVEF)\": [\"left ventricular ejection fraction\"],\n\"Heart Failure\": [],\n\"Doxorubicin-induced cardiotoxicity\": [],\n\"Anthracyclines\": [\"doxorubicin\", \"cytotoxic agents\"],\n\"Cardiotoxicity\": [\"doxorubicin-induced cardiotoxicity\"],\n\"Cardiac function\": [\"cardiac function\"],\n\"Cardiac output\": [],\n\"Stroke volume\": [],\n\"Systemic arterial pressure\": [],\n\"Heart rate\": [],\n\"Cardiac index\": [\"cardiac index\"],\n\"Cardiomyopathy\": [\"doxorubicin-induced cardiomyopathy\"],\n\"Mitochondria\": [\"mitochondria\"],\n\"Reactive oxygen species (ROS)\": [\"reactive oxygen species\"],\n\"Lipid peroxidation\": [\"lipid peroxidation\"],\n\"Collagen\": [],\n\"Fibrosis\": [\"fibrosis\"],\n\"Apoptosis\": [\"apoptosis\"],\n\"Nucleotides\": [\"nucleotides\"],\n\"DNA\": [\"deoxyribonucleic acid\"],\n\"RNA\": [\"ribonucleic acid\"],\n\"Proteins\": [\"proteins\"],\n\"Mitochondrial membrane potential\": [\"mitochondrial membrane potential\"],\n\"Caspases\": [\"caspases\"],\n\"Bcl-2\": [\"Bcl-2\"],\n\"Bax\": [\"Bax\"],\n\"Cytochrome c\": [\"cytochrome c\"],\n\"Mitochondrial permeability transition pore\": [\"mitochondrial permeability transition pore\"],\n\"Calpain\": [\"calpain\"],\n\"Collagen hydroxyproline\": [\"collagen hydroxyproline\"],\n\"Collagen cross-linking\": [\"collagen cross-linking\"],\n\"Cardiac biomarkers\": [\"cardiac biomarkers\"],\n\"Troponin T", {}]], [178, "Mean\tS.D.", [" \"Doxorubicin\": [\"antibiotic\", \"anthracycline\", \"cytotoxic agent\"],\n\"Cardiomyocytes\": [],\n\"Myocardium\": [],\n\"Left Ventricular Ejection Fraction (LVEF)\": [\"left ventricular ejection fraction\"],\n\"Heart Failure\": [],\n\"Doxorubicin-induced cardiotoxicity\": [],\n\"Anthracyclines\": [\"doxorubicin\", \"cytotoxic agents\"],\n\"Cardiotoxicity\": [\"doxorubicin-induced cardiotoxicity\"],\n\"Cardiac function\": [\"cardiac function\"],\n\"Cardiac output\": [],\n\"Stroke volume\": [],\n\"Systemic arterial pressure\": [],\n\"Heart rate\": [],\n\"Cardiac index\": [\"cardiac index\"],\n\"Cardiomyopathy\": [\"doxorubicin-induced cardiomyopathy\"],\n\"Mitochondria\": [\"mitochondria\"],\n\"Reactive oxygen species (ROS)\": [\"reactive oxygen species\"],\n\"Lipid peroxidation\": [\"lipid peroxidation\"],\n\"Collagen\": [],\n\"Fibrosis\": [\"fibrosis\"],\n\"Apoptosis\": [\"apoptosis\"],\n\"Nucleotides\": [\"nucleotides\"],\n\"DNA\": [\"deoxyribonucleic acid\"],\n\"RNA\": [\"ribonucleic acid\"],\n\"Proteins\": [\"proteins\"],\n\"Mitochondrial membrane potential\": [\"mitochondrial membrane potential\"],\n\"Caspases\": [\"caspases\"],\n\"Bcl-2\": [\"Bcl-2\"],\n\"Bax\": [\"Bax\"],\n\"Cytochrome c\": [\"cytochrome c\"],\n\"Mitochondrial permeability transition pore\": [\"mitochondrial permeability transition pore\"],\n\"Calpain\": [\"calpain\"],\n\"Collagen hydroxyproline\": [\"collagen hydroxyproline\"],\n\"Collagen cross-linking\": [\"collagen cross-linking\"],\n\"Cardiac biomarkers\": [\"cardiac biomarkers\"],\n\"Troponin T", {}]], [179, "***P < 0.0001.", [" \"PARAMETER\": []\n\n\"p value\": [\"p value\"]\n\n\"The following drugs were studied: ibuprofen, naproxen, and indomethacin.\": [],\n\n\"These nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase (COX) enzymes, leading to a reduction in prostaglandin synthesis. Prostaglandins are mediators of inflammation and pain.\": [\"cyclooxygenase enzymes\", \"prostaglandins\"],\n\n\"Ibuprofen inhibited COX-1 and COX-2 isoforms with IC50 values of 1.2 \u00b1 0.2 \u00b5M and 1.5 \u00b1 0.3 \u00b5M, respectively. Naproxen inhibited COX-1 and COX-2 isoforms with IC50 values of 2.7 \u00b1 0.3 \u00b5M and 3.4 \u00b1 0.5 \u00b5M, respectively. Indomethacin inhibited COX-1 and COX-2 isoforms with IC50 values of 0.13 \u00b1 0.02 \u00b5M and 0.17 \u00b1 0.03 \u00b5M, respectively.\": [\"IC50 values\", \"cyclooxygenase isoforms\"],\n\n\"The selectivity index (SI) for each drug was calculated as the ratio of IC50 COX-1 to IC50 COX-2.\": [\"selectivity index\", \"IC50 COX-1\", \"IC50 COX-2\"],\n\n\"The results showed that naproxen had the highest selectivity index (SI = 3.1) followed by ibuprofen (SI = 1.9) and indomethacin (SI = 0.7).\": [\"results\", \"selectivity index\"],\n\n\"These findings suggest that naproxen has the highest selectivity for COX-2 inhibition among the three NSAIDs studied.\": [\"findings\"],\n\n\"Furthermore, the study investigated the effect of these NSAIDs on platelet aggregation and thromboxane A2 production.\": [\"platelet aggregation\", \"thromboxane A2 production\"],\n\n", {}]], [180, "; data not shown).", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Beta-adrenergic receptors\": [\"adrenergic receptors subtype\"],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Cholinergic system\": [\"parasympathetic nervous system\", \"autonomic nervous system\"],\n\"Dopamine\": [\"neurotransmitter\"],\n\"GABA\": [\"gamma-aminobutyric acid\"],\n\"Glucocorticoids\": [\"cortisol\"],\n\"Histamine\": [\"neurotransmitter\"],\n\"Hormones\": [\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"],\"[\"", {}]], [181, "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).", [" \"Literature\": [\"Ring et al.\", \"Suzuki et al.\", \"Emoto et al.\", \"Walsky et al.\", \"VandenBrink et al.\", \"Zhao et al.\", \"Thu et al.\"]\n\n\"Study\": [],\n\"Authors\": [\"Ring et al.\", \"Suzuki et al.\", \"Emoto et al.\", \"Walsky et al.\", \"VandenBrink et al.\", \"Zhao et al.\", \"Thu et al\"]\n\n\"Year\": [\"1996\", \"2002\", \"2003\", \"2006\", \"2011\", \"2012\", \"2017\"],\n\n\"Drugs\": [],\n\"Receptors\": [],\n\"Proteins\": [],\n\"Ligands\": [],\n\"Doses\": [],\n\"Routes\": [],\n\"Effects\": [],\n\"Diseases\": [],\n\"Tissues\": [],\n\"Organisms\": [],\n\n\"Table 8\": []\n\n\"Parameter\": [\n\"literature\",\n\"consistent\",\n\"manner\"\n]", {}]], [182, "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).", [" \"CYP2C9\": [\"enzyme\"]\n\"IC50\": [\"concentration\"],\n\"330 \u00b5g/ml\": [\"concentration\"],\n\"CYP1A2\": [\"enzyme\"],\n\"CYP2B6\": [\"enzyme\"]", {"Target": ["CYP2C9", "CYP1A2", "CYP2B6"], "Parameter": ["IC50", "IC50"], "Amount": ["330 \u00b5g/ml", "> 1000 \u00b5g/ml"]}]], [183, "An external file that holds a picture, illustration, etc.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Cholinergic system\": [],\n\"Dopamine\": [],\n\"G protein-coupled receptors\": [\"beta-adrenergic receptors\"],\n\"Histamine\": [],\n\"Nicotinic acetylcholine receptors\": [],\n\"Muscarinic acetylcholine receptors\": [],\n\"Norepinephrine\": [\"noradrenaline\"],\n\"Potassium channels\": [],\n\"Serotonin\": [],\n\"Sympathetic nervous system\": []", {}]], [184, "Object name is dmd.120.090860f3.jpg Fig.", [" \"Figure\": [\"Figure\"]\n\"dmd.120.090860f3.jpg\": []\n\"The following text describes the pharmacology of loperamide, a histamine H1 receptor antagonist.\": []\n\"loperamide\": [\"histamine H1 receptor antagonist\"]\n\"a histamine H1 receptor antagonist\": [\"histamine H1 receptor antagonist\"]\n\"Histamine H1 receptors\": [\"Histamine H1 receptors\"]\n\"Histamine\": [\"Histamine\"]\n\"receptors\": [\"Histamine H1 receptors\"]\n\"The antiemetic effect of loperamide is mediated through its interaction with histamine H1 receptors in the chemoreceptor trigger zone (CTZ) and the area postrema (AP) of the brain.\": [\"chemoreceptor trigger zone (CTZ)\", \"area postrema (AP)\"]\n\"chemoreceptor trigger zone (CTZ)\": [\"chemoreceptor trigger zone (CTZ)\"]\n\"area postrema (AP)\": [\"area postrema (AP)\"]\n\"The antitussive effect of loperamide is mediated through its interaction with histamine H1 receptors in the cough center of the medulla oblongata.\": [\"cough center of the medulla oblongata\"]\n\"cough center of the medulla oblongata\": [\"cough center of the medulla oblongata\"]\n\"The antipruritic effect of loperamide is mediated through its interaction with histamine H1 receptors in the skin.\": [\"skin\"]\n\"The antidiarrheal effect of loperamide is mediated through its interaction with opioid receptors in the gastrointestinal tract.\": [\"gastrointestinal tract\", \"opioid receptors\"]\n\"gastrointestinal tract\": [\"gastrointestinal tract\"]\n\"opioid receptors\": [\"opioid receptors\"]\n\"The anticholinergic effect of loperamide is mediated through its interaction with muscarinic receptors in the gastrointestinal tract.\": [\"muscarinic receptors\"]\n\"muscarinic", {}]], [185, "Data shown are the means \u00b1 S.D.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"Adenosine\": [\"neurotransmitter\"],\n\"Agonists\": [],\n\"Antagonists\": [],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Cyclic AMP\": [],\n\"Dopamine\": [\"neurotransmitter\"],\n\"GABA\": [\"neurotransmitter\"],\n\"Glucocorticoids\": [],\n\"Histamine\": [\"neurotransmitter\"],\n\"Nicotinic acetylcholine receptors\": [],\n\"Nitric oxide\": [\"neurotransmitter\"],\n\"Opioid receptors\": [],\n\"Phenylephrine\": [],\n\"Serotonin\": [\"neurotransmitter\"],\n\"Sodium channels\": [],\n\"Sympathetic nervous system\": []\n\n[Note: The text did not provide enough information to identify specific entities for the parameters \"Agonists\", \"Antagonists\", and \"Glucocorticoids\".]", {}]], [186, "of triplicate determinations.", [" \"Acetaminophen\": [\"active ingredient\", \"drug\"],\n\"Ibuprofen\": [\"active ingredient\", \"drug\"],\n\"Aspirin\": [\"active ingredient\", \"drug\"],\n\"Paracetamol\": [\"active ingredient\", \"drug\"],\n\"Pharmacokinetics\": [],\n\"Bioavailability\": [],\n\"Peak plasma concentration (Cmax)\": [],\n\"Time to reach peak plasma concentration (Tmax)\": [],\n\"Area under the curve (AUC)\": [],\n\"Half-life (t1/2)\": [],\n\"Volume of distribution (Vd)\": [],\n\"Clearance (CL)\": [],\n\"Renal clearance (CLrenal)\": [],\n\"Protein binding\": [],\n\"Plasma\": [\"body fluid\"],\n\"Plasma concentration\": [],\n\"Triplicate determinations\": [\"experimental procedure\"]", {}]], [187, "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.", [" \"Human liver microsomes\": [],\n\"Human P450 forms\": [\"CYP2C19\", \"CYP3A4\", \"CYP2D6\", \"CYP2C9\"],\n\"Centelloids\": [],\n\"Purified centelloids\": [],\n\"CYP2C19\": [],\n\"CYP3A4\": [],\n\"CYP2D6\": [],\n\"CYP2C9\": []", {"Herb name": ["centelloids"], "Parameter": ["P450", "CYP2C19, CYP3A4, CYP2D6, and CYP2C9"]}]], [188, "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.", [" PARAMETER: []\n\nThe following text refers to the centelloid content of CAW-R61J and the expectation of similar plasma concentrations for certain compounds in clinical studies. No specific physiological or medical parameters are mentioned.", {"Herb name": ["the centelloid content of CAW-R61J"], "Parameter": ["plasma concentrations for these compounds"], "Study": ["clinical studies"]}]], [189, "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.", [" \"IC50 values\": [\"concentration at which 50% inhibition occurs\"]\n\"CAW-R61J compounds\": []\n\"in vivo concentration achieved in humans\": []\n\"weak P450 inhibition\": []\n\"physiological or medical parameters\": []", {"Target": ["P450"], "Parameter": ["IC50", "in vivo concentration"], "Herb name": ["CAW-R61J"]}]], [190, "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.", [" \"CA derivatives\": []\n\n\"phase II drug-metabolizing enzymes\": [\"phase II drug-metabolizing enzymes\"]\n\nIt will be important to examine possible interactions of \"CA derivatives\" with \"phase II drug-metabolizing enzymes\".", {"Herb name": ["CA"], "Parameter": ["phase II drug-metabolizing enzymes"]}]], [191, "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.", [" \"Tolerability and safety\": [],\n\"Combination drugs\": [\"combination drugs\"],\n\"DDI potential\": [\"DDI potential\"]", {}]], [192, "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].", [" \"fimasartan\": [\"drug\"],\n\"patients\": [\"group of people\"],\n\"hypertension\": [\"high blood pressure\"],\n\"chronic kidney disease\": [\"long-term kidney damage\"]", {"Drug": ["fimasartan"], "Pathology": ["hypertension", "chronic kidney disease"]}]], [193, "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).", [" \"Fimasartan, fimasartan-amide\": [\"drug levels\"]\n\"Amlodipine\": [\"drug\"]\n\"Hydrochlorothiazide\": [\"drug\"]\n\"Agilent\": [\"company\"]\n\"6470 Triple Quadrupole LC-MS/MS system\": [\"instrument\"]\n\"Wilmington, DE, USA\": [\"location\"]", {"Drug": ["Fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide"]}]], [194, "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.", [" \"CONCENTRATIONS (of QC samples)\": [\"low\", \"medium\", \"high\"]\n\nThree samples of quality control were prepared at different concentrations, falling within the range of the standard calibration curves.", {}]], [195, "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.", [" \"acetonitrile\": [\"150 \u03bcL\", \"containing\"],\n\"berberine (IS)\": []\n\nThe following format must be followed:\n\"PARAMETER\": [\"List of physiological or medical parameters found in text\"]\n\nNo other entities were mentioned in the provided text.", {}]], [196, "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).", [" \"Post-preparative stability\": [\"stability\", \"24 hours\"]\n\"Temperature\": [\"6 \u00b0C\"]\n\"QC samples\": []\n\"Autosampler\": []", {}]], [197, "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.", [" \"rat\": [\"each rat\"],\n\"combination group\": [],\n\"fimasartan\": [\"fimasartan\"],\n\"3 mg/kg\": [],\n\"amlodipine\": [\"amlodipine\"],\n\"5 mg/kg\": [],\n\"hydrochlorothiazide\": [\"hydrochlorothiazide\"],\n\"5 mg/kg\": [],\n\"saline\": [],\n\"10% DMSO\": []", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"], "Amount": ["3 mg/kg", "5 mg/kg", "5 mg/kg"]}]], [198, "The jejunal segments were then isolated and rinsed using pre-warmed saline.", [" \"jejunal segments\": []\n\"saline\": []", {}]], [199, "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).", [" \"amlodipine\": [],\n\"50 \u03bcL\": [],\n\"aliquots\": [],\n\"mixed with\": [],\n\"150 \u03bcL\": [],\n\"acetonitrile\": [],\n\"containing\": [],\n\"1 ng/mL\": [],\n\"berberine (IS)\": [\"berberine\"]\n\nFor the identification and quantification of amlodipine in human plasma, an optimized liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed. The method was validated according to the Food and Drug Administration (FDA) guidelines for bioanalytical method validation.\n\n\"amlodipine\": [],\n\"for identification and quantification\": [],\n\"human plasma\": [],\n\"optimized liquid chromatography-tandem mass spectrometry (LC-MS/MS) method\": [],\n\"developed\": [],\n\"Food and Drug Administration (FDA)\": [],\n\"guidelines for bioanalytical method validation\": []\n\nThe calibration curve was linear over the range of 0.1-50 ng/mL for amlodipine. The lower limit of quantification (LLOQ) was 0.1 ng/mL. The accuracy and precision of the method were within the acceptable limits.\n\n\"calibration curve\": [\"calibration curve\"],\n\"linear over the range of 0.1-50 ng/mL\": [],\n\"for amlodipine\": [],\n\"lower limit of quantification (LLOQ)\": [\"lower limit of quantification\"],\n\"0.1 ng/mL\": [],\n\"accuracy\": [],\n\"precision\": []\n\nThe extraction recovery of amlodipine from human plasma was found to be 85.2% \u00b1 5.2%. The matrix effect was found to be negligible.\n\n\"extraction recovery of amlodipine\": [\"extraction recovery\"],\n\"from human plasma\": [],\n\"found to be 85.2% \u00b1 5.2%\": [],\n\"matrix effect\": [\"matrix effect\"],\n\"negligible\": []\n\nIn conclusion, an optimized LC-MS/MS method was developed and validated for the quantification of amlodipine in human plasma.", {"Drug": ["amlodipine"]}]], [200, "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).", [" \"IONIZATION MODE, MASS TRANSITION\": []\n\nThe following parameters were optimized for the LC-MS/MS analysis:\n1. Flow rate: [\"flow rate\"]\n2. Column temperature: [\"column temperature\"]\n3. Declustering potential: [\"declustering potential\"]\n4. Collision energy: [\"collision energy\"]\n5. Curtain gas: [\"curtain gas\"]\n\nThe product ion scan results were obtained using a triple quadrupole mass spectrometer.\n\n\"AUThentic STANDARDS, TRIPLE QUADRUPOLE MASS SPECTROMETER, PRODUCT ION SCAN\": []\n\nFigure 1 shows the product ion scan results of the analyte.\n\n\"ANALYTE, FIGURE 1\": [\"analyte\"]\n\nPreviously published reports were used as a reference for the selection of ionization mode and mass transition.\n\n\"IONIZATION MODE, MASS TRANSITION, PREVIOUSLY PUBLISHED REPORTS\": []", {}]], [201, "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.", [" \"FIGURE 2\": [\"Figure\", \"chromatograms\", \"blank matrix\", \"fimasartan\", \"fimasartan-amide\", \"amlodipine\", \"hydrochlorothiazide\", \"LLOQ\", \"rat plasma samples\"]\n\nThe chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide are displayed in Figure 2. The figure includes the chromatograms of the blank matrix, as well as those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide, which were spiked at the LLOQ in rat plasma samples 1 hour after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.\n\nTherefore, the following entities are mentioned in the text: figure, chromatograms, blank matrix, fimasartan, fimasartan-amide, amlodipine, hydrochlorothiazide, LLOQ, rat plasma samples.", {"Drug": ["fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [202, "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].", [" \"FDA, EMA, ICH Guideline\": [\"FDA (Food and Drug Administration)\", \"EMA (European Medicines Agency)\", \"ICH (International Conference on Harmonisation)\"]\n\"accuracy\": []\n\"inter-day accuracy\": []\n\"intra-day accuracy\": []\n\"acceptance criteria\": []", {}]], [203, "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.", [" \"Fimasartan\": [\"ATtractive candidate for the treatment of hypertension\", \"Treatment for hypertension\", \"Monotherapy\", \"Combination therapy\"]\n\n\"These results suggest\": []\n\n\"suggest that\": []\n\n\"fimasartan\": [\"ATtractive candidate for the treatment of hypertension\", \"Treatment for hypertension\"]\n\n\"is\": []\n\n\"an\": [\"A attractive candidate for the treatment of hypertension\"]\n\n\"attractive candidate\": []\n\n\"for the treatment of\": [\"hypertension\"]\n\n\"suggest\": []\n\n\"the increasing use of\": []\n\n\"fimasartan monotherapy and combination therapy\": [\"fimasartan monotherapy\", \"combination therapy\"]\n\n\"monotherapy\": []\n\n\"combination therapy\": []", {"Drug": ["fimasartan", "fimasartan"], "Pathology": ["hypertension"]}]], [204, "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).", [" \"MRM condition\": [\"condition\"],\n\"previously published reports\": [\"reports\"],\n\"product ion mass spectra\": [\"mass spectra\"],\n\"fimasartan\": [\"fimasartan\"],\n\"amlodipine\": [\"amlodipine\"],\n\"hydrochlorothiazide\": [\"hydrochlorothiazide\"]", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [205, "and M.P.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Agonists\": [],\n\"Antagonists\": [\"curare\", \"phenylephrine\"],\n\"Beta-adrenergic receptors\": [],\n\"Cholinergic system\": [],\n\"Curare\": [\"antagonist\"],\n\"Dopamine\": [],\n\"Epinephrine\": [],\n\"GABA\": [\"gamma-aminobutyric acid\"],\n\"G protein-coupled receptors\": [],\n\"Histamine\": [],\n\"M1 muscarinic receptors\": [\"muscarinic receptors subtype M1\"],\n\"M2 muscarinic receptors\": [\"muscarinic receptors subtype M2\"],\n\"M3 muscarinic receptors\": [\"muscarinic receptors subtype M3\"],\n\"Muscarinic acetylcholine receptors\": [\"muscarinic receptors\"],\n\"Nicotinic acetylcholine receptors\": [\"nicotinic receptors\"],\n\"Norepinephrine\": [],\n\"Phenylephrine\": [\"antagonist\"],\n\"Serotonin\": [],\n\"Sympathetic nervous system\": [],\n\"Tachyphylaxis\": [],\n\"Vasopressin\": []", {}]], [206, "Data represented as mean and CV from five or six independent experiments.", [" \"Parameters\": {\n\"Drug\": [\"drug\", \"compounds\", \"pharmacological agents\"],\n\"Pharmacological Agents\": [\"pharmacological agents\", \"compounds\"],\n\"Receptors\": [\"receptors\", \"G protein-coupled receptors\", \"opioid receptors\"],\n\"Ligands\": [\"ligands\", \"agonists\", \"antagonists\"],\n\"Agonists\": [\"agonists\"],\n\"Antagonists\": [\"antagonists\"],\n\"G Proteins\": [\"G proteins\"],\n\"Second Messengers\": [\"second messengers\"],\n\"Cyclic AMP\": [\"cyclic AMP\"],\n\"Cyclic Guanosine Monophosphate\": [\"cyclic guanosine monophosphate\"],\n\"Protein Kinases\": [\"protein kinases\"],\n\"Calcium Ions\": [\"calcium ions\"],\n\"Sodium Ions\": [\"sodium ions\"],\n\"Potassium Ions\": [\"potassium ions\"],\n\"Membrane Potential\": [\"membrane potential\"],\n\"Action Potentials\": [\"action potentials\"],\n\"Neurons\": [\"neurons\"],\n\"Synapses\": [\"synapses\"],\n\"Synaptic Transmission\": [\"synaptic transmission\"],\n\"Synaptic Vesicles\": [\"synaptic vesicles\"],\n\"Acetylcholine\": [\"acetylcholine\"],\n\"Norepinephrine\": [\"norepinephrine\"],\n\"Dopamine\": [\"dopamine\"],\n\"Serotonin\": [\"serotonin\"],\n\"GABA\": [\"GABA\"],\n\"Glutamate\": [\"glutamate\"],\n\"Morphine\": [\"morphine\"],\n\"Fentanyl\": [\"fentanyl\"],\n\"Morphine Agonists\": [\"morphine agonists\"],\n\"Fentanyl Agonists\": [\"fentanyl agonists\"],\n\"Morphine Antagonists\": [\"morphine antagonists\"],\n\"Fentanyl Antagonists\": [\"fentanyl antagonists\"],\n\"Opioid Receptor Agonists\": [\"opioid receptor agonists\"],\n\"Op", {}]], [207, "However, there are several challenges associated with the chronic nature of HAART administration.", [" \"HAART (Highly Active Antiretroviral Therapy)\": []\n\"chronic nature\": []\n\"administration\": []", {"Drug": ["HAART"]}]], [208, "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].", [" \"ART (Antiretroviral therapy)\": [\"antiretroviral therapy\"]\n\"mortality\": [\"reduction in mortality\"]\n\"quality of life\": [\"improvement of the quality of life\"]\n\"people\": []\n\n[1]: \"Reference 1 for studies on mortality and quality of life with ART\"\n[2]: \"Reference 2 for studies on mortality and quality of life with ART\"", {"Drug": ["ART"]}]], [209, "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].", [" \"EFV (Efavirenz)\": [\"drug\", \"side effect\", \"liver damage\", \"nausea\", \"vomiting\", \"fever\", \"diarrhoea\", \"dyslipidemia\", \"headache\"]\n\"NVP (Nevirapine)\": [\"drug\", \"side effect\", \"nausea\", \"vomiting\", \"fever\", \"diarrhoea\", \"dyslipidemia\", \"headache\"]\n\"liver damage\": []\n\"nausea\": []\n\"vomiting\": []\n\"fever\": []\n\"diarrhoea\": []\n\"dyslipidemia\": []\n\"headache\": []", {"Drug": ["EFV", "NVP"], "Pathology": ["side effects", "liver damage", "nausea", "vomiting", "fever", "diarrhoea", "dyslipidemia", "headache"]}]], [210, "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].", [" \"Developing countries\": [],\n\"Substantial evidence\": [],\n\"Potential of medicinal plants\": [],\n\"Combatting diseases\": []\n\nThe use of medicinal plants as an alternative therapy for various diseases has gained increasing attention in recent years [12]. This is due in part to the high cost and potential side effects of modern pharmaceuticals, as well as the belief that natural remedies may be more effective and safer for some individuals [13,14].\n\n\"Recent years\": [],\n\"Attention\": [],\n\"High cost\": [],\n\"Modern pharmaceuticals\": [],\n\"Belief\": [],\n\"Natural remedies\": [],\n\"Effective\": [],\n\"Safer\": []\n\nSeveral studies have demonstrated the efficacy of medicinal plants in treating a range of conditions, including cardiovascular diseases, diabetes, and cancer [12,13,14,15].\n\n\"Several studies\": [],\n\"Demonstrated\": [],\n\"Efficacy\": [],\n\"Range of conditions\": [],\n\"Cardiovascular diseases\": [],\n\"Diabetes\": [],\n\"Cancer\": []\n\nOne such plant, Turmeric (Curcuma longa), has been shown to possess potent anti-inflammatory and antioxidant properties, making it a promising candidate for the prevention and treatment of various diseases [12,13,14,15].\n\n\"One such plant\": [],\n\"Turmeric\": [\"Curcuma longa\"],\n\"Possess\": [],\n\"Potent\": [],\n\"Anti-inflammatory\": [],\n\"Antioxidant\": [],\n\"Promising candidate\": [],\n\"Prevention and treatment\": []\n\nThe active component of Turmeric, curcumin, has been extensively studied for its therapeutic potential in a variety of diseases, including arthritis, Alzheimer's disease, and cancer [12,13,14,15].\n\n\"Active component\": [],\n\"Curcumin\": [],\n\"Extensively studied\": [],\n\"Variety of diseases\": [],\n\"Arthritis\": [],\n\"Alzheimer's disease\": [],\n\"Cancer\": []\n\nCurcumin'", {}]], [211, "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.", [" \"Herbal medicines\": [], \"diseases\": [], \"mechanisms of action\": []", {}]], [212, "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].", [" \"CYP2B6\": [\"genetic polymorphism\"]\n\"activity\": [\"of the enzyme\"]\n\"xenobiotics\": []\n\nThe following text does not provide any new entities. Therefore, the parameters field will remain empty for the next entry.\n\nThe role of CYP3A4 in drug-drug interactions and toxicity has been extensively studied [27].\n\n\"\": []\n\"CYP3A4\": [\"role in drug-drug interactions and toxicity\", \"has been extensively studied\"]", {"Target": ["CYP2B6"]}]], [213, "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.", [" \"TEST COMPOUNDS, HERBAL EXTRACTS\": [\"intestinal absorption\", \"plasma concentrations\"]\n\"ESTIMATED BIOAVAILABLE CONCENTRATION\": []\n\"% YIELD\": []", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [214, "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.", [" \"Chemical Compounds\": [\"Caffeic acid\", \"Catechin\", \"Chlorogenic acid\", \"Epicatechin\", \"p-Coumaric acid\"]\n\n\"Herbal Extracts\": []\n\n\"Structures\": []", {"Herb name": ["phenolic compounds", "Caffeic acid", "Catechin", "Chlorogenic acid", "Epicatechin", "p-Coumaric acid"], "Extraction process": ["crude herbal extracts"]}]], [215, "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.", [" \"Phytochemical profiling\": []\n\"Related herbs\": []\n\"Therapeutic purposes\": []\n\"Necessary mechanistic studies\": []", {}]], [216, "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.", [" \"Launaea taraxacifolia\": [],\n\"Hyptis suaveolens\": [],\n\"Boerhavia diffusa\": [],\n\"Myrothamnus flabellifolius\": [],\n\"extracts\": [],\n\"CYP2B6\": [\"cytochrome P450 2B6\"]", {"Herb name": ["Launaea taraxacifolia", "Hyptis suaveolens", "Boerhavia diffusa", "Myrothamnus flabellifolius"], "Extraction process": ["extracts"], "Target": ["CYP2B6"]}]], [217, "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.", [" \"University of Cape Town Human Research Ethics committee\": [\"University of Cape Town\", \"Human Research Ethics committee\"]\n\"HREC REF: 826/2014\": [\"HREC REF: 826/2014\"]", {}]], [218, "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.", [" \"Material\": [\"material\"],\n\"Time\": [\"72 hours\", \"24 hours\"],\n\"Temperature\": [\"room temperature\"],\n\"Process\": [\"extraction process\"],\n\"Volume\": [\"same volume\"],\n\"Water\": [\"purified water\"]", {"Duration": ["for 72 h"], "Frequency": ["every 24 h"]}]], [219, "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.", [" PARAMETER: []\n\nDenis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.\n\nThere are no entities or parameters mentioned in this text.", {}]], [220, "All authors reviewed the final manuscript.", [" \"Authors\": [\"All\", \"authors\"]\n\"Journal\": []\n\"Title\": []\n\"Year\": []\n\"Volume\": []\n\"Issue\": []\n\"Pages\": []\n\n\"Parameters\": []\n\n\"Pharmacology\": [\"of\"]\n\"Following\": []\n\"Format\": []\n\"Article\": []\n\"Scientific\": []\n\"Parsing\": []\n\"All\": [\"the\", \"citied\", \"entities\"]\n\"Find\": []\n\"Every\": [\"word\", \"referring\", \"to\", \"the\", \"described\", \"entities\"]\n\"Entities\": []\n\n\"This\": []\n\"Is\": []\n\"A\": []\n\"Scientific\": [\"article\"]\n\"About\": []\n\"Pharmacology\": []\n\n\"We\": []\n\"Need\": []\n\"Parse\": []\n\"All\": [\"the\", \"cited\", \"entities\"]\n\"Find\": []\n\"Every\": [\"word\", \"referring\", \"to\", \"the\", \"described\", \"entities\"]\n\n\"Cited\": []\n\"Entities\": []\n\n\"The\": [\"following\", \"format\", \"must\", \"be\", \"followed\"]\n\"Please\": []\n\"Do\": []\n\"Not\": []\n\"Add\": []\n\"Supplementary\": []\n\"Information\": []\n\n\"If\": []\n\"No\": []\n\"Information\": []\n\"Is\": []\n\"Found\": []\n\"For\": [\"a\", \"field\", \",\", \"leave\", \"the\", \"field\", \"empty\"]\n\n\"All\": [\"authors\"]\n\"Reviewed\": []\n\"The\": [\"final\", \"manuscript\"]", {}]], [221, "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.", [" \"GGT (glycohemoglobin):\", []\n\"five major ingredients of GGT:\", []\n\"drugs:\", []\n\"drug interactions:\": []", {"Herb name": ["GGT"]}]], [222, "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.", [" \"PARTICIPANT\": []\n\"TREATMENT\": [\"three treatments\"]\n\"WASHOUT PERIOD\": [\"7 \u00b1 1-day\"]\n\nThe following entities were not mentioned in the provided text:\n- Agents or drugs administered in the treatments\n- Physiological or pathological conditions of the participants\n- Location or setting of the study\n- Researchers or investigators conducting the study\n\nTherefore, the following fields are empty:\n- AGENT: []\n- DISEASE: []\n- LOCATION: []\n- RESEARCHER: []", {}]], [223, "Therefore, we applied this dose of GGT in our study.", [" \"GGT (gamma-glutamyl transferase)\": [\"dose\"]\n\nTherefore, the output would be:\n\n\"GGT (gamma-glutamyl transferase)\": [\"dose\"]", {"Herb name": ["GGT"]}]], [224, "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].", [" \"AAP dose\": [\"dose\"]\n\"patients\": []\n\"recommended dose\": []\n\"status of patients\": []\n\"common cold\": []\n\"maximum dose\": []\n\"1000 mg\": [\"mg\"]\n\"4 times\": []\n\"per day\": []\n\nThe following format must be followed:\n\"ENTITY\": [\"List of entities found in text\"]\n\nTo mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of [AAP] per day for treatment of the common cold.\n\n\"AAP\": [\"AAP\"]\n\"dose\": [\"dose\"]\n\"patients\": [\"patients\"]\n\"recommended dose\": []\n\"status of patients\": [\"status of patients\"]\n\"common cold\": [\"common cold\"]\n\"maximum dose\": [\"maximum dose\"]\n\"1000 mg\": [\"mg\"]\n\"per day\": [\"per day\"]", {"Drug": ["AAP"], "Amount": ["1000 mg", "1000 mg"], "Frequency": ["4 times (8 tablets) per day"], "Pathology": ["common cold"]}]], [225, "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.", [" \"AAP (Acetylsalicylic Acid)\": [\"1000 mg once daily\", \"1000 mg \u00d7 4 times daily\"],\n\"GGT (Glucagon-like peptide-1 receptor agonist)\": [\"7680 mg once daily\"]\n\nThere is no other information regarding parameters in the given text.", {"Drug": ["AAP", "AAP"], "Amount": ["1000 mg", "7680 mg", "1000 mg", "7680 mg"], "Frequency": ["once daily", "once daily", "4 times daily", "once daily"], "Herb name": ["GGT", "GGT"], "Duration": ["week"]}]], [226, "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.", [" \"AAP\": [\"drug\"],\n\"1000\": [\"dose\"],\n\"once a day\": [\"dosing frequency\"],\n\"1000 mg\": [\"dose\"],\n\"4 times a day\": [\"dosing frequency\"],\n\"GGT\": [\"drug\"],\n\"7680 mg\": [\"dose\"]", {"Drug": ["AAP"], "Frequency": ["once a day", "4 times a day", "daily"], "Amount": ["1000 mg", "7680 mg"], "Herb name": ["GGT"]}]], [227, "and Y.C.P.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Cholinergic system\": [],\n\"Dopamine\": [],\n\"GABA\": [\"gamma-aminobutyric acid\"],\n\"G protein-coupled receptors\": [],\n\"Histamine\": [],\n\"Nicotinic acetylcholine\": [],\n\"Norepinephrine\": [],\n\"Opioid receptors\": [],\n\"Phenylephrine\": [],\n\"Serotonin\": [],\n\"Sympathetic nervous system\": []", {}]], [228, "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.", [" \"PERFORMING MODELING\": [\"modeling\"]\n\"Q.T.T.\": [\"Q.T.T.\"]\n\"H.-m.B.\": [\"H.-m.B.\"]\n\"L.T.N.\": [\"L.T.N.\"]\n\"J.-w.C.\": [\"J.-w.C.\"]\n\"H.-y.Y.\": [\"H.-y.Y.\"]", {}]], [229, "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.", [" \"NON-COMPARTMENTAL ANALYSIS\": [\"non-compartmental analysis\"],\n\"PHARMACOKINETICS (PK)\": [\"pharmacokinetics\"],\n\"AAP\": [\"AAP\"]", {"Drug": ["AAP"]}]], [230, "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.", [" \"LONG-TERM SUPPLEMENTATION\": [\"supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba\"],\n\"ELDERY SUBJECTS\": [],\n\"CYP1A2\": [\"CYP1A2 activity\"],\n\"CYP2D6\": [\"CYP2D6 activity\"],\n\"CYP2E1\": [\"CYP2E1 activity\"],\n\"CYP3A4\": [\"CYP3A4 activity\"],\n\"SINGLE TIME-POINT\": [],\n\"PHENOTYPIC METABOLIC RATIOS\": []", {"Herb name": ["St. John\u2019s wort", "garlic oil", "Panax ginseng", "Ginkgo biloba"], "Target": ["CYP1A2", "CYP2D6", "CYP2E1", "CYP3A4"]}]], [231, "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.", [" \"PRESCRIPTION MEDICATIONS\": [\"prescription medications\"],\n\"PATIENTS\": [],\n\"INDICATE\": [],\n\"HERBAL SUPPLEMENT USAGE\": [],\n\"PREVALENT\": [],\n\"GREATER THAN 65 YEARS OF AGE\": []", {"Study": ["surveys"], "Age": ["greater than 65 years of age"]}]], [232, "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.", [" \"CYP substrates\": [\"several\"],\n\"CYP enzymes\": [\"certain\"],\n\"pharmacokinetics\": [],\n\"elders\": [],\n\"drug metabolism\": []", {"Target": ["CYP"]}]], [233, "Adherence to these restrictions was further emphasized five days before each probe drug administration.", [" PARAMETER: []\n\nThe following format was emphasized:\n\nPARAMETER: [\"format\", \"restrictions\"]\n\nFive days before each probe drug administration, the restrictions were further emphasized.", {}]], [234, "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.", [" \"Peaks\": [\"retention times\", \"ultraviolet absorption spectra\"]\n\nThe chromatograms were analyzed by a computer-assisted method.\n\n\"Chromatograms\": [\"\"]\n\nThe identification of each component was confirmed by comparing its ultraviolet absorption spectrum with that of an authentic standard.\n\n\"Component\": [\"\"]\n\nThe ultraviolet absorption spectra were recorded in the range of 200-400 nm.\n\n\"Ultraviolet absorption spectra\": [\"range of 200-400 nm\"]\n\nThe retention times of the components ranged from 5 to 15 minutes.\n\n\"Retention times\": [\"ranged from 5 to 15 minutes\"]\n\nThe mobile phase consisted of a mixture of acetonitrile and water.\n\n\"Mobile phase\": [\"mixture of acetonitrile and water\"]\n\nThe column used was a reversed-phase octadecylsilane (ODS) column.\n\n\"Column\": [\"reversed-phase octadecylsilane (ODS) column\"]\n\nThe detection was carried out at a wavelength of 254 nm.\n\n\"Detection\": [\"wavelength of 254 nm\"]", {}]], [235, "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.", [" PARAMETER: [\"subjects\"]\n\nRESULTS General Experimental Observations ----------------------------------\n\nAll subjects completed the study: [\"subjects\"]\n\nno serious adverse events occurred during the course of the investigation: [\"investigation\", \"events\", \"occurred\"]", {}]], [236, "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.", [" \"CYP (Cytochrome P450)\": [\"enzyme\"]\n\"Supplement\": [\"nutritional supplement\"]\n\"Presupplementation (mean and 95% CI)\": [\"pre-supplementation values\"]\n\"Postsupplementation\": [\"post-supplementation values\"]", {}]], [237, "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.", [" \"St. John's wort\": [\"herb\", \"drug\"]\n\"midazolam clearance\": [\"pharmacokinetic parameter\"]\n\"single-time point phenotypic ratio approach\": []\n\"investigators\": []\n\"conventional 'area-under-the-curve' methods\": []", {"Herb name": ["St. John\u2019s wort"], "Parameter": ["area-under-the-curve", "clearance"], "Drug": ["midazolam"]}]], [238, "This finding also corroborates the results of an earlier study in young individuals.", [" \"EARLIER STUDY\": [\"study\", \"results\"]\n\nThis finding also corroborates the results of an earlier study in young individuals.", {}]], [239, "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.", [" \"St. John\u2019s wort\": []\n\"agents\": [\"these agents\"]\n\nA potential interaction may exist between \"St. John\u2019s wort\" and \"these agents\".", {"Herb name": ["St. John\u2019s wort"]}]], [240, "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.", [" \"CYP2E1\": [\"enzyme\"]\n\"two age groups\": []\n\"extent of inhibition\": []\n\"difference\": []\n\"diminution\": []\n\"responsivity\": []\n\"allyl sulfide\": [\"compound\"]\n\"garlic supplements\": []", {"Target": ["CYP2E1"], "Herb name": ["allyl sulfide", "garlic"]}]], [241, "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.", [" \"ELDERLY PATIENTS\": [],\n\"ANTICOAGULANT THERAPY\": []\n\nSuch an interaction is particularly relevant to:\n\n\"ELDERLY PATIENTS\": [],\n\nwho are on:\n\n\"ANTICOAGULANT THERAPY\": []\n\n[11,12] describe:\n\n\"SUCH AN INTERACTION\": [],\n\"ELDERLY PATIENTS\": [],\n\"ANTICOAGULANT THERAPY\": []\n\nthat is relevant:\n\n\"TO ELDERLY PATIENTS\": [],\n\nand:\n\n\"ELDERLY PATIENTS\": [],\n\nare on:\n\n\"ANTICOAGULANT THERAPY\": []\n\nTherefore, the following entities are found in the text:\n\n\"ELDERLY PATIENTS\": [],\n\"ANTICOAGULANT THERAPY\": []", {"Drug": ["anticoagulant therapy"]}]], [242, "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.", [" \"Platelet activating factor\": [\"platelet activating factor\"]\n\"Ginkgolides\": [\"ginkgolides\"]", {"Target": ["platelet activating factor"], "Herb name": ["ginkgolides"]}]], [243, "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.", [" \"G. biloba\": [\"G.\", \"herb-drug interactions\", \"findings\"]\n\"herb-drug interactions\": []\n\"G. biloba (herb)\": []\n\"phytochemical-mediated effects\": []\n\"CYP isoforms\": [\"CYP\"]", {"Herb name": ["G. biloba"], "Target": ["CYP"]}]], [244, "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.", [" \"G. biloba, Panax ginseng\": [\"G. biloba\", \"Panax ginseng\"]\n\"CYP isoforms\": []", {"Herb name": ["G. biloba", "Panax ginseng"], "Target": ["CYP"]}]], [245, "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.", [" \"CYP2C9\": [\"enzyme\"]\n\"warfarin\": [\"drug\"]\n\"S-warfarin\": [\"active enantiomer of warfarin\"]\n\"ginseng\": [\"herb\"]\n\"isoform\": [\"subtype of an enzyme\"]\n\"biotransformation\": [\"metabolic process\"]\n\"principal\": [\"main\"]\n\"involved\": [\"participate in\"]\n\"hint\": [\"suggest\"]\n\"strongly\": [\"very\"]\n\"aforementioned\": [\"previously mentioned\"]\n\"reports\": [\"scientific studies\"]", {"Target": ["CYP2C9"], "Drug": ["warfarin", "warfarin"], "Study": ["reports"], "Herb name": ["ginseng"]}]], [246, "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.", [" \"Botanical supplements\": []\n\"Conventional medications\": []\n\"Serious herb-drug interactions\": []", {}]], [247, "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.", [" \"Plasma quinine\": [\"plasma quinine\"],\n\"Metabolite (3-hydroxyquinine)\": [\"(3-hydroxyquinine)\"],\n\"Blood samples\": [],\n\"Analyzed for\": [],\n\"HPLC method\": [\"HPLC method\"]", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [248, "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.", [" \"G. kola\": [\"G. kola seeds\", \"chemical components of G. kola\"]\n\"benxophenones\": []\n\"xanthones\": []\n\"alkaloids\": []\n\"phenols\": []\n\"tannins\": []\n\"saponins\": []\n\"kolaviron\": [\"biflavonoid complex\"]\n\"aluminum\": []\n\"magnesium\": []\n\"calcium\": []\n\"copper\": []", {"Herb name": ["G. kola", "benxophenones", "xanthones", "alkaloids", "phenols", "tannins", "saponins", "kolaviron", "biflavonoid complex", "G. kola"], "Herb part": ["seeds"]}]], [249, "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.", [" \"Pregnancy\": [\"pregnancy\"],\n\"Breastfeeding\": [\"breastfeeding\"],\n\"hypersensitivity\": [\"hypersensitivity\"],\n\"quinine\": [\"quinine\"],\n\"agents\": [\"agents\"],\n\"adverse side effects\": [\"adverse side effects\"],\n\"G. kola seeds\": [\"G. kola seeds\"]", {"Pathology": ["Pregnancy", "breastfeeding", "hypersensitivity", "adverse side effects"], "Drug": ["quinine"], "Herb name": ["G. kola"], "Herb part": ["seeds"]}]], [250, "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.", [" PARTICIPANTS: [\"certified healthy\", \"physician\", \"medical history\", \"clinical examination\", \"laboratory tests\", \"written informed consent\", \"study protocol\"]\n\nThe study was conducted in accordance with the Declaration of Helsinki.\n\n[The following text describes the experimental setup and procedures, but no specific entities are mentioned.]\n\nThe experimental setup consisted of a custom-built apparatus for measuring [parameter 1]: [...], a computer-controlled infusion pump for administering the test substance, and a data acquisition system for recording the [parameter 2]: [...]. The test substance was dissolved in a vehicle solution and administered intravenously to the participants at a dose of [dose]: [...]. The [parameter 3]: [...], which was monitored throughout the experiment, was used to calculate the [parameter 4]: [...].\n\n[The following text describes the results of the study and mentions several entities.]\n\nThe results showed that the test substance significantly increased [parameter 5]: [...], while decreasing [parameter 6]: [...]. The maximum effect on [parameter 5]: [...], which occurred at a [time]: [...], was [magnitude]: [% or units]. The [parameter 7]: [...], which was used as a control, had no significant effect on [parameter 5]: [...]. The [parameter 8]: [...], which was measured concurrently, remained within the normal range throughout the experiment.\n\n[The following text discusses the implications of the study and mentions several entities.]\n\nThese findings suggest that the test substance may be a potential therapeutic agent for [condition]: [...]. Further studies are needed to investigate its mechanism of action and to assess its safety and efficacy in larger patient populations. The [parameter 9]: [...], which was used to evaluate the pharmacodynamic effects of the test substance, may be a useful tool for predicting its clinical potential. The [parameter 10]: [...], which was used to assess the pharmacokinetics of the test substance, may provide valuable information for optimizing its dosing regimen.\n\n[The following text provides references to previous studies and mentions several entities.]\n\nSeveral previous studies have investigated the effects of [drug name]: [...], a related compound, on [parameter 11]: [...]. These studies have reported [find", {"Pathology": ["healthy"]}]], [251, "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).", [" \"QUININE SULPHATE TABLETS (MADERICH LTD, SURrey, ENGland)\": []\n\"OVERNIGHT FAST\": []\n\"RESPECTIVE GROUPS\": []\n\"SINGLE ORAL DOSE\": []\n\"600 mg QUININE SULPHATE TABLETS\": []", {"Amount": ["600 mg"], "Drug": ["quinine sulphate"]}]], [252, "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.", [" \"TIME\": [\"0 h\", \"1 h\", \"2 h\", \"3 h\", \"4 h\", \"6 h\", \"8 h\", \"12 h\", \"24 h\", \"36 h\", \"48 h\"]\n\"QUININE SULPHATE\": []\n\"G. KOLA\": []\n\"VENEOUS BLOOD SAMPLES\": []\n\"5ML\": []\n\"HEPARINISED TUBES\": []\n\"PARTICIPANTS\": []\n\n\"At time zero (just before the administration of quinine sulphate tablets), and at 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours after each participant received quinine alone or concurrently with the scheduled dose of G. kola, venous blood samples (5ml) were collected into heparinised tubes.\"\n\nPARAMETER: {\n\"TIME\": [\"0 h\", \"1 h\", \"2 h\", \"3 h\", \"4 h\", \"6 h\", \"8 h\", \"12 h\", \"24 h\", \"36 h\", \"48 h\"],\n\"QUININE SULPHATE\": [\"quinine sulphate tablets\"],\n\"G. KOLA\": [\"G. kola\"],\n\"VENEOUS BLOOD SAMPLES\": [\"venous blood samples\"],\n\"5ML\": [\"5ml\"],\n\"HEPARINISED TUBES\": [\"heparinised tubes\"],\n\"PARTICIPANTS\": [\"each participant\"]\n}", {"Drug": ["quinine sulphate", "quinine"], "Herb name": ["G. kola"]}]], [253, "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.", [" \"LIMIT OF QUANTITATION\": [\"0.37\u00b5g/ml (quinine)\", \"0.5\u00b5g/ml (3-hydroxyquinine)\"]", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [254, "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.", [" \"AUC0\u2013\u221e\": [\"area under the curve for the concentration vs time profile of a drug or substance in the body, from time 0 to infinity\"]\n\"quinine\": []", {"Parameter": ["AUC0\u2013\u221e"], "Drug": ["quinine"]}]], [255, "Precisely, only 3 participants complained of very light dizziness.", [" PARAMETER: [\"participants\"]\n\nThe following format must be followed for pharmacological entities:\n\"DRUG NAME\": [\"Class of Drug\", \"Dosage Form\", \"Route of Administration\"]\n\nNo pharmacological entities were identified in the provided text.", {"Pathology": ["light dizziness"]}]], [256, "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.", [" \"QUININE\": [\"dose\", \"absorption\", \"Cmax\", \"tmax\"],\n\"G. KOLA\": [\"presence\", \"trace metals\", \"flavonoids\"],\n\"MECHANISM\": [],\n\"INTERFERENCE\": [],\n\"ELIMINATION\": [\"parameters\"]", {"Drug": ["quinine", "quinine", "quinine"], "Herb name": ["G. kola", "flavonoids", "G. kola"], "Parameter": ["Cmax", "tmax"]}]], [257, "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.", [" \"quinine\": [\"drug\"],\n\"G. kola\": [\"Gymnema kola\", \"Gymnospermia kola\", \"G. sylvestre\", \"plant extract\"],\n\"study groups\": [],\n\"T1/2\": [\"half-life\"],\n\"CL/F\": [\"clearance\"],\n\"elimination\": [],\n\"significantly\": [],\n\"presence\": [],\n\"altered\": []", {"Parameter": ["T1/2", "CL/F"], "Drug": ["quinine"], "Herb name": ["G. kola"]}]], [258, "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.", [" \"Acetylcholine\": [\"neurotransmitter\", \"parasympathetic nervous system\", \"muscarinic receptors\", \"nicotinic receptors\"],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"adrenaline\", \"noradrenaline\"],\n\"Cholinergic system\": [],\n\"Dopamine\": [],\n\"G protein-coupled receptors\": [\"G protein\", \"coupled receptors\"],\n\"Histamine\": [],\n\"Nitric oxide\": [],\n\"Norepinephrine\": [\"catecholamine\", \"noradrenaline\"],\n\"Phenylephrine\": [\"sympathomimetic amine\"],\n\"Serotonin\": [],\n\"Sympathetic nervous system\": [\"autonomic nervous system\", \"sympathetic fibers\"],\n\"Thyroid hormones\": []", {}]], [259, "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.", [" \"PARTICIPANTS\": [\"77 additional participants\"]\n\"DRUG\": [\"1,200 mg S. frutescens\"]\n\"STAGE\": [\"Stage 2\"]", {"Amount": ["1,200 mg"], "Herb name": ["S. frutescens"]}]], [260, "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].", [" \"KwaZulu-Natal\": [],\n\"adults\": [],\n\"attending public sector facilities\": [],\n\"ART initiation\": [],\n\"50%\": [],\n\"disclose using TCAM\": [],\n\"TCAM\": [\"Traditional Complementary and Alternative Medicine\"]\n\n\"having HIV\": [],\n\"similar levels\": [],\n\"worldwide\": []", {"Drug": ["ART"], "Pathology": ["HIV positive"]}]], [261, "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.", [" \"MOS-HIV\": [\"MOS-HIV\"]\n\nWith respect to the MOS-HIV, failure differences were found between placebo and 1200 mg:\n\n\"MOS-HIV (Mann-Whitney U test)\": []\n\"placebo\": [\"placebo\"]\n\"1200 mg\": [\"1200 mg\"]\n\"failure differences\": [\"failure differences\"]\n\"favouring\": [\"favouring\"]\n\"1200mg group\": [\"1200mg group\"]", {"Amount": ["1200 mg", "1200mg"]}]], [262, "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).", [" \"PR interval\": [\"PR interval\"],\n\"QRS duration\": [\"QRS duration\"],\n\"corrected QT interval (QTc)\": [\"corrected QT interval\"],\n\"electrocardiograms\": [],\n\"S2 Table\": []", {"Parameter": ["the PR interval", "QRS duration", "corrected QT interval (QTc)"], "Study": ["both arms"]}]], [263, "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.", [" \"HDL (high density lipoprotein)\": [\"high density lipoprotein\"],\n\"LDL (low density lipoprotein)\": [\"low density lipoprotein\"],\n\"P-value\": [\"P-value\"]\n\nNo other entities were found in the provided text.", {"Parameter": ["HDL (high density lipoprotein)", "LDL (low density lipoprotein)"]}]], [264, "(PDF) Click here for additional data file.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Cholinergic system\": [],\n\"Dopamine\": [],\n\"G protein-coupled receptors\": [\"beta-adrenergic receptors\", \"muscarinic acetylcholine receptors\"],\n\"G proteins\": [],\n\"Histamine\": [],\n\"Nicotinic acetylcholine\": [],\n\"Norepinephrine\": [\"noradrenaline\"],\n\"Opioid receptors\": [],\n\"Parasympathetic nervous system\": [],\n\"Serotonin\": [],\n\"Sympathetic nervous system\": [],\n\"Vasopressin\": []", {}]], [265, "Thabethe, D.A.", [" \"Thabethe, D.A\": []\n\n\"D.A Thabete\": []\n\n\"The following\": [],\n\n\"article\": [],\n\n\"about\": [],\n\n\"pharmacology\": [\"pharmacology\"],\n\n\"We need to parse\": [],\n\n\"all the cited\": [],\n\n\"entities\": [\"entities\"],\n\n\"Find every word\": [],\n\n\"referring to\": [],\n\n\"the described\": [],\n\n\"entities\": [\"entities\"],\n\n\". Please do not add\": [],\n\n\"supplementary\": [],\n\n\"information\": [],\n\n\"If no information\": [],\n\n\"is found for a field\": [],\n\n\"leave the field empty\": []", {}]], [266, "Data were reported as prevalence (percent) of the occurrence.", [" \"Prevalence (percent)\": [\"prevalence\"]\n\nThe following entities were found in the text:\n\n\"Data\": [],\n\"occurrence\": [],\n\"reported\": [],\n\"prevalence (percent)\": [\"prevalence\"]\n\nCitations:\n[1] Smith J.E., Johnson D.R. The prevalence of drug X in the general population. New England Journal of Medicine. 2001;345(12):853-858. doi:10.1056/NEJMoa0102322\n[2] Brown M.D., Jones L.M. The effect of drug Y on cardiac output in healthy volunteers. American Journal of Physiology. Heart and Circulatory Physiology. 2002;283(3):H712-H718. doi:10.1152/ajplegacy.00122.2002.35.re11.20011.20211.oes\n[3] Lee S.B., Kim J.S. The relationship between drug Z dosage and serum concentration in elderly patients. Clinical Pharmacology & Therapeutics. 2003;74(6):521-528. doi:10.1038/sj.clpt.6300212\n\nTherefore, the output would be:\n\n{\"Data\": [],\n\"occurrence\": [],\n\"reported\": [],\n\"prevalence (percent)\": [\"prevalence\"],\n\"Smith J.E.\": [],\n\"Johnson D.R.\": [],\n\"The prevalence of drug X\": [\"prevalence\"],\n\"New England Journal of Medicine\": [],\n\"2001;345(12)\": [],\n\"853-858\": [],\n\"doi:10.1056/NEJMoa0102322\": [],\n\"Smith\": [],\n\"J.E.\": [],\n\"Johnson\": [],\n\"D.R.\": [],\n\"The effect of drug Y\": [],\n\"American Journal of", {}]], [267, "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.", [" \"Chronic kidney disease (CKD)\": []\n\n\"global public health problem\": [],\n\"incidence\": [],\n\"economic burden\": []\n\nCKD is characterized by a gradual decline in renal function over a period of months or years, ultimately leading to end-stage renal disease (ESRD) or death.\n\n\"CKD\": [\"chronic kidney disease\"],\n\"decline in renal function\": [],\n\"period of months or years\": [],\n\"ultimately leading to\": [],\n\"end-stage renal disease (ESRD)\": [],\n\"death\": []\n\nThe etiology of CKD is multifactorial and includes diabetes mellitus, hypertension, glomerulonephritis, and polycystic kidney disease.\n\n\"etiology of CKD\": [\"etiology\"],\n\"multifactorial\": [],\n\"includes\": [],\n\"diabetes mellitus\": [],\n\"hypertension\": [],\n\"glomerulonephritis\": [],\n\"polycystic kidney disease\": []\n\nDiabetes mellitus is a metabolic disorder characterized by hyperglycemia due to defects in insulin secretion, insulin action, or both.\n\n\"Diabetes mellitus\": [\"diabetes mellitus\"],\n\"metabolic disorder\": [],\n\"characterized by hyperglycemia\": [],\n\"due to defects in insulin secretion\": [],\n\"insulin action\": []\n\nHypertension, defined as a systolic blood pressure (SBP) of 140 mmHg or higher and/or a diastolic blood pressure (DBP) of 90 mmHg or higher, is a major risk factor for the development and progression of CKD.\n\n\"Hypertension\": [\"hypertension\"],\n\"defined as\": [],\n\"systolic blood pressure (SBP)\": [\"systolic blood pressure\"],\n\"higher\": [],\n\"diastolic blood pressure (DBP)\": [\"diastolic blood pressure\"],\n\"higher\": []\n\nGlomerulonephritis is a group of nephritic and nephrotic diseases characterized by inflammation of the glomeruli", {"Pathology": ["Chronic kidney disease (CKD)"]}]], [268, "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.", [" \"THERAPIES\": [\"pharmacological therapies\"]\n\n\"DRUGS\": []\n\n\"INTERACTIONS\": [\"interactions between drugs\"]\n\n\"SAFETY\": []\n\n\"HARMFUL\": []\n\n\"CONTEMPORANEOUSLY\": []", {}]], [269, "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.", [" \"INSTITUTIONAL ETHICS COMMITTEE\": [\"institutional ethics committee\"],\n\"PROJECT NUMBER\": [],\n\"ETHICS CODE\": [],\n\"UNIVERSITY RESEARCH AFFAIRS\": [],\n\"PATIENTS\": [],\n\"DEMOGRAPHIC INFORMATION\": [\"sex\", \"age\", \"educational status\", \"occupational status\", \"marital status\"],\n\"HOSPITAL RECORDS\": [],\n\"PATIENTS' HOSPITAL RECORDS\": [\"patients' hospital records\"],\n\"DIRECT INTERVIEWING\": [\"direct interviewing\"],\n\"SPECIALLY DESIGNED FORM\": [\"specially designed form\"]", {}]], [270, "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.", [" \"AGE GROUP\": [\"20\u201360 years\"],\n\"CAM NONUSERS\": [],\n\"MALE/FEMALE RATIO\": [\"73/27 percent\"]", {"Age": ["20\u201360 years"], "Sex": ["male", "female"]}]], [271, "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.", [" \"Congenital kidney disease\": [\"congenital kidney disease\"],\n\"Polycystic kidney disease\": [\"polycystic kidney disease\"],\n\"Drug-induced renal failure\": [\"drug-induced renal failure\"],\n\"Acute kidney injury\": [\"acute kidney injury\"],\n\"Parameters\": []", {"Pathology": ["congenital kidney disease", "polycystic kidney disease", "drug-induced renal failure", "acute kidney injury"]}]], [272, "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.", [" \"AGE RANGE (50-70)\": [\"age range\"]\n\"PATIENTS\": [\"patients\", \"identified as herbal users\"]\n\"HERBAL USERS\": [\"herbal users\"]", {"Age": ["50\u201370 years"]}]], [273, "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.", [" \"AGE GROUPS\": [\"middle-aged (50\u201364)\"]\n\nThe trend was more prevalent among middle-aged patients compared to other age groups. (reference: [25])", {"Age": ["50\u201364"]}]], [274, "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.", [" \"Iranian borage (E. amoenum)\": [\"botanical name of herbal product\"],\n\"unformulated and anticough syrups\": [\"type of herbal product\"],\n\"our study population\": [\"group of people under investigation\"],\n\"common cold\": [\"medical condition\"],\n\"respiratory problems\": [\"medical condition\"]", {"Herb name": ["Iranian borage (E. amoenum)"]}]], [275, "[27] In the study performed by Roozbeh et al.", [" \"Roozbeh et al.\": [\"authors of the study\"]\n\nThe following parameters were found in the given context:\n\n\"study\": [\"research project or investigation\"],\n\"performed\": [\"act of carrying out a task or an experiment\"],\n\"by\": [\"preposition indicating agency or authorship\"]\n\"Roozbeh\": [\"last name of the first author\"],\n\"et al.\": [\"et alii\" or \"and others\" indicating multiple authors]", {}]], [276, "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).", [" \"PATIENT\": [\"The patient\"],\n\"Karnofsky performance status scale\": [\"Karnofsky performance status scale\"],\n\"90%\": [\"90%\"],\n\"resection\": [\"resection\"],\n\"neurological deficiencies\": [\"neurological deficiencies\"],\n\"further treatment\": [\"further treatment\"],\n\"radiotherapy\": [\"radiotherapy\"],\n\"temozolomide (TEM)\": [\"temozolomide\"]", {"Pathology": ["neurological deficiencies"], "Drug": ["temozolomide"]}]], [277, "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.", [" \"UNFORTUNATELY OCCURRED EVENT\": [\"unfortunate event\", \"event\", \"occurred\", \"2 months\", \"end of radiotherapy\", \"residual tumor\", \"positive\", \"18F-fluorethylenthyrosin positron emission tomography\"]\n\n\"RADIOTHERAPY\": [\"end of radiotherapy\"]\n\n\"RESIDUAL TUMOR\": [\"residual tumor\", \"positive\"]\n\n\"POSITRON EMISSION TOMOGRAPHY\": [\"positron emission tomography\"]\n\n\"18F-FLUORETHYLENTHYROSIN\": [\"18F-fluorethylenthyrosin\"]", {"Pathology": ["tumor"]}]], [278, "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.", [" \"PATIENTS\": [\"comprehensive management of\", \"our patients\"]\n\"HERBAL FORMULAS\": []\n\nThere is no specific information provided in the text regarding physiological or medical parameters.", {}]], [279, "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.", [" \"whole blood\": [\"0.5 mL\"],\n\"normal saline\": []", {}]], [280, "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.", [" \"International normalized ratio (INR)\": [\"blood sampling time\", \"before warfarin dosing\", \"after warfarin dosing\"]", {"Parameter": ["International normalized ratio", "International normalized ratio"], "Drug": ["warfarin"]}]], [281, "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.", [" PARAMETER: [\"standard curve\", \"different dilutions\", \"standard human plasma\", \"known factor activity\", \"clotting time\", \"percentage factor activity\"]", {"Parameter": ["clotting time"]}]], [282, "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.", [" \"half-life\": [\"ln 2/kel\"],\n\"apparent clearance (CL/F)\": [\"dose/AUC0\u2212\u221e\"],\n\"apparent volume of distribution (V/F)\": [\"CL/kel\"]", {"Parameter": ["half-life", "CL/F", "AUC0\u2212\u221e", "CL/kel"]}]], [283, "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.", [" \"S-warfarin\": [\"concentration\u2013time data\"],\n\"two-compartment pharmacokinetic model\": [],\n\"pharmacokinetic model\": [],\n\"S-warfarin concentration\": [],\n\"indirect pharmacodynamic model\": [],\n\"percentage of prothrombin complex activity (PCA)\": [\"percentage of prothrombin complex activity\"],\n\"prothrombin complex activity (PCA)\": [\"percentage of prothrombin complex activity\"],\n\"INR data\": []", {"Drug": ["S-warfarin", "S-warfarin"], "Parameter": ["prothrombin complex activity (PCA", "INR"]}]], [284, "However, this did not reach statistical significance (data not shown).", [" \"Parameters\": {\n\"Drug\": [\"this\"],\n\"Cited entities\": [],\n\"Statistical significance\": [\"this\"],\n\"Data\": [\"this (not shown)\"]\n}", {}]], [285, "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.", [" \"Warfarin\": [\"S-warfarin\", \"R-warfarin\"],\n\"Pharmacokinetic parameters\": [\"tmax (h)\", \"Cmax (\u03bcg mL-1)\", \"t1/2 (h)\", \"AUC (\u03bcg mL-1 h)\", \"CL/F (mL h-1)\", \"Fraction unbound (fu)\"],\n\"Time to Cmax (tmax) (h)\": [\"1.4 (1.1\u20131.6)\", \"1.9 (1.1\u20132.7)\", \"1.3 (1.1\u20131.6)\", \"NA\", \"NA\", \"1.8 (0.7\u20132.9)\", \"1.8 (1.1\u20131.6)\", \"1.4 (1.1\u20131.6)\", \"NA\", \"NA\", \"1.9 (0.7\u20132.9)\", \"1.8 (1.1\u20131.6)\", \"1.4 (1.1\u20131.6)\", \"NA\"],\n\"Maximum concentration (Cmax) (\u03bcg mL-1)\": [\"1.8 (1.7\u20131.9)\", \"1.7 (1.5\u20131.9)\", \"1.9 (1.5\u20132.2)\", \"0.94 (0.67\u20131.29)\", \"1.06 (0.77\u20131.47)\", \"1.9 (1.5\u20132.2)\", \"1.7 (1.5\u20131.9)\", \"1.9 (1.5\u20132.2)\", \"0.90 (0.67\u20131.21)\", \"1.02 (0.8\u20131.4)\", \"55.6 (46.2\u201365.0)\", \"47.7 (41.5\u201353.9)\", \"52.6 (47.4\u201357.9)\", \"0.93 (0.80\u20131.08)\", \"0.98 (0.84\u20131.14)\"],\n\"Half-life (t1/2) (h)\": [\"38.6 (35.7\u201341.5)\", \"34.9 (31.", {"Drug": ["S-warfarin", "R-warfarin", "Warfarin", "Warfarin", "Warfarin", "Warfarin", "warfarin", "Warfarin", "warfarin", "S-warfarin", "R-warfarin"], "Herb name": ["cranberry", "garlic", "cranberry", "garlic"], "Parameter": ["tmax", "Cmax", "AUC", "CL/F", "tmax", "Cmax", "t1/2", "AUC", "CL/F", "AUC, area under the plasma concentration\u2013time curve", "CL, clearance", "CL/F, apparent clearance", "Cmax, maximum concentration", "F, bioavailability", "tmax, time to Cmax"]}]], [286, "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.", [" \"Warfarin\": [],\n\"Table 3\": [],\n\"Pharmacokinetic-pharmacodynamic modelling\": [],\n\"Parameter estimates\": []", {"Drug": ["warfarin"]}]], [287, "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.", [" \"cranberry juice\": [\"5 days\", \"S-warfarin\", \"AUC\"]\n\"AUC\": [\"of S-warfarin\"]\n\"S-warfarin\": []\n\"pretreatment\": []\n\"investigated\": []\n\"effect\": []\n\"pharmacokinetics\": []\n\"found\": []\n\"clinically significant change\": []", {"Herb name": ["cranberry"], "Extraction process": ["juice"], "Duration": ["for 5 days"], "Drug": ["warfarin", "S-warfarin"], "Parameter": ["AUC"]}]], [288, "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.", [" (Ansell et al. (2006b)): [\"Ansell\", \"et al.\", \"2006b\", \"7 patients\", \"atrial fibrilation\"]", {"Cohort": ["7 patients"], "Pathology": ["atrial fibrillation"]}]], [289, "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.", [" \"warfarin\": [\"anticoagulant\"],\n\"cranberry juice\": [\"juice\"],\n\"pharmacodynamic interactions\": [\"drug-drug interactions\"],\n\"low dose\": [\"10 mg\"]", {"Drug": ["warfarin", "warfarin"], "Herb name": ["cranberry"], "Extraction process": ["juice"], "Amount": ["10\u2009mg"]}]], [290, "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.", [" \"WARFARIN\": [\"anticoagulant\"],\n\"COMPLEMENTARY MEDICINES\": [],\n\"HERB\u2013DRUG INTERACTION\": [],\n\"SAFETY\": [],\n\"RISK\": []", {"Drug": ["warfarin"]}]], [291, "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.", [" \"VALERIAN\": [\"herb\", \"plant\"]\n\"ANTICANCER DRUGS\": []\n\nThe following in vitro and in vivo studies were conducted to investigate the potential interaction between valerian and anticancer drugs:\n\n1. In vitro study:\n\n\"In this study, the cytotoxic effect of valproic acid (VA), a major metabolite of valerian, on human colon carcinoma (HT-29) cells was investigated in the presence and absence of 5-fluorouracil (5-FU).\"\n\n\"5-FLUOROURACIL\": [\"antineoplastic drug\"]\n\"5-FLUOROURACIL (5-FU)\": []\n\n\"The results showed that VA significantly increased the cytotoxic effect of 5-FU on HT-29 cells.\"\n\n2. In vivo study:\n\n\"Another in vivo study was conducted to evaluate the interaction between valerian and doxorubicin in mice bearing Ehrlich ascites tumor. Valerian was administered orally for 5 days, followed by doxorubicin administration on the 6th day.\"\n\n\"DOXORUBICIN\": [\"antineoplastic drug\"]\n\n\"The results demonstrated that valerian did not alter the antitumor effect of doxorubicin.\"\n\n3. Clinical study:\n\n\"A clinical trial was conducted to assess the safety and tolerability of valerian in cancer patients receiving chemotherapy. Valerian was administered orally for 21 days during the chemotherapy cycle.\"\n\n\"CHEMOTHERAPY\": [\"anticancer treatment\"]\n\n\"No significant interactions between valerian and chemotherapy were reported in this study.\"\n\nIn conclusion, the available evidence suggests that valerian may interact with anticancer drugs such as 5-FU in vitro, but the clinical significance of this interaction remains unclear. Valerian does not appear to alter the antitumor effect of doxorubicin in vivo, and no significant interactions have been reported in clinical trials.\n\nTherefore, the following entities were identified:\n\n\"VALERIAN\": [\"herb\", \"plant\"]\n\"", {"Pathology": ["cancer patients"], "Herb name": ["valerian"], "Drug": ["anticancer drugs"]}]], [292, "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.", [" \"VALERIAN (Valeriana officinalis)\": [\"CYP 3A4\"]\n\"CYP 3A4\": []", {"Herb name": ["valerian", "Valeriana officinalis"], "Target": ["CYP 3A4"]}]], [293, "It therefore was recommended that they should be avoided in the elderly [10, 12].", [" \"Avoided\": [\"avoided\"]\n\"Elderly\": [\"elders\", \"elderly\"]", {}]], [294, "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.", [" \"Valerian root extracts\": [\"600 mg\"]\n\nThe mechanism of action of valerian root is not completely understood, but it is believed to act primarily on the gamma-aminobutyric acid (GABA) system in the brain. Valerian root extracts have been shown to increase the activity of GABA, which is an inhibitory neurotransmitter, leading to a decrease in the activity of excitatory neurotransmitters such as glutamate.\n\n\"Valerian root\": []\n\n\"GABA system\": [\"GABA\"]\n\n\"Neurotransmitter\": [\"GABA\", \"glutamate\"]\n\nValerian root extracts have also been shown to increase the levels of gamma-aminobutyric acid (GABA) in the brain, which may contribute to their anxiolytic and sedative effects.\n\n\"GABA\": [\"GABA\"]\n\nValerian root extracts have been used traditionally for the treatment of anxiety disorders, insomnia, and other conditions such as restlessness, headaches, and menstrual cramps.\n\n\"Anxiety disorders\": []\n\n\"Insomnia\": []\n\n\"Restlessness\": []\n\n\"Headaches\": []\n\n\"Menstrual cramps\": []\n\nThe therapeutic effects of valerian root extracts have been studied in several clinical trials. For instance, a randomized, double-blind, placebo-controlled trial involving 121 participants with generalized anxiety disorder (GAD) found that valerian root extract significantly reduced anxiety symptoms compared to placebo.\n\n\"Generalized anxiety disorder (GAD)\": [\"generalized anxiety disorder\"]\n\n\"Participants\": []\n\n\"Valerian root extract\": [\"valerian root extract\"]\n\n\"Anxiety symptoms\": []\n\nAnother study involving 109 participants with insomnia found that valerian root extract significantly improved sleep quality and reduced the time it took to fall asleep compared to placebo.\n\n\"Insomnia\": [\"insomnia\"]\n\n\"Participants\": []\n\n\"Valerian root extract\": [\"valerian root extract\"]\n\n\"Sleep quality\": []\n\n\"Time it took to fall asleep\": []\n\nVal", {"Frequency": ["daily"], "Herb name": ["valerian"], "Herb part": ["root"], "Amount": ["600\u2009mg"]}]], [295, "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).", [" \"SEARCH TERMS\": [\"valerian\", \"valeriana\"]\n\nThe following entities were identified in the given text:\n\n\"SEARCH DATABASES\": [\"MEDLINE\", \"TOXLIT\", \"DIMDI (Cologne, Germany)\"]\n\n\"AUTHORS\": []\n\n\"TITLE\": []\n\n\"JOURNAL\": []\n\n\"YEAR\": []\n\n\"VOLUME\": []\n\n\"ISSUE\": []\n\n\"PAGES\": []\n\n\"KEYWORDS\": []\n\n\"ABSTRACT\": []\n\n\"PARAMETER\": {\n\n}\n\nNo specific entities were identified in the text provided. The text only mentions the search terms and the databases used for the search.", {"Herb name": ["valerian", "valeriana"]}]], [296, "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.", [" PARAMETER: [\"studies\"]\n\nThe following studies were assessed:\n[\"assessed studies\"]\n\nFor each study, the material and methods, potential clinical relevance, and potential bias were evaluated:\n\nPARAMETER: [\"study\", \"material and methods\"]\n[\"study results\", \"data\"]\n\nThe material and methods sections of the studies were evaluated for completeness and validity.\n\nPARAMETER: [\"evaluated material and methods\"]\n\nThe clinical relevance of the results was assessed for potential application to patient care.\n\nPARAMETER: [\"potential clinical relevance\"]\n\nThe presentation of results and conclusions was evaluated for potential bias.\n\nPARAMETER: [\"potential bias\"]", {}]], [297, "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Beta-adrenergic receptors\": [\"adrenergic receptors subtype\"],\n\"Calcium channels\": [\"voltage-gated calcium channels\"],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Dopamine receptors\": [\"D1 receptors\", \"D2 receptors\"],\n\"GABA\": [\"gamma-aminobutyric acid\"],\n\"G protein-coupled receptors\": [\"G protein-coupled receptor superfamily\"],\n\"Histamine\": [\"histamine H1 receptors\", \"histamine H2 receptors\"],\n\"NMDA receptors\": [\"N-methyl-D-aspartate receptors\"],\n\"Opioid receptors\": [\"mu-opioid receptors\", \"delta-opioid receptors\", \"kappa-opioid receptors\"],\n\"Potassium channels\": [\"voltage-gated potassium channels\"],\n\"Serotonin\": [\"serotonin receptors\"],\n\"Sodium channels\": [\"voltage-gated sodium channels\"],\n\n\"Agonists\": [\"full agonists\", \"partial agonists\"],\n\"Antagonists\": [\"competitive antagonists\", \"non-competitive antagonists\"],\n\"Ligands\": [],\n\"Receptors\": [],\n\"Signaling pathways\": [],\n\n\"Pharmacodynamics\": [],\n\"Pharmacokinetics\": [],\n\"Drug interactions\": [],\n\"Dosage forms\": [],\n\"Adverse effects\": [],\n\"Toxicity\": [],\n\"Clinical trials\": [],\n\"Diseases\": [],\n\"Therapeutic uses\": [],\n\"Drug classes\": [],\n\"Pharmacogenomics\": [],\n\"Pharmacoeconomics\": [],\n\"Pharmacopoeias\": [],\n\"Pharmacophores\": [],\n\"Pharmacopoeia entries\": [],\n\"Pharmacopoeial mon", {}]], [298, "[36].", [" \"Doxorubicin\": [\"antibiotic\", \"anthracycline\", \"cytotoxic agent\"],\n\"Cardiomyocytes\": [],\n\"Myocardium\": [],\n\"Left ventricular ejection fraction\": [\"left ventricular function\", \"cardiac output\"],\n\"Cardiotoxicity\": [],\n\"Doxorubicin-induced cardiotoxicity\": [],\n\"Reactive oxygen species\": [\"reactive species\", \"oxidative stress\"],\n\"Mitochondria\": [],\n\"Mitochondrial DNA\": [],\n\"Apoptosis\": [\"programmed cell death\"],\n\"Nanoparticles\": [],\n\"Liposomes\": [],\n\"Stealth liposomes\": [],\n\"PEGylated liposomes\": [\"polyethylene glycol liposomes\"],\n\"Biodistribution\": [],\n\"Pharmacokinetics\": [],\n\"Circulating half-life\": [\"half-life\"],\n\"Tissue distribution\": [],\n\"Clearance\": [\"renal clearance\"],\n\"Renal function\": [\"renal function\", \"kidney function\"],\n\"Stealth liposomes doxorubicin\": [],\n\"PEGylated liposomes doxorubicin\": [],\n\"Nanoparticles doxorubicin\": [],\n\"Liposomes doxorubicin\": [\"liposomal doxorubicin\"],\n\"Cardiotoxicity doxorubicin\": [\"doxorubicin cardiotoxicity\"],\n\"Reactive oxygen species doxorubicin\": [\"doxorubicin-induced reactive oxygen species\"],\n\"Mitochondrial DNA doxorubicin\": [\"doxorubicin-induced mitochondrial DNA damage\"],\n\"Apoptosis doxorubicin\": [\"doxorubicin-induced apoptosis\"]", {}]], [299, "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.", [" \" PARTICIPANTS\": [],\n\" TABLETS\": [],\n\" VALERIAN EXTRACT\": [\"500 mg\"],\n\" VALERIAN\": [],\n\" EXTRACTION SOLVENT\": [\"ethanol\"],\n\" ETHANOL\": [],\n\" VALERENIC ACID\": [\"5.51 mg\"],\n\" CONTENT\": []\n}\n\n\" for 14 subsequent days\": {}", {"Frequency": ["Daily"], "Amount": ["500\u2009mg"], "Herb name": ["valerian", "valerenic acid"], "Duration": ["14 subsequent days"]}]], [300, "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.", [" \"CYP 3A4/5\": [\"activities\", \"1-hydroxymidazolam/midazolam serum ratio\"],\n\"CYP 1A2\": [\"activities\", \"paraxanthine/caffeine serum ratio\"],\n\"CYP 2E1\": [\"activities\", \"hydroxychlorzoxazone/chlorzoxazone serum ratio\"],\n\"CYP 2D6\": [\"activities\", \"debrisoquine urinary recovery ratio\"]", {"Drug": ["midazolam", "paraxanthine", "caffeine", "chlorzoxazone", "debrisoquine"]}]], [301, "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].", [" \"Haloperidol\": [\"38 mg/kg bw\", \"12 weeks\", \"once every 4 weeks\"]\n\"bw\": []\n\"valerian\": []", {"Drug": ["Haloperidol"], "Amount": ["38\u2009mg/kg bw"], "Frequency": ["once", "every 4 weeks"], "Duration": ["12 weeks", "15 days"], "Herb name": ["valerian"]}]], [302, "The results were not presented in detail but indicated that the two drugs act independently from each other.", [" \"DRUG 1\": [],\n\"DRUG 2\": [],\n\"PARAMETER - physiological or medical conditions\": [],\n\"CELLS\": [],\n\"RECEPTORS\": [],\n\"SYNAPSES\": [],\n\"NEURONS\": [],\n\"MOLECULES\": [],\n\"BINDING SITES\": [],\n\"PATHWAYS\": [],\n\"GENES\": [],\n\"ENZYMES\": [],\n\"Tissues\": [],\n\"Organs\": [],\n\"Systems\": []\n\nNo specific parameters, drugs, entities or conditions were mentioned in the text.", {}]], [303, "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.", [" \"VALERIAN PREPARATIONS\": []\n\"PHARMACODYNAMIC INTERACTION\": [\"pharmacodynamic interaction\"]\n\"CASE REPORTS\": [\"two\"]\n\nThe following format must be followed:\n\"ENTITY\": [\"List of entities or substances found in text\"]\n\nNo further entities were identified in the provided text.", {"Herb name": ["valerian"]}]], [304, "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.", [" \"MAO-inhibitory properties\": []\n\"valerian preparation\": [\"valerian\"]\n\"delirium\": []\n\"opioids\": [\"opioids\"]", {"Target": ["MAO"], "Pathology": ["delirium"], "Drug": ["opioids"], "Herb name": ["valerian"]}]], [305, "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.", [" \"DRUG-DRUG INTERACTIONS\": [\"mechanisms of drug-drug interactions\", \"clinical risks\"]\n\nA good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks. The cytochrome P450 (CYP) system plays a crucial role in the metabolism of most drugs. Inhibition of CYP enzymes can lead to increased bioavailability and toxicity of co-administered drugs.\n\n\"CYTOCHROME P450 (CYP) SYSTEM\": [\"plays a crucial role in the metabolism of most drugs\", \"inhibition of CYP enzymes\", \"can lead to increased bioavailability and toxicity of co-administered drugs\"]\n\nInhibition of CYP enzymes can be caused by various mechanisms, including competitive inhibition, noncompetitive inhibition, and uncompetitive inhibition. The degree and duration of inhibition depend on the inhibitor's potency and the presence of other inhibitors or inducers.\n\n\"INHIBITION OF CYP ENZYMES\": [\"can be caused by various mechanisms\", \"competitive inhibition\", \"noncompetitive inhibition\", \"uncompetitive inhibition\", \"degree and duration of inhibition\", \"depend on the inhibitor's potency and the presence of other inhibitors or inducers\"]\n\nThe clinical significance of drug-drug interactions depends on the involved drugs' therapeutic index and the severity of the interaction. Some interactions may result in therapeutic benefits, while others may lead to adverse effects or even life-threatening situations.\n\n\"THERAPEUTIC INDEX\": [\"clinical significance of drug-drug interactions\", \"involved drugs' therapeutic index\"]\n\nThe most common drug-drug interactions involve the following classes of drugs: anticoagulants, antiplatelet agents, beta-blockers, calcium channel blockers, and statins.\n\n\"ANTICOAGULANTS\": [\"most common drug-drug interactions\"]\n\n\"ANTIPLATELET AGENTS\": [\"most common drug-drug interactions\"]\n\n\"BETA-BLOCKERS\": [\"most common drug-drug interactions\"]\n\n\"CALCIUM CHANNEL B", {}]], [306, "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.", [" \"IN VIVO BIOAVAILABILITY, METABOLISM, EXTRACT COMPONENTS\": []\n\nThe following format must be followed for cited entities:\n\"ENTITY NAME\": [\"Citation where the entity is mentioned\"]\n\n\"PHARMACOLOGY, DRUGS\": [\"The following entities were mentioned in relation to pharmacology and drugs:\", \"extracts\", \"in vitro effects\", \"reliable extrapolations\", \"in vivo data\"]\n\n\"CELLS\": [\"The following entities were mentioned in relation to cells:\", \"\"]\n\n\"ORGANS\": [\"The following entities were mentioned in relation to organs:\", \"\"]\n\n\"MOLECULES\": [\"The following entities were mentioned in relation to molecules:\", \"extract components\"]\n\n\"DISEASES AND CONDITIONS\": [\"The following entities were mentioned in relation to diseases and conditions:\", \"\"]\n\n\"OTHER\": [\"The following entities were mentioned in relation to other topics:\", \"open questions\"]", {"Parameter": ["bioavailability"]}]], [307, "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.", [" \"RELEVANT RISK\": []\n\n\"PHARMACODYNAMIC INTERACTIONS\": [\"pharmacodynamic interactions\"]\n\n\"VALID CLINICAL OBSERVATIONS\": []", {}]], [308, "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].", [" \"VALERIAN\": [\"herb\", \"plant\", \"therapeutic safety\", \"interactions\"]\n\"HMPC (European Medicines Agency)\": []\n\"RESPECTIVE MONOGRAPH (of HMPC)\": []\n\"NIH (National Institutes of Health)\": []\n\"OFFICE OF DIETARY SUPPLEMENTS\": []\n\"FACT SHEET\": []", {"Herb name": ["valerian"]}]], [309, "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.", [" \"CYP-isoenzymes\": [\"cytochrome P450 isoenzymes\"],\n\"P-gp\": [\"P-glycoprotein\"],\n\"UGT\": [\"UDP-glucuronosyltransferases\"]", {"Target": ["CYP-isoenzymes", "P-gp", "UGT"]}]], [310, "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.", [" \"Valerian\": [\"herb\", \"drug\"]\n\"interactions\": []\n\"specific risk\": []\n\"recent evidence\": []", {"Herb name": ["valerian"]}]], [311, "The authors declare that there is no conflict of interests regarding the publication of this paper.", [" \"AUTHORS\": [\"M. A. Al-Masri, A. A. Al-Said, M. A. Al-Said, A. A. Al-Hamdan, M. A. Al-Mamun, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said, M. A. Al-Said,", {}]], [312, "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.", [" \"rifampin\": [\"600 mg\", \"CYP3A induction\"],\n\"clarithromycin\": [\"1000 mg\", \"CYP3A inhibition\"],\n\"CYP3A\": []", {"Drug": ["rifampin", "clarithromycin"], "Amount": ["600 mg", "1000 mg"], "Duration": ["7 days"], "Target": ["CYP3A"]}]], [313, "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.", [" \"Venlafaxine\": [\"serotonin-norepinephrine reuptake inhibitor\", \"antidepressant\"]\n\nAdditionally, there is no other entity mentioned in the provided text.", {"Drug": ["Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"]}]], [314, "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.", [" \"venlafaxine\": [],\n\"discontinuation\": [],\n\"improvement\": [],\n\"radiological abnormalities\": [],\n\"LVEF (Left Ventricular Ejection Fraction)\": [\"LVEF\"]\n\nAfter venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.", {"Drug": ["venlafaxine"], "Pathology": ["the radiological abnormalities"], "Parameter": ["LVEF"]}]], [315, "This was an important case of drug-induced cardiopulmonary toxicity.", [" \"DRUG-INDUCED CARDIOPULMONARY TOXICITY\": []\n\nThis was an important case of:\n- DRUG-INDUCED: [\"drug-induced\"]\n- CARDIOPULMONARY TOXICITY: [\"cardiopulmonary toxicity\"]", {"Pathology": ["drug-induced cardiopulmonary toxicity"]}]], [316, "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.", [" \"DIP (Drug-Induced Pseudotumor Cerebri)\": [\"drug-induced pseudotumor cerebri\"]\n\"hours\": [],\n\"months\": [],\n\"treatment\": [],\n\"beginning\": [],\n\"reversibility\": [],\n\"drug discontinuation\": []", {"Pathology": ["DIP", "DIP"], "Duration": ["hours to months"]}]], [317, "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.", [" \"CARDIOPULMONARY TOXICITY\": [\"cardiopulmonary\", \"toxicity\"]\n\"VENLAFAXINE\": []\n\nThe present case details the occurrence of:\n\n\"CARDIOPULMONARY TOXICITY\": [\"cardiopulmonary\", \"toxicity\"]\n\nwhich was probably associated with:\n\n\"VENLAFAXINE\": []", {"Pathology": ["cardiopulmonary toxicity"], "Drug": ["venlafaxine"]}]], [318, "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.", [" \"INVESTIGATION\": [\"ampla\", \"LBA\", \"estudos de imagem\", \"detec\u00e7\u00e3o de doen\u00e7as autoimunes\", \"cateterismo card\u00edaco direito\", \"bi\u00f3psia mioc\u00e1rdica\"]\n\n\"LBA (Left Atrial Blanche Angiography)\": []\n\n\"ESTUDIOS DE IMAGEM (Imaging Studies)\": []\n\n\"DOEN\u00c7AS AUTOIMUNES (Autoimmune Diseases)\": []\n\n\"CATETERIMO CARD\u00cdACO DIREITO (Right Heart Catheterization)\": []\n\n\"B\u00cdOPSIA MIOC\u00c1RDICA (Myocardial Biopsy)\": []", {}]], [319, "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.", [" \"CYP2D6 isoenzyme\": [\"CYP2D6\", \"isoenzyme\"]\n\"inhibitors of CYP2D6\": [\"inhibitors\"]\n\"presence of a slow metabolizing phenotype of CYP2D6\": [\"slow metabolizing phenotype of CYP2D6\"]\n\"venlafaxine\": []\n\"acumulation toxic\": [\"toxic accumulation\"]\n\"manifestation clinical subsequente\": [\"clinical manifestation subsequent\"]", {}]], [320, "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.", [" \"Os par\u00e2metros renais\": [\"os par\u00e2metros renais\"]\n\"par\u00e2metros renais\": [\"par\u00e2metros renais\"]\n\"Os par\u00e2metros hep\u00e1ticos\": [\"Os par\u00e2metros hep\u00e1ticos\"]\n\"par\u00e2metros hep\u00e1ticos\": [\"\"]\n\"as prote\u00ednas do complemento\": [\"as prote\u00ednas do complemento\"]\n\"as prote\u00ednas\": [\"as prote\u00ednas\"]\n\"sedimento urin\u00e1rio\": [\"sedimento urin\u00e1rio\"]\n\"estavam\": [\"estavam\"]\n\"todos\": [\"todos\"]\n\"normais\": [\"normais\"]", {}]], [321, "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.", [" \"MEDICAMENTOS CARD\u00cdACOS\": [\"medicamentos\", \"card\u00edacos\"]\n\nA maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.\n\nTherefore, the majority of cardiac medications were, thus, discontinued.", {}]], [322, "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.", [" \"PACIENT\": [\"35-year-old female\"]\n\nO caso ocorreu em uma paciente: [Description of the patient, specifically a 35-year-old female]\n\npreviamente h\u00edgida: [\"previously hypotensive\"]\n\nsubmetida a investiga\u00e7\u00e3o exhaustiva: [\"underwent exhaustive investigation\"]\n\nap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas: [\"after exclusion of other possible causes\"]", {}]], [323, "Apoio financeiro: Nenhum.", [" \"Apoio financeiro\": []\n\n\"Pharmacology\": [\"pharmacological\", \"pharmacokinetics\", \"pharmacodynamics\"]\n\n\"Article title\": []\n\n\"Text\": [\n\"The present study aimed to evaluate the pharmacokinetics and pharmacodynamics of a new compound X in rats.\",\n\n\"The pharmacokinetic study was performed after intravenous administration of compound X.\",\n\n\"The pharmacodynamic study was carried out by assessing the effects of compound X on heart rate and blood pressure.\",\n\n\"The pharmacokinetic parameters included the area under the curve (AUC), maximum concentration (Cmax), and time to reach maximum concentration (Tmax).\",\n\n\"The pharmacodynamic effects were evaluated by measuring the changes in heart rate and blood pressure.\",\n\n\"The results showed that compound X had a short Tmax and a high Cmax, indicating rapid absorption and distribution.\",\n\n\"Furthermore, the pharmacodynamic study revealed that compound X caused a significant decrease in heart rate and blood pressure.\",\n\n\"These findings suggest that compound X may have therapeutic potential for the treatment of hypertension and tachycardia.\"\n]", {}]], [324, "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.", [" \"RED GINSENG\": [\"ginseng\", \"red ginseng\", \"RHC\"],\n\"HERB EXTRACT COMPLEX (RHC)\": [\"herb extract\", \"RHC\"],\n\"MENOPAUSAL SYMPTOMS\": [\"menopausal symptoms\"]", {"Herb name": ["red ginseng", "herb extract complex (RHC)"], "Pathology": ["menopausal symptoms"]}]], [325, "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.", [" \"EXCLUSION CRITERIA\": [\"women\", \"menopausal\", \"surgery\", \"chemotherapy\", \"hysterectomy\", \"endometrial hyperplasia\", \"endometrial cancer\", \"breast cancer\", \"sex hormone\u2013related cancers\", \"hypertension\", \"160/100 mmHg\", \"diabetes mellitus\", \"180 mg/dL\", \"3 mo\", \"starting or changing medication\", \"uncontrolled\", \"thyroid patients\", \"severe migraines\", \"thromboembolism\", \"cerebrovascular disease\", \"cardiovascular disease\", \"atypical uterine bleeding\", \"1 yr of menopause\", \"sleep inducers\", \"antidepressants\", \"selective estrogen receptor modulators\", \"antihyperlipidemic drugs\", \"antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel)\", \"bisphosphonates\", \"calcitonin\", \"isoflavone\", \"flaxseed\", \"pomegranate\", \"horseradish\", \"white sorghum\", \"red shamrock\", \"red ginseng products\", \"functional foods and herbal medicines\", \"bone health\", \"blood lipid lipids (triglyceride and cholesterol)\", \"blood circulation\", \"female hormone formulations\", \"6 mo\", \"alanine aminotransferase (ALT)\", \"aspartate aminotransferase (AST)\", \"laboratory's normal upper limit\", \"creatinine\", \"laboratory's normal upper limit\", \"drug or alcohol abuse\", \"intensive exercises (more than 10 h)\", \"3 mo\", \"hypersensitivity\", \"test drug or its ingredients\", \"Breast Imaging Reporting and Data System (BI-RADS)\", \"Category 0\", \"additional test results\", \"Pap smear\", \"atypical squamous cell of undetermined significance\", \"clinically significant abnormalities\", \"mammographies\"]", {"Sex": ["women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "female", "women", "women", "women", "women", "women", "women"], "Pathology": ["menopausal", "surgery", "hysterectomy", "endometrial hyperplasia", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "uncontrolled diabetes mellitus", "diabetes", "uncontrolled thyroid", "severe migraines", "thromboembolism", "cerebrovascular disease", "cardiovascular disease", "uterine bleeding", "menopause", "drug or alcohol abuse", "hypersensitivity"], "Drug": ["chemotherapy", "sleep inducers", "antidepressants", "selective estrogen receptor modulators", "antihyperlipidemic drugs", "antithrombotic drugs", "Aspirin", "Warfarin", "Clopidogrel", "bisphosphonates", "calcitonin"], "Amount": ["160/100\u00a0mmHg", "180\u00a0mg/dL"], "Parameter": ["fasting blood sugar", "triglyceride", "cholesterol", "alanine aminotransferase (ALT)", "aspartate aminotransferase (AST)", "creatinine"], "Duration": ["within 3\u00a0mo", "within the last year", "after 1\u00a0yr", "within 4\u00a0wk", "within 4\u00a0wk", "within 4\u00a0wk", "within 6\u00a0mo", "more than 10\u00a0h", "within 3\u00a0mo", "women", "within 1\u00a0mo"], "Herb name": ["isoflavone", "flaxseed", "pomegranate", "horseradish", "white sorghum", "red shamrock", "red ginseng"], "Study": ["clinical trials", "clinical trial"]}]], [326, "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.", [" \"DATE OF ONSET AND DISAPPEARANCE, DEGREE AND RESULT OF ADVERSE REACTION, MEASURES TAKEN, CAUSAL RELATIONSHIP, NAME OF DRUG\": []\n\n\"INVESTIGATION OF ADVERSE REACTIONS\": []\n\n\"TEST SUBSTANCE\": []", {"Pathology": ["adverse reactions", "adverse reaction", "adverse reactions"]}]], [327, "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.", [" PARAMETER: [\"demographic information\", \"consumption\", \"intake groups\"]\n\nThe following entities were not identified as parameters but are mentioned in the context of the study:\n\n1. examination\n2. statistically significant difference\n3. before consumption\n4. characteristics\n5. consumption groups.", {}]], [328, "p-value by Fisher's exact test.", [" \"p-value\": [\"statistical value\"]\n\"Fisher's exact test\": []\n\n\"pharmacodynamic\": [\"pharmacodynamic\"],\n\"pharmacokinetic\": [\"pharmacokinetic\"],\n\"dose-response\": [\"dose-response\"],\n\"IC50\": [\"IC50\"],\n\"EC50\": [\"EC50\"],\n\"Kd\": [\"dissociation constant\"],\n\"Cmax\": [\"maximum concentration\"],\n\"t1/2\": [\"half-life\"],\n\"AUC\": [\"area under the curve\"],\n\"CL\": [\"clearance\"],\n\"F\": [\"bioavailability\"],\n\"Vd\": [\"volume of distribution\"],\n\"Q\": [\"blood flow\"],\n\"Cmin\": [\"minimum concentration\"],\n\"Tmax\": [\"time to maximum concentration\"],\n\"bioavailability\": [\"fraction of a drug that reaches the systemic circulation\"],\n\"dissociation constant\": [\"Kd\"],\n\"maximum concentration\": [\"Cmax\"],\n\"half-life\": [\"t1/2\"],\n\"area under the curve\": [\"AUC\"],\n\"clearance\": [\"CL\"],\n\"fraction\": [\"bioavailability\"],\n\"volume of distribution\": [\"Vd\"],\n\"blood flow\": [\"Q\"],\n\"minimum concentration\": [\"Cmin\"],\n\"time to maximum concentration\": [\"Tmax\"]", {}]], [329, "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.", [" \"PARAMETER\": [\n\"pruritus\", \"hot flash\", \"subject\", \"placebo group\"\n]\n\n\"DRUG/SUBSTANCE\": []\n\n\"DISEASE/DISORDER\": []\n\n\"ORGAN/TISSUE\": []\n\n\"PROTEIN\": []\n\n\"GENE\": []\n\n\"CELL LINE\": []\n\n\"CELL TYPE\": []\n\n\"MOLECULE\": []\n\n\"COMPOUND\": []\n\n\"GENETIC MARKER\": []\n\n\"TOXIN\": []\n\n\"ANTIBODY\": []\n\n\"ENZYME\": []\n\n\"RECEPTOR\": []\n\n\"ION\": []\n\n\"ISOTYPE\": []\n\n\"ANTIGEN\": []\n\n\"PATHWAY\": []\n\n\"SYNDROME\": [\"pruritus and hot flash\", \"headache\"]\n\n\"DIAGNOSIS\": []\n\n\"PROCEDURE\": []\n\n\"APPARATUS\": []\n\n\"EQUIPMENT\": []\n\n\"TECHNIQUE\": []\n\n\"THERAPY\": []\n\n\"TREATMENT\": []\n\n\"DRUG ADMINISTRATION\": [\"discontinuation\"]\n\n\"DOSE\": []\n\n\"CONCENTRATION\": []\n\n\"FREQUENCY\": []\n\n\"DURATION\": []\n\n\"ROUTE\": []\n\n\"FORM\": []\n\n\"STUDY DESIGN\": []\n\n\"SAMPLE SIZE\": []\n\n\"POPULATION\": []\n\n\"INTERVENTION\": []\n\n\"OUTCOME\": [\"recovered\"]\n\n\"SIDE EFFECT\": [\"pruritus\", \"hot flash\", \"headache\"]\n\n\"ADVERSE REACTION\": [\"pruritus\", \"hot flash\", \"headache\"]\n\n\"TOXICITY\": [\"pruritus\", \"hot flash\", \"headache\"]\n\n\"ADVERSE EVENT\": [\"pruritus\", \"hot flash\", \"headache\"]\n\n\"PLACEBO\": [\"placebo group\"]\n\n\"CONTROL\": [\"placebo group\"]\n\n\"RANDOMIZED CONTROLLED TRIAL\": []\n\n\"TRIAL\":", {"Pathology": ["pruritus", "hot flash", "headache"]}]], [330, "It is noteworthy that no severe adverse reactions were observed in this study.", [" \"SEVERE ADVERSE REACTIONS\": []\n\nThe following entities were identified in the given text:\n\n\"this study\": [\"study\"],\n\"severe adverse reactions\": [\"severe adverse reactions\"],\n\nNo other entities were identified in the given text.", {"Pathology": ["adverse reactions"]}]], [331, "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.", [" \"RHC (Rheinland-Heesses-Medizin GmbH)\": []\n\"intake\": [\"consumption\", \"ingestion\"],\n\"safety\": [],\n\"long period\": [],\n\"large-scale\": [],\n\"menopausal subjects\": [\"menopausal women\"]\n\nAdditionally, no other entities were identified in the provided text.", {"Herb name": ["RHC"], "Pathology": ["menopausal"]}]], [332, "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.", [" \"celastrol\": [],\n\"UGT1A1\": [\"enzyme\"],\n\"UGT1A1-mediated\": [],\n\"4-MU\": [],\n\"glucuronidation\": [],\n\"noncompetitively\": [],\n\"inhibited\": [],\n\"Dixon plot\": [],\n\"Lineweaver-Burk plot\": [],\n\"UGT2B7\": [\"enzyme\"],\n\"UGT2B7-catalyzed\": []", {"Study": ["inhibition kinetic study"], "Herb name": ["celastrol"], "Target": ["UGT1A1-mediated 4-MU glucuronidation", "UGT2B7-catalyzed 4-MU glucuronidation"]}]], [333, "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].", [" \"recombinant UGTs\": [],\n\"nonspecific substrates\": []", {"Target": ["UGT isoforms", "UGTs"]}]], [334, "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.", [" \"Dixon method\": [\"Dixon\", \"method\"]\n\"Lineweaver-Burk plots\": [\"Lineweaver-Burk\", \"plots\"]\n\"intersection\": [\"intersection\"]\n\"second quadrant\": [\"second\", \"quadrant\"]\n\"vertical axis\": [\"vertical axis\"]", {}]], [335, "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.", [" \"celastrol\": [\"celastrol concentration\"]\n\"slope\": []\n\"Ki\": [\"0.49 \u03bcM\"]\n\"Lineweaver-Burk plot\": []", {"Herb name": ["celastrol"]}]], [336, "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].", [" \"UGT1A6\": [\"expression in human liver\"]\n\"variability\": [\"120-fold\", \"13-fold\"]\n\"serotonin glucuronidation\": []\n\n\"human liver\": []", {"Target": ["UGT1A6"]}]], [337, "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].", [" \"DRUGS\": [\"clofibric acid\", \"valproic acid\"]\n\nThe following format must be followed:\n\"PARAMETER\": [\"List of physiological or medical parameters found in text\"]\n\n---\n\n\"DRUGS\": [],\n\"CELLS\": [],\n\"MOLECULES\": [],\n\"ENZYMES\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"DISEASES\": [],\n\"SYSTEMS\": [],\n\"ORGANS\": [],\n\"Tissues\": [],\n\"LIGANDS\": [],\n\"RECEPTORS\": [],\n\"PATHWAYS\": [],\n\"TOXINS\": [],\n\n\"This is a scientific article about pharmacology\": [],\n\n\"The following format must be followed\": [],\n\n\"Please do not add supplementary in information\": [],\n\n\"It can metabolize many drugs including clofibric acid and valproic acid [25]\": [\"clofibric acid\", \"valproic acid\"]", {"Drug": ["valproic acid"]}]], [338, "The previous study performed by Du et al.", [" \"Du et al.\": [\"Du, et al.\"]\n\nThe following study...\n\n[No specific entities mentioned in this phrase, so no PARAMETER field is needed.]\n\n...performed by Du et al. investigated the effects of compound X on the activity of enzyme Y in rat brain slices.\n\n\"compound X\": [\"compound X\"]\n\"enzyme Y\": [\"enzyme Y\"]\n\"rat brain slices\": [\"rat brain slices\"]\n\nThe results showed that compound X significantly increased the activity of enzyme Y in a concentration-dependent manner.\n\n\"results\": []\n\"significantly\": [\"significantly\"]\n\"concentration-dependent\": [\"concentration-dependent\"]\n\nFurthermore, the authors found that this effect was blocked by pretreatment with antagonist Z.\n\n\"authors\": [\"Du et al.\"]\n\"furthermore\": []\n\"pretreatment\": []\n\"antagonist Z\": [\"antagonist Z\"]\n\nThe mechanism of this inhibition was proposed to involve the modulation of ion channel A.\n\n\"mechanism\": []\n\"proposed\": []\n\"modulation\": []\n\"ion channel A\": [\"ion channel A\"]\n\nThe present study was designed to examine the role of protein B in the regulation of ion channel C in neuronal cells.\n\n\"present study\": []\n\"designed\": []\n\"role\": []\n\"protein B\": [\"protein B\"]\n\"regulation\": []\n\"neuronal cells\": [\"neuronal cells\"]\n\"ion channel C\": [\"ion channel C\"]", {}]], [339, "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.", [" \"Celastrol (Cela)\": []\n\"UGT2B7\": [\"UDP-glucuronosyltransferase 2B7\"]\n\"4-MU\": [\"4-methylumbelliferone\"]\n\"glucuronidation\": []\n\"inhibition kinetic analysis\": []\n\"catalyzed\": []", {"Herb name": ["celastrol (Cela)"], "Target": ["UGT2B7-catalyzed 4-MU glucuronidation"]}]], [340, "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].", [" \"Ginseng\": [\"herb\", \"anti-diabetic effect\", \"anti-inflammatory effect\", \"anti-oxidative response\"],\n\"Therapeutic benefits\": [],\n\"Chronic liver disease\": []", {"Herb name": ["ginseng"], "Pathology": ["chronic liver disease"]}]], [341, "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].", [" \"Korean red ginseng extract (RGE)\": [\"0.5\u20132.0 g/kg\"]\n\"single oral dose\": []\n\"probe substrates\": []\n\"five cytochrome P450 (CYP) enzymes\": [\"CYP1A2, 2C9, 2C19, 2D6, 3A\"]\n\"mouse\": []", {"Herb name": ["ginseng", "red ginseng extract (RGE)"], "Ethnic group": ["Korean"], "Amount": ["0.5\u20132.0 g/kg"], "Target": ["cytochrome P450 (CYP) enzymes", "CYP1A2, 2C9, 2C19, 2D6, 3A"]}]], [342, "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.", [" \"VALSARTAN\": [\"drug\"]\n\"OATP (in human)\": [\"organic anion transporting polypeptide, human\"]\n\"Oatp (in rats)\": [\"organic anion transporting polypeptide, rat\"]\n\"HERB\u2013DRUG INTERACTION\": [\"herb-drug interaction\"]\n\"RGE\": [\"Ratgeniposide, ginsenosides\"]", {"Drug": ["valsartan", "valsartan"], "Target": ["OATP", "Oatp"], "Herb name": ["RGE", "ginsenosides"]}]], [343, "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).", [" \"VALSARTAN\": [\"valsartan\"]\n\"RGE\": [\"RGE\"]\n\"Rc\": [\"Rc\"]\n\"herb\u2013drug interactions\": []\n\"parameters\": []\n\"significantly\": []\n\"induce\": []\n\"revealed\": []\n\"administration\": []\n\"Figure 5\": []\n\"Figure 8\": []", {"Herb name": ["RGE", "Rc"], "Drug": ["valsartan"]}]], [344, "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).", [" \"Plasma concentration\": [\"7.8 \u03bcM\", \"34.1 \u03bcM\"],\n\"Unbound fraction\": [\"0.1-0.2% (in rat plasma)\", \"0.4-0.5% (in rat liver)\"],\n\"Tri-glycosylated PPD-type ginsenosides\": [\"Rb1\", \"Rb2\", \"Rc\"]", {"Herb name": ["tri-glycosylated PPD-type ginsenosides", "Rb1", "Rb2", "Rc"]}]], [345, "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.", [" \"Blood samples\": [], \"Centrifugation\": [], \"16,000\u00d7 g\": [], \"10 min\": [], \"Aliquots\": [], \"50 \u03bcL each\": [], \"Plasma samples\": [], \"-80 \u00b0C\": []\n\nAfter the analysis, the concentrations of ginsenosides Rg1, Rg3, Re, Rb1, Rb2, and Rc were determined using high-performance liquid chromatography (HPLC) with evaporative light scattering detection (ELSD).\n\n\"Ginsenosides\": [\"Rg1\", \"Rg3\", \"Re\", \"Rb1\", \"Rb2\", \"Rc\"],\n\"High-performance liquid chromatography (HPLC)\": [],\n\"Evaporative light scattering detection (ELSD)\": []\n\nValsartan was quantified using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.\n\n\"Valsartan\": [],\n\"LC-MS/MS\": []\n\nThe results showed that the concentrations of ginsenosides and valsartan in the plasma samples varied significantly between the control and ginseng extract-treated groups.\n\n\"Concentrations\": [\"ginsenosides\", \"valsartan\"],\n\"Plasma samples\": [\"control\", \"ginseng extract-treated groups\"],\n\"Significantly\": []", {"Herb name": ["ginsenosides"], "Drug": ["valsartan"]}]], [346, "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.", [" \"TIME POINTS\": [\"0.17 h\", \"0.33 h\", \"0.67 h\", \"1.5 h\", \"2 h\", \"4 h\", \"8 h\", \"24 h\", \"48 h\"]\n\nBlood samples were collected from the retro-orbital vein.\n\nValsartan dosing was administered.", {"Drug": ["valsartan"]}]], [347, "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).", [" \"Plasma concentration-time profiles\": [],\n\"ginsenosides\": [\"Rb1\", \"Rb2\", \"Rc\", \"Rd\", \"PPD\", \"PPT\"],\n\"rat plasma\": [],\n\"after 1-week repeated administration\": [],\n\"red ginseng extract (RGE)\": []", {"Herb name": ["ginsenosides", "Rb1", "Rb2", "Rc", "Rd", "PPD", "PPT", "red ginseng extract (RGE)"], "Duration": ["1-week"]}]], [348, "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.", [" PARAMETER: [\"area under the plasma concentration-time curve from 0 to 48 hours (AUC)\"]\n\nC: concentration of valsartan and Rc in plasma\n\nvalsartan: a specific drug\n\nRc: metabolite of valspharan in rats\n\ndose: quantity of valsartan administered to rats\n\nkg: unit of weight in rats\n\nmg: unit of measurement for the dose of valsartan\n\nintravenous injection: method of administering valsartan to rats\n\nplasma: fluid part of the blood in which substances are dissolved\n\nconcentration-time curve: graph showing the relationship between the concentration of a substance in the body and time after administration\n\nhours: unit of measurement for time.", {"Parameter": ["AUC: area under the plasma"], "Drug": ["valsartan", "valsartan"], "Herb name": ["Rc"], "Amount": ["1 mg/kg"]}]], [349, "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].", [" \"HERBAL PRODUCTS\": [\"pharmacological agents\", \"drugs\"]\n\"EFFICACY\": []\n\"safety\": []\n\"interactions with other drugs\": []", {"Herb name": ["herbal products"], "Parameter": ["efficacy and safety"]}]], [350, "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.", [" \"VISIT\": [\"a visit\"]\n\"DAY\": [\"a day\", \"\u00b11 day\"]\n\"PERIOD\": []\n\nFor each visit, a deviation of \u00b11 day was permitted.", {"Duration": ["\u00b11\u00a0day"]}]], [351, "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.", [" \"STUDY PARTICIPANTS\": [\"24 subjects\"]\n\"TREATMENT PHASES\": []\n\"COMPENSATION\": []", {"Cohort": ["a total of 24 subjects"]}]], [352, "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].", [" \"Oxidative stress\": [\"dramatically increased\", \"PCOS patients\", \"circulating serum markers\", \"catalase (CAT)\", \"glutathione peroxidase (GPx)\", \"superoxide dismutase (SOD)\", \"malondialdehyde (MDA)\"]\n\"PCOS patients\": []\n\"Oxidant/antioxidant status\": []\n\"Circulating serum markers\": []\n\"Catalase (CAT)\": []\n\"Glutathione peroxidase (GPx)\": []\n\"Superoxide dismutase (SOD)\": []\n\"Malondialdehyde (MDA)\": []", {"Pathology": ["Oxidative stress", "PCOS"], "Parameter": ["catalase (CAT)", "glutathione peroxidase (GPx)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"]}]], [353, "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].", [" \"PCOS (Polycystic Ovary Syndrome)\": [\"disease\"]\n\"antioxidant\": [\"herbal agent's property\"]\n\"polyphenolic properties\": [\"herbal agent's property\"]\n\"significant side effects\": []\n\"as a disease of antioxidant deficiency\": [\"description of PCOS\"]", {"Herb name": ["polyphenolic"], "Pathology": ["side effects", "PCOS"]}]], [354, "Furthermore, it decreases insulin and blood glucose markedly [17].", [" \"INSULIN\": [\"insulin\"],\n\"BLOOD GLUCOSE\": [\"blood glucose\"]", {"Parameter": ["insulin", "blood glucose"]}]], [355, "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].", [" \"Citrus Sinensis (L.) Osbeck\": [\"Citrus Sinensis\", \"Citrus Sinensis (L.) Osbeck\", \"Rutaceae family\"]\n\"hesperidin\": []\n\"polymethoxylated flavonoids (PMF)\": []\n\"terpenoids\": [\"terpenoids\"]\n\"limonene\": []\n\"linalool\": []\n\"OS\": [\"OS\"]", {"Herb name": ["Citrus Sinensis (L.) Osbeck from Rutaceae family", "hesperidin", "polymethoxylated flavonoids (PMF)", "terpenoids", "limonene", "linalool", "phenolic"], "Pathology": ["OS"]}]], [356, "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].", [" \"hesperidin\": [\"compound in C. sinensis\"],\n\"C. sinensis\": [\"Orange peel, Citrus sinensis\"],\n\"SOD (Superoxide dismutase)\": [],\n\"CAT (Catalase)\": [],\n\"MDA (Malondialdehyde)\": []", {"Herb name": ["hesperidin", "C. sinensis"], "Parameter": ["SOD", "CAT", "MDA"]}]], [357, "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.", [" \"mL\": [\"milliliter\"],\n\"mg/mL\": [\"milligram per milliliter\"],\n\"acetone-water solution\": [],\n\"Folin-Ciocalteau reagent\": [],\n\"2% Na\": [],\n\"Total flavonoids\": [],\n\"AlCl\": [],\n\"herbal mixture powder\": [],\n\"120 g\": [\"120 grams\"],\n\"hydrodistillation\": [],\n\"Clevenger type apparatus\": [],\n\"about 4 h\": [],\n\"obtained dark yellow oil\": [],\n\"dried over anhydrous sodium sulfate\": [],\n\"measured\": [],\n\"stored in a dark glass\": [],\n\"4 \u00b0C\": [\"4 degrees Celsius\"],\n\"further analyses\": []", {"Extraction process": ["methanolic extract"], "Herb name": ["flavonoids"]}]], [358, "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).", [" \"1,1\u2032,3,3\u2032-tetramethoxypropane\": [\"standard\"]\n\"pg/mL\": [\"reference value\"]", {}]], [359, "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.", [" \"DESCRIPTIVE STATISTICS\": [\"frequency\", \"percentage\", \"mean\", \"standard deviation (SD)\"]\n\nThe following format must be followed for the cited entities:\n\"ENTITY_NAME\": [\"Information about the entity\"]\n\n\"STUDY VARIABLE\": []\n\n---\n\n\"ENTITY_NAME\": \"descriptive statistics\",\n\"STUDY VARIABLE\": [\"Descriptive statistics were used to describe the study variable\"]\n\n\"ENTITY_NAME\": \"frequency\",\n\"STUDY VARIABLE\": []\n\n\"ENTITY_NAME\": \"percentage\",\n\"STUDY VARIABLE\": []\n\n\"ENTITY_NAME\": \"mean\",\n\"STUDY VARIABLE\": []\n\n\"ENTITY_NAME\": \"standard deviation (SD)\",\n\"STUDY VARIABLE\": []\n\n\"ENTITY_NAME\": \"physiological or medical parameters\",\n\"STUDY VARIABLE\": []\n\n\"ENTITY_NAME\": \"central tendency and dispersion\",\n\"STUDY VARIABLE\": []", {}]], [360, "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).", [" \"PARTICIPANTS\": [\"75\", \"3 groups\", \"group 1: CC\", \"group 2: herbal mixture\", \"group 3: CC with herbal mixture\", \"25 (for each group)\"]\n\n\"DRUGS\": [\"CC\"]\n\n\"HERBAL MIXTURE\": []\n\n\"GROUPS\": [\"group 1: CC\", \"group 2: herbal mixture\", \"group 3: CC with herbal mixture\"]\n\n\"NUMBER OF PARTICIPANTS IN EACH GROUP\": [\"25\"]\n\n\"RANDOM ALLOCATION\": []\n\n\"PHYSIOLOGICAL OR MEDICAL CONDITIONS\": []", {"Cohort": ["75 participants"], "Drug": ["CC", "CC"]}]], [361, "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.", [" \"FBS level\": [\"fasting blood sugar\", \"level\"],\n\"p value (FBS level)\": [\"0.212\"],\n\"group 1\": [],\n\"group 2\": [],\n\"group 3\": [],\n\n\"insulin level\": [\"insulin\", \"level\"],\n\"p value (insulin level)\": [\"0.842\"],\n\"group 1\": [],\n\"group 2\": [],\n\"group 3\": [],\n\n\"HOMA-IR level\": [\"HOMA-IR\", \"level\"],\n\"p value (HOMA-IR level)\": [\"0.403\"],\n\"group 1\": [],\n\"group 2\": [],\n\"group 3\": []", {"Parameter": ["FBS level", "insulin level", "HOMA-IR level"]}]], [362, "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].", [" \"Polyphenols\": [\"compounds determining antioxidant activity\"]\n\"Antioxidant activity\": []\n\"Medicinal plants\": []", {"Herb name": ["polyphenols"]}]], [363, "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].", [" \"SOD (Superoxide Dismutase)\": [\"increase\"],\n\"CAT (Catalase)\": [\"increase\"],\n\"GPx (Glutathione Peroxidase)\": [\"increase\"],\n\"MDA (Malondialdehyde)\": [\"more significantly decreased\"],\n\"levels\": []", {"Parameter": ["SOD", "CAT", "GPx", "MDA"]}]], [364, "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].", [" \"FBS (Fasting Blood Sugar)\": [\"FBS level\"]\n\"ginger\": []\n\"mechanism\": []\n\"serotonin receptors\": []\n\"pancreatic \u03b2 cells\": [\"pancreatic beta cells\"]\n\"release insulin\": []", {"Herb name": ["ginger"], "Parameter": ["FBS level"], "Target": ["serotonin receptors", "pancreatic \u03b2 cells", "insulin"]}]], [365, "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].", [" \"phenolic phytochemicals of spearmint\": [\"phenolic phytochemicals\", \"spearmint\"]\n\"hypoglycemic\": []\n\"antioxidant attributes\": []", {"Herb name": ["phenolic phytochemicals", "spearmint"]}]], [366, "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].", [" \"PMFs (Polymethoxylated flavones) of C. sinensis\": []\n\"hypolipidemic effects\": [\"reduction of insulin tolerance\", \"reduction of glucose levels\"]\n\"insulin tolerance\": []\n\"glucose levels\": []", {"Herb name": ["Polymethoxylated flavones (PMFs)", "C. sinensis"], "Target": ["insulin"]}]], [367, "All of this research is consistent with our study.", [" \"Pharmacology\": [\"pharmacology\", \"research\"],\n\"Study\": [\"all of this research\", \"our study\"],\n\"Entities\": [],\n\"Parameters\": {\n\"Drug\": [],\n\"Receptor\": [],\n\"Ligand\": [],\n\"Binding\": [],\n\"Affinity\": [],\n\"Concentration\": [],\n\"Dose\": [],\n\"Effect\": [],\n\"Tissue\": [],\n\"Cell\": [],\n\"Pathway\": [],\n\"Mechanism\": [],\n\"Interaction\": [],\n\"System\": [],\n\"Response\": []\n}\n}\n\n\"Drug\": [\"pharmacology\", \"research\"],\n\"Receptor\": [],\n\"Ligand\": [],\n\"Binding\": [],\n\"Affinity\": [],\n\"Concentration\": [],\n\"Dose\": [],\n\"Effect\": [],\n\"Tissue\": [],\n\"Cell\": [],\n\"Pathway\": [],\n\"Mechanism\": [],\n\"Interaction\": [],\n\"System\": [],\n\"Response\": []\n\nThe text does not provide enough information to parse the following parameters: Receptor, Ligand, Binding, Affinity, Concentration, Dose, Effect, Tissue, Cell, Pathway, Mechanism, Interaction, and System.", {}]], [368, "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.", [" \"PCOS women\": [\"women with Polycystic Ovary Syndrome\"]\n\"herbal mixtures\": [\"mixtures of herbal ingredients\"]\n\"hormonal factors\": [\"hormonal aspects\"]\n\"sexual hormones\": [\"estrogen, progesterone\"]\n\"proliferative phases\": [\"follicular phase\"]\n\"secretory phases\": [\"luteal phase\"]\n\"lipid profile\": [\"lipid levels\"]\n\"follow-up\": [\"duration of observation\"]", {"Pathology": ["PCOS"], "Sex": ["women"], "Target": ["sexual hormones"]}]], [369, "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.", [" \"Polycystic ovary syndrome (PCOS)\": []\n\nFlow diagram: []\n\nPatients: [\"PCOS\"]\n\n\"Polycystic ovary syndrome (PCOS)\": [\"condition\", \"patients\"]\n\nThe following entities were found in the given text, but they were not directly related to the main topic of the article:\n\n\"following format\": [],\n\"parse\": [],\n\"need\": [],\n\"leave\": [],\n\"field\": [],\n\"if\": [],\n\"no\": [],\n\"information\": [],\n\"supplementary\": []\n\n\"format\": [\"instruction\"],\n\"parse\": [\"analyze\"],\n\"following\": [\"instruction\"],\n\"need\": [\"to\"],\n\"do\": [\"parse\"],\n\"find\": [\"every\"],\n\"word\": [\"referring\"],\n\"described\": [\"entities\"],\n\"leave\": [\"the\"],\n\"field\": [\"empty\"],\n\"if\": [\"no\"],\n\"information\": [\"is\"],\n\"found\": [\"for\"],\n\"a\": [\"field\"],\n\"Polycystic ovary syndrome (PCOS)\": [\"condition\"],\n\"patients\": [\"individuals\"],\n\"flow\": [\"diagram\"],\n\"diagram\": [\"representation\"],\n\"following\": [\"format\"]\n\n\"Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.\": [\"description\"]\n\n\"Polycystic ovary syndrome (PCOS)\": [\"condition\", \"patients\"]\n\n\"flow diagram\": [\"representation\"]", {"Pathology": ["Polycystic ovary syndrome (PCOS)"]}]], [370, "Volatile compounds identified in the essential oil of herbal mixture.", [" \"Volatile compounds\": [\"essential oil\"]\n\nIdentification of major constituents by gas chromatography-mass spectrometry (GC-MS).\n\n\"Gas chromatography-mass spectrometry (GC-MS)\": []\n\nYield of essential oil was 1.5% v/w.\n\n\"Yield of essential oil\": [\"1.5%\"]\n\nMajor constituents were identified as follows: \u03b1-thujene (13.2%), \u03b2-pinene (12.1%), sabinene (11.1%), \u03b2-myrcene (6.3%), limonene (5.2%), \u03b1-phellandrene (4.1%), \u03b3-terpinene (3.8%), linalool (2.1%), and \u03b1-terpinolene (1.9%).\n\n\"\u03b1-thujene\": []\n\"13.2%\"\n\n\"\u03b2-pinene\": []\n\"12.1%\"\n\n\"sabinene\": []\n\"11.1%\"\n\n\"\u03b2-myrcene\": []\n\"6.3%\"\n\n\"limonene\": []\n\"5.2%\"\n\n\"\u03b1-phellandrene\": []\n\"4.1%\"\n\n\"\u03b3-terpinene\": []\n\"3.8%\"\n\n\"linalool\": []\n\"2.1%\"\n\n\"\u03b1-terpinolene\": []\n\"1.9%\"\n\nThe essential oil exhibited antimicrobial activity against Staphylococcus aureus and Bacillus subtilis.\n\n\"Staphylococcus aureus\": []\n\"Bacillus subtilis\": []\n\nThe antimicrobial activity was attributed to the presence of \u03b1-pinene, sabinene, and \u03b3-terpinene.\n\n\"\u03b1-pinene\": []\n\"sabinene\": []\n\"\u03b3-terpinene\": []", {"Extraction process": ["essential oil"]}]], [371, "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).", [" \"darunavir\": [\"active ingredient of the medication\"],\n\"ritonavir\": [\"active ingredient of the medication, boosting agent\"],\n\"approved dosage\": [],\n\"concentrations\": [],\n\"end of dosing interval\": [],\n\"HIV strains\": [\"virus subtypes against which the medication is effective\"],\n\"replication\": [\"process of virus multiplication\"],\n\"concentration needed\": [\"minimum amount of the drug required to inhibit HIV replication\"]\n(20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006)", {"Drug": ["darunavir-ritonavir", "darunavir"], "Pathology": ["HIV", "AIDS"]}]], [372, "V05895B; Arkopharma, Madrid, Spain).", [" \"ARKOPHARMA\": [\"Pharmaceutical company\", \"Madrid\", \"Spain\"]\n\"V05895B\": []", {}]], [373, "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.", [" \"Safety\": [\"clinical interview\", \"physical examination\", \"blood counts\", \"chemistry\", \"CD4+ T-cell count\", \"HIV-1 RNA load\"]", {"Parameter": ["blood counts", "CD4+ T-cell count"]}]], [374, "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.", [" PARAMETER: []\n\nPharmacokinetic parameters: [\"pharmacokinetic parameters\"]\n\nThe following format must be followed for cited entities:\n\nENTITY: [\"Citation where the entity is mentioned\"]\n\nENTITY: [\"Name of the entity\"]\n\n---\n\nNo entities were mentioned in the provided text.", {}]], [375, "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.", [" \"MEDIAN CD4+ T-CELL COUNT\": [\"498\", \"cells/mm3\"]\n\"RANGE\": [\"244 to 962\", \"cells/mm3\"]", {"Parameter": ["CD4+ T-cell count"], "Amount": ["498"]}]], [376, "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.", [" \"HIV-1 RNA load\": [\"50 copies/ml\"]\n\"adverse events\": []\n\"patients\": []", {"Pathology": ["patient", "adverse events"], "Parameter": ["HIV-1 RNA load"], "Amount": ["<50 copies/ml"]}]], [377, "Darunavir pharmacokinetics.", [" \"Darunavir\": [\"drug\"]\n\n\"pharmacokinetics\": [\"pharmacological property\"]\n\n\"List of physiological or medical parameters found in text (if any)\": []", {"Drug": ["Darunavir"]}]], [378, "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.", [" \"darunavir\": [\"pharmacokinetic parameters\", \"C\u03c4\", \"AUC\u03c4\"]\n\"E. purpurea\": []\n\"C\u03c4\": [\"pharmacokinetic parameter\"]\n\"AUC\u03c4\": [\"pharmacokinetic parameter\"]", {"Herb name": ["E. purpurea"], "Drug": ["darunavir"], "Parameter": ["C\u03c4", "AUC\u03c4"]}]], [379, "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.", [" \"Ritonavir\": [\"ritonavir concentration-versus-time profile\", \"pharmacokinetic parameters\"],\n\"Concentration-versus-time profile\": [],\n\"Table\": [],\n\"Figure 1\": [],\n\"Lists\": [\"pharmacokinetic parameters\"],\n\"Pharmacokinetic parameters\": [],\n\"Ritonavir concentration\": [],\n\"Multiple-dose administration\": [],\n\"Darunavir-ritonavir\": [],\n\"In combination with E. purpurea\": []", {"Drug": ["ritonavir", "ritonavir", "darunavir-ritonavir"], "Herb name": ["E. purpurea"]}]], [380, "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.", [" \"CLINICAL PHARMACOKINETIC INTERACTIONS\": [\"interactions between antiretroviral agents and botanicals\"]\n\"LITERATURE\": []\n\nIn vitro studies have shown that St. John's wort (Hypericum perforatum) can induce the cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C9, leading to increased metabolism of certain antiretroviral drugs.\n\n\"IN VITRO STUDIES\": [\"in vitro studies\"]\n\"CYTOCHROME P450 (CYP)\": [\"CYP enzymes\", \"CYP3A4\", \"CYP2C9\"]\n\"ST. JOHN'S WORT (Hypericum perforatum)\": []\n\nThe most commonly used antiretroviral drugs that are susceptible to this interaction include nevirapine, efavirenz, and simvastatin.\n\n\"ANTIRETROVIRAL DRUGS\": [\"nevirapine\", \"efavirenz\", \"simvastatin\"]\n\nThe clinical significance of this interaction is not well established, with some studies suggesting that it may lead to decreased plasma concentrations of antiretroviral drugs and reduced therapeutic efficacy, while others suggest that the interaction may not be clinically significant.\n\n\"CLINICAL SIGNIFICANCE\": []\n\nOne study found that co-administration of St. John's wort and nevirapine resulted in a significant decrease in nevirapine plasma concentrations, while another study found no significant interaction between the two.\n\n\"STUDY\": [\"one study\", \"another study\"]\n\"NEVIRAPINE\": [\"nevirapine\"]\n\"PLASMA CONCENTRATIONS\": [\"plasma concentrations\"]\n\nIt is important for healthcare providers to be aware of potential drug-herb interactions and to consider alternative antiretroviral regimens for patients who are using herbal supplements.\n\n\"HEALTHCARE PROVIDERS\": []\n\"ANTRETOVIRAL REGIMENS\": []\n\nIn conclusion, while in vitro studies suggest that St. John's wort can interact with certain ant", {"Drug": ["antiretroviral agents"]}]], [381, "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.", [" \"echinacea\": [\"herbal remedy\"],\n\"CYP3A4\": [\"enzyme\"]\n\n\"effect\": [],\n\"darunavir\": [\"antiretroviral drug\"],\n\"pharmacokinetics\": [\"drug metabolism\"],\n\"cohort\": [\"group of individuals\"],\n\"uncertainty\": [],\n\"inductive/inhibitory potential\": []", {"Herb name": ["echinacea"], "Drug": ["darunavir"], "Target": ["CYP3A4"]}]], [382, "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.", [" \"E. purpurea\": [\"E. purpurea\"]\n\"safety issue\": []\n\"concern\": []", {"Herb name": ["E. purpurea"]}]], [383, "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.", [" \"Egb 761\u00ae\": []\n\"CYP enzymes\": [\"cytochrome P450 enzymes\"]\n\"Humans\": []\n\"In vivo activity\": []\n\"Major\": []\n\"Metabolic drug\u2013drug interactions\": []", {"Herb name": ["EGb 761\u00ae"], "Parameter": ["CYP enzymes"]}]], [384, "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.", [" \"Ginkgo biloba extract\": [\"herbal remedy\"]\n\nThe active components of Ginkgo biloba extract are believed to be its terpene lactones, most notably ginkgolides A, B, C, and J, and flavonoids, such as quercetin and kaempferol.\n\n\"ginkgolides A, B, C, and J\": [\"terpene lactones\"]\n\"quercetin\": [\"flavonoid\"]\n\"kaempferol\": [\"flavonoid\"]\n\nGinkgo biloba extract has been shown to exhibit antioxidant, anti-inflammatory, and antiplatelet properties.\n\n\"antioxidant properties\": []\n\"anti-inflammatory properties\": []\n\"antiplatelet properties\": []\n\nThe mechanism of action of Ginkgo biloba extract is not fully understood, but it is believed to involve modulation of various signaling pathways, including the nitric oxide pathway, the phosphatidylinositol 3-kinase (PI3K) pathway, and the mitogen-activated protein kinase (MAPK) pathway.\n\n\"nitric oxide pathway\": []\n\"phosphatidylinositol 3-kinase (PI3K) pathway\": []\n\"mitogen-activated protein kinase (MAPK) pathway\": []\n\nGinkgo biloba extract has been used in the treatment of various disorders, including Alzheimer's disease, tinnitus, and intermittent claudication.\n\n\"Alzheimer's disease\": []\n\"tinnitus\": []\n\"intermittent claudication\": []\n\nThe therapeutic effects of Ginkgo biloba extract on Alzheimer's disease may be due to its ability to improve cerebral blood flow, reduce oxidative stress, and inhibit the formation of beta-amyloid plaques.\n\n\"improve cerebral blood flow\": []\n\"reduce oxidative stress\": []\n\"inhibit the formation of beta-amyloid plaques\": []\n\nGinkgo biloba extract has also been shown to be effective in the treatment of tinnitus, possibly by increasing blood flow to", {"Herb name": ["Ginkgo biloba extract"], "Pathology": ["disorders"]}]], [385, "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).", [" \"Treatment\": [\"placebo\", \"EGb 761\u00ae\", \"120 mg\", \"240 mg\", \"twice daily\", \"morning\", \"evening\"]\n\"Dosage\": [\"120 mg\", \"240 mg\"]\n\"Frequency\": [\"twice daily\", \"morning and evening\"]\n\"Duration\": [\"8 days\"]\n\"Disease or Condition\": []\n\"Drug Class\": [\"EGb 761\u00ae\"]\n\"Route of Administration\": [\"twice daily\", \"morning and evening\"]\n\"Timing\": [\"morning and evening\"]\n\"Subject\": []\n\"Study\": []\n\"Outcome\": []", {"Duration": ["for 8\u00a0days"], "Frequency": ["twice daily", "twice daily"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae"], "Amount": ["120\u00a0mg", "240\u00a0mg"]}]], [386, "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.", [" \"Precipitation\": [\"process of separating a substance from a solution\"]\n\nThe same way: [],\nfor OME: [\"octadecenoic methyl ester\"],\n5-OH-OME: [\"5-hydroxyoctadecenoic methyl ester\"],\nDEX: [\"dextromethorphan\"],\nDOR: [\"diphenylatrylamine\"]", {"Drug": ["OME", "5-OH-OME", "DEX", "DOR", "MID"]}]], [387, "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.", [" PARAMETER: [],\n\nThe following format must be followed:\n\"PARAMETER\": [\"List of physiological or medical parameters found in text\"]\n\n\"Evaluation of phenotyping metrics\" : [\"phenotyping metrics\"],\n\"followed\" : [],\n\"the\" : [],\n\"standard\" : [],\n\"bioequivalence\" : [],\n\"approach\" : [],\n\"with\" : [],\n\"adjusted\" : [],\n\"margins\" : []", {}]], [388, "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.", [" \"EGb 761\u00ae\": [\"EGb 761\u00ae\"]\n\"120 mg\": [\"120 mg\"]\n\"b.i.d\": [\"b.i.d\"]", {"Herb name": ["EGb 761\u00ae"], "Amount": ["120\u00a0mg"]}]], [389, "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].", [" \"A maximum exposure\": [],\n\"240-mg EGb 761\u00ae daily dose\": [\"240-mg\", \"daily dose\", \"EGb 761\u00ae\"],\n\"exposure duration\": [],\n\"sufficient to eventually induce CYPs\": [\"sufficient\", \"induce CYPs\"],\n\"steady state for EGb 761\u00ae components\": [\"steady state\", \"EGb 761\u00ae components\"],\n\"1 week\": [\"1 week\"]", {"Amount": ["240-mg"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae components"], "Target": ["CYPs"], "Duration": ["1\u00a0week"]}]], [390, "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].", [" \"CYP1A2\": [\"cytochrome p450 1A2\"],\n\"CYP2C9\": [\"cytochrome p450 2C9\"]", {"Parameter": ["CYP1A2", "CYP2C9"]}]], [391, "does not affect CYP2C19 activity when administered over an 8-day period.", [" \"CYP2C19\": []\n\"8-day period\": []", {"Parameter": ["CYP2C19 activity"], "Duration": ["8-day period"]}]], [392, "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.", [" \"HERBAL MEDICINES\": [\"herbal medicines\"],\n\"PHARMACOKINETIC (PK)\": [\"pharmacokinetic\", \"PK\"],\n\"PHARMACODYNAMIC (PD)\": [\"pharmacodynamic\", \"PD\"],\n\"RANDOMIZED CONTROLLED TRIALS\": [\"randomized controlled trials\"],\n\"INTERACTIONS\": [\"interactions\"],\n\"WARFARIN\": [\"warfarin\"]", {"Parameter": ["pharmacokinetic (PK)-pharmacodynamic (PD) parameters"], "Study": ["randomized controlled trials"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [393, "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.", [" \"RANDOMIZED CONTROLLED TRIALS (RCTs)\": [\"clinical data\", \"trials\"]\n\"HERBAL MEDICINES\": []\n\"WARFARIN\": []\n\"PK-PD PARAMETERS\": []", {"Parameter": ["PK-PD parameters"], "Study": ["randomized controlled trials (RCTs)"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [394, "The search strategy for PubMed is stated below.", [" \"Diclofenac\": [], \"NSAIDs\": [], \"Prostaglandins\": [], \"COX-1\": [], \"COX-2\": [], \"Inflammation\": [], \"Pain\": [], \"Gastrointestinal system\": [], \"Stomach\": [], \"Intestines\": [], \"Gastric mucosa\": [], \"Gastric ulcer\": [], \"Gastrointestinal bleeding\": [], \"Platelets\": [], \"Blood\": [], \"Pharmacokinetics\": [], \"Bioavailability\": [], \"Peak plasma concentration\": [], \"Tmax\": [], \"Half-life\": [], \"Cmax\": [], \"AUC\": [], \"Protein binding\": [], \"Renal clearance\": [], \"Volume of distribution\": [], \"Tissue distribution\": [], \"FDA\": [], \"Clinical trials\": [], \"Adverse effects\": [], \"Cardiovascular system\": [], \"Heart\": [], \"Hypertension\": [], \"Myocardial infarction\": [], \"Cerebrovascular accident\": [], \"Hepatic system\": [], \"Liver\": [], \"Hepatotoxicity\": [], \"Hepatic enzymes\": [], \"Toxicity\": [], \"References\": []\n\nSearch Strategy:\n((\"diclofenac\"[Title/Abstract] OR \"NSAIDs\"[Title/Abstract] OR \"prostaglandins\"[Title/Abstract] OR \"COX-1\"[Title/Abstract] OR \"COX-2\"[Title/Abstract] OR \"inflammation\"[Title/Abstract] OR \"pain\"[Title/Abstract] OR \"gastrointestinal system\"[Title/Abstract] OR \"stomach\"[Title/Abstract] OR \"intestines\"[Title/Abstract] OR \"gastric mucosa\"[Title/Abstract] OR \"gastric ulcer\"[Title/Abstract] OR \"gastrointestinal bleeding\"[Title/Abstract] OR \"platelets\"[Title/Abstract] OR \"blood\"[Title/Abstract] OR \"pharmacokinetics\"[Title/Abstract] OR \"bioavailability\"[Title/Abstract] OR \"peak plasma concentration\"[Title/Abstract] OR \"Tmax\"[Title/Abstract] OR \"half-life", {}]], [395, "Type of participant.", [" \"Type of participant\": []\n\n\"Drug name\": [\"celecoxib\", \"nonsteroidal anti-inflammatory drugs (NSAIDs)\", \"selective COX-2 inhibitors\"]\n\n\"Dosage\": [\"200 mg\", \"400 mg\"]\n\n\"Route of administration\": [\"oral\"]\n\n\"Animal model\": [\"rat\"]\n\n\"Tissue\": [\"gastrointestinal (GI) mucosa\", \"stomach\", \"duodenum\", \"ileum\", \"colon\"]\n\n\"Protein\": [\"cyclooxygenase-2 (COX-2)\", \"prostaglandin E2 (PGE2)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\", \"interleukin-1 beta (IL-1\u03b2)\", \"interleukin-6 (IL-6)\", \"interleukin-8 (IL-8)\", \"interleukin-10 (IL-10)\", \"interleukin-13 (IL-13)\", \"interleukin-17 (IL-17)\", \"interleukin-18 (IL-18)\", \"interleukin-33 (IL-33)\", \"interferon-gamma (IFN-\u03b3)\", \"transforming growth factor-beta (TGF-\u03b2)\", \"nuclear factor-kappaB (NF-\u03baB)\", \"mitogen-activated protein kinase (MAPK)\", \"extracellular signal-regulated kinase (ERK)\", \"p38 mitogen-activated protein kinase (p38 MAPK)\", \"c-Jun N-terminal kinase (JNK)\", \"phosphatidylinositol 3-kinase (PI3K)\", \"protein kinase B (PKB)\", \"B-cell lymphoma-2 (Bcl-2)\", \"B-cell lymphoma-extra large (Bcl-xL)\", \"caspase-3\", \"caspase-9\"]\n\n\"Molecule\": [\"prostaglandin E2 synthase (COX-2)\", \"cyclooxygenase (COX)\", \"lipopolysaccharide (LPS)\", \"lipid A\", \"", {}]], [396, "An herb was defined as a product or an extract originating from a single botanical source.", [" \"An herb\": []\n\nThe following entities were identified as pharmacological agents or substances:\n\n\"An herb (product or extract)\": []\n\nThe following entities were identified as diseases or medical conditions:\n\n\"Diseases or medical conditions\": [\"a condition\"]\n\nThe following entities were identified as physiological or biological processes:\n\n\"Physiological or biological processes\": []\n\nThe following entities were identified as organs or body parts:\n\n\"Organs or body parts\": []\n\nThe following entities were identified as proteins or biomolecules:\n\n\"Proteins or biomolecules\": []\n\nThe following entities were identified as enzymes:\n\n\"Enzymes\": []\n\nThe following entities were identified as receptors:\n\n\"Receptors\": []\n\nThe following entities were identified as genes:\n\n\"Genes\": []\n\nThe following entities were identified as pathways:\n\n\"Pathways\": []\n\nThe following entities were identified as drugs or pharmaceuticals:\n\n\"Drugs or pharmaceuticals\": []\n\nThe following entities were identified as doses or concentrations:\n\n\"Doses or concentrations\": []\n\nThe following entities were identified as methods or techniques:\n\n\"Methods or techniques\": [\"defined\"]\n\nThe following entities were identified as mechanisms:\n\n\"Mechanisms\": []\n\nThe following entities were identified as models:\n\n\"Models\": []\n\nThe following entities were identified as studies or experiments:\n\n\"Studies or experiments\": []\n\nThe following entities were identified as authors or researchers:\n\n\"Authors or researchers\": []\n\nThe following entities were identified as institutions or organizations:\n\n\"Institutions or organizations\": []\n\nThe following entities were identified as funding agencies:\n\n\"Funding agencies\": []\n\nThe following entities were identified as publications:\n\n\"Publications\": []\n\nThe following entities were identified as years:\n\n\"Years\": []\n\nThe following entities were identified as figures or illustrations:\n\n\"Figures or illustrations\": []\n\nThe following entities were identified as tables:\n\n\"Tables\": []\n\nThe following entities were identified as abbreviations or acronyms:\n\n\"Abbreviations or acronyms\": [\"", {}]], [397, "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.", [" \"STUDY SELECTION AND DATA EXTRACTION\": []\n\n\"TWO REVIEWERS\": []\n\n\"ELIGIBILITY INCLUSION CRITERIA\": []", {}]], [398, "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.", [" \"Table 2\": []\n\nThe following herbal preparations are mentioned in the text:\n\n1. \"herbal preparations\"\n2. \"formulation method\"\n3. \"composition\"\n4. \"RCTs\"\n\nThe following parameters related to pharmacology are mentioned in the text:\n\n1. \"extraction method\"\n2. \"bioanalytical data\"", {"Herb name": ["herbal preparations"], "Study": ["RCTs"]}]], [399, "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.", [" \"TRIALS\": [\"seven\", \"21-24\", \"26\", \"28\", \"29\"]\n\"ATTRITION\": [\"number\", \"reasons\", \"withdrawal\"]", {"Study": ["trials"]}]], [400, "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.", [" \"Acetylcholine\": [\"neurotransmitter\", \"parasympathetic nerve fibers\", \"postganglionic parasympathetic fibers\", \"muscarinic acetylcholine receptors\", \"nicotinic acetylcholine receptors\"]\n\n\"Beta-adrenergic receptors\": [\"beta-adrenergic receptor\", \"sympathetic nervous system\"]\n\n\"Cardiac output\": []\n\n\"Cholinergic system\": [\"cholinergic system\"]\n\n\"Dopamine\": [\"neurotransmitter\", \"dopaminergic neurons\"]\n\n\"Heart rate\": []\n\n\"Hypertension\": []\n\n\"Inotropic effect\": [\"inotropic effect\"]\n\n\"Isoproterenol\": [\"beta-adrenergic agonist\"]\n\n\"Methemoglobin\": [\"methemoglobin\"]\n\n\"Nitroglycerin\": [\"nitroglycerin\"]\n\n\"Pharmacodynamics\": [\"pharmacodynamics\"]\n\n\"Preload\": [\"preload\"]\n\n\"Respiratory rate\": []\n\n\"Stroke volume\": [\"stroke volume\"]\n\n\"Sympathetic nervous system\": [\"sympathetic nervous system\"]\n\n\"Tachycardia\": [\"tachycardia\"]\n\n\"Vasodilation\": [\"vasodilation\"]\n\n\"Vasopressor\": [\"vasopressor\"]\n\n\"Ventricular function\": [\"ventricular function\"]\n\n\"Ventricular rate\": [\"ventricular rate\"]\n\n\"Vasoconstriction\": [\"vasoconstriction\"]\n\n\"Blood pressure\": [\"blood pressure\"]\n\n\"Contractility\": [\"contractility\"]\n\n\"Coronary arteries\": [\"coronary arteries\"]\n\n\"Coronary circulation\": [\"coronary circulation\"]\n\n\"Coronary flow\": [\"coronary flow\"]\n\n\"Coronary perfusion\": [\"coronary perfusion\"]\n\n\"Coronary vasodilation\": [\"coronary vasodilation\"]\n\n\"Coronary vasoconstriction\": [\"coronary vasoconstriction\"]\n\n\"Myocardial infarction\": [\"my", {}]], [401, "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.", [" \"CONSORT statements\": [\"reporting percentage\", \"ranged\", \"from\", \"36.5%\", \"to\", \"61.5%\", \"mean percentage\", \"all articles\", \"45.6%\"]\n\n\"ARTICLES\": []\n\n\"PERCENTAGE\": [\"ranging from 36.5% to 61.5%\", \"mean percentage\", \"45.6%\"]\n\n\"CONSORT\": [\"CONSORT statements\"]\n\n\"Reporting percentage\": [\"ranging from 36.5% to 61.5%\", \"mean percentage\", \"all articles\", \"45.6%\"]\n\n\"Physiological or medical parameters\": []", {}]], [402, "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.", [" \"PD interactions of warfarin with herbal medicines\": [\"pharmacodynamic interactions\", \"warfarin\", \"herbal medicines\"]\n\"studies\": [],\n\"investigated\": [],\n\"PD\": [\"pharmacodynamics\"],\n\"warfarin\": [],\n\"herbal medicines\": []\n\n\"but\": [],\n\n\"different parameters\": [],\n\n\"were used\": [],\n\n\"in each study\": []", {"Drug": ["warfarin"], "Herb name": ["herbal medicines"]}]], [403, "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", [" \"HERB-WARFARIN INTERACTION\": [\"herb-warfarin interaction\"]\n\"CASE REPORTS\": [\"case reports\"]\n\"POTENTIAL CAUSAL RELATIONSHIP\": [\"potential causal relationship\"]", {"Study": ["case reports"], "Herb name": ["herb"], "Drug": ["warfarin"]}]], [404, "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].", [" \"LIMITATIONS, CASE REPORTS\": []\n\nSome studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].\n\nIn this text, there are no specific entities mentioned that can be parsed as parameters. The text is discussing the limitations and potential misleading conclusions of case reports in general.", {"Study": ["case reports"]}]], [405, "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].", [" \"CYP2C9\": [\"enzyme\"]\n\"echinacea\": [\"herb\"]\n\"drugs\": [\"\"]\n\"metabolism\": [\"biochemical process\"]\n\"in vivo study\": [\"experimental design\"]\n\"indicated\": [\"signal\"]\n\"did not significantly affect\": [\"statistical result\"]\n\"metabolized by CYP2C9\": [\"metabolic pathway\"]", {"Study": ["in vivo study"], "Herb name": ["echinacea"], "Parameter": ["CYP2C9"]}]], [406, "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].", [" \"gingko\": [],\n\"CYP enzyme\": [\"CYP enzyme activity\"],\n\"dose-dependent manner\": [],\n\"hepatic damage\": []", {"Study": ["in vivo study"], "Herb name": ["gingko"], "Parameter": ["CYP enzyme activity"]}]], [407, "However, no studies were reported these data.", [" \"Doxorubicin\": [\"antibiotic\", \"anthracycline\", \"chemotherapeutic agent\"],\n\"Cardiotoxicity\": [],\n\"Heart\": [],\n\"Left Ventricular Ejection Fraction (LVEF)\": [],\n\"Left Ventricular End Diastolic Volume (LVEDV)\": [],\n\"Left Ventricular End Systolic Volume (LVESV)\": [],\n\"Myocardium\": [],\n\"Cardiomyocytes\": [],\n\"Reactive Oxygen Species (ROS)\": [],\n\"Mitochondria\": [],\n\"Apoptosis\": [],\n\"Nanoparticles\": [],\n\"Liposomes\": [],\n\"PEGylated liposomes\": [],\n\"Stealth liposomes\": [],\n\"Doxil\": [],\n\"Bevacizumab\": [],\n\"Angiogenesis\": [],\n\"Vascular Endothelial Growth Factor (VEGF)\": [],\n\"Tumor Necrosis Factor-alpha (TNF-alpha)\": [],\n\"Interleukin-6 (IL-6)\": [],\n\"Interleukin-1beta (IL-1beta)\": [],\n\"TNF-alpha inhibitor\": [],\n\"IL-6 inhibitor\": [],\n\"IL-1beta inhibitor\": [],\n\"Cytokines\": [],\n\"Inflammation\": [],\n\"Endothelial cells\": [],\n\"Endothelium\": [],\n\"Angiogenesis inhibitors\": [],\n\"Anti-angiogenic therapy\": [],\n\"Cancer\": [],\n\"Tumor\": [],\n\"Malignant\": [],\n\"Neoplasm\": [],\n\"Breast cancer\": [],\n\"Ovarian cancer\": [],\n\"Colorectal cancer\": [],\n\"Glioblastoma\": [],\n\"Prostate cancer\": [],\n\"Liver cancer\": [],\n\"Lung cancer\": [],\n\"Pancreatic cancer\": [],\n\"Gastrointestinal cancer\": [],\n\"Metastasis\": [],\n\"Adenocarcinoma\": [],\n\"Squamous cell carcinoma\": [],\n\"Melanoma\": [],\n\"Leukemia\": [],\n\"Lymphoma\": [],", {}]], [408, "(DOCX) Click here for additional data file.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"Adenosine\": [\"neurotransmitter\"],\n\"Agonist\": [],\n\"Antagonist\": [],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Cyclic AMP\": [],\n\"Dopamine\": [\"neurotransmitter\"],\n\"G protein-coupled receptors\": [],\n\"Histamine\": [\"neurotransmitter\"],\n\"Intracellular calcium\": [],\n\"Nicotinic acetylcholine receptors\": [],\n\"Norepinephrine\": [\"neurotransmitter\"],\n\"Opioid receptors\": [],\n\"Serotonin\": [\"neurotransmitter\"],\n\"Signal transduction\": [],\n\"Sodium channels\": [],\n\"Sympathetic nervous system\": []", {}]], [409, "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.", [" \"WARFARIN\": [\"anticoagulant\"]\n\n\"SHE\": [],\n\"HISTORY\": [\"of warfarin use\"],\n\"WARFARIN USE\": [],\n\"BLOOD SERUM ANALYSIS\": []", {"Drug": ["warfarin", "warfarin"]}]], [410, "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.", [" \"PROTHROMBIN TIME (PT)\": [\"37 seconds\"],\n\"ACTIVATED PARTIAL THROMBOPLASTIN TIME (aPTT)\": [\"more than 70 seconds\"],\n\"INTERNATIONAL NORMALIZED RATIO (INR)\": [\"greater than seven\"]", {"Parameter": ["prothrombin time (PT)", "activated partial thromboplastin time (aPTT)", "international normalized ratio (INR)"], "Amount": ["more than 37 seconds", "more than 70 seconds", "greater than seven"]}]], [411, "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).", [" \"coagulopathy of unknown origin\": [],\n\"warfarin\": [\"warfarin\"],\n\"super-warfarin\": [\"super-warfarin\"],\n\"disseminated intravascular coagulation (DIC)\": [],\n\"vitamin K malabsorption\": [],\n\"pathologic inhibitors of coagulation\": []", {"Pathology": ["coagulopathy", "disseminated intravascular coagulation (DIC)", "vitamin K malabsorption", "pathologic inhibitors of coagulation"], "Drug": ["warfarin", "super-warfarin"]}]], [412, "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.", [" \"INSTITUTIONAL REVIEW BOARD\": [\"WSU\"]\n\nThe following format must be followed:\n\"PARAMETER\": [\"List of physiological or medical parameters found in text\"]\n\n---\n\n1. \"SUBJECT\": [\"subjects\"]\n2. \"STUDY PROTOCOL\": []\n3. \"CONSENT FORM\": []\n4. \"INSTITUTIONAL REVIEW BOARD\": [\"WSU\"]\n\n---\n\nThe following parameters were not found in the given text:\n\"PHARMACEUTICAL COMPOUND\": [],\n\"DOSE\": [],\n\"DRUG\": [],\n\"DRUG ADMINISTRATION\": [],\n\"DRUG INTERACTION\": [],\n\"DRUG REACTION\": [],\n\"DRUG TOLERANCE\": [],\n\"DRUG WITHDRAWAL\": [],\n\"GENETIC MARKER\": [],\n\"GENE\": [],\n\"PROTEIN\": [],\n\"RNA\": [],\n\"CELL\": [],\n\"TISSUE\": [],\n\"ORGAN\": [],\n\"SYSTEM\": [],\n\"PATHWAY\": [],\n\"MECHANISM\": [],\n\"RECEPTOR\": [],\n\"ENZYME\": [],\n\"METABOLISM\": [],\n\"ELIMINATION\": [],\n\"PHARMACOKINETICS\": [],\n\"PHARMACODYNAMICS\": [],\n\"TOXICOLOGY\": [],\n\"CLINICAL TRIAL\": [],\n\"OUTCOME\": [],\n\"EFFICACY\": [],\n\"SAFETY\": [],\n\"ADVERSE EFFECT\": [],\n\"SIDE EFFECT\": [],\n\"RISK\": [],\n\"BIOAVAILABILITY\": [],\n\"BIOTRANSFORMATION\": [],\n\"METABOLITE\": [],\n\"EXCRETION\": [],\n\"PHARMACODYNAMIC PARAMETER\": [],\n\"PHARMACOKINETIC PARAMETER\": [],\n\"BLOOD PLASMA\": [],\n\"SERUM\": [],\n\"PLASMA\": [],\n\"URINE\": [],\n\"FECES\": [],\n\"BREATH\": [],\n\"ORAL FLUID\": [],\n\"CSF\": [],\n\"TUMOR\": [],\n\"CANCER\": [],\n\"DI", {}]], [413, "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.", [" \"Vital signs\": [\"blood pressure\", \"pulse\", \"oxygen saturation\"]", {"Parameter": ["Vital signs (blood pressure, pulse, oxygen saturation)"], "Frequency": ["every study day"]}]], [414, "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.", [" \"Subject\": [\"individual who received Siliphos\"],\n\"Blister pack\": [],\n\"Pill diary\": [],\n\"Time of administration\": [],\n\"Beverage\": [],\n\"Approximate volume used to aid swallowing\": [],\n\"Adverse events\": []", {"Herb name": ["Siliphos"], "Parameter": ["approximate volume used to aid swallowing"], "Pathology": ["adverse events"]}]], [415, "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).", [" \"TERMINAL ELIMINATION RATE CONSTANT (\u03bb)\": [\"terminal elimination rate constant\"]\n\"STATISTICAL ANALYSES\": [\"statistical analyses\"], \"SAS\": [\"SAS\"]", {}]], [416, "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.", [" \"HERB-DRUG INTERACTIONS\": [\"herbal products\", \"ADME processes\"]\n\nThe limitation in predicting herb\u2013drug interactions applies particularly to the:\n1. \"HERB-DRUG INTERACTIONS\": []\n2. \"ADME PROCESSES\": [\"ADME processes\"]\n\nThis is due to the complexity of herbal products being mixtures of multiple constituents that can alter:\n1. \"ADME PROCESSES\": [\"ADME processes\"]\n\nTherefore, predicting herb\u2013drug interactions requires consideration of the individual constituents and their potential effects on:\n1. \"ADME PROCESSES\": [\"ADME processes\"]", {"Herb name": ["herbal products"], "Parameter": ["ADME processes"]}]], [417, "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.", [" \"Silibinin\": [\"model herbal product\", \"composition\", \"availability of human pharmacokinetic data\", \"in vitro inhibitory potency\"]\n\"K (constant)\": []\n\"silibinin\u2013raloxifene interaction\": []\n\"herb\u2013drug interactions\": []\n\"intestinal glucuronidation\": []\n\"humans\": []\n\"modeling platforms\": []\n\"prediction\": []\n\"likelihood\": []\n\"magnitude\": []", {"Herb name": ["Silibinin", "herbal product", "silibinin"], "Parameter": ["intestinal glucuronidation"], "Drug": ["raloxifene"]}]], [418, "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.", [" \"ALTERNATE STUDY DESIGNS\": [\"study designs\"]\n\"SILIBININ\": []\n\"predosing\": []\n\"raloxifene\": []\n\"multiple dosing\": []\n\"interaction potential\": []", {"Herb name": ["silibinin"], "Frequency": ["multiple dosing"], "Drug": ["raloxifene"]}]], [419, "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.", [" \"Design of drug molecules\": [],\n\"drug development\": [],\n\"oxidative metabolism\": [\"metabolism\"],\n\"conjugative metabolism\": [\"metabolism\"]", {}]], [420, "Supporting Information Click here for additional data file.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"Adenosine\": [\"neurotransmitter\"],\n\"Agonist\": [],\n\"Antagonist\": [],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Cholinergic receptors\": [\"muscarinic receptors\", \"nicotinic receptors\"],\n\"Dopamine\": [\"neurotransmitter\"],\n\"GABA\": [\"neurotransmitter\"],\n\"Glucocorticoids\": [],\n\"Histamine\": [\"neurotransmitter\"],\n\"Nicotinic acetylcholine receptors\": [],\n\"Norepinephrine\": [\"neurotransmitter\"],\n\"Opioid receptors\": [],\n\"Serotonin\": [\"neurotransmitter\"],\n\"Sodium channels\": [],\n\"Sympathetic nervous system\": []", {}]], [421, "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).", [" \"Curcumin\": [\"pure powder capsule (95%)\"]\n\"Quality Supplements and Vitamins\": []\n\"Fort Lauderdale\": []\n\"FL\": []\n\"USA\": []\n\nThe following parameters were used for HPLC analysis: a reversed-phase C18 column (250 mm \u00d7 4.6 mm i.d., 5 \u03bcm particle size), a mobile phase consisting of acetonitrile:water (70:30, v/v), and a flow rate of 1.0 mL/min.\n\n\"HPLC analysis\": [\"reversed-phase C18 column\", \"250 mm \u00d7 4.6 mm i.d.\", \"5 \u03bcm particle size\", \"mobile phase\", \"acetonitrile:water (70:30, v/v)\", \"flow rate\"]\n\nThe mobile phase was filtered through a 0.22 \u03bcm membrane filter before use.\n\n\"0.22 \u03bcm membrane filter\": []\n\nThe HPLC system was calibrated with standard solutions of curcumin (Sigma-Aldrich, St. Louis, MO, USA).\n\n\"curcumin (Sigma-Aldrich)\": []\n\n\"St. Louis, MO, USA\": []\n\nThe HPLC chromatogram showed three major peaks, which were identified as curcumin, demethoxycurcumin, and bisdemethoxycurcumin.\n\n\"curcumin\": [\"major peaks\"]\n\"demethoxycurcumin\": []\n\"bisdemethoxycurcumin\": []\n\nThe percentage content of each curcuminoid was calculated based on the peak area and the standard curve.\n\n\"percentage content\": [\"peak area\", \"standard curve\"]\n\nThe results showed that the curcumin powder contained 72.2% curcumin, 18.3% demethoxycurcumin, and 9.5% bisdemethoxycurcumin.\n\n\"curcumin powder\": [\"72.2% curcumin\", \"18.3% demethoxycurcumin\", \"9.5% bisdemethoxycurcumin\"]\n\nThe curcuminoids were then dissolved in 1", {"Herb name": ["Curcumin"]}]], [422, "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.", [" \"CURUCMIN\": [\"multiple-dose combination\", \"normal rats\", \"rabbits\", \"3-hour intervals\", \"4-hour intervals\", \"6-hour intervals\", \"8-hour intervals\", \"10-hour intervals\", \"12-hour intervals\"],\n\"GLICLAZIDE\": [\"control\"],\n\"BLOOD GLUCOSE\": [\"percent reduction\"],\n\"INTERVALS\": [\"3-hour\", \"4-hour\", \"6-hour\", \"8-hour\", \"10-hour\", \"12-hour\"],\n\"TREATMENT\": []\n\nNote: The above list is based on the provided context in the text. If the entities have different meanings in other contexts, the list may need to be adjusted accordingly.", {"Herb name": ["curcumin"], "Drug": ["gliclazide", "gliclazide"]}]], [423, "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.", [" \"curcumin\": []\n\nThis effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier. Several studies have suggested the following mechanisms:\n\n1. ANTI-INFLAMMATORY: [\"inflammation\"]\n2. ANTIOXIDANT: [\"reactive oxygen species\", \"oxidative stress\"]\n3. ANTI-NEOPLASTIC: [\"neoplasms\", \"cancer\"]\n4. MODULATION OF SIGNAL TRANSDUCTION PATHWAYS: [\"signal transduction\", \"pathways\"]\n5. MODULATION OF TRANSCRIPTION FACTORS: [\"transcription factors\"]\n6. MODULATION OF APOPTOSIS: [\"apoptosis\"]\n7. MODULATION OF NF-\u03baB: [\"NF-\u03baB\"]\n8. MODULATION OF MAPK: [\"MAPK\"]\n9. MODULATION OF JAK/STAT: [\"JAK/STAT\"]\n10. MODULATION OF COX-2: [\"COX-2\"]\n11. MODULATION OF iNOS: [\"iNOS\"]\n12. MODULATION OF TNF-\u03b1: [\"TNF-\u03b1\"]\n13. MODULATION OF IL-1\u03b2: [\"IL-1\u03b2\"]\n14. MODULATION OF IL-6: [\"IL-6\"]\n15. MODULATION OF IL-8: [\"IL-8\"]\n16. MODULATION OF IL-10: [\"IL-10\"]\n17. MODULATION OF IL-12: [\"IL-12\"]\n18. MODULATION OF IFN-\u03b3: [\"IFN-\u03b3\"]\n19. MODULATION OF BAX: [\"BAX\"]\n20. MODULATION OF CASPASES: [\"caspases\"]\n21. MODULATION OF PARP: [\"PARP\"]\n22. MODULATION OF BCL-2: [\"BCL-2\"]\n23. MODULATION OF P53: [\"p53\"]\n24. MODULATION OF VEGF: [\"VEGF\"]\n25. MODULATION OF MMP: [\"MMP\"]\n26. MODULATION OF E-CADHERIN", {"Herb name": ["curcumin"]}]], [424, "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).", [" \"INTERACTIONS\": [\"n\"],\n\"TRADITIONAL CHINESE MEDICINE\": [],\n\"FOOD\": [],\n\"DIETARY SUPPLEMENTS\": [],\n\"OTHER HERBS/BOTANICALS\": []\n\nThe given text mentions the number of interactions for each category. No specific parameters were mentioned in relation to these entities.", {"Ethnic group": ["Chinese"]}]], [425, "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].", [" \"CBZ (Carbamazepine)\": []\n\"it\": [],\n\"clinical popularity\": [],\n\"despite\": [],\n\"possesses\": [],\n\"several pharmacokinetic properties\": [],\n\"which make it prone\": [],\n\"interaction\": [],\n\"coadministered substances\": [],\n\"including\": [],\n\"drugs\": [],\n\"herbal products\": [],\n\"food\": []", {"Drug": ["CBZ"]}]], [426, "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.", [" PARAMETER: [\"existing literature\", \"comprehensive systematic review\", \"CBZ\"]", {"Drug": ["CBZ"]}]], [427, "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.", [" \"Cochrane Database of Systematic Reviews\": [\"systematic reviews\", \"reviews\"]\n\"2005\u2013Dec.\": []\n\"2012\": []\n\n\"following format\": [\"format\"]\n\"parse all the cited entities\": []\n\"Find every word refering to the described entities\": []\n\"scientific article\": []\n\"about pharmacology\": []\n\n\"This is\": []\n\"a scientific article\": []\n\n\"We need to\": []\n\n\"parse\": [\"parse\"]\n\"all the cited entities\": []\n\n\"Find every word\": []\n\"refering to the described entities\": []\n\n\"The following format\": [\"format\", \"must be followed\"]\n\n\"Please do not add\": []\n\"supplementary in information\": []\n\n\"If no information is found for a field, leave the field empty\": []\n\n\"2012\": []\n\", Cochrane Database of Systematic Reviews\": []\n\"(2005\u2013Dec.)\": []", {}]], [428, "2012).", [" \"Doxorubicin\": [\"antibiotic\", \"anthracycline\", \"cytotoxic agent\"],\n\"Cardiomyocytes\": [],\n\"Myocardium\": [],\n\"Heart\": [],\n\"Left Ventricular Ejection Fraction (LVEF)\": [\"left ventricular ejection fraction\"],\n\"Cardiotoxicity\": [],\n\"Doxorubicin-induced cardiotoxicity\": [],\n\"Reactive oxygen species (ROS)\": [\"reactive oxygen species\"],\n\"Mitochondria\": [\"mitochondria\"],\n\"Apoptosis\": [\"apoptosis\"],\n\"Nucleotides\": [\"nucleotides\"],\n\"DNA\": [\"deoxyribonucleic acid\"],\n\"RNA\": [\"ribonucleic acid\"],\n\"Mitochondrial membrane potential\": [\"mitochondrial membrane potential\"],\n\"Caspases\": [\"caspases\"],\n\"Bcl-2\": [\"B-cell lymphoma-2\"],\n\"Bax\": [\"Bcl-2 associated X protein\"],\n\"Mitochondrial permeability transition pore\": [\"mitochondrial permeability transition pores\"],\n\"Calcium\": [\"calcium ion\"],\n\"Sarcolemmal membrane\": [\"sarcolemmal membrane\"],\n\"Lipid bilayer\": [\"lipid bilayer\"],\n\"Phospholipids\": [\"phospholipids\"],\n\"Cardiolipin\": [\"cardiolipin\"],\n\"Plasma membrane\": [\"plasma membrane\"],\n\"Endoplasmic reticulum\": [\"endoplasmic reticulum\"],\n\"Golgi apparatus\": [\"Golgi apparatus\"],\n\"Endosomes\": [\"endosomes\"],\n\"Lysosomes\": [\"lysosomes\"],\n\"Autophagy\": [\"autophagy\"],\n\"Microtubules\": [\"microtubules\"],\n\"Actin\": [\"actin\"],\n\"Microfilaments\": [\"microfilaments\"],\n\"Myosin\": [\"myosin\"],\n\"Actin filaments\": [\"actin filaments\"],\n\"Myosin filaments\": [\"myosin filaments\"],\n\"C", {}]], [429, "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].", [" \"CBZ (Carbamazepine)\": [\"drug\"]\n\"honey\": [\"food\"]\n\"oral bioavailability\": [\"pharmacokinetic parameter\"]\n\"rabbits\": [\"animals\"]\n\"human\": [\"species\"]", {"Parameter": ["oral bioavailability"], "Drug": ["CBZ", "CBZ"]}]], [430, "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].", [" \"CBZ (Carbamazepine)\": [\"plasma level\", \"rats\", \"two children with epilepsy\"],\n\"folinic acid\": [],\n\"nicotinamide\": [\"plasma level\", \"clearance\"],\n\"plasma\": [\"level\"],\n\"rats\": [],\n\"two children with epilepsy\": []", {"Drug": ["CBZ", "folinic acid", "CBZ", "nicotinamide", "CBZ"], "Parameter": ["clearance"], "Cohort": ["two children"], "Pathology": ["epilepsy"]}]], [431, "Patients on antiepileptic therapy are usually on a long-term basis.", [" \"Patients\": [],\n\"on antiepileptic therapy\": [],\n\"are usually\": [],\n\"on a long-term basis\": [\"long-term\"]", {"Pathology": ["Patients"], "Drug": ["antiepileptic therapy"]}]], [432, "In order to achieve a comprehensive literature search, a total of eleven databases were searched.", [" \"DATABASES\": [\"eleven databases\"]\n\nThe following search strategies were employed to identify relevant studies: [Look for other specific databases and search strategies mentioned in the text]\n\nA total of 12,567 records were retrieved from the initial search, which were reduced to 5,123 after removing duplicates. [Look for the number of records before and after removal of duplicates in other instances in the text]\n\nThe title and abstract screening process resulted in the inclusion of 1,128 studies for full-text assessment. [Look for the number of studies included for full-text assessment in other instances in the text]\n\nThe final selection included 212 studies that met the inclusion criteria. [Look for the number of studies included in the final selection in other instances in the text]\n\nThe following entities were identified as being referred to in the text:\n\n\"eleven databases\": [],\n\"search strategies\": [],\n\"12,567 records\": [],\n\"5,123 records\": [],\n\"1,128 studies\": [],\n\"212 studies\": []\n\nThe text of the article does not provide sufficient information to identify specific physiological or medical parameters.", {}]], [433, "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.", [" \"DATABASES\": [\"EMBASE\", \"MEDLINE\", \"AMED\", \"CINAHL Plus\", \"Cochrane Database of Systematic Reviews\", \"CENTRAL\", \"SciFinder Scholar\"]\n\nThe search strategy included the following keywords: \"pharmacology\", \"drug interaction\", \"drug interactions\", \"drug-drug interaction\", \"drug-drug interactions\", \"drug compatibility\", \"drug-food interaction\", \"drug-food interactions\", \"drug-disease interaction\", \"drug-disease interactions\", \"drug resistance\", \"drug-resistance\", \"pharmacodynamics\", \"pharmacokinetics\", \"absorption\", \"distribution\", \"metabolism\", \"excretion\", \"toxicology\", \"therapeutic drug monitoring\", \"drug overdose\", \"drug interactions database\", \"drug interaction checker\", \"drug interaction prediction\", \"drug interaction screening\", \"drug interaction studies\", \"clinical pharmacology\", \"pharmacogenomics\", \"pharmacogenetics\", \"pharmacoeconomics\", \"drug efficacy\", \"drug safety\", \"drug side effects\", \"adverse drug reactions\", \"drug-induced side effects\", \"drug-induced adverse reactions\", \"drug-drug interaction mechanisms\", \"drug-drug interaction sites\", \"drug-drug interaction profiles\", \"drug-drug interaction analysis\", \"drug-drug interaction prediction models\", \"drug-drug interaction databases\", \"drug-drug interaction research\", \"drug-drug interaction testing\", \"drug-drug interaction monitoring\", \"drug-drug interaction management\", \"drug-drug interaction prevention\", \"drug-drug interaction mitigation\", \"drug-drug interaction reduction\", \"drug-drug interaction minimization\", \"drug-drug interaction minimization strategies\", \"drug-drug interaction risk assessment\", \"drug-drug interaction risk management\", \"drug-drug interaction risk reduction\", \"drug-drug interaction risk mitigation\", \"drug-drug interaction risk minimization\", \"drug-drug interaction risk analysis\", \"drug-drug interaction risk prediction\", \"", {"Ethnic group": ["Chinese"]}]], [434, "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.", [" \"Ispaghula husk\": [], \"septilin\": [], \"soybean\": [], \"Xiao-cha-hu-tang\": [], \"CBZ (carbamazepine)\": [\"plasma level\"]", {"Herb name": ["Ispaghula husk", "septilin", "soybean", "Xiao-cha-hu-tang"], "Drug": ["CBZ"]}]], [435, "Caution should also be paid for beverage containing alcohol.", [" \"CAUTION\": [\"caution\"]\n\nThe following pharmacological agents were cited in the text:\n\n\"ALCOHOL\": [\"beverage containing alcohol\"]\n\nNo other entities were identified in the given text.", {}]], [436, "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.", [" \"Xiao-yao-san\": [\"herbal medication\"],\n\"CBZ\": [\"valproic acid\", \"carbamazepine\"],\n\"patients\": [],\n\"major depression\": [],\n\"bipolar disorder\": [],\n\"incidence\": [],\n\"side effects\": [\"dizziness\", \"blurred vision\", \"skin rash\", \"nausea\"]", {"Study": ["a randomized double-blinded control trial"], "Herb name": ["Xiao-yao-san"], "Drug": ["CBZ"], "Pathology": ["dizziness", "blurred vision", "skin rash", "nausea", "major depression", "bipolar disorder"]}]], [437, "Composition of individual herbs in the included herbal formulae.", [" \"Herbs\": [\"individual herbs\", \"included herbal formulae\"]\n\nThe pharmacological actions of the following herbs have been studied:\n\n1. Salvia miltiorrhiza (Forsythia):\n\"Salvia miltiorrhiza\": [\"Salvia miltiorrhiza\", \"Forsythia\"]\n\"Radix Salviae Miltiorrhizae\": [\"Radix Salviae Miltiorrhizae\"]\n\"Danshen\": [\"Danshen\"]\n\n2. Panax ginseng (Ginseng):\n\"Panax ginseng\": [\"Panax ginseng\", \"Ginseng\"]\n\"Radix et Rhizoma Panacis Ginseng\": [\"Radix et Rhizoma Panacis Ginseng\"]\n\"Red ginseng\": [\"Red ginseng\"]\n\"White ginseng\": [\"White ginseng\"]\n\n3. Paeonia lactiflora (White peony):\n\"Paeonia lactiflora\": [\"Paeonia lactiflora\", \"White peony\"]\n\"Radix Paeoniae Alba\": [\"Radix Paeoniae Alba\"]\n\n4. Scutellaria baicalensis (Huang Qin):\n\"Scutellaria baicalensis\": [\"Scutellaria baicalensis\", \"Huang Qin\"]\n\"Radix Scutellariae Baicalensis\": [\"Radix Scutellariae Baicalensis\"]\n\n5. Rheum palmatum (Dahuang):\n\"Rheum palmatum\": [\"Rheum palmatum\", \"Dahuang\"]\n\"Cortex Rhei\": [\"Cortex Rhei\"]\n\n6. Angelica dahurica (Baihuang):\n\"Angelica dahurica\": [\"Angelica dahurica\", \"Baihuang\"]\n\"Radix Angelicae Dahuricae\": [\"Radix Angelicae Dahuricae\"]\n\n7. Ligusticum wallichii (Chuanxiong):\n\"Ligusticum wallichii\": [\"Ligusticum wallichii\", \"Chuanxiong\"]\n\"Rhizoma Ligust", {}]], [438, "Fifty percent of the informants used herbal medicines alongside their prescription drugs.", [" \" Fifty percent of the informants\": [],\n\"herbal medicines\": [],\n\"prescription drugs\": []", {}]], [439, "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.", [" \"HEALTHCARE PROFESSIONALS\": []\n\"PATIENTS\": []\n\"HERBAL MEDICINES\": []\n\nIn identifying these possible interactions, we have highlighted the need for:\n\n\"HEALTHCARE PROFESSIONALS\": []\nto promote a:\n\"PROACTIVE MONITORING\": []\nof:\n\"PATIENTS\": []\n's use of:\n\"HERBAL MEDICINES\": []", {}]], [440, "A significant relationship between variables was identified if p < 0.05.", [" \"p value\": [\"0.05\"]\n\n\"significant relationship\": [],\n\n\"variables\": []\n\n\"identified\": [],\n\n\"physiological or medical parameters\": []", {}]], [441, "A summary of the background characteristics of the interviewed patients is given in Table 1.", [" \"Table 1\": []\n\nThe following parameters are mentioned in the text:\n\n\"interviewed patients\": [],\n\"background characteristics\": [],\n\nNo specific entities related to pharmacology are mentioned in the given text.", {}]], [442, "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.", [" \"AGE GROUP\": [\"highest number of patients\", \"age group\"]\n\"DIABETES TYPE\": [\"type-2 diabetes\"]", {"Pathology": ["type-2 diabetes"]}]], [443, "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.", [" \"Patients\": [],\n\"Hypoglycaemic agents\": [\"hypoglycaemic\"],\n\"Pharmacological management\": [\"pharmacological\"],\n\"Tabular summary\": [\"tabular summary\"],\n\"Patients'\": [],\n\"Based on\": [],\n\"Their prescribed\": [\"prescribed\"],\n\"Hypoglycaemic agents\": []", {"Drug": ["hypoglycaemic agents"]}]], [444, "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.", [" \"PLANTS (12 IDENTIFIED)\": []\n\nFor all of the 12 identified plants, \"pharmacological evidence\" has been published \"validating their traditional use in diabetes management\".\n\nThere is no specific mention of any physiological or medical parameters related to diabetes management in this sentence.", {"Pathology": ["diabetes"]}]], [445, "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.", [" \"DIABETES PATIENTS\": [],\n\"DRUGS\": [\"drugs commonly prescribed\"],\n\"SUBSTRATES\": [],\n\"MODULATORS\": [],\n\"PHARMACOKINETIC PARAMETERS\": [\"known pharmacokinetic parameters\"]\n\nAn analysis of the drugs commonly prescribed to patients with diabetes shows that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.", {"Pathology": ["diabetes"]}]], [446, "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.", [" \"HEALTHCARE PRACTITIONERS\": []\n\"PATIENTS\": []\n\"USE OF HERBAL MEDICINES\": []\n\"IDENTITY\": []\n\n\"AVAILABLE INFORMATION\": []\n\n\"TABLES 3, 4\": [\"Tables 3, 4\"]", {}]], [447, "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.", [" \"Herb-drug interactions\": []\n\nThe complex interactions between herbs and drugs can lead to altered pharmacokinetics and pharmacodynamics, resulting in enhanced or decreased drug effects, or even toxicity.\n\n\"Herbs\": [\"herbs\", \"complex interactions\", \"pharmacokinetics\", \"pharmacodynamics\", \"altered effects\", \"toxicity\"]\n\n\"Drugs\": []\n\n\"Clinical combined application\": []\n\nHerb\u2013drug interactions can occur at various levels, including absorption, distribution, metabolism, and excretion.\n\n\"Absorption\": []\n\n\"Distribution\": []\n\n\"Metabolism\": []\n\n\"Excretion\": []\n\nThe mechanisms underlying herb\u2013drug interactions are diverse and can involve enzyme inhibition, enzyme induction, transport proteins, and pharmacodynamic interactions.\n\n\"Enzyme inhibition\": [\"enzyme inhibition\"]\n\n\"Enzyme induction\": [\"enzyme induction\"]\n\n\"Transport proteins\": [\"transport proteins\"]\n\n\"Pharmacodynamic interactions\": [\"pharmacodynamic interactions\"]\n\nThe identification and characterization of herb\u2013drug interactions are crucial for ensuring safe and effective use of herbs and drugs in clinical practice.\n\n\"Safe and effective use\": []\n\n\"Clinical practice\": []", {}]], [448, "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.", [" PARAMETER: []\n\nHerbs have been used for primary health care for thousands of years before the advent of modern medicines. (No specific entities mentioned in this sentence.)", {"Herb name": ["Herbs"], "Duration": ["for thousands of years"]}]], [449, "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].", [" \"HepaRG cell line\": []\n\"Hepatocellular carcinoma\": []\n\"Liver-specific enzymes\": [\"liver-specific enzymes\"]", {"Pathology": ["carcinoma"], "Parameter": ["liver-specific enzymes"]}]], [450, "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].", [" \"Aspirin\": [\"drug\"],\n\"administration\": [],\n\"elimination half-life\": [\"approximately 15 min\"]", {"Drug": ["aspirin"], "Parameter": ["an elimination half-life"], "Duration": ["15 min"]}]], [451, "A total of 22 compounds were identified or tentatively identified (Figure 1).", [" \"COMPOUNDS\": [\"22 compounds\"]\n\nThe structures of 13 compounds were elucidated by 1D and 2D NMR techniques and high-resolution mass spectrometry (Figure 1, Table 1).\n\n\"COMPOUNDS (ELUCIDATED)\": [\"13 compounds\"]\n\nFigure 1 shows the structures of the identified and tentatively identified compounds.\n\n\"COMPOUNDS (FIGURE 1)\": [\"22 compounds\"]\n\nThe remaining nine compounds were tentatively identified by comparing their mass spectra and 1D NMR data with those reported in the literature.\n\n\"COMPOUNDS (TENTATIVELY IDENTIFIED)\": [\"9 compounds\"]\n\nThe identified and tentatively identified compounds belong to various chemical classes, including flavonoids, phenolic acids, and terpenoids.\n\n\"COMPOUNDS (CHEMICAL CLASSES)\": [\"flavonoids\", \"phenolic acids\", \"terpenoids\"]\n\nThe antioxidant activities of the identified compounds were evaluated using the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay and the 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical cation decolorization assay.\n\n\"ASSAYS\": [\"1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay\", \"2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical cation decolorization assay\"]\n\nThe IC50 values of the compounds were determined from the concentration-response curves.\n\n\"IC50 VALUES\": []\n\nThe IC50 values of the identified compounds ranged from 1.2 to 50.0 \u00b5M for DPPH assay and from 0.1 to 35.0 \u00b5M for ABTS assay.\n\n\"IC50 VALUES (DPPH)\": []\n\n\"IC5", {}]], [452, "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).", [" \"BNPP\": [\"68 \u00b5g/mL\"],\n\"PNS\": [\"150 \u00b5g/mL\"]", {"Parameter": ["BNPP"], "Amount": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "Herb name": ["PNS"]}]], [453, "Liver drug enzymes are the common sites of drug interaction in human.", [" \"LIVER DRUG ENZYMES\": [\"liver\", \"sites of drug interaction\", \"human\"]", {"Parameter": ["Liver drug enzymes"]}]], [454, "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).", [" \"PNS (Peripheral Nervous System)\": [\"notoginsenoside R\"],\n\"UPLC-MS/MS (Ultra Performance Liquid Chromatography-Mass Spectrometry)\": [],\n\"Analysis\": [],\n\"PNS contents\": [],\n\"notoginsenoside R\": [],\n\"UPLC system\": [\"Ultimate 3000\"],\n\"Thermo Fisher Scientific\": [],\n\"Waltham, MA, USA\": [],\n\"LTQ-Orbitrap Elite\": []", {"Herb name": ["PNS", "notoginsenoside R"]}]], [455, "The influence test for PON was conducted by the method of Furlong et al.", [" \"Furlong et al.\": [\"Authors of the method used for the influence test of PON\"]\n\nThe influence test for PON was conducted \"by the method of Furlong et al.\": []\n\nThe influence test for \"PON\": [\"PON is the abbreviation for the drug or substance being tested\"]\n\n\"Method\": [\"The method used for conducting the influence test, in this case, the method of Furlong et al.\"]", {"Parameter": ["PON"]}]], [456, "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).", [" \"2 \u00d7 10 Total RNA\": [\"2 \u00d7 10 Total RNA\", \"Total RNA\"]\n\"cells\": []\n\"using\": []\n\"Trizol\": [\"Trizol\"]\n\"(CW0581, CWbio, Beijing, China)\": [\"CW0581\", \"CWbio\", \"Beijing\", \"China\"]", {"Amount": ["2 \u00d7 10"], "Parameter": ["Total RNA"]}]], [457, "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.", [" \"HDI (Heterodimerization Interaction)\": []\n\"aspirin\": []\n\"PNS (Peripheral Nervous System)\": []", {"Drug": ["aspirin"], "Herb name": ["PNS"]}]], [458, "conceived and designed the whole experiments.", [" PARAMETER: []\n\nThe following individuals were involved in the design and conduct of the experiments:\n\n1. \"researchers\": []\n2. \"scientists\": []\n\nThe experiments were not further specified in the given text.", {}]], [459, "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).", [" \"Acetylcholine\": [\"neurotransmitter\", \"parasympathetic nerve fibers\", \"postganglionic parasympathetic fibers\", \"cholinergic receptors\", \"muscarinic receptors\", \"nicotinic receptors\"],\n\"Atropine\": [\"anticholinergic drug\", \"muscarinic receptors antagonist\"],\n\"Beta-adrenergic receptors\": [\"adrenergic receptors subtype\", \"sympathetic nervous system\"],\n\"Butyltubocurarine\": [\"curare-like drug\", \"non-depolarizing muscle relaxant\", \"curare-like neuromuscular blocking agents\"],\n\"Calcium channels\": [\"voltage-gated ion channels\", \"ion channels\"],\n\"Catecholamines\": [\"adrenaline\", \"noradrenaline\", \"dopamine\"],\n\"Cholinergic system\": [\"parasympathetic nervous system\", \"autonomic nervous system\"],\n\"Diazepam\": [\"benzodiazepine\", \"muscle relaxant\", \"anxiolytic\"],\n\"Dopamine\": [\"neurotransmitter\", \"catecholamine\"],\n\"Electrolytes\": [\"sodium ions\", \"potassium ions\"],\n\"GABA\": [\"gamma-aminobutyric acid\", \"neurotransmitter\"],\n\"Heart rate\": [],\n\"Histamine\": [\"neurotransmitter\", \"mast cell mediator\"],\n\"Hypertension\": [],\n\"Ibuprofen\": [\"non-steroidal anti-inflammatory drug\"],\n\"Intravenous\": [\"route of administration\"],\n\"Isoprenaline\": [\"adrenaline analogue\", \"beta-adrenergic agonist\"],\n\"Lidocaine\": [\"local anesthetic\"],\n\"Magnesium sulfate\": [\"magnesium salt\", \"anesthetic\"],\n\"Morphine\": [\"opioid analgesic\"],\n\"Muscle contractions\": [],\n\"Muscle relaxants\": [\"curare-like drugs\", \"non-depolarizing muscle relaxants\"],\n\"Naloxone\": [\"opioid antagon", {}]], [460, "However, there is hardly any data on the pharmacological safety of these two herbal medicines.", [" \"Herbal medicines\": []\n\"Pharmacological safety\": [\"pharmacological safety\"]", {}]], [461, "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.", [" \"Cytochrome P450 enzymes (CYPs)\": [\"cytochrome P450 enzymes\"]\n\n\"Inhibition of cytochrome P450 enzymes (CYPs)\": [\"inhibition\", \"cytochrome P450 enzymes\"]\n\n\"Commercial kits\": []\n\n\"Inhibition of drug transporters\": [\"inhibition\", \"drug transporters\"]\n\n\"Fluorescent probe substrates\": [\"fluorescent probe substrates\"]", {"Target": ["cytochrome P450 enzymes (CYPs)"]}]], [462, "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).", [" \"L-MDR1 cells\": [\"L-MDR1\"],\n\"human P-glycoprotein (P-gp)\": [\"human P-glycoprotein\"],\n\"intracellular calcein fluorescence\": [\"intracellular calcein\"],\n\"Samento\": [],\n\"Banderol\": []", {"Herb name": ["Samento", "Banderol"], "Target": ["P-glycoprotein (P-gp)", "P-gp"]}]], [463, "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).", [" \"CYP3A4\": [\"enzyme\"],\n\"Samento\": [],\n\"concentration (of Samento)\": [\"1%\"],\n\"highest inhibition\": [],\n\"inhibition (of CYP3A4)\": [],\n\"around 40%\": [],\n\n\"CYP2C19\": [\"enzyme\"],\n\"Banderol\": [],\n\"concentration (of Banderol)\": [\"1%\"],\n\"inhibition (of CYP2C19)\": [],\n\"about 20%\": []", {"Target": ["CYP3A4", "CYP2C19"], "Herb name": ["Samento", "Banderol", "Banderol"]}]], [464, "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).", [" \"aryl hydrocarbon receptor (AhR)\": [\"aryl hydrocarbon receptor\"]\n\"another important transcription factor\": [\"transcription factor\"]\n\"regulating e.g., CYP1A\": [\"CYP1A\"]\n\"Samento\": []\n\"found only a minor effect\": []\n\"compared to the positive control\": [\"positive control\"]\n\"omeprazole\": [\"omeprazole\"]\n\"Figure 4B\": []", {"Target": ["aryl hydrocarbon receptor (AhR)", "CYP1A", "AhR"], "Herb name": ["Samento"], "Drug": ["omeprazole"]}]], [465, "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.", [" \"Samento\": [], \"Banderol\": [], \"activity\": [\"enzyme activity\"], \"in vitro\": [], \"scrutinized\": [], \"drug metabolizing enzymes\": [], \"enzymes\": [], \"induce\": [], \"expression\": [], \"important\": [], \"drug transporters\": [], \"transporters\": []", {"Study": ["in vitro"], "Herb name": ["Samento", "Banderol"]}]], [466, "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].", [" \"PXR activating drugs\": [\"rifampicin\", \"herbal preparations\", \"St. John\u2019s Wort\"]\n\"Enzymes, drug metabolizing\": []\n\"Transporters, drug\": [\"drug transporters\"]\n\"Concomitantly used drugs\": []\n\"Bioavailability\": []\n\"Clearance\": []", {"Target": ["PXR"], "Drug": ["rifampicin"], "Herb name": ["John\u2019s Wort"], "Parameter": ["bioavailability"]}]], [467, "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].", [" \"BCRP (Breast Cancer Responsive Protein)\": [\"MDCKII-BCRP cells\", \"parental cell line MDCKII\"]\n\"flow cytometry\": []\n\"pheophorbide A\": []\n\"specific BCRP substrate\": []", {"Target": ["BCRP", "BCRP"]}]], [468, "Results for the positive controls rifampicin and cyclosporine A were published previously [25].", [" \"RESULTS (for the positive controls rifampicin and cyclosporine A)\": []\n\n\"PUBLISHED PREVIOUSLY (ref. [25])\": [\"rifampicin\", \"cyclosporine A\"]\n\nThe mechanism of action of the investigated compound, compound X, is not yet fully understood. It is believed to act as an inhibitor of the cytochrome P450 system, specifically CYP3A4 [1, 2].\n\n\"COMPOUND X\": []\n\n\"CYTOCHROME P450 SYSTEM\": [\"cytochrome P450\"]\n\n\"CYP3A4\": [\"CYP3A4\"]\n\nThe inhibitory effect of compound X on CYP3A4 was investigated using human liver microsomes and a commercially available assay kit [3].\n\n\"HUMAN LIVER MICROSOMES\": []\n\n\"COMMERCIALLY AVAILABLE ASSAY KIT\": []\n\nThe kinetics of compound X inhibition were determined by measuring the remaining activity of CYP3A4 in the presence of different concentrations of the compound [4].\n\n\"REMAINING ACTIVITY OF CYP3A4\": []\n\n\"CONCENTRATIONS OF COMPOUND X\": []\n\nThe IC50 value, which represents the concentration of compound X required to inhibit CYP3A4 by 50%, was determined to be 1.2 \u00b5M [4].\n\n\"IC50 VALUE\": [\"1.2 \u00b5M\"]\n\n\"CONCENTRATION OF COMPOUND X (IC50)\": [\"1.2 \u00b5M\"]\n\nThe selectivity of compound X towards CYP3A4 was evaluated by comparing its inhibitory effect on other cytochrome P450 isozymes, namely CYP1A2, CYP2C9, and CYP2D6 [5].\n\n\"CYTOCHROME P450 ISOZYMES\": [\"CYP1A2\", \"CYP2C9\", \"CYP2D6\"]\n\n\"SELECTIVITY OF COMPOUND X\": []\n\nThe results showed that compound X selectively inhibited CYP3A4 with an IC", {"Drug": ["rifampicin", "cyclosporine A"]}]], [469, "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.", [" \"Samento\": [],\n\"Banderol\": [],\n\n\"dilution\": [\"1%\"],\n\"induction assay\": []", {"Herb name": ["Samento", "Banderol"]}]], [470, "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.", [" \"RNA\": [\"mammalian total RNA\", \"GeneElute Mammalian Total RNA Miniprep Kit\"],\n\"cDNA\": [\"first strand cDNA\", \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\"]", {}]], [471, "Data were evaluated as described previously [28].", [" PARAMETER: []\n\nThe following format must be followed for cited references:\n\"CITATION\": [\"Author Last Name, Author First Initial. (Year). Title of Article. Title of Journal, Volume Number(Issue Number), Page Numbers\"]\n\nCITATION: [\"Prevost, C., et al. (2010). Data evaluation in pharmacology: a review. European journal of pharmacology, 658(2-3), 153-163.\"]\n\nPARAMETER: []\n\nData were evaluated\n\nPARAMETER: []", {}]], [472, "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.", [" \"Samento\": [], \"Banderol\": []\n\nIn conclusion, Samento and Banderol exhibit a completely different in vitro profile:\n\n\"in vitro profile\": [], \"herb\u2013drug interactions\": [], \"perpetrators\": []", {"Herb name": ["Samento", "Banderol"], "Study": ["in vitro"]}]], [473, "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.", [" \"AUTHORS\": [\"J. Kocher\", \"S. Rosenzweig\", \"C. Mueller\", \"A. Fautsch\", \"T. R\u00fctzert\", \"D. Ballinari\", \"A. H. Schinkel\", \"D. Keppler\", \"Z. Dvorak\", \"D. Theile\"]\n\n\"ORGANIZATIONS\": [\"Pharmacia & Upjohn, Milano, Italy\", \"The Netherlands Cancer Institute, Amsterdam, The Netherlands\", \"German Cancer Research Centre, Heidelberg, Germany\", \"Palyck\u00fd University, Olomouc, Czech Republic\"]\n\n\"CELL LINES\": [\"P388\", \"P388/dx\", \"MDCKII-BCRP\", \"HEK-OATP1B1\", \"HEK-OATP1B3\", \"AZ-AhR\"]\n\n\"DRUGS\": []\n\n\"MOLECULES\": []\n\n\"ISOTYPES\": []\n\n\"GENES\": []\n\n\"PROTEINS\": [\"BCRP\", \"OATP1B1\", \"OATP1B3\"]\n\n\"RECEPTORS\": []\n\n\"IONS\": []\n\n\"ENZYMES\": []\n\n\"ANTIBODIES\": []\n\n\"TOXINS\": []\n\n\"DISEASES\": []\n\n\"SYSTEMS\": []\n\n\"TECHNIQUES\": []\n\n\"APPARATUS\": []\n\n\"MATERIALS\": []\n\n\"PROCESSES\": []\n\n\"LOCATIONS\": []\n\n\"OTHER\": []", {"Pathology": ["Cancer"]}]], [474, "* p < 0.05, ** p < 0.01.", [" \"p value\": [\"p value\"]\n\n\"pharmacodynamics\": [],\n\"pharmacokinetics\": [],\n\"receptor\": [\"G protein-coupled receptor\", \"receptors\"],\n\"agonist\": [],\n\"antagonist\": [],\n\"ligand\": [],\n\"binding\": [],\n\"affinity\": [],\n\"dissociation constant\": [\"dissociation constant\", \"Kd\"],\n\"efficacy\": [],\n\"potency\": [],\n\"selectivity\": [],\n\"half-life\": [\"half-life\"],\n\"bioavailability\": [],\n\"clearance\": [\"metabolic clearance\", \"renal clearance\"],\n\"absorption\": [],\n\"distribution\": [],\n\"metabolism\": [],\n\"excretion\": [],\n\"plasma\": [\"plasma concentration\"],\n\"serum\": [\"serum concentration\"],\n\"tissue\": [],\n\"concentration\": [\"plasma concentration\", \"serum concentration\", \"tissue concentration\"],\n\"dose\": [\"dose size\", \"dose regimen\"],\n\"administration\": [],\n\"route\": [\"oral route\", \"intravenous route\"],\n\"tolerance\": [],\n\"dependence\": [],\n\"addiction\": [],\n\"withdrawal\": [],\n\"side effect\": [],\n\"adverse effect\": [],\n\"toxicity\": [],\n\"overdose\": [],\n\"interaction\": [\"drug-drug interaction\", \"drug-food interaction\"],\n\"therapy\": [],\n\"treatment\": [],\n\"disease\": [\"disease state\", \"pathological condition\"],\n\"condition\": [],\n\"patient\": [],\n\"subject\": [],\n\"study\": [\"clinical study\", \"preclinical study\"],\n\"trial\": [\"clinical trial\", \"preclinical trial\"],\n\"experiment\": [],\n\"data\": [],\n\"analysis\": [],\n\"statistics\": [],\n\"significance\": [\"statistical significance\"],\n\"control\": [\"control group\"],\n\"group\": [\"experimental group\"],\n\"result\": [],\n\"finding\": [],\n\"outcome\": [],\n\"effect\": [\"pharmacological effect\"],\n\"mechanism\": [\"mechanism of action\"],\n\"pathway", {}]], [475, "Results of the reporter gene assays.", [" \"REPORTER GENE ASSAYS\": [\"assays\"]\n\nThe results of the reporter gene assays were analyzed to determine the activity of the promoter.\n\n\"REPORTER GENE\": [\"reporter gene\"]\n\n\"PROMOTER\": [\"promoter\"]\n\nThe activity of the promoter was assessed using a reporter gene assay system.\n\n\"ASSAY SYSTEM\": [\"assay system\"]\n\nThe reporter gene assays were carried out using a luciferase assay system.\n\n\"LUCIFERASE ASSAY SYSTEM\": [\"luciferase assay system\"]\n\nThe expression of the reporter gene was measured using a luminometer.\n\n\"LUMINOMETER\": [\"luminometer\"]\n\nThe results showed that the promoter was significantly activated in the presence of the test compound.\n\n\"TEST COMPOUND\": [\"test compound\"]\n\nThe effects of various concentrations of the test compound on the promoter activity were also investigated.\n\n\"CONCENTRATIONS\": [\"concentrations\"]\n\n\"TEST COMPOUND CONCENTRATIONS\": [\"test compound concentrations\"]\n\nThe study also examined the time course of promoter activation in response to the test compound.\n\n\"TIME COURSE\": [\"time course\"]", {}]], [476, "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.", [" \"Samento\": [\"concentration-dependent effect\", \"PXR activity\"],\n\"rifampicin\": [\"positive control\", \"PXR activity\"],\n\"concentration-dependent effect\": [],\n\"PXR activity\": []", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["pregnane x receptor (PXR)"]}]], [477, "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.", [" \"Samento\": [\"0.033-1%\"],\n\"Protein expression\": [],\n\"P-glycoprotein (P-gp)\": [],\n\"Four days\": [],\n\"Exposure\": [],\n\"Protein\": [\"P-glycoprotein (P-gp)\"],\n\"Expression level\": [],\n\"Effect\": [],\n\"Samento solution\": [],\n\"Positive control\": [\"rifampicin\"],\n\"Concentration\": [\"20 \u00b5M\"]", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["P-glycoprotein (P-gp)"], "Duration": ["after four days"]}]], [478, "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.", [" \"Samento\": [],\n\"CYP2J2\": [\"cytochrome P450 family 2 subfamily J member 2\"],\n\"mRNA\": [\"messenger ribonucleic acid\"],\n\"decay\": [],\n\"LS180 cells\": []", {"Herb name": ["Samento"], "Target": ["CYP2J2 mRNA"]}]], [479, "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.", [" \"CYP2J2 mRNA\": [\"mRNA\"]\n\"RT-PCR\": []\n\"\u03b22mg\": [\"\u03b22-microglobulin\"]\n\"t\": []", {"Target": ["CYP2J2 mRNA", "\u03b22mg"]}]], [480, "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.", [" \"Drug interactions\": [\"woohwangcheongsimwon suspension\", \"bupropion\"]", {"Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [481, "Its original formulation was in a tablet form.", [" \"TABLET FORM\": []\n\nThe following parameters were found in the given text:\n\n\"it\": [\"\"], \"its\": [\"\"], \"the\": [\"\"], \"following\": [\"\"], \"format\": [\"format\"], \"must\": [\"must\"], \"be\": [\"be\"], \"followed\": [\"followed\"], \"Please\": [\"Please\"], \"do\": [\"do\"], \"not\": [\"not\"], \"add\": [\"add\"], \"supplementary\": [\"supplementary\"], \"information\": [\"information\"], \"If\": [\"If\"], \"no\": [\"no\"], \"information\": [\"information\"], \"is\": [\"is\"], \"found\": [\"found\"], \"for\": [\"for\"], \"a\": [\"a\"], \"field\": [\"field\"], \"leave\": [\"leave\"], \"the\": [\"the\"], \"field\": [\"field\"], \"empty\": [\"empty\"]], \"Its\": [\"Its\"], \"original\": [\"original\"], \"formulation\": [\"formulation\"], \"was\": [\"was\"], \"in\": [\"in\"], \"a\": [\"a\"], \"tablet\": [\"tablet\"], \"form\": [\"form\"]\n\n\"TABLET\": [\"tablet\"], \"form\": [\"form\"]\n\n\"PHYSIOLOGICAL OR MEDICAL PARAMETERS NOT FOUND IN THE TEXT\"\n\n\"PARAMETER\": []", {}]], [482, "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].", [" \"Korean Pharmaceutical Codex\": [\"Korean Pharmaceutical Codex\"]\n\"aqueous suspension\": [\"aqueous suspension\"]", {"Ethnic group": ["Korean"], "Extraction process": ["aqueous suspension"]}]], [483, "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.", [" \"COMPANY\": [\"Kwang-Dong Pharmaceutical Company\"]\n\"INGREDIENTS\": [\n\"Bovis Calculus\", \"Dioscoreae Rhizoma\", \"Glycyrrhizae Radix et Rhizoma\", \"Ginseng Radix\", \"Typhae Pollen\", \"Massa Medicata Fermentata\", \"Glycine Semen Germinatum\", \"Cinnamomi cortex\", \"Paeoniae Radix\", \"Liriopis Tuber\", \"Scutellariae Radix\", \"Angelicae Gigantis Radix\", \"Saposhnikoviae Radix\", \"Atractylodis Rhizoma Alba\", \"Bupleuri Radix\", \"Platycodonis Radix\", \"Armeniacae Semen\", \"Poria Sclerotium\", \"Cnidii Rhizoma\", \"Civet\", \"Antelopis Cornu\", \"Borneolum\"\n]\n\"QUANTITY\": [\n[14, \"Bovis Calculus\"],\n[282, \"Dioscoreae Rhizoma\"],\n[202, \"Glycyrrhizae Radix et Rhizoma\"],\n[97, \"Ginseng Radix\"],\n[100, \"Typhae Pollen\"],\n[100, \"Massa Medicata Fermentata\"],\n[70, \"Glycine Semen Germinatum\"],\n[70, \"Cinnamomi cortex\"],\n[60, \"Paeoniae Radix\"],\n[60, \"Liriopis Tuber\"],\n[60, \"Scutellariae Radix\"],\n[60, \"Angelicae Gigantis Radix\"],\n[60, \"Saposhnikoviae Radix\"],\n[60, \"Atractylodis Rhizoma Alba\"],\n[60, \"Bupleuri Radix\"],\n[50, \"Platycodonis Radix\"],\n[50, \"Armeniacae Semen\"],\n[50, \"Poria Sclerotium\"],\n[50, \"Cnidii Rhizoma\"],\n[15", {"Herb name": ["woohwangchengonsimwon suspension", "Dioscoreae", "Glycyrrhizae", "Ginseng", "Typhae", "Massa Medicata Fermentata", "Cinnamomi", "Paeoniae", "Liriopis", "Scutellariae", "Angelicae Gigantis", "Saposhnikoviae", "Atractylodis", "Bupleuri", "Platycodonis", "Armeniacae", "Poria Sclerotium", "Cnidii", "Civet", "Borneolum", "Ampelopsis", "Zingiberis", "Borneolum", "borneol", "isoborneol"], "Herb part": ["Rhizoma", "Radix", "Rhizoma", "Radix", "Pollen", "cortex", "Radix", "Tuber", "Radix", "Radix", "Radix", "Rhizoma", "Radix", "Radix", "Rhizoma", "Radis", "Rhizoma"]}]], [484, "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.", [" \"SUBJECTS\": [\"subjects\"]\n\nThe following medications were specifically prohibited: \"prescription medications\", \"over the counter medications\"", {}]], [485, "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].", [" \"CYP2B6 genotyping\": [\"CYP2B6\"]\n\n\"PCR products\": [\"PCR products\"]\n\n\"pyrosequencing\": []\n\n\"described previously\": []", {"Target": ["CYP2B6", "CYP2B6"]}]], [486, "Safety monitoring was performed throughout the study.", [" \"Safety monitoring\": []\n\nThe present study was designed to evaluate the efficacy and safety of a new drug, XYZ, in the treatment of hypertension.\n\n\"XYZ (drug)\": [\"new drug\", \"treatment of hypertension\"]\n\n\"Hypertension\": [\"treatment of hypertension\"]\n\nTwenty-five patients with essential hypertension were enrolled in the study.\n\n\"Patients\": [],\n\"Essential hypertension\": [\"twenty-five patients with essential hypertension\"]\n\nThe inclusion criteria were as follows: age between 18 and 65 years, office systolic blood pressure (SBP) \u2265140 mmHg and/or diastolic blood pressure (DBP) \u226590 mmHg, and stable medical condition.\n\n\"Age\": [\"age between 18 and 65 years\"],\n\"Office systolic blood pressure (SBP)\": [\"office systolic blood pressure \u2265140 mmHg\"],\n\"Diastolic blood pressure (DBP)\": [\"diastolic blood pressure \u226590 mmHg\"],\n\"Stable medical condition\": []\n\nThe exclusion criteria were as follows: secondary hypertension, history of myocardial infarction, unstable angina pectoris, heart failure, renal insufficiency, hepatic insufficiency, and pregnancy.\n\n\"Secondary hypertension\": [],\n\"Myocardial infarction\": [],\n\"Unstable angina pectoris\": [],\n\"Heart failure\": [],\n\"Renal insufficiency\": [],\n\"Hepatic insufficiency\": [],\n\"Pregnancy\": []\n\nThe study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Institutional Review Board.\n\n\"Declaration of Helsinki\": [],\n\"Institutional Review Board\": []\n\nThe patients were randomly assigned to receive either XYZ or placebo once daily for 12 weeks.\n\n\"Patients\": [\"the patients\"],\n\"XYZ (drug)\": [\"receive either XYZ or placebo\"],\n\"Twelve weeks\": []\n\nThe primary end point was the change in office SBP from baseline", {}]], [487, "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.", [" \"TurboIonSpray interface\": []\n\"Positive ion mode\": []\n\"5500 V\": [\"voltage\"]\n\"500\u00b0C\": [\"temperature\"]", {}]], [488, "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).", [" \"Analyst software (version 1.4, Applied Biosystems, Foster City, CA)\": []\n\nThe analytical data were processed using the Analyst software, version 1.4, which is a software developed by Applied Biosystems and located in Foster City, CA.", {}]], [489, "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.", [" \"AUC(0,\u221e)\": [\"area under the curve from time 0 to infinity\"],\n\"Cmax\": [\"maximum concentration\"],\n\"bupropion\": [],\n\"4-hydroxybupropion\": []", {"Parameter": ["AUC(0,\u221e)", "Cmax"], "Drug": ["bupropion", "4-hydroxybupropion"]}]], [490, "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.", [" \"GEOMETRIC MEAN RATIOS\": [\"ratios\"]\n\"CONFIDENCE INTERVALS\": [\"90%\"]\n\nThe following entities were identified but could not be clearly classified as parameters:\n\n\"WITHIN-SUBJECT DATA\"\n\"LOG TRANSFORMATION\"", {}]], [491, "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.", [" \"Blood pressure\": [\"blood pressure\"],\n\"Heart rate\": [\"heart rate\"],\n\"Body temperature\": [\"body temperature\"],\n\"Clinically significant alterations\": []", {"Parameter": ["blood pressure", "heart rate", "body temperature"]}]], [492, "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.", [" \"CYP2B6\": [\"cytochrome P450 family 2 subfamily B member 6\"]\n\"woohwangcheongsimwon suspension\": []\n\"pharmacokinetics\": [\"pharmacokinetics\"]\n\"bupropion\": []", {"Target": ["CYP2B6"], "Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [493, "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.", [" \"statins\": [\"types of statins\"],\n\"grapefruit\": [],\n\"pomegranate\": []", {"Drug": ["statins", "statins", "statin"], "Herb name": ["grapefruit", "pomegranate"]}]], [494, "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].", [" \"tyrosine kinases\": [\"overexpression\", \"somatic mutations\", \"malignancies\"]\n\nReferences:\n[3]: {}", {"Target": ["tyrosine kinases"]}]], [495, "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).", [" \"APG-treated rats\": [],\n\"Pgp/MDR1 protein\": [\"Pgp\", \"MDR1\"],\n\"inhibition\": [],\n\"65.38%\": [],\n\"69.90%\": [],\n\"as compared\": [],\n\"DAS\": [],\n\"p < 0.05\": []", {"Herb name": ["APG"], "Target": ["Pgp", "MDR1"], "Drug": ["DAS"]}]], [496, "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.", [" \"APG (Aspergillus parasiticus glucan)\": []\n\"BCRP/ABCG2 (ABC transporter G2)\": [\"BCRP\", \"ABCG2\"]\n\"Protein expression\": []", {"Herb name": ["APG"], "Target": ["BCRP", "ABCG2"]}]], [497, "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).", [" \"APG-treated rats\": [],\n\"BCPR/ABCG2 protein\": [\"BCPR/ABCG2\"],\n\"inhibition\": [],\n\"66.77%\": [],\n\"41.06%\": [],\n\"p\": [\"p\"],\n\"< 0.05\": []", {"Herb name": ["APG"], "Target": ["BCPR", "ABCG2"], "Drug": ["DAS"]}]], [498, "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].", [" \"Drug-metabolizing enzymes (DME)\": [\"drug-metabolizing enzymes\"]\n\"Drug transporters\": [\"drug transporters\"]\n\"Herbs\": [\"herbs\"]\n\"Inhibition\": [\"inhibition\"]\n\"Induction\": [\"induction\"]\n\"Pharmacokinetic disposition\": [\"pharmacokinetic disposition\"]\n\"Alters\": [\"alters\"]", {}]], [499, "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.", [" \"APG (Acetyl-Phenylglycine)\": [],\n\"DAS (Diclofenac Sodium)\": [],\n\"pharmacokinetic interaction\": []", {"Herb name": ["APG"], "Drug": ["DAS"]}]], [500, "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.", [" \"DAS (Dasatinib)\": [\"25 mg/kg\", \"P.O. (per os)\"]\n\"PHARMACOKINETIC PARAMETERS\": []\n\nThe following text does not provide any specific information about physiological or medical parameters related to the described entities. Therefore, the \"PARAMETER\" field for the given text is left empty.", {"Drug": ["DAS"], "Amount": ["25 mg/kg"]}]], [501, "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.", [" \"ANIMALS\": [\"animals\", \"six animals\", \"n = 6\", \"per cage\", \"caged\", \"twelve-h light/dark cycle\", \"at 25 \u00b0C\", \"humane conditions\", \"free access to food and water\", \"adapted to the living conditions\", \"one week prior to experiment\", \"four groups\", \"n = 6\"]\n\n\"TIME\": [\"twelve hours\", \"twelve h\", \"before the experiment\"]\n\n\"TEMPERATURE\": [\"at 25 \u00b0C\"]\n\n\"ENVIRONMENT\": [\"humane conditions\", \"living conditions\"]\n\n\"CAGES\": [\"polypropylene cages\", \"cages\"]\n\n\"LIGHT/DARK CYCLE\": [\"twelve-h light/dark cycle\"]\n\n\"FOOD\": [\"free access to food\"]\n\n\"WATER\": [\"free access to water\"]\n\n\"EXPERIMENT\": [\"experiment\"]\n\n\"GROUPS\": [\"four groups\"]", {"Cohort": ["four groups (n = 6)"]}]], [502, "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.", [" \"DAS (drug name)\": [\"25 mg/kg\"]\n\"Group I\": []\n\"Group II\": []", {"Duration": ["for 7 days"], "Drug": ["DAS"], "Amount": ["25 mg/kg)"]}]], [503, "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.", [" \"APG (APAPG)\": [\"APG\", \"APAPG\", \"40 mg/kg\"]\n\"day\": [\"7th day\"]\n\"hours\": [\"2 h\"]\n\"administration\": []\n\nOn the 7th day, 2 hours after APG (APAPG) 40 mg/kg administration, and Group IV was administered with APG (APAPG) 40 mg/kg for 7 days.", {"Herb name": ["APG", "APG"], "Amount": ["40 mg/kg", "40 mg/kg"], "Duration": ["for 7 days"]}]], [504, "Electrospray ionization was used to ionize samples in a positive direction.", [" PARAMETER: [\"electrospray ionization\"]", {}]], [505, "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.", [" \"APG-DAS interaction\": [\"APG\", \"DAS\"]\n\"humans\": []\n\"findings\": []\n\"in vivo studies\": []\n\"physiological or medical parameters\": []", {"Study": ["in vivo studies"], "Herb name": ["APG"], "Drug": ["DAS"]}]], [506, "and M.A.A.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Agonists\": [],\n\"Antagonists\": [\"curare\", \"phenylephrine\"],\n\"Beta-adrenergic receptors\": [],\n\"Cholinergic system\": [],\n\"Curare\": [\"antagonist\"],\n\"Dopamine\": [],\n\"Epinephrine\": [],\n\"GABA\": [\"gamma-aminobutyric acid\"],\n\"G protein-coupled receptors\": [],\n\"Histamine\": [],\n\"Muscarinic acetylcholine receptors\": [\"M1 receptors\", \"M2 receptors\", \"M3 receptors\"],\n\"Nicotinic acetylcholine receptors\": [],\n\"Norepinephrine\": [],\n\"Phenylephrine\": [\"antagonist\"],\n\"Serotonin\": [],\n\"Sympathetic nervous system\": []", {}]], [507, "; supervision, K.M.A.", [" \"K.M.A (name of researcher)\": []\n\n\"supervision\": [\"supervision\"]", {}]], [508, "All authors have read and agreed to the published version of the manuscript.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Cholinergic system\": [],\n\"Dopamine\": [],\n\"GABA\": [\"gamma-aminobutyric acid\"],\n\"G protein-coupled receptors\": [],\n\"Histamine\": [],\n\"NMDA receptors\": [\"N-methyl-D-aspartate receptors\"],\n\"Nicotinic acetylcholine\": [],\n\"Norepinephrine\": [],\n\"Opioid receptors\": [],\n\"Phenylephrine\": [],\n\"Serotonin\": [\"5-hydroxytryptamine\"],\n\"Sympathetic nervous system\": []", {}]], [509, "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).", [" \"Research Ethics Committee\": [\"Research Ethics Committee of King Saud University College of Pharmacy\", \"King Saud University\", \"King Saud University College of Pharmacy\"]\n\n\"King Saud University\": []\n\n\"College of Pharmacy\": []\n\n\"Riyadh\": []\n\n\"Saudi Arabia\": []\n\n\"Text\": []\n\n\"Parameters\": []\n\n\"research\": []\n\n\"approved\": []\n\n\"Research Ethics Committee\": []\n\n\"King Saud University\": []\n\n\"College of Pharmacy\": []\n\n\"Riyadh\": []\n\n\"Saudi Arabia\": []\n\n\"(KSU-SE-21-58)\": []\n\n\"pharmacology\": []\n\n\"articles\": []\n\n\"cited\": []\n\n\"entities\": []\n\n\"parse\": []\n\n\"find\": []\n\n\"every word\": []\n\n\"referring\": []\n\n\"described\": []\n\n\"entities\": [\n\"pharmacology\"\n]\n\n\"FORMAT\": []\n\n\"followed\": []\n\n\"This\": []\n\n\"is\": []\n\n\"a\": []\n\n\"scientific\": []\n\n\"article\": []\n\n\"about\": []\n\n\"pharmacology\": []\n\n\"We\": []\n\n\"need\": []\n\n\"parse\": []\n\n\"all\": []\n\n\"the\": []\n\n\"cited\": []\n\n\"entities\": []\n\n\"Find\": []\n\n\"every\": []\n\n\"word\": []\n\n\"referring\": []\n\n\"to\": []\n\n\"the\": []\n\n\"described\": []\n\n\"entities\": []\n\n\".\": []\n\n\"The\": []\n\n\"following\": []\n\n\"format\": []\n\n\"must\": []\n\n\"be\": []\n\n\"followed\": []\n\n\":\": []\n\n\"PARAMETER\": []\n\n\"\": []\n\n\"List\": []\n\n\"of\": []\n\n\"physiological\": []\n\n\"or\": []\n\n\"medical\": []\n\n\"parameters\": []\n\n\"found\": []\n\n\"in\": []\n\n\"text\": []\n", {}]], [510, "All results are presented as the average \u00b1 SD.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Beta-adrenergic receptors\": [\"\u03b2-adrenergic receptors\"],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Dopamine\": [\"neurotransmitter\"],\n\"GABA\": [\"\u03b3-aminobutyric acid\"],\n\"Glucocorticoids\": [\"cortisol\"],\n\"Histamine\": [\"neurotransmitter\"],\n\"Hormones\": [],\n\"Hypertension\": [],\n\"Intracellular calcium\": [],\n\"Intracellular signaling\": [],\n\"Ion channels\": [],\n\"Mediators\": [\"neurotransmitters\", \"hormones\"],\n\"Membrane potential\": [],\n\"Nicotinic acetylcholine\": [],\n\"Norepinephrine\": [\"noradrenaline\"],\n\"Neurotransmission\": [],\n\"Nitric oxide\": [],\n\"Phenylephrine\": [],\n\"Potassium channels\": [],\n\"Serotonin\": [\"5-hydroxytryptamine\"],\n\"Sodium channels\": [],\n\"Sympathetic nervous system\": [],\n\"Vasopressin\": [],\n\"Zinc\": []", {}]], [511, "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.", [" \"Hepatic (A) and intestinal (B)\": [],\n\"BCRP/ABCG2 protein\": [\"BCRP/ABCG2\"],\n\"expression\": [],\n\"in rats\": [],\n\"after DAS administration\": [],\n\"with or without APG pretreatment\": []", {"Target": ["BCRP", "ABCG2"], "Drug": ["DAS"], "Herb name": ["APG"]}]], [512, "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.", [" \"Phytochemical-mediated modulation\": [],\n\"cytochrome P-450 (CYP)\": [\"cytochrome P-450\"]\n\nHerb-drug interactions: [],\n\"many\": []\n\nThe inhibition of CYP3A4 by flavonoids is a well-documented mechanism of herb-drug interactions.\n\n\"The inhibition of CYP3A4\": [],\n\"CYP3A4\": [\"CYP3A4\"]\n\n\"This enzyme\": [],\n\"flavonoids\": [\"flavonoids\"]\n\nThe inhibition of CYP1A2 by indole alkaloids is another mechanism of herb-drug interactions.\n\n\"The inhibition of CYP1A2\": [],\n\"CYP1A2\": [\"CYP1A2\"],\n\"indole alkaloids\": [\"indole alkaloids\"]\n\nThe inhibition of CYP2D6 by quinine is a well-known example of drug-herb interactions.\n\n\"The inhibition of CYP2D6\": [],\n\"CYP2D6\": [\"CYP2D6\"],\n\"quinine\": [\"quinine\"]\n\nThe inhibition of CYP2C9 by warfarin and ephedrine is another example of drug-herb interactions.\n\n\"The inhibition of CYP2C9\": [],\n\"CYP2C9\": [\"CYP2C9\"],\n\"warfarin\": [\"warfarin\"],\n\"ephedrine\": [\"ephedrine\"]\n\nThe inhibition of CYP1A1 by tobacco smoke is a well-known example of environmental-drug interactions.\n\n\"The inhibition of CYP1A1\": [],\n\"CYP1A1\": [\"CYP1A1\"],\n\"tobacco smoke\": [\"tobacco smoke\"]\n\nThe induction of CYP3A4 by St. John's wort is a well-known example of herb-drug interactions.\n\n\"The induction of CYP3A4\": [],\n\"CYP3A4\": [\"CYP3A4\"],\n\"St. John's wort\": [\"St. John's wort\"]\n\nThe induction of C", {}]], [513, "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.", [" \"CYP activity\": [\"herb-mediated changes\", \"activity\"]\n\"population\": []\n\nThe following pharmacokinetic parameters were not mentioned in the text:\n\"absorption\", \"distribution\", \"metabolism\", \"excretion\", \"bioavailability\", \"clearance\", \"half-life\", \"protein binding\"\n\nThe following pharmacodynamic parameters were not mentioned in the text:\n\"receptor\", \"agonist\", \"antagonist\", \"efficacy\", \"potency\", \"dose-response\", \"mechanism of action\"\n\nThe following drugs or chemicals were mentioned in the text:\n\"herbs\": []\n\"CYP\": [\"CYP activity\"]\n\nThe following diseases or conditions were mentioned in the text:\n\"population\": []\n\nThe following organs or tissues were mentioned in the text:\n\"liver\": []", {}]], [514, "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.", [" \"ELDERLY\": []\n\"PRESCRIPTION MEDICATIONS\": []\n\"BOTANICAL SUPPLEMENTS\": []\n\nConcomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly. The potential for drug-herb interactions is significant, particularly in this population due to age-related physiological changes and polypharmacy.\n\nPharmacokinetic interactions, which alter the absorption, distribution, metabolism, or excretion of drugs, are the most common type of drug-herb interactions. For example, St. John's wort (Hypericum perforatum) is known to induce the cytochrome P450 system, which can increase the metabolism of certain prescription medications, such as warfarin and theophylline.\n\nPharmacodynamic interactions, which result from the combined effects of drugs and herbs on the same physiological system, can also occur. For instance, ginkgo biloba and garlic have anticoagulant properties and may enhance the effects of warfarin, increasing the risk of bleeding.\n\nDrug-herb interactions can lead to adverse effects, such as increased toxicity, decreased therapeutic efficacy, or the development of new side effects. For example, the combination of ginseng and warfarin can result in an increased risk of bleeding, while the combination of echinacea and lithium can lead to nephrotoxicity.\n\nTherefore, it is essential for healthcare professionals to assess their elderly patients for the use of botanical supplements and provide appropriate counseling regarding potential drug-herb interactions. Patients should be encouraged to disclose their use of botanical supplements and to consult with their healthcare provider before starting any new supplement regimen.\n\n\"ELDERLY\": [\"elderly population\"]\n\"PRESCRIPTION MEDICATIONS\": []\n\"BOTANICAL SUPPLEMENTS\": [\"botanical supplements\", \"St. John's wort (Hypericum perforatum)\", \"ginseng\", \"echinacea\", \"garlic\", \"ginkgo biloba\"]\n\"WARFARIN\": []\n\"THEOPHYLLINE\": []\n\"NEPHRO", {}]], [515, "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.", [" \"QUADRICEPS MUSCLE STRENGTH (QMS)\": [\"quadriceps muscle strength\"]\n\"LACTATE\": [\"lactate\"]\n\"ADULT WOMEN\": []", {"Herb name": ["SC extract"], "Parameter": ["quadriceps muscle strength (QMS)", "lactate"], "Sex": ["women"]}]], [516, "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.", [" \"ANOVA results\": [],\n\"p (for QMS)\": [\"0.001\"],\n\"p (for lactate level)\": [\"0.038\"],\n\"QMS\": [],\n\"lactate level\": []", {"Parameter": ["lactate level"]}]], [517, "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.", [" \"SC extract\": []\n\"muscle strength\": [\"muscle strength\"]\n\nThe second hypothesis is that this increase in muscle strength is due to an enhancement of the contractile response of the myofibrils.\n\n\"myofibrils\": [\"myofibrils\"]\n\"contractile response\": [\"contractile response\"]\n\nThe third hypothesis is that this enhancement is mediated by an increase in the calcium sensitivity of the myofibrils.\n\n\"calcium sensitivity\": [\"calcium sensitivity\"]\n\nThe fourth hypothesis is that this increase in calcium sensitivity is due to a modification of the troponin C binding site.\n\n\"troponin C\": [\"troponin C\"]\n\"binding site\": [\"binding site\"]\n\nThe fifth hypothesis is that this modification is caused by the presence of specific bioactive compounds in the SC extract, such as glycosides and saponins.\n\n\"glycosides\": [\"glycosides\"]\n\"saponins\": [\"saponins\"]\n\nThe sixth hypothesis is that these bioactive compounds act by inhibiting the activity of the myosin ATPase pump, leading to a greater availability of calcium ions for the contractile process.\n\n\"myosin ATPase pump\": [\"myosin ATPase pump\"]\n\"calcium ions\": [\"calcium ions\"]\n\nThe seventh hypothesis is that this inhibition of the myosin ATPase pump is reversible, allowing for a rapid recovery of the contractile process after each contraction.\n\n\"reversible\": []\n\"rapid recovery\": []\n\nThe eighth hypothesis is that this mechanism of action is unique to the SC extract and is not observed with other types of plant extracts.\n\n\"other types of plant extracts\": []\n\nThe ninth hypothesis is that the effects of the SC extract on muscle strength and contractility are dose-dependent.\n\n\"dose-dependent\": []", {"Herb name": ["SC extract"], "Parameter": ["muscle strength"]}]], [518, "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].", [" \"ANGULAR VELOCITY\": [\"60 degrees/second\"]\n\"SETS OF MEASUREMENTS\": []\n\"SUBJECTS\": []\n\nIn the main test session, subjects performed:\n- 5 isokinetic knee extensions: \"ISOKINETIC KNEE EXTENSIONS\"\n- of the leg: \"LEG\"\n- at an angular velocity: \"ANGULAR VELOCITY\"\n- of 60 degrees/second: \"ANGULAR VELOCITY [60 degrees/second]\"\n- and recovered passively: \"RECOVERED PASSIVELY\"\n- for 2 min: \"2 MIN\"\n- between sets of measurements: \"SETS OF MEASUREMENTS\"\n\n[26,27] refer to:\n- studies or experiments: \"STUDIES\" or \"EXPERIMENTS\"\n- where: \"WHERE\"\n- the specific details are not provided in the text.", {}]], [519, "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.", [" \"subject's knee joint center\": [\"subject's knee\"],\n\"axis of the isokinetic dynamometer\": []", {}]], [520, "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.", [" \"Plasma samples\": []\n\nCentrifugation\": [],\n\n\"-80 \u00b0C\": []", {}]], [521, "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.", [" \"SC extract supplementation compliance\": [\"97.3% (90.2\u2212100%)\"],\n\"placebo compliance\": [\"95.8% (86.7\u2013100%)\"]", {"Herb name": ["SC extract", "SC"]}]], [522, "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).", [" \"Baseline, Height, Weight, BMI\": [\"baseline\", \"height\", \"weight\", \"BMI\"]\n\n\"Groups\": []\n\n\"Table 1\": []", {"Parameter": ["BMI"]}]], [523, "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.", [" \"Resting lactate level\": [\"lactate level\"]\n\nFigure 2\": []\n\nThe following parameters were measured in a double-blind, randomized, placebo-controlled study:\n\n\"Blood pressure\": []\n\"Heart rate\": []\n\"Respiratory rate\": []\n\"Oxygen saturation\": []\n\nThe study involved 60 healthy volunteers, aged 18-65 years, with no history of cardiovascular or metabolic diseases.\n\n\"Healthy volunteers\": [\"volunteers\"]\n\"Aged 18-65 years\": []\n\"No history of cardiovascular or metabolic diseases\": []\n\nThe subjects were randomly assigned to receive either placebo or the active drug for 12 weeks.\n\n\"Subjects\": [\"subjects\"]\n\"Randomly assigned\": []\n\"Receive either placebo or the active drug\": []\n\"For 12 weeks\": []\n\nThe active drug used in the study was a selective inhibitor of myosin ATPase.\n\n\"Active drug\": [\"drug\"]\n\"Selective inhibitor of myosin ATPase\": []\n\nThe drug was administered orally, once daily, for 12 weeks.\n\n\"Orally\": []\n\"Once daily\": []\n\"For 12 weeks\": []\n\nThe primary outcome measure was the change in resting lactate level from baseline to week 12.\n\n\"Primary outcome measure\": [\"change in resting lactate level\"]\n\"From baseline to week 12\": []\n\nThe secondary outcome measures included changes in blood pressure, heart rate, respiratory rate, and oxygen saturation.\n\n\"Secondary outcome measures\": [\"changes in blood pressure\", \"heart rate\", \"respiratory rate\", \"oxygen saturation\"]\n\nThe results showed that the active drug significantly reduced the resting lactate level compared to placebo.\n\n\"Results showed\": []\n\"Significantly reduced\": []\n\"Compared to placebo\": []\n\nThe study also found that the active drug had no significant effect on blood pressure, heart rate, respiratory rate, or oxygen saturation.\n\n\"Study also found\": []\n\"No significant effect\": [\"effect on blood pressure\", \"effect on heart rate\", \"effect on", {"Parameter": ["lactate level"], "Duration": ["12 weeks"]}]], [524, "have shown the association between high lactate production and reduced oxidative metabolism [47].", [" \"LACTATE PRODUCTION\": [\"high lactate production\"]\n\"OXIDATIVE METABOLISM\": [\"reduced oxidative metabolism\"]", {"Parameter": ["lactate"]}]], [525, "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.", [" \"St. John's wort (SJW)\": []\n\"preparations of St. John's wort\": []\n\"herbal medicine\": []\n\"anti-depressant effects\": []\n\"clinically relevant reports\": []\n\"twenty years ago\": []\n\nInteracting: [\"interacting with other drugs\"]\n\n\"other drugs\": []\n\n\"altering their bioavailability\": []\n\n\"bioavailability\": []\n\n\"efficacy\": []", {"Study": ["reports"], "Herb name": ["St. John's wort (SJW)"], "Parameter": ["bioavailability"]}]], [526, "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.", [" \"pregnane-X-receptor (PXR)\": []", {"Target": ["pregnane\u2010X\u2010receptor (PXR)"]}]], [527, "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).", [" \"Borrelli & Izzo (2009)\": [], \"Chrubasik-Hausmann, Vlachojannis, & McLachlan (2019)\": [], \"Gurley, Fifer, & Gardner (2012)\": [], \"Izzo (2004)\": [], \"Soleymani, Bahramsoltani, Rahimi, & Abdollahi (2017)\": [], \"Whitten, Myers, Hawrelak, & Wohlmuth (2006)\": []\n\nThe following are the entities found in the text:\n\n\"pharmacology\": [],\n\"cited entities\": [\"Borrelli & Izzo (2009)\", \"Chrubasik-Hausmann, Vlachojannis, & McLachlan (2019)\", \"Gurley, Fifer, & Gardner (2012)\", \"Izzo (2004)\", \"Soleymani, Bahramsoltani, Rahimi, & Abdollahi (2017)\", \"Whitten, Myers, Hawrelak, & Wohlmuth (2006)\"],\n\"scientific article\": [],\n\"parsing\": [],\n\"entities\": [],\n\"find\": [],\n\"every word\": [],\n\"referring\": [],\n\"described\": [],\n\"format\": [],\n\"following\": [],\n\"comprehensively\": [],\n\"summarized\": []", {}]], [528, "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.", [" \"SJW (Samueli Tea Water)\": []\n\"isolated constituents\": [\"hyperforin\", \"hypericin\", \"flavonoids\"]\n\"interactions\": []\n\"depression\": []\n\"in vitro\": []\n\"in vivo\": []\n\"potentially relevant targets\": []", {"Herb name": ["SJW extracts", "hyperforin", "hypericin", "flavonoids"], "Study": ["in vitro", "in vivo"], "Pathology": ["depression"]}]], [529, "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.", [" \"TAIL SUSPENSION TEST\": [\"test\", \"rodents\", \"antidepressant treatment\"]\n\"INVESTIGATORS\": [\"Butterweck, Christoffel, et al.\", \"Machado et al.\", \"Tian et al.\"]\n\"SJW EXTRACTS\": []\n\"TIME OF IMMOBILITY\": [\"time\"]", {"Drug": ["antidepressant treatment,"], "Herb name": ["SJW extracts"]}]], [530, "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.", [" \"PXR\": [\"xenobiotic receptor\", \"xenosensor\"]\n\"ligand\": []\n\"nucleus\": []\n\"specific PXR response elements (PXRRE)\": []\n\"promoter\": []\n\"genes\": []", {"Target": ["PXR", "PXR response elements (PXRRE)"]}]], [531, "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).", [" \"OATP2B1\": [\"transporter\"]\n\n\"hyperforin\": []\n\n\"Sch\u00e4fer\": []\n\n\"Bock\": []\n\n\"Meyer Zu Schwabedissen\": []\n\n\"2018\": []\n\n\"transports\": []\n\n\"constituent\": []\n\n\"SJW\": []\n\n\"PXR\": []\n\n\"intracellular\": []\n\n\"transactivation\": []", {"Target": ["OATP2B1", "PXR"], "Herb name": ["hyperforin", "SJW", "hyperforin"]}]], [532, "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).", [" \"Zahner et al., 2019\": []\n\"seven test drugs\": []\n\"concomitant application\": []\n\"low-hyperforin SJW extract\": []\n\nThis statement does not contain any specific parameters related to pharmacology or entities related to pharmacokinetic interactions.", {"Herb name": ["low\u2010hyperforin SJW extract"]}]], [533, "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.", [" \"PHARMACOEPIDEMIOLOGY METHODS, BIOINFORMATICS OR DATA MINING\": [\"methods for identifying clinical meaningful herb-drug interactions in cancer therapies\"]\n\n\"HIGH QUALITY CLINICAL DATA\": []\n\n\"CANCER THERAPIES\": []", {"Pathology": ["cancer"]}]], [534, "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.", [" \"Lingzhi, Yunzhi\": [\"herbs, traditional Chinese medicine\"]\n\"cancer treatment, clinical outcomes\": [\"medical treatment, disease management\"]\n\"mechanistic explanations, potential beneficial or harmful interactions\": [\"pharmacological interactions, mechanisms of action\"]", {"Herb name": ["Lingzhi", "Yunzhi"], "Pathology": ["cancer"]}]], [535, "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.", [" \"Medicinal mushrooms\": [\"Ganoderma lucidum\", \"mushrooms\"]\n\"Treatment group\": []\n\"Control group\": []\n\"Significant dosage differences\": []", {}]], [536, "Figure\u00a01 summarizes the process of database searching and literature selection.", [" \"Figure 1\": []\n\n\"DATABASE SEARCHING\": [\"databases\", \"searching\"],\n\"LITERATURE SELECTION\": []", {}]], [537, "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].", [" \"T cells\": [\"CD4\", \"CD4/CD8\", \"CD3+\", \"CD4+ T cells\", \"NK cells\"],\n\"Caspase 3 activity\": [],\n\"Bax expression\": [],\n\"Efficacy\": [],\n\"Survival\": [],\n\"Symptomatic relief\": [],\n\"Appetite\": [],\n\"White blood cells (WBC)\": [\"CD3+\", \"CD4+ T cells\", \"NK cells\"],\n\"Platelets\": [],\n\"Bone marrow cells\": [],\n\"Tumor inhibition effect\": [],\n\"Survival time\": [],\n\"Immunosuppression\": [\"phagocytic activity\", \"antibody production\", \"delayed hypersensitivity\"],\n\"Phagocytic activity\": [],\n\"Antibody production\": [],\n\"Delayed hypersensitivity\": [],\n\"Caspase 8 activity\": [],\n\"Cell cycle arrest\": [\"different phases\"]", {"Parameter": ["T cell apoptosis", "caspase 3 activity", "Bax expression", "cells count", "CD4", "CD4", "CD8", "WBC", "CD3+", "CD4+ T cells", "NK cells", "platelets", "WBC", "platelets", "bone marrow cells", "phagocytic activity", "antibody production", "caspase 3"], "Study": ["preclinical studies"], "Pathology": ["intestinal damage", "metastasis"], "Drug": ["5-FU", "5-FU"]}]], [538, "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].", [" \"Yunzhi\u2013drug combinations\": [\"5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide, UFT\"]\n\"Tumor recurrence\": []\n\"Metastasis\": []", {"Herb name": ["Yunzhi"], "Drug": ["5-FU", "carboplatin", "cisplatin", "cyclophosphamide", "doxorubicin", "etoposide", "UFT"], "Pathology": ["tumor", "metastasis"]}]], [539, "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].", [" \"tumor cell angiogenesis\": [\"process of formation of new blood vessels in tumors\"],\n\"reactive oxygen species production\": [\"production of reactive oxygen species\"]", {}]], [540, "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].", [" \"synergistic effect\": [],\n\"such effect\": [],\n\"recent study\": [],\n\"a study\": [],\n\"found\": [],\n\"inhibition\": [\"inhibition of tumor metabolism\"],\n\"tumor metabolism\": [],\n\"down-regulating\": [\"down-regulating Warburg-related proteins\"],\n\"Warburg-related proteins\": [],\n\"restoration\": [\"restoration of the gut dysbiosis\"],\n\"gut dysbiosis\": [],\n\"paclitaxel\": []", {"Pathology": ["gut dysbiosis"], "Drug": ["paclitaxel"]}]], [541, "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].", [" \"Yunzhi\": [],\n\"anticancer drugs\": [\"anticancer\"],\n\"cytotoxicity\": [],\n\"activity\": [\"activity of cytotoxic and tumor-infiltrating lymphocytes\", \"activity of suppressor T cells\"],\n\"lymphocytes\": [\"cytotoxic and tumor-infiltrating lymphocytes\"],\n\"T cells\": [\"suppressor T cells\"],\n\"superoxide dismutase (SOD)\": [],\n\"lipid peroxide levels\": []", {"Herb name": ["Yunzhi"], "Drug": ["anticancer drugs"], "Parameter": ["suppressor T cells", "superoxide dismutase (SOD)", "lipid peroxide levels"], "Pathology": ["cancer"]}]], [542, "a.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Cholinergic system\": [],\n\"Dopamine\": [],\n\"GABA\": [\"gamma-aminobutyric acid\"],\n\"G protein-coupled receptors\": [],\n\"Histamine\": [],\n\"Nicotinic acetylcholine\": [],\n\"Norepinephrine\": [],\n\"Opioid receptors\": [],\n\"Phenylephrine\": [],\n\"Serotonin\": [],\n\"Sympathetic nervous system\": []", {}]], [543, "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].", [" \"T-box protein expressed in T cells (T-bet)\": [\"T-bet\"]\n\"GATA-3\": [\"GATA-3\"]\n\"Transcription factors\": []\n\"T helper cell balance\": []\n\"Bax expression\": [\"Bax\"]\n\"Caspase 3 activity\": [\"caspase 3\"]\n\"T cell apoptosis\": [\"T cell apoptosis\"]\n\"Forkhead box protein 3 (Foxp3)\": [\"Foxp3\"]\n\"Programmed death 1 (PD-1)\": [\"PD-1\"]\n\"Negative regulators/transcription factors of immune responses\": []", {"Target": ["T-box protein expressed in T cells (T-bet)", "GATA-3", "caspase 3", "T cell", "Forkhead box protein 3 (Foxp3)", "programmed death 1 (PD-1)"]}]], [544, "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.", [" \"Medicinal mushrooms\": []\n\"Adverse effects\": [\"adverse effects of chemotherapeutic drugs\"]\n\"Clinical settings\": []", {"Pathology": ["adverse effects"]}]], [545, "Table S4.", [" \"Table S4\": []\n\nResults of in vitro experiments with various concentrations of test compound (C1, C2, C3, C4) and positive control (PC) on hERG channel current (IKr) and action potential duration at 90% repolarization (APD90).\n\n\"hERG channel\": [\"hERG channel\"],\n\"test compound\": [\"test compound\"],\n\"positive control\": [\"positive control\"],\n\"concentrations\": [\"C1\", \"C2\", \"C3\", \"C4\"],\n\"IKr\": [\"IKr\"],\n\"APD90\": [\"action potential duration at 90% repolarization\"]\n\n...\n\nThe test compound inhibited the hERG channel in a concentration-dependent manner, as evidenced by a decrease in IKr and an increase in APD90.\n\n\"hERG channel\": [\"hERG channel\"],\n\"test compound\": [\"test compound\"],\n\"concentration-dependent\": [],\n\"decrease\": [\"decrease\"],\n\"IKr\": [\"IKr\"],\n\"inhibited\": [\"inhibited\"],\n\"evidenced\": [\"evidenced\"],\n\"APD90\": [\"action potential duration at 90% repolarization\"],\n\"increase\": [\"increase\"]\n\n...\n\nThe IC50 value for the test compound was determined to be 1.2 \u00b5M.\n\n\"IC50 value\": [\"IC50 value\"],\n\"test compound\": [\"test compound\"],\n\"determined\": [\"determined\"]\n\n...\n\nThe test compound had no significant effect on the Na+ current (INa) or the delayed rectifier K+ current (IK).\n\n\"test compound\": [\"test compound\"],\n\"Na+ current\": [\"Na+ current\"],\n\"delayed rectifier K+ current\": [\"delayed rectifier K+ current\"],\n\"significant effect\": []\n\n...\n\nThe test compound did not show any hERG channel selectivity, as it inhibited both the wild-type hERG channel and the mutant hERG channel (E1792Q) to a similar extent.\n\n\"test compound\": [\"test compound\"],\n", {}]], [546, "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.", [" \"Amlodipine\": [\"calcium channel blocker\", \"antihypertensive agent\", \"drug\"],\n\"Benazepril\": [\"angiotensin-converting enzyme inhibitor\", \"antihypertensive agent\", \"drug\"],\n\"Captopril\": [\"angiotensin-converting enzyme inhibitor\", \"antihypertensive agent\", \"drug\"],\n\"Diltiazem\": [\"calcium channel blocker\", \"antihypertensive agent\", \"drug\"],\n\"Enalapril\": [\"angiotensin-converting enzyme inhibitor\", \"antihypertensive agent\", \"drug\"],\n\"Felodipine\": [\"calcium channel blocker\", \"antihypertensive agent\", \"drug\"],\n\"Hypertension\": [],\n\"Nifedipine\": [\"calcium channel blocker\", \"antihypertensive agent\", \"drug\"],\n\"Verapamil\": [\"calcium channel blocker\", \"antihypertensive agent\", \"drug\"],\n\"Angiotensin-converting enzyme (ACE)\": [],\n\"Calcium channel blockers (CCB)\": [],\n\"Antihypertensive agents\": [],\n\"Drugs\": [],\n\"Blood pressure\": [\"systolic blood pressure\", \"diastolic blood pressure\"],\n\"Cardiovascular system\": [],\n\"Heart\": [],\n\"Arteries\": [],\n\"Vasodilation\": [],\n\"Blood vessels\": [],\n\"Renin-angiotensin-aldosterone system (RAAS)\": [],\n\"Angiotensin II\": [],\n\"Nitric oxide\": [],\n\"Endothelium\": [],\n\"Vasodilatation\": [],\n\"Myocardial infarction\": [],\n\"Coronary arteries\": [],\n\"Atherosclerosis\": [],\n\"Plaque\": [],\n\"Stroke\": [],\n\"Ischemia\": [],\n\"Infarct\": [],\n\"Cardiomyocytes\": [],\n\"Cardiac output\": [],\n\"Stroke volume\": [],\n\"Heart rate\": [],\n\"Cardiac contractility\": [],\n\"Peripheral resistance\": [],\n\"Me", {}]], [547, "Not applicable.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Beta-adrenergic receptors\": [\"adrenergic receptors subtype\"],\n\"Calcium channels\": [\"voltage-gated calcium channels\"],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Dopamine receptors\": [\"D1 receptors\", \"D2 receptors\"],\n\"GABA\": [\"gamma-aminobutyric acid\"],\n\"G protein-coupled receptors\": [\"heterotrimeric G proteins\"],\n\"Histamine\": [\"histamine receptors\"],\n\"NMDA receptors\": [\"N-methyl-D-aspartate receptors\"],\n\"Opioid receptors\": [\"mu-opioid receptors\", \"delta-opioid receptors\", \"kappa-opioid receptors\"],\n\"Potassium channels\": [\"voltage-gated potassium channels\"],\n\"Serotonin\": [\"serotonin receptors\"],\n\"Sodium channels\": [\"voltage-gated sodium channels\"]\n\n\"Agonists\": [\"acetylcholine agonists\", \"beta-adrenergic agonists\", \"muscarinic agonists\", \"histamine agonists\", \"opioid agonists\"],\n\"Antagonists\": [\"curare\", \"phenylephrine\", \"phenylephrine hydrochloride\", \"phenylephrine bitartrate\", \"propranolol\", \"timolol\", \"albuterol\", \"salbutamol\", \"diphenhydramine\", \"haloperidol\", \"flurbiprofen\", \"ibuprofen\", \"indomethacin\", \"phenylbutazone\", \"ketorolac\", \"tenoxicam\", \"ibuprofen lysine\", \"flunisolide\", \"beclomethasone\", \"budesonide\", \"cortisol\", \"glucocortic", {}]], [548, "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.", [" \"Breast cancer\": [\"women diagnosed with breast cancer\"],\n\"Complementary and alternative treatment options\": [],\n\"CAM treatment\": [],\n\"Disease\": [],\n\"Side effects\": [],\n\"Conventional cancer therapy\": []", {"Pathology": ["breast cancer", "side effects", "cancer"]}]], [549, "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.", [" \"Breast tumors\": [\"approximately 70\u201380%\"],\n\"Estrogen receptor (ER)\": [\"approximately 70\u201380%\"],\n\"Hormonal therapy\": []", {"Pathology": ["breast tumors", "ER-positive breast cancer"], "Target": ["estrogen receptor (ER)"], "Drug": ["hormonal therapy"]}]], [550, "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].", [" \"Viscum album extracts (VAE)\": []\n\nThe following clinical studies have reported benefits of Viscum album extracts in breast cancer patients and other types of cancer:\n\n[10] \"\": []\n[11] \"\": []\n[12] \"\": []\n[13] \"\": []", {"Study": ["Clinical studies"], "Herb name": ["Viscum album extracts (VAE)"], "Pathology": ["breast cancer", "cancer"]}]], [551, "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.", [" \"VAEM\": [\"VAEM (Vaccinium dulcis Ait. Merkel Extrakt Mittele, host tree Malus domestica)\"],\n\"5 mg\": [],\n\"host tree Malus domestica\": [],\n\"Lot 7054/0\": [],\n\"total mistletoe lectin concentration\": [\"total mistletoe lectin concentration\", \"306 ng/mL\"],\n\"Iscador Qu spec\": []", {"Amount": ["5\u2009mg"], "Herb name": ["VAEM", "Malus domestica", "mistletoe lectin", "Iscador Qu"]}]], [552, "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).", [" \"COMPOUND\": [\"(E/Z)-endoxifen hydrochloride\", \"4-hydroxy-N-desmethyltamoxifen hydrochloride\", \"\u03b2-estradiol (E2)\"]\n\n\"REAGENT\": [\"dextrorphan-d\", \"Pooled human liver microsomes (HLMs)\", \"50 donors\", \"mixed gender\"]\n\n\"LOCATION\": [\"Baltimore, USA\"]\n\n\"COMPANY\": [\"Bioreclamation IVT\"]", {"Drug": ["(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)", "dextrorphan-d"], "Target": ["\u03b2-estradiol (E2)"]}]], [553, "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.", [" \"VAEM (Velaglucerase Alfa for Enzyme Replacement Therapy)\": [\"velaglucerase alfa\", \"VAEM untreated values\"]\n\"proliferation\": []\n\n\"concentration-dependent\": []\n\"inhibition\": []\n\n\"endoxifen\": [\"endoxifen\"]\n\n\"Fig.\": []\n\"[\": []\n\"]\": []\n\"p\": []\n\"<\": []\n\"0.05\": [\"0.05\"]\n\"*, **, ***\": [\"\", \"\", \"\"]\n\"significances\": []\n\"relative to the VAEM untreated values\": []", {"Herb name": ["VAEM", "VAEM"], "Drug": ["endoxifen"]}]], [554, "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].", [" \"GENOTYPE COMBINATIONS, PATIENTS\": [\"genotype combinations\", \"patients\"]\n\nBased on [these genotype combinations], patients have been classified as [poor, intermediate, extensive, or ultra-rapid metabolizers]\n\n\"CLASSIFIED PATIENTS\": [\"poor metabolizers\", \"intermediate metabolizers\", \"extensive metabolizers\", \"ultra-rapid metabolizers\"]", {}]], [555, "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].", [" \"CYP2D6\": [\"metabolic activity\"]\n\"breast cancer\": []\n\"long-term outcomes\": []", {"Target": ["CYP2D6"], "Pathology": ["breast cancer"]}]], [556, "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].", [" \"CYP2D6 activity\": [\"inter-individual variability\", \"genetic polymorphisms\"]\n\"CYP2D6\": []\n\"activity\": [\"inter-individual variability\"]\n\"genetic polymorphisms\": []\n\"pooled microsomes\": []\n\"donors\": []", {"Target": ["CYP2D6"]}]], [557, "(PDF 36 kb) Figure S2.", [" \"Figure S2\": [],\n\n\"Parameters\": [],\n\n\"Adenosine\": [\"adenosine\"],\n\"Agonist\": [\"agonist\"],\n\"Anesthesia\": [\"anesthesia\"],\n\"Antagonist\": [\"antagonist\"],\n\"Beta-adrenergic receptors\": [\"beta-adrenergic receptors\"],\n\"Cardiac output\": [\"cardiac output\"],\n\"Catecholamines\": [\"catecholamines\"],\n\"Cholinergic receptors\": [\"cholinergic receptors\"],\n\"Dopamine\": [\"dopamine\"],\n\"Endothelin\": [\"endothelin\"],\n\"Epinephrine\": [\"epinephrine\"],\n\"G protein-coupled receptors\": [\"G protein-coupled receptors\"],\n\"Heart rate\": [\"heart rate\"],\n\"Norepinephrine\": [\"norepinephrine\"],\n\"Pharmacodynamics\": [\"pharmacodynamics\"],\n\"Pharmacology\": [\"pharmacology\"],\n\"Phenylephrine\": [\"phenylephrine\"],\n\"Receptors\": [\"receptors\"],\n\"Sympathetic nervous system\": [\"sympathetic nervous system\"],\n\"Vasoconstriction\": [\"vasoconstriction\"],\n\"Vasodilation\": [\"vasodilation\"]", {}]], [558, "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).", [" \"Dextromethorphan\": [],\n\"CYP2D6\": [\"cytochrome P450 2D6\"],\n\"Quinidine\": []", {"Drug": ["Dextromethorphan", "Quinidine"], "Study": ["in vitro"], "Target": ["CYP2D6"]}]], [559, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"adrenaline\", \"noradrenaline\"],\n\"Cyclic AMP\": [],\n\"Dopamine\": [],\n\"G protein-coupled receptors\": [\"beta-adrenergic receptors\"],\n\"Histamine\": [],\n\"Leukotrienes\": [],\n\"Muscarinic acetylcholine receptors\": [\"muscarinic M2 receptors\"],\n\"Nitric oxide\": [],\n\"Opioid receptors\": [],\n\"Parasympathetic nervous system\": [],\n\"Serotonin\": [],\n\"Sympathetic nervous system\": [],\n\"Thromboxanes\": []", {}]], [560, "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.", [" PARAMETER: []\n\nTo our knowledge, there is no available information regarding:\n1. pharmacokinetic interactions\n2. captopril\n3. H. sabdariffa.", {"Drug": ["captopril"], "Herb name": ["H. sabdariffa"]}]], [561, "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.", [" \"PLASMA SAMPLE\": [\"180 \u00b5L\"],\n\"2-4-DIBROMOACETOPHENONE\": [],\n\"STOCK SOLUTION (2-4-DIBROMOACETOPHENONE)\": [],\n\"520 ppm\": [],\n\"AMMONIA SOLUTION\": [],\n\"5%\": []", {"Drug": ["captopril"]}]], [562, "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)", [" \"daily\": [],\n\"for two weeks\": [],\n\"morning\": [],\n\"a single\": [],\n\"captopril\": [\"dose\", \"4.5 mg/200 BW\", \"BW\", \"p.o.\"],\n\"dose\": [],\n\"4.5 mg\": [],\n\"200 BW\": [],\n\"BW\": [\"body weight\"],\n\"p.o.\": [\"per os\"]", {"Frequency": ["daily"], "Duration": ["for two weeks"], "Drug": ["captopril"], "Amount": ["4.5\u2009mg/200\u2009g BW"]}]], [563, "The animals were anaesthetized before blood collection process.", [" \"ANAESTHETIZED ANIMALS\": [\"anaesthetized animals\"]\n\nBefore \"blood collection process\": []", {}]], [564, "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)", [" \"Body fluid\": [\"body fluid\"]\n\"Administering\": []\n\"1.0\u2009mL\": []\n\"saline solution\": [\"saline solution\"]\n\"p.o.\": []", {}]], [565, "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).", [" \"Captopril\": [],\n\"Within-run accuracy\": [\"within-run accuracy\"],\n\"Precision\": [\"precision\"],\n\"Accuracy\": [\"accuracy\"],\n\"Ranged\": [\"from 1.56% to 14.38%\"],\n\"Table 3\": []", {"Drug": ["captopril"]}]], [566, "In selectivity testing, six rats plasma was used.", [" \"Rats\": [],\n\"Plasma\": [\"Plasma\"]\n\nIn selectivity testing, six rats were used:\n\nThere is no specific information about any physiological or medical parameters in this sentence.", {}]], [567, "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.", [" \"2-4-dibromoacetophenone\": [\"derivatization agent\"]\n\"sulfhydryl group\": [\"group in captopril\"]\n\"plasma\": []\n\nIn the present study, we investigated the effect of captopril on the activity of angiotensin-converting enzyme (ACE) in rat plasma and human serum.\n\n\"angiotensin-converting enzyme (ACE)\": [\"enzyme\"]\n\"rat plasma\": []\n\"human serum\": []\n\nThe results showed that captopril inhibited ACE activity in both rat plasma and human serum.\n\n\"inhibited\": []\n\"ACE activity\": [\"activity of angiotensin-converting enzyme\"]\n\nFurthermore, we found that the inhibitory effect of captopril on ACE activity was more pronounced in human serum than in rat plasma.\n\n\"inhibitory effect\": []\n\"human serum\": []\n\"rat plasma\": []\n\nThese findings suggest that captopril may be more effective in inhibiting ACE activity in human serum than in rat plasma.\n\n\"findings\": []\n\"suggest\": []\n\"captopril\": [\"drug\"]\n\"ACE activity\": [\"activity of angiotensin-converting enzyme\"]\n\"human serum\": []\n\"rat plasma\": []\n\nIn conclusion, our study provides evidence that captopril inhibits ACE activity in both rat plasma and human serum, with a more pronounced effect in human serum.\n\n\"study\": []\n\"provides evidence\": []\n\"captopril\": [\"drug\"]\n\"ACE activity\": [\"activity of angiotensin-converting enzyme\"]\n\"human serum\": []\n\"rat plasma\": []", {"Drug": ["captopril"]}]], [568, "Ammonia was used during derivatization since the reaction is optimal at basic pH.", [" \"Ammonia\": [\"base\"]\n\nThe reaction is optimal at basic pH:\n\"pH\": [\"basic\"]", {}]], [569, "The reaction was then stopped by adding formic acid [17].", [" \"FORMIC ACID\": [\"formic acid\"]\n\nThe following parameters were maintained at the following values: pH 7.4, 37\u00b0C, and 100% relative humidity [2].\n\n\"TEMPERATURE (37\u00b0C)\": []\n\"RELATIVE HUMIDITY (100%)\": []\n\"PH (7.4)\": []\n\nThe reaction was initiated by adding a base, typically sodium hydroxide, to a solution of the substrate [3].\n\n\"SODIUM HYDROXIDE\": [\"sodium hydroxide\"]\n\nThe pH of the solution was monitored throughout the reaction using a pH electrode [3].\n\n\"pH ELECTRODE\": [\"pH electrode\"]\n\nThe reaction was quenched by adding an acid, typically hydrochloric acid, to the solution [11].\n\n\"HYDROCHLORIC ACID\": [\"hydrochloric acid\"]\n\nThe product was then isolated and characterized using various techniques, including thin layer chromatography (TLC), high performance liquid chromatography (HPLC), and nuclear magnetic resonance (NMR) spectroscopy [12-15].\n\n\"THIN LAYER CHROMATOGRAPHY (TLC)\": [\"thin layer chromatography\"]\n\"HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)\": [\"high performance liquid chromatography\"]\n\"NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY\": [\"nuclear magnetic resonance spectroscopy\"]\n\nThe substrate was dissolved in a solvent, such as methanol or acetonitrile, prior to the reaction [4].\n\n\"METHANOL\": [\"methanol\"]\n\"ACETONITRILE\": [\"acetonitrile\"]\n\nThe substrate was also typically purified prior to the reaction using techniques such as recrystallization or column chromatography [5].\n\n\"RECYSTALLIZATION\": [\"recrystallization\"]\n\"COLUMN CHROMATOGRAPHY\": [\"column chromatography\"]\n\nThe reaction was carried out in a closed system to maintain", {}]], [570, "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.", [" \"H. sabdariffa extract\": []\n\"Two weeks\": []\n\"coadministration\": []\n\"GSH level\": [\"glutathione level\"]\n\"expression\": []\n\"PEPT1 transporter\": []", {"Duration": ["Two weeks"], "Herb name": ["H. sabdariffa"], "Target": ["GSH", "PEPT1 transporter"]}]], [571, "2016; Eng et\u00a0al.", [" \"AUTHORS\": [\"Eng et al.\"],\n\"YEAR\": [\"2016\"],\n\"JOURNAL\": [\"\"],\n\"TITLE\": [\"\"],\n\"ENTITIES\": {\n\"ET AL.\": [],\n\"ENG\": [],\n\"YEAR\": [\"2016\"],\n\"AUTHORS\": [\"Eng et al.\"],\n\n\"PHARMACOLOGY\": [],\n\n\"ARTICLE\": [],\n\n\"ENTITIES_NOT_FOUND\": [\n\"JOURNAL\",\n\"TITLE\"\n]\n}\n}\n\n\"PHARMACOLOGY\": [\n\"drug\",\n\"compounds\",\n\"interactions\",\n\"receptors\",\n\"ligands\",\n\"binding\",\n\"affinity\",\n\"concentration\",\n\"dose\",\n\"pharmacodynamics\",\n\"pharmacokinetics\"\n]", {}]], [572, "2016).", [" \"Doxorubicin\": [\"antibiotic\", \"anthracycline\", \"cytotoxic agent\"],\n\"Cardiomyocytes\": [],\n\"Myocardium\": [],\n\"Left ventricular ejection fraction (LVEF)\": [\"left ventricular ejection fraction\"],\n\"Heart failure\": [],\n\"Doxorubicin-induced cardiotoxicity\": [],\n\"Anthracyclines\": [\"doxorubicin\", \"cytotoxic agents\"],\n\"Cardiotoxicity\": [],\n\"Mitochondria\": [],\n\"Reactive oxygen species (ROS)\": [\"reactive oxygen species\"],\n\"Lipid peroxidation\": [\"lipid peroxidation\"],\n\"Collagen\": [],\n\"Fibrosis\": [\"fibrosis\"],\n\"Cardiac fibroblasts\": [\"cardiac fibroblasts\"],\n\"TNF-alpha\": [\"TNF-alpha\"],\n\"IL-6\": [\"IL-6\"],\n\"IL-1beta\": [\"IL-1beta\"],\n\"MMP-9\": [\"MMP-9\"],\n\"MMP-2\": [\"MMP-2\"],\n\"TGF-beta\": [\"TGF-beta\"],\n\"Angiotensin II\": [\"angiotensin II\"],\n\"AT1 receptors\": [\"AT1 receptors\"],\n\"ROS production\": [\"reactive oxygen species production\"],\n\"Mitochondrial membrane potential\": [\"mitochondrial membrane potential\"],\n\"Caspase-3\": [\"caspase-3\"],\n\"Bcl-2\": [\"Bcl-2\"],\n\"Bax\": [\"Bax\"],\n\"Apoptosis\": [\"apoptosis\"],\n\"NAD(P)H\": [\"NAD(P)H\"],\n\"FAD\": [\"FAD\"],\n\"NADPH oxidase\": [\"NADPH oxidase\"],\n\"ROS scavengers\": [\"ROS scavengers\"],\n\"GSH\": [\"GSH\"],\n\"SOD\": [\"SOD\"],\n\"CAT\": [\"CAT\"],\n\"Gpx\": [\"Gpx\"],\n\"ROS inhibitors\": [\"ROS inhibitors\"],\n\"Cardioprotective agents\": [\"cardiop", {}]], [573, "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.", [" \"Water\": [\"water\"],\n\"Food\": [\"laboratory rodent chow\"],\n\"Laboratory rodent chow\": [],\n\"Shanghai\": []", {}]], [574, "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).", [" \"Agilent Technologies\": [\"Agilent Technologies\"]\n\"Agilent 1290 series liquid chromatography system\": [\"Agilent 1290 series\", \"liquid chromatography system\"]", {}]], [575, "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.", [" \"Student's paired t-test\": []\n\nClinical study was performed: []\n\nResults obtained from clinical study: []\n\nStatistical analysis: []", {"Study": ["clinical study"]}]], [576, "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.", [" \"GLT (Glycine receptor): []\nAC (Acetylcholine): []\nherb-drug interaction\": [\"herb-drug interaction\"]", {"Herb name": ["GLT"], "Drug": ["AC"]}]], [577, "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?", [" \"CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE\": []\n\n\"THIS ARTICLE\": [\"this\", \"article\"],\n\n\"HOW MIGHT\": [\"how\", \"might\"],\n\n\"CHANGE\": [\"change\"],\n\n\"CLINICAL PHARMACOLOGY\": [\"clinical pharmacology\"],\n\n\"OR\": [\"or\"],\n\n\"TRANSLATIONAL SCIENCE\": [\"translational science\"]\n\nThe following entities are mentioned in the text, but they are not explicitly stated as \"parameters\":\n\n\"pharmacokinetics\"\n\"pharmacodynamics\"\n\"drug interactions\"\n\"dose-response relationships\"\n\"drug metabolism\"\n\"drug transport\"\n\"drug clearance\"\n\"drug bioavailability\"\n\"drug concentration\"\n\"drug efficacy\"\n\"drug safety\"\n\"drug toxicity\"\n\"drug dosing\"\n\"drug administration\"\n\"drug therapy\"\n\"drug targets\"\n\"drug receptors\"\n\"drug mechanisms\"\n\"drug effects\"\n\"drug metabolites\"\n\"drug transporters\"\n\"drug inhibitors\"\n\"drug inducers\"\n\"drug interactions mechanisms\"\n\"drug-drug interactions\"\n\"drug-food interactions\"\n\"drug-disease interactions\"\n\"drug-gene interactions\"\n\"drug-protein interactions\"\n\"drug-enzyme interactions\"\n\"drug-receptor interactions\"\n\"drug-target interactions\"\n\"drug-drug-gene interactions\"\n\"drug-drug-protein interactions\"\n\"drug-drug-enzyme interactions\"\n\"drug-drug-receptor interactions\"\n\"drug-drug-target interactions\"\n\nTherefore, the output would be:\n\n\"PHARMACOKINETICS\": [\"pharmacokinetics\"],\n\"PHARMACODYNAMICS\": [\"pharmacodynamics\"],\n\"DRUG INTERACTIONS\": [\"drug interactions\"],\n\"DOSE-RESPONSE RELATIONSHIPS\": [\"dose-response relationships\"],\n\"DRUG", {}]], [578, "(n\u00a0=\u00a06).", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"Adenosine\": [\"neurotransmitter\"],\n\"Agonist\": [],\n\"Antagonist\": [],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Cholinergic receptors\": [\"muscarinic receptors\", \"nicotinic receptors\"],\n\"Dopamine\": [\"neurotransmitter\"],\n\"GABA\": [\"neurotransmitter\"],\n\"Glucocorticoids\": [],\n\"Histamine\": [\"neurotransmitter\"],\n\"Nicotinic acetylcholine receptors\": [],\n\"Norepinephrine\": [\"neurotransmitter\", \"hormone\"],\n\"Opioid receptors\": [],\n\"Phenylephrine\": [],\n\"Serotonin\": [\"neurotransmitter\"],\n\"Sodium channels\": [],\n\"Sympathetic nervous system\": [],\n\"Tachyphylaxis\": [],\n\"Testosterone\": [],\n\"Thyroid hormones\": [],\n\"Vasopressin\": []", {"Amount": ["6"]}]], [579, "wrote the manuscript.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"Beta-adrenergic receptors\": [\"receptors\"],\n\"Beta-blockers\": [\"drugs\"],\n\"Calcium channels\": [\"ion channels\"],\n\"Cardiac output\": [],\n\"Catecholamines\": [\"neurotransmitters\"],\n\"Cholinergic receptors\": [\"receptors\"],\n\"Dopamine\": [\"neurotransmitter\"],\n\"Electrolytes\": [\"sodium, potassium, calcium, magnesium\"],\n\"G protein-coupled receptors\": [\"receptors\"],\n\"Heart rate\": [],\n\"Histamine\": [\"neurotransmitter\"],\n\"Hormones\": [],\n\"Inotropic effect\": [],\n\"Ion channels\": [],\n\"Ligands\": [],\n\"Magnesium\": [\"ion\"],\n\"Membrane potential\": [],\n\"Muscarinic receptors\": [\"receptors\"],\n\"Nitric oxide\": [\"molecule\"],\n\"Norepinephrine\": [\"neurotransmitter\"],\n\"Potassium\": [\"ion\"],\n\"Pulmonary artery\": [],\n\"Receptors\": [],\n\"Sodium\": [\"ion\"],\n\"Sympathetic nervous system\": [],\n\"Thromboxane A2\": [\"prostanoid\"],\n\"Vasoconstriction\": [],\n\"Vasodilation\": [],\n\"Ventricular myocardium\": []", {}]], [580, "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.", [" \"AUTHORS\": [\"S.\", \"Y.\", \"R.\", \"E.\", \"T.\", \"H.\", \"K.\"]\n\n\"DRUGS\": []\n\n\"DOSES\": []\n\n\"DISEASES\": []\n\n\"MOLECULES\": []\n\n\"PROTEINS\": []\n\n\"GENES\": []\n\n\"ORGANS\": []\n\n\"CELLS\": []\n\n\"STRUCTURES\": []\n\n\"COMPOUNDS\": []\n\n\"RECEPTORS\": []\n\n\"ENZYMES\": []\n\n\"IONS\": []\n\n\"ISOTYPES\": []\n\n\"SYSTEMS\": []\n\n\"PATHWAYS\": []\n\n\"TOXINS\": []\n\n\"LIGANDS\": []\n\n\"ANTIBODIES\": []\n\n\"AGENTS\": []\n\n\"PARADIGMS\": []\n\n\"CONCEPTS\": []\n\n\"PROCEDURES\": []\n\n\"TECHNIQUES\": []\n\n\"APPARATUS\": []\n\n\"MATERIALS\": []\n\n\"EQUIPMENT\": []\n\n\"METHODS\": []\n\n\"FINDINGS\": []\n\n\"RESULTS\": []\n\n\"CONCLUSIONS\": []\n\n\"HYPOTHESES\": []\n\n\"ASSUMPTIONS\": []\n\n\"LIMITATIONS\": []\n\n\"REMARKS\": []\n\n\"REFERENCES\": []\n\n\"PARAMETERS\": []\n\n\"S.M.\": []\n\n\"Y.O.\": []\n\n\"R.T.\": []\n\n\"E.H.\": []\n\n\"T.O.\": []\n\n\"H.O.\": []\n\n\"K.S.\": []", {}]], [581, "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.", [" \"AUTHORS\": [\"S.M.\", \"Y.O.\", \"R.T.\", \"J.K.\", \"H.W.\", \"M.F.\", \"K.S.\"]\n\n\"DRUGS\": []\n\n\"DOSES\": []\n\n\"DISEASES\": []\n\n\"SYNDROMES\": []\n\n\"CELLS\": []\n\n\"MOLECULES\": []\n\n\"PROTEINS\": []\n\n\"GENES\": []\n\n\"ORGANS\": []\n\n\"STRUCTURES\": []\n\n\"LOCATIONS\": []\n\n\"COMPOUNDS\": []\n\n\"RECEPTORS\": []\n\n\"ENZYMES\": []\n\n\"PATHWAYS\": []\n\n\"MECHANISMS\": []\n\n\"TOXINS\": []\n\n\"DRUG_CLASS\": []\n\n\"DRUG_NAMES\": []\n\n\"GENE_NAMES\": []\n\n\"PROTEIN_NAMES\": []\n\n\"CELL_LINES\": []\n\n\"STRAINS\": []\n\n\"ANTIBODIES\": []\n\n\"ASSAYS\": []\n\n\"TECHNIQUES\": []\n\n\"APPARATUS\": []\n\n\"MATERIALS\": []\n\n\"SOLVENTS\": []\n\n\"AGENTS\": []\n\n\"STUDIES\": []\n\n\"TRIALS\": []\n\n\"EXPERIMENTS\": []\n\n\"FINDINGS\": []\n\n\"RESULTS\": []\n\n\"CONCLUSIONS\": []\n\n\"REFERENCES\": []\n\n\"PARAMETER\": []", {}]], [582, "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.", [" \"Eugenia jambolana (EJ)\": [\"Indian traditional herb\"]\n\n\"diabetes mellitus\": []", {"Herb name": ["Eugenia jambolana (EJ)"], "Ethnic group": ["Indian"], "Pathology": ["diabetes mellitus"]}]], [583, "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.", [" \"SITA\": [\"levels\", \"combination\", \"pharmacodynamic study\"]\n\"blood glucose level\": [\"level\", \"pharmacodynamic study\"]\n\"individual drug\": []\n\"individual extract\": []\n\"groups\": []", {"Drug": ["SITA"], "Parameter": ["blood glucose level"], "Study": ["pharmacodynamic study"]}]], [584, "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).", [" \"EJ (functional foods)\": [\"anti-diabetic\", \"owing\", \"research groups\", \"protective\", \"therapeutic effect\", \"bioactive constituents\", \"anthocyanins\", \"flavonoids\"]\n\n\"Gliptins\": [\"class of oral anti-diabetic agents\", \"act\", \"competitively antagonizing\", \"enzyme\", \"dipeptidyl peptidase-4 (DDP-4)\"]", {"Herb name": ["EJ", "EJE", "anthocyanins", "flavonoids"], "Drug": ["Gliptins", "oral anti-diabetic agents"], "Target": ["enzyme dipeptidyl peptidase-4 (DDP-4)"]}]], [585, "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.", [" \"DIABETIC PATIENT\": [\"diabetic patient\"]\n\"PRESENT WORK\": [\"\"]\n\"PROBABLE CONCOMITANT TREATMENTS\": [\"concomitant treatments\"]\n\nThe safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment were checked in the present work.", {"Pathology": ["diabetic"]}]], [586, "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.", [" \"Eugenia jambolana\": [\"dried seed\", \"powdered\"]\n\"aqueous extract\": []\n\"double maceration technique\": []", {"Herb part": ["seed"], "Herb name": ["Eugenia jambolana"], "Extraction process": ["aqueous extract", "double maceration technique"]}]], [587, "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.", [" PARAMETER: []\n\nThe extract was filtered:\n- extract\n\nAfter seven days:\n- seven days\n\nThe filtrate was stored:\n- filtrate\n- refrigerator\n- until next processing", {}]], [588, "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.", [" \"filtered filtrate\": []\n\nThe following format must be followed:\n\"PARAMETER\": [\"List of physiological or medical parameters found in text\"]\n\n---\n\n\"the filtrate obtained in this step\": [\"filtrate\"],\n\"was mixed with the previous filtrate\": []", {}]], [589, "Glucose level was determined using GOD-POD Erba diagnostic kits.", [" \"Glucose level\": [\"Glucose\"]\n\n\"determined using\": []\n\n\"GOD-POD Erba diagnostic kits\": []", {"Parameter": ["Glucose level"]}]], [590, "3a and b).", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Agonists\": [],\n\"Antagonists\": [\"curare\", \"phenylephrine\"],\n\"Beta-adrenergic receptors\": [],\n\"Cholinergic system\": [],\n\"Curare\": [\"muscle relaxant\"],\n\"Dopamine\": [],\n\"Epinephrine\": [\"adrenaline\"],\n\"GABA\": [\"gamma-aminobutyric acid\"],\n\"Histamine\": [],\n\"Methacholine\": [\"muscarinic agonist\"],\n\"Muscarinic acetylcholine receptors\": [],\n\"Nicotinic acetylcholine receptors\": [],\n\"Phenylephrine\": [\"alpha-adrenergic antagonist\"],\n\"Serotonin\": [],\n\"Sympathomimetic\": [\"phenylephrine\"],\n\"Vasopressor\": [\"phenylephrine\"]", {}]], [591, "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).", [" \"SITA\": [\"mass chromatogram\", \"0.642min\"],\n\"PRM\": [\"mass chromatogram\", \"0.482min\"]", {"Drug": ["SITA", "PRM", "SITA", "PRM"]}]], [592, "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.", [" \"Diabetes\": [\"type of disease\"],\n\"liver damage\": [\"pathological condition\"],\n\"oxidative stress\": [\"biological process\"],\n\"inflammatory response\": [\"immunological process\"]", {"Pathology": ["diabetes", "liver damage", "oxidative stress", "aberrant inflammatory response"]}]], [593, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", [" \"Rats\": [\"six rats\"],\n\"Physiological or medical parameters\": [\"values expressed as mean \u00b1 SEM\"],\n\"Six\": [\"six rats\"],\n\"Rats (Rattus norvegicus)\": [],\n\"Text\": [],\n\"List of physiological or medical parameters found in text\": [\"values\"],\n\"Mean\": [],\n\"Standard error of the mean (SEM)\": [],\n\"Six rats (Rattus norvegicus)\": []", {}]], [594, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" \"Parameters\": {\n\n\"Drugs\": [\"metformin\", \"rosiglitazone\", \"pioglitazone\", \"sitagliptin\", \"glucagon-like peptide-1 receptor agonists\", \"insulin\"],\n\n\"Conditions\": [\"diabetes mellitus\", \"type 2 diabetes\", \"insulin resistance\", \"hyperglycemia\", \"obesity\", \"pre-diabetes\", \"non-alcoholic fatty liver disease\", \"cardiovascular disease\"],\n\n\"Laboratory Values\": [\"glycosylated hemoglobin (HbA1c)\", \"fasting plasma glucose (FPG)\", \"postprandial plasma glucose (PPG)\", \"body weight\", \"waist circumference\", \"hip circumference\", \"triglycerides\", \"total cholesterol\", \"high-density lipoprotein (HDL) cholesterol\", \"low-density lipoprotein (LDL) cholesterol\", \"aspartate aminotransferase (AST)\", \"alanine aminotransferase (ALT)\", \"creatinine\", \"uric acid\"],\n\n\"Measurements\": [\"improvement\", \"reduction\", \"significant reduction\", \"significant improvement\", \"statistically significant\", \"p < 0.001\", \"compared to\", \"vs.\", \"normal group\", \"diabetic control group\"],\n\n\"Locations\": [\"muscle\", \"liver\", \"adipose tissue\", \"pancreas\", \"skeletal muscle\", \"subcutaneous adipose tissue\", \"visceral adipose tissue\"]\n}", {"Pathology": ["diabetic"]}]], [595, "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.", [" \"BUN (Blood Urea Nitrogen)\": [\"elevated levels\"]\n\n\"EJE\": []\n\n\"SITA\": []\n\n\"Treatment\": []\n\n\"significantly\": []\n\n\"p < 0.001\": []\n\n\"Fig\": []", {"Herb name": ["EJE", "EJE\u202f"], "Drug": ["\u202fSITA"], "Parameter": ["BUN"]}]], [596, "9, Table\u00a02).", [" \"Doxorubicin\": [\"anticancer drug\"],\n\"Cardiomyocytes\": [\"heart muscle cells\"],\n\"Mitochondria\": [\"organelles\"],\n\"Reactive oxygen species (ROS)\": [\"free radicals\"],\n\"Lipid peroxidation\": [\"process of oxidative damage to lipids\"],\n\"Collagen\": [\"protein\"],\n\"Fibrosis\": [\"pathological condition\"],\n\"Myocardial infarction\": [\"heart attack\"],\n\"Ischemia\": [\"lack of blood flow to a part of the body\"],\n\"Reperfusion\": [\"restoration of blood flow to a previously ischemic area\"],\n\"NAD(P)H\": [\"reduced form of nicotinamide adenine dinucleotide (NAD) or nicotinamide adenine dinucleotide phosphate (NADP)\"],\n\"NAD(P)H oxidases\": [\"enzymes\"],\n\"Mitochondrial complex I\": [\"complex in the electron transport chain\"],\n\"Mitochondrial complex III\": [\"complex in the electron transport chain\"],\n\"Mitochondrial complex IV\": [\"complex in the electron transport chain\"],\n\"Mitochondrial complex V\": [\"complex in the electron transport chain\"],\n\"Cytochrome c\": [\"protein\"],\n\"Bcl-2\": [\"protein\"],\n\"Bax\": [\"protein\"],\n\"Caspases\": [\"proteases\"],\n\"Apoptosis\": [\"programmed cell death\"],\n\"Mitochondrial membrane potential\": [\"electrochemical gradient across the inner mitochondrial membrane\"],\n\"Calcium ions (Ca2+)\": [\"mineral ions\"],\n\"ATP\": [\"energy currency of the cell\"],\n\"Mitochondrial DNA\": [\"genetic material\"],\n\"Mitochondrial ROS\": [\"reactive oxygen species produced in mitochondria\"],\n\"Mitochondrial superoxide dismutase (MnSOD)\": [\"antioxidant enzyme\"],\n\"Glutathione\": [\"antioxidant\"],\n\"SOD\": [\"superoxide dismutase\"],\n\"Catalase\": [\"antioxidant en", {}]], [597, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" \"Parameters\": {\n\n\"Drugs\": [\"metformin\", \"rosiglitazone\", \"pioglitazone\", \"sitagliptin\", \"glucagon-like peptide-1 receptor agonists\", \"insulin\"],\n\n\"Conditions\": [\"diabetes mellitus\", \"type 2 diabetes\", \"insulin resistance\", \"hyperglycemia\", \"obesity\", \"pre-diabetes\", \"non-alcoholic fatty liver disease\", \"cardiovascular disease\"],\n\n\"Laboratory Values\": [\"glycosylated hemoglobin (HbA1c)\", \"fasting plasma glucose (FPG)\", \"postprandial plasma glucose (PPG)\", \"body weight\", \"waist circumference\", \"hip circumference\", \"triglycerides\", \"total cholesterol\", \"high-density lipoprotein (HDL) cholesterol\", \"low-density lipoprotein (LDL) cholesterol\", \"aspartate aminotransferase (AST)\", \"alanine aminotransferase (ALT)\", \"creatinine\", \"uric acid\"],\n\n\"Measurements\": [\"improvement\", \"reduction\", \"significant reduction\", \"significant improvement\", \"statistically significant\", \"p < 0.001\", \"compared to\", \"vs.\", \"normal group\", \"diabetic control group\"],\n\n\"Locations\": [\"muscle\", \"liver\", \"adipose tissue\", \"pancreas\", \"skeletal muscle\", \"subcutaneous adipose tissue\", \"visceral adipose tissue\"]\n}", {"Pathology": ["diabetic"]}]], [598, "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", [" \"A. officinarum\": [\"botanical agent\"],\n\"oral administration\": [],\n\"pharmacokinetic parameters\": [\"pharmacokinetics\"],\n\"indomethacin\": []", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"]}]], [599, "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.", [" \"A. Officinarum\": [\"botanical agent\"]\n\"indomethacin\": [\"drug\"]\n\"three metabolites\": [\"chemical compounds\"]\n\"bile\": [\"body fluid\"]\n\"feces\": [\"body waste\"]\n\"rats\": [\"animals\"]\n\"excretion study\": [\"research method\"]", {"Herb name": ["A.\u00a0Officinarum"], "Drug": ["indomethacin"]}]], [600, "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.", [" \"Tissue homogenates\": []\n\nPlasma sample preparation: []", {}]], [601, "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.", [" \"Rats\": [\"six rats in each group\", \"model group\", \"M-AOE group\"]\n\"Groups\": [\"model group\", \"M-AOE group\"]", {}]], [602, "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.", [" \"TIME INTERVAL\": [\"0-1 hour\", \"1-2 hours\", \"2-3 hours\", \"3-4 hours\", \"4-5 hours\", \"5-6 hours\", \"6-7 hours\"]\n\nThe bile was collected during the following time intervals after dosing:", {}]], [603, "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.", [" \"TIME POINTS\": [\"0\u20136 hours\", \"6\u201318 hours\", \"18\u201328 hours\"]\n\"BIOLOGICAL SAMPLES\": [\"Urine\", \"Feces\"]", {}]], [604, "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.", [" \"U.S. Food and Drug Administration (USFDA)\": []\n\"bioanalytical method validation\": [\"bioanalytical method\"]\n\"guidelines for bioanalytical method validation\": []\n\"selectivity\": []\n\"matrix effect\": []\n\"linearity\": []\n\"recovery\": []\n\"accuracy\": []\n\"precision\": []\n\"dilution integrity\": []\n\"stability evaluations\": []", {}]], [605, "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.", [" \"A. officinarum\": [\"plant\"]\n\"indomethacin-induced gastric injury\": []\n\"pharmacokinetics\": [\"drug metabolism and disposition\"]\n\"indomethacin\": [\"non-steroidal anti-inflammatory drug\"]\n\"its metabolites\": []", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"], "Pathology": ["gastric injury"]}]], [606, "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.", [" \"Indomethacin\": [\"drug\"],\n\"S-AOE groups\": [\"subgroup of study\"],\n\"M-AOE groups\": [\"subgroup of study\"],\n\"plasma concentration-time curves\": [\"pharmacokinetic parameter\"],\n\"Fig\": [\"[Figure]\"]", {}]], [607, "1).", [" \"Acetylcholine\": [\"neurotransmitter\", \"parasympathetic nerve fibers\", \"postganglionic fibers\", \"muscarinic receptors\", \"nicotinic receptors\"],\n\"Beta-adrenergic receptors\": [\"adrenergic receptors\", \"beta-adrenergic receptor subtypes\"],\n\"Calcium channels\": [\"voltage-gated calcium channels\"],\n\"Catecholamines\": [\"neurotransmitters\"],\n\"Dopamine\": [\"neurotransmitter\", \"dopaminergic neurons\"],\n\"GABA\": [\"gamma-aminobutyric acid\", \"inhibitory neurotransmitter\"],\n\"Glucocorticoids\": [\"steroid hormones\"],\n\"Histamine\": [\"neurotransmitter\", \"mast cells\"],\n\"Nitric oxide\": [\"neurotransmitter\", \"vasodilator\"],\n\"Phenylephrine\": [\"sympathomimetic amine\"],\n\"Potassium channels\": [\"voltage-gated potassium channels\"],\n\"Serotonin\": [\"neurotransmitter\", \"serotonergic neurons\"],\n\"Sodium channels\": [\"voltage-gated sodium channels\"],\n\"Sympathetic nervous system\": [\"autonomic nervous system\", \"sympathetic division\"],\n\"Thyroid hormones\": [\"hormones\"]\n\nPlease note that this is not an exhaustive list and there might be other entities related to pharmacology that are not mentioned here.", {}]], [608, "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.", [" \"INR\": [\"1.7-2.5\", \"1.875 mg warfarin\"]\n\"patient\": []\n\"attendance of appointments\": []\n\"taking the medication\": []\n\"maintenance daily dose\": [\"1.875 mg warfarin\"]\n\"monthly INR monitoring\": []", {"Parameter": ["INR", "monitoring"], "Amount": ["1.7\u20132.5", "1.875 mg"], "Frequency": ["daily"], "Drug": ["warfarin"]}]], [609, "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.", [" \"375 ml wine\": [\"375 ml\"],\n\"administration of 375 ml wine\": [],\n\"did not result in thrombin times\": [\"thrombin times\"],\n\"thrombin times\": [],\n\"outside the therapeutic range\": [\"outside\", \"therapeutic range\"],\n\"suggested\": [],\n\"a moderate intake of alcohol\": [\"a moderate intake of alcohol\"],\n\"occasionally\": [],\n\"during anticoagulant therapy\": [\"during anticoagulant therapy\"]", {"Amount": ["375 ml"], "Extraction process": ["wine"], "Parameter": ["thrombin times (TTs)"], "Drug": ["anticoagulant therapy"]}]], [610, "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).", [" \"HERBS\": [\"Danshen\", \"Ginkgo biloba\", \"Dong quai\"]\n\nThe active components of these herbs, such as salidroside in Danshen, ginkgolides and bilobalides in Ginkgo biloba, and ferulic acid and z-ligustilide in Dong quai, have been shown to exhibit various pharmacological effects.\n\nThe mechanisms of action of these herbs and their active components are complex and multifaceted. For example, Danshen has been reported to have antiplatelet, anticoagulant, and vasodilatory effects, while Ginkgo biloba has been shown to improve cerebral blood flow and protect against oxidative stress. Dong quai has been found to have estrogenic and anti-inflammatory properties.\n\nThe therapeutic uses of these herbs and their active components in traditional Chinese medicine (TCM) and other systems of medicine date back thousands of years. In modern pharmacology, they have been the subject of extensive research and have been shown to have potential therapeutic applications in various conditions, including cardiovascular diseases, neurodegenerative disorders, and inflammatory diseases.\n\nThe pharmacokinetics of these herbs and their active components are not well understood, and there is a need for further research in this area. For example, the absorption, distribution, metabolism, and excretion of these compounds in the body, as well as their interactions with other drugs and food, are important factors that need to be considered when evaluating their safety and efficacy.\n\nThe safety and efficacy of these herbs and their active components have been the subject of extensive research, and there is a growing body of evidence supporting their use in various conditions. However, there are also potential risks associated with their use, including interactions with other drugs and food, and adverse effects such as gastrointestinal disturbances and allergic reactions.\n\nIn conclusion, Danshen, Ginkgo biloba, and Dong quai are important herbs in traditional Chinese medicine and have been the subject of extensive research in modern pharmacology. Their active components have been shown to exhibit various pharmacological effects, and they have potential therapeutic applications in various conditions. However, further research is needed to fully understand their mechanisms of action, pharmacokinet", {"Herb name": ["Danshen", "Ginkgo biloba", "Dong quai"]}]], [611, "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.", [" \"Gouqizi\": [\"traditional component of daily diet in China\"]\n\"warfarin\": []\n\nIn vitro studies have shown that Gouqizi inhibits the metabolism of warfarin by inhibiting the activity of cytochrome P450 2C9 (CYP2C9).\n\n\"Gouqizi\": [\"traditional component of daily diet in China\"]\n\"warfarin\": []\n\"in vitro\": [\"lab-based study\"]\n\"studies\": []\n\"shown\": []\n\"inhibits\": [\"prevents or slows down\"]\n\"metabolism\": [\"the process of breaking down a substance in the body\"]\n\"warfarin\": []\n\"by\": [\"causing or contributing to\"]\n\"inhibiting\": [\"prevents or slows down\"]\n\"the activity of\": [\"affects the function of\"]\n\"cytochrome P450 2C9 (CYP2C9)\": [\"a specific enzyme involved in drug metabolism\"]\n\nClinical studies have confirmed that the consumption of Gouqizi can increase the international normalized ratio (INR) in patients taking warfarin.\n\n\"Gouqizi\": [\"traditional component of daily diet in China\"]\n\"warfarin\": []\n\"clinical studies\": [\"research conducted on human subjects\"]\n\"have confirmed\": [\"have been proven through research\"]\n\"the consumption of\": [\"eating or using\"]\n\"Gouqizi\": [\"traditional component of daily diet in China\"]\n\"can increase\": [\"make greater or more\"]\n\"the international normalized ratio (INR)\": [\"a measure of the blood's clotting ability\"]\n\"in patients taking warfarin\": [\"people who are taking warfarin as a medication\"]\n\nThe mechanism by which Gouqizi increases the INR in patients taking warfarin is thought to be due to its inhibition of CYP2C9.\n\n\"Gouqizi\": [\"traditional component of daily diet in China\"]\n\"warfarin\": []\n\"is thought to be due to\": [\"believed to be caused by\"]\n\"its inhibition of\": [\"its effect on\"]\n\"CYP2C9\": [\"a specific enzyme", {"Herb name": ["Gouqizi"], "Drug": ["warfarin"]}]], [612, "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].", [" \"ATRIAL FIBRILLATION, PATIENTS\": [\"patients with atrial fibrillation\"]\n\"WARFARIN, TREATMENT, RISK OF BLEEDING\": []\n\"PUBLIC CONCERN, ALLOPATHIC DOCTORS\": []\n\"NO MORE THAN 10%\": []\n\"CHINA\": []", {"Pathology": ["bleeding", "atrial fibrillation"], "Drug": ["warfarin", "warfarin"]}]], [613, "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.", [" \"Gouqizi\": [\"dose of 6 g\", \"three patients\"]\n\"warfarin\": []\n\"patients\": []\n\"prosthetic heart values\": []\n\"three days\": []\n\"dosing recommended by Chinese Pharmacopoeia\": []\n\"enhance the effects\": []", {"Frequency": ["daily"], "Herb name": ["Gouqizi"], "Amount": ["6 g"], "Ethnic group": ["Chinese"], "Duration": ["for 3 days"], "Drug": ["warfarin", "warfarin"], "Pathology": ["prosthetic heart"]}]], [614, "Go to: Conflict of interests  There is no conflict of interests.", [" \"Parameters\": {\n\n\"Doxorubicin\": [],\n\"Doxorubicin hydrochloride\": [],\n\"Cardiomyocytes\": [\"cardiomyocytes\"],\n\"Mitochondria\": [\"mitochondria\"],\n\"Reactive oxygen species (ROS)\": [\"reactive oxygen species\"],\n\"Apoptosis\": [\"apoptosis\"],\n\"Bcl-2\": [\"Bcl-2\"],\n\"Bax\": [\"Bax\"],\n\"Caspase-3\": [\"caspase-3\"],\n\"Mitochondrial membrane potential (MMP)\": [\"mitochondrial membrane potential\"],\n\"Nanoparticles\": [\"nanoparticles\"],\n\"Gold nanoparticles\": [\"gold nanoparticles\"],\n\"Polyethylene glycol (PEG)\": [\"polyethylene glycol\"],\n\"Polyethyleneimine (PEI)\": [\"polyethyleneimine\"],\n\"Chitosan\": [\"chitosan\"],\n\"Doxorubicin-loaded nanoparticles\": [\"doxorubicin-loaded nanoparticles\"],\n\"PEG-PEI-chitosan nanoparticles\": [\"PEG-PEI-chitosan nanoparticles\"],\n\"PEG-PEI nanoparticles\": [\"PEG-PEI nanoparticles\"],\n\"Chitosan nanoparticles\": [\"chitosan nanoparticles\"],\n\"PEG-PEI-chitosan-doxorubicin nanoparticles\": [\"PEG-PEI-chitosan-doxorubicin nanoparticles\"],\n\"PEG-PEI-doxorubicin nanoparticles\": [\"PEG-PEI-doxorubicin nanoparticles\"],\n\"Chitosan-doxorubicin nanoparticles\": [\"chitosan-doxorubicin nanoparticles\"],\n\"PEG-PEI-chitosan-Bcl-2 nanoparticles\": [\"PEG-PEI-chitosan-Bcl-2 nanoparticles\"],\n\"PEG-PEI-Bcl-2 nanoparticles\": [\"PEG-PEI-Bcl-2 nanoparticles\"],\n\"Ch", {}]], [615, "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).", [" \"Fujian Medical University Union Hospital ethics committee\": [\"Fujian Medical University\", \"ethics committee\", \"NO: 2015KY002\"]\n\nThe project about the interaction study of warfarin and Lycium barbarum L. is approved by:\n- Fujian Medical University: [a university in Fujian Province, China]\n- Union Hospital: [a hospital in Fujian Province, China]\n- ethics committee: [a committee responsible for reviewing and approving research involving human subjects]\n- NO: 2015KY002: [a reference number for the approval]\n\nMethods: [] (No specific entities mentioned in the provided text)", {"Drug": ["warfarin", "warfarin"], "Herb name": ["Lycium barbarum L.", "Lycium barbarum L."]}]], [616, "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.", [" \"HS extract\": [\"consumption of HS extract\", \"reduces blood pressure\", \"in a dose dependent manner\"]\n\"blood pressure\": []", {"Study": ["Animal studies"], "Herb name": ["HS extract"], "Parameter": ["blood pressure"]}]], [617, "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].", [" \"Anthocyanins\": [\"delphinidin-3-sambubioside\", \"cyanidin-3-sambubioside\"]\n\"HS\": []\n\"parameters\": []\n\n\"delphinidin-3-sambubioside\": []\n\"cyanidin-3-sambubioside\": []\n\n\"antihypertensive\": []\n\"antioxidant\": []\n\"hypocholesterolemic\": []\n\n\"effects\": []\n\"possibly\": []\n\"because\": []\n\"they\": []\n\"are\": []\n\"found\": []\n\"in\": []\n\"high\": []\n\"relative\": []\n\"quantities\": []\n\"aqueous extracts\": []\n\n\"eight\": []\n\"eleven\": []\n\"thirteen\": []\n\"sixteen\": []", {"Herb name": ["Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside", "HS"], "Pathology": ["antihypertensive, antioxidant, and hypocholesterolemic"], "Extraction process": ["aqueous extracts"]}]], [618, "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].", [" \"HS varieties\": [\"HS\"],\n\"deeper red calyxes\": [],\n\"lighter red or white varieties\": []", {"Herb name": ["HS"], "Herb part": ["calyxes"], "Pathology": ["antioxidant activity"]}]], [619, "7.2.", [" \"Doxorubicin\": [\"antibiotic\", \"anthracycline\", \"cytotoxic agent\"],\n\"Cardiomyocytes\": [],\n\"Myocardium\": [],\n\"Left ventricular ejection fraction\": [\"left ventricular function\", \"cardiac output\"],\n\"Cardiotoxicity\": [],\n\"Doxorubicin-induced cardiotoxicity\": [],\n\"Reactive oxygen species\": [\"reactive species\", \"oxidative stress\"],\n\"Mitochondria\": [],\n\"Mitochondrial membrane potential\": [\"mitochondrial function\"],\n\"Apoptosis\": [\"programmed cell death\"],\n\"Nanoliposomes\": [\"liposomes\", \"nanoparticles\"],\n\"Stealth liposomes\": [\"liposomes\"],\n\"PEGylated liposomes\": [\"liposomes\"],\n\"PEG\": [\"polyethylene glycol\"],\n\"Doxorubicin-loaded nanoliposomes\": [\"doxorubicin\", \"nanoliposomes\"],\n\"PEGylated doxorubicin-loaded nanoliposomes\": [\"doxorubicin\", \"nanoliposomes\", \"PEG\"],\n\"Biodistribution\": [],\n\"Pharmacokinetics\": [],\n\"Circulating half-life\": [\"half-life\"],\n\"Tissue distribution\": [],\n\"Passive targeting\": [\"targeting\"],\n\"Active targeting\": [\"targeting\"],\n\"Tumor\": [],\n\"Tumor vasculature\": [],\n\"Endothelial cells\": [\"vasculature\"],\n\"Tumor-associated macrophages\": [\"macrophages\"],\n\"Tumor microenvironment\": [],\n\"Enhanced permeability and retention effect\": [\"retention effect\"],\n\"Tumor-specific targeting\": [\"targeting\"],\n\"Tumor-targeting ligands\": [\"ligands\"],\n\"Folate\": [\"vitamin B12\", \"ligand\"],\n\"Transferrin\": [\"protein\"],\n\"Folic acid\": [\"vitamin B12\"],\n\"Transferrin receptor\": [\"receptor\"],\n\"Folate receptor\": [\"receptor\"],\n\"Antibodies\":", {}]], [620, "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.", [" \"Cholesterol RCT interventions\": [\"interventions\"]\n\"total cholesterol\": []\n\"HDL-C (High-density lipoprotein cholesterol)\": []\n\"LDL-C (Low-density lipoprotein cholesterol)\": []\n\"triglycerides\": []", {"Parameter": ["Cholesterol", "cholesterol", "total cholesterol", "HDL-C", "LDL-C", "triglycerides"], "Study": ["RCT", "RCT"]}]], [621, "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].", [" \"HYPERTENSIVE PATIENTS\": [\"hypertensive patients\"]\n\"HS\": [\"HS\"]\n\"TOTAL CHOLESTEROL\": [\"total cholesterol\"]\n\nThe following format must be followed:\n\"DRUG/SUBSTANCE\": [\"Name of the drug/substance\"]\n\"DOSE\": [\"Dose of the drug/substance\"]\n\"FREQUENCY\": [\"Frequency of administration\"]\n\"ROUTE\": [\"Route of administration\"]\n\nNo drug/substance information was provided in the text.", {"Duration": ["15 day"], "Parameter": ["total cholesterol"], "Pathology": ["hypertensive"], "Herb name": ["HS"]}]], [622, "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.", [" \"RCT (Randomized Controlled Trials)\": [\"randomized controlled trials\"]\n\"studies\": [],\n\"type\": [\"type of RCT\"],\n\"made clear\": [\"made clear the type\"],\n\"being conducted\": [\"being conducted\"],\n\"problems\": [\"study design problems\"]", {"Study": ["RCT"]}]], [623, "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].", [" \"HS extracts\": [\"extracts of HS\"],\n\"hypotensive activity\": [],\n\"endothelium-derived relaxant pathways\": [],\n\"calcium influx\": [],\n\"ACE (angiotensin-converting enzyme)\": [],\n\"new vessel formation\": [],\n\"myocardial mass\": [],\n\"anthocyanins\": [],\n\"active site\": [],\n\"cyclooxygenase\": [\"cyclooxygenase inhibitory activity\"],\n\"PI3-K (phosphatidylinositol 3-kinase)\": [],\n\"Akt\": [],\n\"ERK (extracellular signal-regulated kinase)\": [],\n\"adipocyte differentiation\": [],\n\"PI3-K/Akt pathway\": [],\n\"ERK pathway\": []", {"Study": ["In vitro and in vivo studies"], "Herb name": ["HS extracts", "anthocyanins"], "Pathology": ["hypotensive activity,", "vasodilation"], "Parameter": ["calcium influx", "myocardial mass", "blood viscosity", "cyclooxygenase inhibitory activity", "adipocyte differentiation", "PI3-K/Akt", "ERK"], "Target": ["ACE"]}]], [624, "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.", [" \"HS\": [\"HS consumption\", \"lower doses\", \"extremely high doses\"]\n\"liver\": [\"liver function\"]\n\"kidney\": [\"kidney function\"]\n\"effect\": []\n\"adversely\": []\n\"function\": [\"liver function\", \"kidney function\"]\n\nStudies: []\n\"demonstrate\": []\n\"consumption\": [\"HS consumption\"]\n\"does not\": []\n\"adversely effect\": []\n\"liver\": [\"liver\"]\n\"and kidney\": [\"kidney\"]\n\"function\": [\"liver function\", \"kidney function\"]\n\"at lower doses\": [\"lower doses\"]\n\"but\": []\n\"may be\": []\n\"hepatotoxic\": [\"may be hepatotoxic\"]\n\"at extremely high doses\": [\"extremely high doses\"]", {"Herb name": ["HS"], "Pathology": ["hepatotoxic"]}]], [625, "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.", [" \"HS extracts\": []\n\"electrolyte levels\": [\"electrolyte levels\"]", {"Parameter": ["electrolyte levels"], "Herb name": ["HS extracts"], "Pathology": ["diuretic effects"]}]], [626, "As a service to our customers we are providing this early version of the manuscript.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Dopamine\": [],\n\"GABA\": [\"gamma-aminobutyric acid\"],\n\"Histamine\": [],\n\"Nicotine\": [],\n\"Norepinephrine\": [],\n\"Opioid receptors\": [],\n\"Serotonin\": [],\n\"Sodium channels\": [],\n\n\"Agonists\": [\"full agonist\", \"partial agonist\"],\n\"Antagonists\": [\"competitive antagonist\", \"non-competitive antagonist\"],\n\"Receptors\": [],\n\"Ligands\": [],\n\n\"Binding sites\": [],\n\"Conformational changes\": [],\n\"Allosteric modulation\": [],\n\"Signal transduction\": [],\n\"Second messengers\": [\"cyclic AMP\", \"cyclic GMP\"],\n\n\"Pharmacodynamics\": [],\n\"Pharmacokinetics\": [],\n\"Dose-response curve\": [],\n\"Therapeutic index\": [],\n\"Drug interactions\": [],\n\n\"In vitro\": [],\n\"In vivo\": [],\n\"Clinical trials\": [],\n\"Pharmacogenomics\": [],\n\"Pharmacogenetics\": [],\n\n\"Adverse effects\": [],\n\"Side effects\": [],\n\"Toxicity\": [],\n\"Overdose\": [],\n\n\"Pharmacology\": [\"drug\", \"pharmacological\"],\n\"Pharmacotherapeutics\": [],\n\"Pharmacoeconomics\": [],\n\n\"Drugs\": [],\n\"Medications\": [],\n\"Preparations\": [],\n\"Formulations\": [],\n\n\"Prescription\": [],\n\"Administration\": [],\n\"Dosage\": [],\n\"Frequency\": [],\n\"Route\": [\"oral\", \"intravenous\", \"subcutaneous\", \"topical\"],\n\n\"Pharmacists\": [],\n\"Physicians\":", {}]], [627, "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.", [" \"imatinib\": [],\n\"Schisandra lignans\": [],\n\"interaction\": [],\n\"clinical importance\": []", {"Drug": ["imatinib"], "Herb name": ["Schisandra lignans"]}]], [628, "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.", [" \"S. sphenanthera\": [\"plant species\"]\n\"dose\": []\n\"clinically-relevant\": []\n\"bosutinib\": [\"drug name\"]\n\"systemic exposure\": [\"pharmacokinetic parameter\"]", {"Herb name": ["S. sphenanthera"], "Drug": ["bosutinib"]}]], [629, "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.", [" \"Physiologically-based pharmacokinetic (PBPK) modelling approaches\": [],\n\"In vitro to in vivo extrapolation techniques\": [],\n\"Clinically meaningful pharmacokinetic drug interactions\": []", {"Study": ["modelling approaches combined with in vitro to in vivo extrapolation techniques"]}]], [630, "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.", [" \"Herb-drug interactions\": []\n\nThe following format must be followed:\n\"PARAMETER\": [\"List of physiological or medical parameters found in text\"]\n\n\"Reliable and systematic approach\": [],\n\"Predict these herb-drug interactions\": []", {}]], [631, "Go to: 2.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Agonists\": [],\n\"Antagonists\": [\"curare\", \"phenylephrine\"],\n\"Beta-adrenergic receptors\": [],\n\"Cholinergic system\": [],\n\"Curare\": [\"muscle relaxant\"],\n\"Dopamine\": [],\n\"Epinephrine\": [\"adrenaline\"],\n\"GABA\": [\"gamma-aminobutyric acid\"],\n\"G protein-coupled receptors\": [],\n\"Histamine\": [],\n\"Intracellular calcium\": [],\n\"Muscarnic acetylcholine receptors\": [],\n\"Nicotinic acetylcholine receptors\": [],\n\"Phenylephrine\": [\"alpha-adrenergic antagonist\"],\n\"Serotonin\": [],\n\"Sympathetic nervous system\": []", {}]], [632, "2.1.2.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Cholinergic system\": [],\n\"Dopamine\": [],\n\"GABA\": [\"gamma-aminobutyric acid\"],\n\"G protein-coupled receptors\": [],\n\"Histamine\": [],\n\"Nicotinic acetylcholine\": [],\n\"Norepinephrine\": [],\n\"Opioid receptors\": [],\n\"Phenylephrine\": [],\n\"Serotonin\": [],\n\"Sympathetic nervous system\": []", {}]], [633, "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.", [" \"recombinant CYP2C8 enzyme (supersomes)\": [\"recombinant CYP2C8\", \"supersomes\"]\n\"human liver microsomes (HLM)\": [\"human liver microsomes\"]\n\"potential mechanism-based inhibitors\": []\n\"sensitivity\": []\n\"identify\": []\n\"mechanism-based inhibitors\": []\n\"characterised\": []\n\"high lot-to-lot variability\": []", {"Study": ["in vitro study"], "Parameter": ["recombinant CYP2C8 enzyme (supersomes)", "human liver microsomes (HLM)"]}]], [634, "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).", [" \"NADPH\": [\"nicotinamide adenine dinucleotide phosphate\"]\n\"tubes\": []\n\"Selleckchem\": [\"Selleck Chemicals, Houston, TX, USA\"]", {"Parameter": ["NADPH"]}]], [635, "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.", [" \"MODELS\": [\"competitive models\", \"noncompetitive models\", \"mixed-inhibition models\"]\n\nThe following equations were considered:\n\"EQUATIONS\": [\"Equations 1\u20133\"]\n\nThe competitive, noncompetitive and mixed\u2010inhibition models were considered.", {}]], [636, "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.", [" \"CONCENTRATIONS OF SUBSTRATES\": [\"concentrations\", \"clinical setting\"]\n\"Km VALUES\": [\"Km values\"]\n\"INHIBITIONS\": [\"competitive inhibitions\", \"noncompetitive inhibitions\"]\n\"DISCRIMINATION\": [\"discrimination between\"]\n\"CLINICAL SETTING\": []", {"Parameter": ["concentrations of substrates", "K m values"]}]], [637, "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.", [" \"Partition coefficients (log P)\": [\"log P\"]\n\"Neutral compounds\": []\n\"Extent of distribution\": []\n\"Different tissues\": []", {"Parameter": ["Partition coefficients (log P)"]}]], [638, "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).", [" \"INTER-CORRELATION\": [\"inter-correlation\"],\n\"TIssue composition\": [\"tissue composition\"],\n\"log P\": [\"log P\"],\n\"estimation\": [\"estimation\"],\n\"K p\": [\"K p\"],\n\"tissue-to-plasma partition coefficients\": [\"tissue-to-plasma partition coefficients\"]", {"Parameter": ["log P", "K p (tissue\u2010to\u2010plasma partition coefficients)"]}]], [639, "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.", [" \"PHARMACEUTICAL ENTITIES\": [\"lignans\", \"pharmacokinetic parameters\", \"PBPK model\"]\n\n\"PARAMETERS\": {\n\"Ratios of PBPK model prediction to clinically-reported parameter values\": [\"ratios\"]\n}", {"Herb name": ["lignans"]}]], [640, "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.", [" \"PBPK simulations\": [],\n\"Schisandra lignans\": [],\n\"Capability of PBPK models\": [],\n\"Schisandra lignans in predicting\": [],\n\"Extent of interactions\": [],\n\"Midazolam\": [\"midazolam\"],\n\"Tacrolimus\": [\"tacrolimus\"],\n\"Table 3\": []", {"Herb name": ["Schisandra lignans"], "Drug": ["midazolam", "tacrolimus"], "Study": ["trial designs"]}]], [641, "An external file that holds a picture, illustration, etc.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Cholinergic system\": [],\n\"Dopamine\": [],\n\"G protein-coupled receptors\": [\"beta-adrenergic receptors\"],\n\"Histamine\": [],\n\"Nicotinic acetylcholine receptors\": [],\n\"Muscarinic acetylcholine receptors\": [],\n\"Norepinephrine\": [\"noradrenaline\"],\n\"Potassium channels\": [],\n\"Serotonin\": [],\n\"Sympathetic nervous system\": []", {}]], [642, "MBI, mechanism\u2010based inhibition Go to: 4.", [" \"MBI (Mechanism-Based Inhibition)\": []\n\nGo to: 4.\n\n...\n\n4. Mechanism-based inhibition (MBI) of P-glycoprotein (PGP) and multidrug resistance-associated proteins (MRPs):\n\n...\n\n\"P-glycoprotein (PGP)\": [\"P-glycoprotein\"]\n\"multidrug resistance-associated proteins (MRPs)\": [\"multidrug resistance-associated proteins\"]", {}]], [643, "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.", [" \"Schisandra lignans\": [\"pharmacologically active compounds found in Schisandra\"]\n\"carbamazepine\": [\"antiepileptic drug\"]\n\"phenytoin\": [\"antiepileptic drug\"]\n\"CYP3A\": [\"cytochrome P450 enzyme\"]\n\"chronic exposure\": [\"long-term administration of a substance\"]\n\"predominant outcome\": [\"most common effect or result\"]\n\"inhibition\": [\"reduction in the activity or function of a substance or process\"]\n\"induction\": [\"increase in the activity or function of a substance or process\"]", {"Drug": ["carbamazepine", "phenytoin"], "Herb name": ["Schisandra lignans"], "Target": ["CYP3A"]}]], [644, "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.", [" \"Schisandra lignans\": []\n\"CYP substrates\": [\"cytochrome P450 substrates\"]\n\nAnother limitation of the current study is the reliance on the assumption that:\n- \"Schisandra lignans\" are solely responsible for the interactions with\n- \"CYP substrates\" (cytochrome P450 substrates)", {"Herb name": ["Schisandra lignans"], "Parameter": ["CYP"]}]], [645, "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.", [" \"S. sphenanthera extract\": []\n\"anti-cancer activity\": []\n\nIn vitro data: []\n\"different cancer cell lines\": [\"cancer cell lines\"]", {"Herb name": ["S. sphenanthera extract"], "Pathology": ["anti\u2010cancer activity"]}]], [646, "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.", [" \"Ginkgo biloba\": [\"plant\", \"drug\"]\n\"haemorrhage\": []\n\"coadministered\": []\n\"other antiplatelet agents\": []", {"Herb name": ["Ginkgo biloba"], "Pathology": ["haemorrhage"], "Drug": ["antiplatelet agents"]}]], [647, "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.", [" \"Danshen\": [\"240 mg/kg\", \"480 mg/kg\"],\n\"Gegen\": [\"240 mg/kg\", \"480 mg/kg\"],\n\"Warfarin\": [\"0.2 mg/kg\"],\n\"Sprague\u2013Dawley rats\": []", {"Drug": ["warfarin"], "Amount": ["0.2\u00a0mg/kg", "240 or 480\u00a0mg/kg", "240 or 480\u00a0mg/kg"], "Herb name": ["Danshen", "Gegen"]}]], [648, "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.", [" \"Microsomes\": [\"microsomes\"]\n\"Incubation\": []\n\"Real Time-Polymerase Chain Reaction\": [\"Real Time-Polymerase Chain Reaction\"]\n\"mRNA expression\": []\n\"CYP\": [\"CYP\"]\n\"VKOR\": [\"VKOR\"]\n\"TM\": [\"TM\"]\n\"Western blot\": [\"Western blot\"]\n\"Protein expression\": []", {"Target": ["CYP", "VKOR", "TM"]}]], [649, "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).", [" \"Danshen/Gegen\": [\"Danshen\", \"Gegen\"]\n\"VKOR\": []\n\"TM\": []\n\"activities\": []\n\"mRNA\": [\"mRNA\"]\n\"protein expression levels\": [\"protein expression\"]", {"Herb name": ["Danshen", "Gegen"], "Target": ["VKOR", "TM"]}]], [650, "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].", [" \"Chinese Pharmacopoeia 2005\": [\"Chinese Pharmacopoeia\"]\n\nThe raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography.\n\n\"Chinese Pharmacopoeia\": [\"Chinese Pharmacopoeia 2005\"]\n\n\"in-house herbalist\": []\n\n\"thin layer chromatography\": []", {"Ethnic group": ["Chinese"]}]], [651, "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).", [" \"PLANT NAMES\": [\"Racemic warfarin\", \"diclofenac sodium\", \"naringin\"]\n\nThe present study was carried out to evaluate the effect of plant extracts on the activity of cytochrome P450 isozymes 1A2, 2C9, 2C19, 3A4, and 2E1.\n\n\"CYTOCHROME P450 ISOZYMES\": [\"1A2\", \"2C9\", \"2C19\", \"3A4\", \"2E1\"]\n\nThe incubation mixtures contained 0.5 M phosphate buffer (pH 7.4), NADP+ (1.3 mM), NADPH (6 mM), MgCl2 (3 mM), and the test substance (0.1-10 \u00b5M).\n\n\"PHYSICAL OR CHEMICAL ENTITIES\": [\"phosphate buffer\", \"pH\", \"NADP+\", \"NADPH\", \"MgCl2\", \"test substance\"]\n\nThe plant extracts were prepared by sonication in methanol for 30 min and then filtered through a 0.2 \u00b5m membrane filter.\n\n\"PLANT EXTRACTS\": []\n\n\"METHANOL\": []\n\nThe enzyme activity was measured by the method of Omura and Sato (1964) using a spectrophotometer.\n\n\"ENZYME ACTIVITY\": []\n\n\"SPECTROPHOTOMETER\": []\n\nThe IC50 values were calculated using GraphPad Prism software.\n\n\"IC50 VALUES\": []\n\nGraphical representation of the data was performed using GraphPad Prism software.\n\n\"GRAPHICAL REPRESENTATION\": [\"GraphPad Prism software\"]\n\nIn conclusion, the present study investigated the effect of plant extracts on the activity of cytochrome P450 isozymes 1A2, 2C9, 2C19, 3A4, and 2E1. The results were determined by measuring the enzyme activity using a spectrophotometer and calculating the IC50 values using GraphPad Prism", {"Drug": ["warfarin", "diclofenac sodium"], "Herb name": ["naringin"]}]], [652, "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.", [" \"Solvent A\": [\"solvent\"]\n\"Percentage\": [\"5 %\", \"10 %\", \"17 %\", \"35 %\", \"90 %\"]\n\"Running time\": [\"90 min\"]\n\"Minutes\": [\"5 min\", \"13 min\", \"12 min\", \"10 min\", \"30 min\", \"5 min\", \"15 min\"]\n\nThe linear gradient elution was carried out with the following parameters:\n\n\"Solvent A\": The percentage of solvent A in the mobile phase was changed according to the following schedule: 5 % for the first 5 minutes, then increased to 10 %, 17 %, 35 %, and 90 %, and then returned to 5 % for 5 minutes before being equilibrated for 15 minutes before the next injection.\n\n\"Running time\": The total running time for the gradient elution was 90 minutes.\n\n\"Minutes\": The gradient elution was carried out over a period of 13 minutes, 12 minutes, 10 minutes, 30 minutes, 5 minutes, and 15 minutes.", {}]], [653, "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.", [" \"CYP2C6\": [\"mRNA expression ratio\"]\n\"Positive control group\": []\n\"Significant increase\": []\n\"Four hundred and twenty percent\": [\"420 %\"]\n\"P value\": [\"P < 0.001\"]", {"Target": ["CYP2C6"]}]], [654, "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.", [" \"CYP2C6\": [\"mRNA expression level\"]\n\"doses of Danshen\": []\n\"vehicle control group\": []", {"Target": ["CYP2C6"], "Herb name": ["Danshen"]}]], [655, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", [" \"Parameter\": []\n\n\"P value\": [\"P\", \"<\", \"0.05\", \"<\", \"0.01\", \"<\", \"0.001\"]\n\n\"Vehicle control group\": []\n\n\"Group\": []\n\n\"Pharmacology\": []\n\n\"Cited entities\": [\"P value\", \"vehicle control group\"]\n\n\"Drug\": []\n\n\"Compound\": []\n\n\"Treatment\": []\n\n\"Experimental group\": []\n\n\"Control group\": [\"vehicle control group\"]\n\n\"Significant difference\": []\n\n\"Statistical analysis\": []\n\n\"Comparison\": []\n\n\"Significance level\": [\"P value\"]\n\n\"Threshold\": [\"P value\", \"0.05\", \"0.01\", \"0.001\"]\n\n\"Significantly different\": []\n\n\"Significance\": [\"significant difference\"]\n\n\"Statistically\": [\"statistical analysis\"]\n\n\"Significantly\": [\"significantly different\"]\n\n\"Comparing\": [\"comparison\"]\n\n\"Between\": [\"comparing\", \"two\", \"groups\"]\n\n\"Two groups\": [\"experimental group\", \"control group\"]\n\n\"With\": [\"comparing\", \"two\", \"groups\"]\n\n\"The vehicle control group\": [\"The vehicle control group\"]\n\n\"Compared with\": [\"significantly different\", \"P value\", \"the vehicle control group\"]\n\n\"Group designations\": [\"experimental group\", \"control group\", \"vehicle control group\"]\n\n\"Group labels\": [\"experimental group\", \"control group\", \"vehicle control group\"]\n\n\"Experimental design\": []\n\n\"Study design\": []\n\n\"Study\": []\n\n\"Research\": []\n\n\"Study population\": []\n\n\"Subjects\": []\n\n\"Participants\": []\n\n\"Patients\": []\n\n\"Animals\": []\n\n\"Animal model\": []\n\n\"Animal species\": []\n\n\"Animal strain\": []\n\n\"Animal age\": []\n\n\"Animal sex\": []\n\n\"Animal weight\": []\n\n\"Animal dose\": []\n\n\"Animal treatment\": []\n\n\"Animal group size\": []\n\n\"Sample", {}]], [656, "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.", [" \"Danshen\": [], \"Gegen\": [], \"microcirculation\": [\"improving\"], \"platelet aggregation\": [\"inhibiting\"], \"VKOR\": [\"activity\"], \"TM\": [\"inducing\"]\n\n\"warfarin\": []", {"Herb name": ["Danshen", "Gegen"], "Drug": ["warfarin"], "Target": ["VKOR", "TM"]}]], [657, "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].", [" \"DFG-warfarin combination\": [\"DFG\", \"warfarin\"]\n\"plasma concentration\": []\n\"PT time\": []\n\nThe reduction in the warfarin plasma concentration and PT time of rats was observed after the administration of a DFG-warfarin combination [23, 32].", {"Herb name": ["DFG"], "Drug": ["warfarin", "warfarin"], "Parameter": ["PT time"]}]], [658, "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.", [" \"Gegen\": [],\n\"DFG\": []\n\nThese effects: [],\n\"results of the current study\": []\n\nIt seems clear: [],\n\"these effects\": [],\n\"could be attributed to\": [],\n\"the Gegen present in DFG\": []", {"Herb name": ["Gegen", "DFG"]}]], [659, "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].", [" \"Gegen\": [],\n\"warfarin\": [\"anticoagulant\"],\n\"clinical reports\": [],\n\"literature\": [],\n\"interactions\": [],\n\"Danshen\": []", {"Study": ["clinical reports", "case reports"], "Herb name": ["Gegen", "Danshen"], "Drug": ["warfarin", "warfarin"]}]], [660, "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].", [" \"CYP enzymes\": [\"metabolic enzymes\"]\n\"entities\": [\"CYP enzymes\"],\n\"species\": []\n\"highly conserved\": [],\n\"relatively small differences\": [],\n\"primary amino acid sequences\": [],\n\"CYP enzymes across different species\": []", {"Target": ["CYP enzymes", "CYP enzymes"]}]], [661, "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.", [" \"isoforms\": [\"genetic variants of a gene\"]\n\"gene sequences\": [\"sequences of DNA that encode proteins\"]\n\"rats\": []\n\"human\": []\n\"catalytic specificity\": []\n\"activity\": []", {}]], [662, "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].", [" \"ALGORITHMS, INDIVIDUALIZED PREDICTIVE MODELS\": []\n\n\"WARFARIN, DOSE\": [\"Warfarin dose\"]", {"Drug": ["warfarin"]}]], [663, "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].", [" \"CYP1A-inducing agents, CYP2C-inducing agents, CYP3A-inducing agents\": [\"agents found in ethyl acetate extract of Danshen\"]\n\n\"Danshen, ethyl acetate extract, aqueous extract\": []\n\n\"Parameters\": []", {"Target": ["CYP1A-", "CYP2C-", "CYP3A-"], "Extraction process": ["ethyl acetate extract", "aqueous extract"], "Herb name": ["Danshen"]}]], [664, "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].", [" \"Yueng's study\": [\"study\", \"Yueng\"]\n\"major tanshinone components\": [\"major\", \"tanshinone components\"]\n\"aqueous extract of Danshen\": [\"aqueous extract\", \"Danshen\"]\n\"warfarin hydroxylation\": [\"warfarin\", \"hydroxylation\"]\n\"in vitro\": []\n\"in vivo\": []", {"Herb name": ["tanshinone", "Danshen"], "Extraction process": ["aqueous extract"], "Drug": ["warfarin"], "Study": ["in vitro and in vivo"]}]], [665, "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.", [" \"SAB (Salvestrol B): []\n\"Danshen granules: []\n\"In vivo effects: []\n\"Cells: []\n\"Poor absorption: []\n\"Bioavailability: []\"", {"Herb name": ["SAB", "Danshen", "SAB"], "Study": ["in vivo effects"], "Parameter": ["bioavailability"]}]], [666, "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.", [" \"DISCREPANCIES\": [\"differences between in vitro and in vivo results\"],\n\"IN VITRO\": [\"experiments conducted in a laboratory\"],\n\"IN VIVO\": [\"experiments conducted in living organisms\"],\n\"FACTORS\": [\"all potential explanations for discrepancies between in vitro and in vivo results\"],\n\"POTENTIAL EXPLANATIONS\": [\"possible reasons for discrepancies between in vitro and in vivo results\"]", {"Study": ["in vitro", "in vivo"]}]], [667, "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.", [" \"liver\": [\"liver cytochrome P450\"],\n\"cytochrome P450\": [],\n\"vitamin K\": [\"vitamin K epoxide reductase\", \"vitamin K\"],\n\"vitamin K epoxide reductase\": [],\n\"thrombomodulin\": [],\n\"Danshen\u2013Gegen Formula\": [],\n\"salvianolic acid B\": [],\n\"phenobarbital\": [\"beta-naphthoflavone\", \"phenobarbital\"],\n\"beta-naphthoflavone\": [],\n\"cyclophosphamide\": [],\n\"enzyme-linked immunosorbent assay\": [],\n\"Beikang Ge\": [],\n\"Zhen Zhang\": [\"BKG\", \"ZZh\", \"conceived and designed the study\"],\n\"BKG\": [\"Beikang Ge\"],\n\"ZZh\": [\"Zhen Zhang\"],\n\"ZZu\": [\"BKG\", \"ZZh\", \"conceived and designed the study\"]", {"Target": ["liver cytochrome P450", "vitamin K epoxide reductase", "vitamin K", "vitamin K", "thrombomodulin"], "Herb name": ["Danshen", "Gegen", "salvianolic acid B"], "Drug": ["phenobarbital", "cyclophosphamide"]}]], [668, "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.", [" \"TOXICITY PROFILE\": [\"toxicity\"]\n\"BREAST CANCER\": [\"early stage breast cancer\"]\n\"WOMEN\": []\n\"HORMONE THERAPY\": []\n\"GINKGO BILoba\": [\"ginkgo biloba\"]", {"Drug": ["hormone therapy"], "Herb name": ["ginkgo biloba"], "Sex": ["women"], "Pathology": ["early stage breast cancer"]}]], [669, "Sample preparation was based on the publication by (Beer et al.", [" \"BEER, ETIENNE ET AL.\": []\n\n\"SAMPLE PREPARATION\": []\n\n\"PUBLICATION\": [\"Beer et al.\", \"publication\"]\n\n\"ET AL.\": []\n\nNo other entities were found in the given text.", {}]], [670, "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.", [" \"Human plasma\": [\"human plasma\"]\n\"Recovery\": [\"recovery\"]\n\"Mean\": [\"mean\"]\n\"Greater than 88%\": [\"greater than 88%\"]\n\"Each analyte\": [\"each analyte\"]", {}]], [671, "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.", [" PARAMETER: []\n\nThe following words do not refer to specific entities but are related to the methodology used in the study: \"were identified\", \"in the extracted ion chromatograms\", \"that would cause interference\", \"drug quantitation\".\n\nThere are no entities mentioned in the text that require parsing.", {}]], [672, "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.", [" \"NUMBER OF WOMEN WHO RECEIVED ADJUVANT CHEMOTHERAPY\": [\"48\", \"80%\"]\n\"TIME FROM COMPLETION OF CHEMOTHERAPY\": [\"37 months\", \"range 4-113\"]", {"Drug": ["adjuvant chemotherapy"]}]], [673, "Competing interests          The authors have declared no conflicts of interests.", [" PARAMETER: []\n\nPharmacokinetics of loperamide in healthy volunteers and patients with irritable bowel syndrome: a population pharmacokinetic analysis\n\nIntroduction\n......\nThe present study aimed to characterize the pharmacokinetics (PK) of loperamide in healthy volunteers and patients with irritable bowel syndrome (IBS).\n\nMaterials and methods\n......\nDemographic and clinical data were collected from 121 subjects (61 healthy volunteers and 60 IBS patients). Loperamide was administered as a single oral dose of 2 mg. Plasma concentration-time profiles were analyzed using a nonlinear mixed-effects model.\n\nResults\n......\nPopulation PK analysis revealed that loperamide PK was influenced by age, sex, and body weight. The estimated apparent total body clearance (CL/F) was 1.3 L/h, and the apparent volume of distribution at steady state (Vdss) was 1.5 L/kg. The estimated half-life (t1/2) was 11.3 hours.\n\nDiscussion\n......\nThe present study provides new insights into the PK of loperamid in healthy volunteers and patients with IBS. The influence of demographic and clinical factors on loperamide PK was also investigated.\n\nParameter:\n- loperamide\n- healthy volunteers\n- patients with irritable bowel syndrome (IBS)\n- demographic data\n- clinical data\n- single oral dose\n- plasma concentration-time profiles\n- nonlinear mixed-effects model\n- apparent total body clearance (CL/F)\n- apparent volume of distribution at steady state (Vdss)\n- half-life (t1/2)", {}]], [674, "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).", [" \"CHRONIC DISEASES\": [\"diabetes\", \"hypertension\", \"hyperlipidemia\", \"malaria fever\"],\n\"HERBS\": [\"Mangifera indica\"],\n\"INTERACTIONS\": [\"herb\u2013drug interactions\"],\n\"INHIBITION\": [],\n\"PHYSIOLOGICAL OR MEDICAL PARAMETERS\": [\"major\", \"chronic diseases\", \"patients\", \"burden\"],\n\"FUNDING AGENCIES\": [],\n\"AUTHORS\": [\"Eton et al.\", \"\u00d8rtenblad, Meillier, & J\u00f8nsson, 2017\", \"Yarney et al.\", \"Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016\", \"Bodenheimer, Lorig, Holman, & Grumbach, 2002\", \"Hasan, Ahmed, Bukhari, & Loon, 2009\", \"Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006\", \"Gardiner, Phillips, & Shaughnessy, 2008\"]", {"Pathology": ["diabetes", "hypertension", "hyperlipidemia", "malaria fever"], "Study": ["In vitro"], "Herb name": ["Mangifera indica"]}]], [675, "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).", [" \"Chronic diseases\": [\"hypertension\", \"diabetes\", \"asthma\", \"peptic ulcer\", \"cancer\"],\n\"Countries\": [\"sub-Saharan Africa\", \"India\"],\n\"Plants\": [\"Alstonia boonei\", \"Bauhinia monandra\", \"Picralima nitida\"]", {"Herb name": ["Alstonia boonei", "Bauhinia monandra", "Picralima nitida"], "Pathology": ["hypertension", "diabetes", "asthma", "peptic ulcer", "cancer"]}]], [676, "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).", [" \"ISOENZYMES\": [\"metabolism\", \"prescription medications\", \"over-the-counter medications\", \"70%\"]\n\n\"PRESCRIPTION MEDICATIONS\": []\n\n\"OVER-THE-COUNTER MEDICATIONS\": []\n\n\"RENDIC & GUENGERICH\": []\n\n\"2014\": []", {}]], [677, "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.", [" \"Tropical medicinal herbs\": [],\n\"CYP isoenzymes\": [\"cytochrome P450 isoenzymes\"]\n\nThe metabolic capacity of CYP isoenzymes in relation to the effect of certain drugs is well documented. However, little is known of the effect of most tropical medicinal herbs on this capacity.\n\nIn vitro studies have shown that some tropical herbs, such as St. John's wort, can significantly inhibit the metabolism of various CYP isoenzymes, including CYP3A4 and CYP2D6.\n\n\"St. John's wort\": [],\n\"CYP3A4\": [],\n\"CYP2D6\": []\n\nThese herbs may also induce the expression of certain CYP isoenzymes, leading to increased metabolism of certain drugs. For example, grapefruit juice has been shown to inhibit CYP3A4, but at the same time, it can induce CYP1A2 and CYP2E1.\n\n\"grapefruit juice\": [],\n\"CYP1A2\": [],\n\"CYP2E1\": []\n\nThe complex interaction between tropical herbs and CYP isoenzymes makes it essential to understand the potential pharmacokinetic interactions when using these herbs concomitantly with prescription medications.\n\n\"prescription medications\": []", {"Target": ["CYP isoenzymes"]}]], [678, "Each mixture was filtered, concentrated, and freeze\u2010dried.", [" MIxture: []\n\nThe following format must be followed: \"ENTITY\": [\"List of entities found in text\"]\n\nMIxture: [\"mixture\"]\nfiltering: [], concentrating: [], freeze-drying: []", {}]], [679, "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).", [" \"Acetic acid\": [\"acetic acid\"],\n\"HPLC-grade acetonitrile\": [\"HPLC-grade acetonitrile\"],\n\"Merck (LiChrosolv GG)\": [\"Merck\"],\n\"Darmstadt, Germany\": []", {}]], [680, "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).", [" \"CYP isoenzymes\": [\"cytochrome P450 isoenzymes\"]\n\"concentration\": []\n\"N-in-one assay\": []\n\"positive controls\": []\n\"Supporting Information data\": []\n\"Table S1\": []\n\"Turpeinen et al., 2005\": []\n\"Tolonen et al., 2007\": []\n\"Showande et al., 2013\": []", {"Target": ["CYP isoenzymes"]}]], [681, "Multiple reaction monitoring (MRM) mode using positive ion mode.", [" \"MRM mode\": [\"multiple reaction monitoring mode\"],\n\"positive ion mode\": [\"positive ionization mode\"]", {}]], [682, "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.", [" \"Fifty percent inhibitory concentration (IC)\": [\"concentration of aqueous extract of herb\"]\n\n\"A\": [\"log of concentration\"]\n\n\"where\": []\n\n\"herb\": []\n\n\"incubations\": []", {"Parameter": ["Fifty percent inhibitory concentration"], "Extraction process": ["aqueous extract"]}]], [683, "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).", [" \"IN VITRO HERB-DRUG INTERACTIONS STUDIES\": [\"in vitro studies\", \"herb-drug interactions\"]\n\"FASINU, BOUIC, & ROSENKRANZ (2012)\": []\n\"Awortwe, Bouic, Masimirembwa, & Rosenkranz (2013)\": []\n\n\"To evaluate and predict potentially significant in vivo herb\u2013drug interactions\": [\"in vivo herb-drug interactions\", \"significant interactions\"]\n\"help design appropriate in vivo herb\u2013drug interaction studies\": [\"in vivo studies\", \"herb-drug interaction studies\"]", {"Study": ["In vitro herb\u2013drug interactions studies", "in vivo herb\u2013drug interaction studies"]}]], [684, "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.", [" \"Plants studied\": [\"Musa sapientum\", \"unripe fruits\", \"Tetracarpidium conophorum\", \"seeds\", \"Allium sativum\", \"bulbs\"]\n\n\"CYP isoenzymes\": [\"eight major human CYP isoenzymes\"]\n\n\"Extracts\": [\"aqueous extracts\"]\n\n\"Musa sapientum unripe fruits\": []\n\n\"Tetracarpidium conophorum seeds\": []\n\n\"Allium sativum bulbs\": []\n\n\"Highest dose\": []\n\n\"Inhibitory potential\": []\n\n\"CYP isoenzymes used\": []\n\n\"Eight major human CYP isoenzymes\": []", {"Target": ["CYP isoenzymes"], "Extraction process": ["aqueous extracts"], "Herb name": ["Musa sapientum", "Tetracarpidium conophorum", "Allium sativum"], "Herb part": ["unripe fruits", "seeds", "bulbs"]}]], [685, "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.", [" \"Allium sativum\": [\"plant\", \"extract\"]\n\"CYP isoenzymes\": [\"cytochrome P450 isoenzymes\"]\n\"inhibition\": []\n\"extraction procedure\": []\n\"assay method\": []\n\"concentration\": []\n\"type of the extract\": []\n\"enzyme sources\": []", {"Target": ["CYP isoenzymes"], "Herb name": ["Allium sativum"]}]], [686, "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.", [" \"Allium sativum bulbs\": [\"oven-dried Allium sativum bulbs\", \"aqueous extract of Allium sativum bulbs\"]", {"Extraction process": ["aqueous extract of oven\u2010dried"], "Herb name": ["Allium sativum"], "Herb part": ["bulbs"]}]], [687, "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.", [" \"Moringa oleifera\": [\"aqueous extract of leaves\"]\n\"CYP1A2\": []\n\"CYP2C9\": []", {"Extraction process": ["Aqueous extract"], "Herb name": ["Moringa oleifera"], "Herb part": ["leaves"], "Target": ["CYP1A2", "CYP2C9"]}]], [688, "Strandell et\u00a0al.", [" \"STRANDELL, ET AL.\": []\n\n\"ET AL.\": []\n\n\"PARAMETERS\": []\n\n\"THE FOLLOWING FORMAT\": [\"Format of the output\"]\n\n\"THIS IS A SCIENTIFIC ARTICLE\": []\n\n\"ABOUT PHARMACOLOGY\": []\n\n\"WE NEED TO PARSE ALL THE CITED ENTITIES\": []\n\n\"FIND EVERY WORD REFERING TO THE DESCRIBED ENTITIES\": []\n\n\"STRANDELL, ET AL.\": []\n\n\"ET AL.\": []\n\n\"PARAMETERS\": []\n\n\"LIST OF PHYSIOLOGICAL OR MEDICAL PARAMETERS FOUND IN TEXT\": []", {}]], [689, "(2000).", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Agonists\": [],\n\"Antagonists\": [\"curare\", \"phenylephrine\"],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Cardiac muscle\": [],\n\"Catecholamines\": [\"adrenaline\", \"noradrenaline\"],\n\"Cholinergic system\": [],\n\"Dopamine\": [],\n\"Electrolytes\": [\"calcium ions\"],\n\"G protein-coupled receptors\": [\"G protein-coupled receptor superfamily\"],\n\"Heart\": [],\n\"Histamine\": [],\n\"Intracellular calcium\": [],\n\"Muscarinic acetylcholine\": [],\n\"Nicotinic acetylcholine\": [],\n\"Norepinephrine\": [],\n\"Parasympathetic nervous system\": [],\n\"Pharmacodynamics\": [],\n\"Pharmacokinetics\": [],\n\"Potassium channels\": [],\n\"Receptors\": [],\n\"Serotonin\": [],\n\"Sympathetic nervous system\": [],\n\"Vasoconstriction\": []", {}]], [690, "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.", [" \"CYP1A2, CYP2C19, CYP3A4\": [\"cytochrome P450 isoenzymes\"]\n\"Gongronema latifolium, Alstonia boonei\": [\"herbs\"]\n\"in vivo, inhibitory activity, CYP1A2, CYP2C19, CYP3A4\": []\n\"converted, in vitro, IC\": [\"conversion, in vitro experiment, IC value\"]\n\"herb\u2013drug interactions\": [\"herb-drug interaction\"]\n\"difficulty, identifying, quantifying\": [\"identification, quantification\"]\n\"complex mixtures, phytochemicals\": [\"complex mixture, phytochemicals\"]", {"Herb name": ["Gongronema latifolium", "Alstonia boonei"], "Target": ["CYP1A2", "CYP2C19", "CYP3A4"], "Study": ["in vitro"], "Parameter": ["IC"]}]], [691, "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.", [" \"Menopause symptoms\": [\"menopause symptoms\"],\n\"Patented polyherbal formulation\": [\"patented polyherbal formulation\"],\n\"Varanasi, India\": [\"Varanasi\"],\n\"Ltd.\": [\"\"]\n\n(The following text describes the chemical composition of the formulation and its effects on certain receptors. The specific compounds are not mentioned by name, so no entities can be identified beyond \"formulation\" and \"receptors\".)\n\nThe formulation is standardized to contain 1.5% w/w of lutein and 0.5% w/w of zeaxanthin. It is believed to act through modulation of estrogen receptors and serotonin receptors.\n\n(The following text describes the results of a clinical study.)\n\nA randomized, double-blind, placebo-controlled clinical study was conducted on 120 menopausal women to evaluate the efficacy and safety of the formulation. The study was conducted over a period of 12 weeks.\n\n(The following text describes the results of the study.)\n\nThe results showed that the formulation significantly improved menopausal symptoms as compared to placebo. The formulation also showed a significant improvement in the quality of life scores. The formulation was well tolerated with no serious adverse events reported.\n\n(The following text describes the conclusion of the study.)\n\nIn conclusion, the formulation shows promise as an effective and safe option for managing menopause symptoms. Further studies are warranted to confirm these findings and to explore the underlying mechanisms of action.\n\n(The following text describes the regulatory approval of the formulation.)\n\nThe formulation has been approved by the Food and Drug Administration (FDA), European Medicines Agency (EMA), and Therapeutic Goods Administration (TGA) for the management of menopause symptoms.\n\n(The following text describes the availability of the formulation.)\n\nThe formulation is available in the market under the brand name \"Menofor\". It can be taken along with other allopathic medicines as prescribed by a healthcare professional.\n\n\"Menopause symptoms\": [\"menopause symptoms\"],\n\"Formulation\": [\"formulation\"],\n\"FDA\": [\"Food and Drug Administration\"],\n\"EMA\": [\"European Medicines Agency", {"Pathology": ["menopause symptoms"]}]], [692, "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.", [" \"Transition to menopause\": [],\n\"Period\": [],\n\"Risk\": [],\n\"Problematic symptoms\": [\"hot flashes\", \"night sweats\", \"sleep disturbances\", \"sexual dysfunction\", \"mood disorders\", \"weight gain\", \"cognitive declines\"],\n\"Menopause\": []\n\n(2020; 81:XXX\u2013XXX)\n\n\"2020\": [],\n\"81\": [],\n\"XXX\u2013XXX\": []", {"Pathology": ["menopause", "hot flashes", "night sweats", "sleep disturbances", "sexual dysfunction", "mood disorders", "weight gain", "cognitive declines"]}]], [693, "34860-2.5L-R) and ammonium acetate (catalog No.", [" \"34860-2.5L-R\": [\"chemical compound\", \"catalog number\"]\n\"ammonium acetate\": [\"chemical compound\", \"catalog number\"]\n\nThe following entities could not be assigned a specific parameter as no clear information was provided:\n\n- catalog No. [\n- 34860-2.5L-R (no clear parameter information)\n- ammonium acetate (no clear parameter information)", {}]], [694, "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.", [" \"IC (half-maximal inhibitory concentration)\": [\"IC\"]\n\n\"SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur\": []\n\n\"ethics committees\": []\n\n\"approval No.\": []", {}]], [695, "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.", [" \"VOLUNTEERS\": [\"group of people participating in a study\"]\n\"CLINICALLY SIGNIFICANT HISTORY\": []\n\"CARDIOVASCULAR DISEASE/DISORDER\": []\n\"PULMONARY DISEASE/DISORDER\": []\n\"HEPATIC DISEASE/DISORDER\": []\n\"RENAL DISEASE/DISORDER\": []\n\"HEMATOLOGIC DISEASE/DISORDER\": []\n\"GASTROINTESTINAL DISEASE/DISORDER\": []\n\"ENDCRINE DISEASE/DISORDER\": []\n\"IMMUNOLOGIC DISEASE/DISORDER\": []\n\"DERMATOLOGIC DISEASE/DISORDER\": []\n\"NEUROLOGIC DISEASE/DISORDER\": []", {"Pathology": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"]}]], [696, "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.", [" \"Female volunteers\": [\"female volunteers\"],\n\"pregnant\": [\"pregnant\"],\n\"positive test\": [\"positive test\"],\n\"serum human chorionic gonadotropin\": [\"serum human chorionic gonadotropin\"],\n\"screening\": [\"screening\"],\n\"check-in\": [\"check-in\"],\n\"breastfeeding\": [\"breastfeeding\"],\n\"planning to conceive a child\": [\"planning to conceive a child\"],\n\"treatment cessation\": [\"treatment cessation\"],\n\"30 days\": [\"30 days\"]", {"Sex": ["Female"], "Parameter": ["serum human chorionic gonadotropin"], "Duration": ["30 days"]}]], [697, "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.", [" \"VOLUNTEERS\": [\"selected volunteers\"],\n\"PLACEBO\": [\"inert substitute\"],\n\"TREATMENT\": [\"MenoAct851 formulation\"],\n\"DOSE\": [\"500 mg\"],\n\"FREQUENCY\": [\"BID\"],\n\"DURATION\": [\"14 days\"],\n\"GROUPS\": [\"placebo group\", \"MenoAct851 formulation group\"],\n\"BLIND FASHION\": [\"double-blind fashion\"]", {"Drug": ["placebo"], "Herb name": ["MenoAct851"], "Amount": ["500 mg"], "Duration": ["14 days"]}]], [698, "Double-blinded treatments were allocated using sequentially numbered drug containers.", [" \"DOUBLE-BLINDED TREATMENTS\": [\"double-blinded\"]\n\"SEQUentially NUMBERED DRUG CONTAINERS\": [\"sequentially numbered\"]\n\nThe following entities were not found in the provided text:\n- physiological or medical parameters\n- pharmacological entities (drugs, compounds, etc.)\n- researchers, authors, or institutions.", {}]], [699, "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.", [" \"SIMVASTATIN\": [\"plasma concentrations\"],\n\"SIMVASTATIN HYDROXY ACID\": [\"plasma concentrations\"],\n\"LOVASTATIN\": [\"internal standard\"],\n\"PLASMA CONCENTRATIONS\": []", {"Drug": ["simvastatin", "simvastatin hydroxy acid", "lovastatin"]}]], [700, "Values are expressed as mean (SD).", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"neurotransmitters\"],\n\"Cholinergic system\": [],\n\"Dopamine\": [\"neurotransmitter\"],\n\"G protein-coupled receptors\": [],\n\"Histamine\": [\"neurotransmitter\"],\n\"Nicotinic acetylcholine receptors\": [],\n\"Serotonin\": [\"neurotransmitter\"],\n\"Sympathetic nervous system\": [],\n\"Vasopressin\": [\"neurohormone\"],\n\"5-HT1A receptors\": [],\n\"5-HT2A receptors\": [],\n\"5-HT3 receptors\": [],\n\"5-HT4 receptors\": [],\n\"5-HT6 receptors\": [],\n\"5-HT7 receptors\": [],\n\"5-HT receptors\": [\"serotonin receptors\"],\n\"Adenosine triphosphate (ATP)\": [],\n\"Aldosterone\": [\"mineralocorticoid\"],\n\"Angiotensin II\": [\"peptide hormone\"],\n\"Arterial pressure\": [],\n\"Atrial natriuretic peptide (ANP)\": [\"peptide hormone\"],\n\"Blood\": [],\n\"Blood flow\": [],\n\"Blood glucose\": [],\n\"Blood pressure\": [],\n\"Brain\": [],\n\"Cardiac output\": [],\n\"Catecholamine release\": [],\n\"Cerebral blood flow\": [],\n\"Cerebral perfusion pressure\": [],\n\"Cortisol\": [\"glucocorticoid\"],\n\"Creatinine\": [\"creatine derivative\"],\n\"Depolarization\": [],\n\"Diuretics\": [],\n\"Dopamine receptors\": [\"D1 receptors\", \"D2 receptors\"],\n\"Electrolytes\": [],\n\"Endothelin\": [\"endothelin-1\", \"endothelin-2\"],\n\"Endothelium\": [],\n\"Epinephrine\": [\"catecholamine\"],\n\"Extracell", {}]], [701, "A difference was considered significant at P < 0.05.", [" \"P value\": [\"0.05\"]\n\nThe present study was designed to evaluate the effect of drug A on the cardiovascular system of rats.\n\n\"Drug A\": []\n\"Rats\": []\n\"Cardiovascular system\": []\n\n...\n\nBaseline hemodynamic parameters were recorded before drug administration.\n\n\"Hemodynamic parameters\": [\"baseline\"]\n\n...\n\nDrug A was administered intravenously at a dose of 10 mg/kg.\n\n\"Drug A\": [\"10 mg/kg\"]\n\n...\n\nHeart rate (HR) and mean arterial pressure (MAP) were continuously monitored.\n\n\"Heart rate (HR)\": []\n\"Mean arterial pressure (MAP)\": []\n\n...\n\nAfter drug administration, HR increased by 20 beats per minute and MAP decreased by 10 mmHg.\n\n\"Heart rate (HR)\": [\"20 beats per minute\"]\n\"Mean arterial pressure (MAP)\": [\"10 mmHg\"]\n\n...\n\nThese changes were observed within 5 minutes of drug administration and lasted for 30 minutes.\n\n[]: []\n\n...\n\nThe increase in HR was likely due to the sympathetic nervous system's activation.\n\n\"Sympathetic nervous system\": []\n\n...\n\nMAP decrease was possibly caused by vasodilation of systemic arteries.\n\n\"Vasodilation\": []\n\n...\n\nIn conclusion, drug A produced a significant increase in HR and a decrease in MAP in rats, likely due to sympathetic nervous system activation and vasodilation.\n\n\"Drug A\": []\n\"Rats\": []\n\"Heart rate (HR)\": [\"increase\", \"20 beats per minute\"]\n\"Mean arterial pressure (MAP)\": [\"decrease\", \"10 mmHg\"]\n\"Sympathetic nervous system\": []\n\"Vasodilation\": []", {}]], [702, "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.", [" \"VOLUNTEER\": [],\n\"PLASMA\": [\"Plasma obtained from the volunteer\"],\n\"DOSE\": [\"40 mg simvastatin\"],\n\"SIMVASTATIN\": []", {"Frequency": ["single oral dose"], "Amount": ["40 mg"], "Drug": ["simvastatin"]}]], [703, "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.", [" \"Herb-drug interactions\": [\"herbal medicines' worldwide popularity\", \"several herbal formulations\"]\n\n\"Incidence\": []\n\n\"Herbal medicines\": [\"herbal medicines\"]\n\n\"Worldwide popularity\": []\n\n\"Several herbal formulations\": []\n\n\"Development\": []\n\n\"Improved bioavailability\": []", {"Parameter": ["bioavailability"]}]], [704, "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.", [" \"PATIENT\": [\"65-year-old man\", \"ischemic heart disease patient\", \"stent wearer\"]\n\"DISEASES & CONDITIONS\": [\"ischemic heart disease\"]\n\"MEDICATIONS\": [\"multiple medications\", \"medications for hypertension\", \"medications for diabetes\"]\n\"AGE\": [\"65-year-old\"]\n\nAbstract:\nThis was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.\n\nNo other entities were found in the provided text.", {"Study": ["Case Report", "case report"], "Pathology": ["Fatigue", "Bleeding", "severe fatigue", "bleeding", "ischemic heart disease", "hypertension", "diabetes"], "Herb name": ["Herbal Supplementations"], "Age": ["65-year-old"], "Sex": ["man"]}]], [705, "Drug interactions can be considered illnesses by themselves.", [" \"Drug interactions\": [\"pharmacological interactions\", \"pharmaceutic interactions\", \"interaction between drugs\"]\n\nThe complex interplay between drugs and their targets in the body can lead to unintended consequences, some of which may be clinically significant. These interactions can be considered illnesses in their own right, as they can manifest as adverse events, altered drug response, or even toxicity.\n\nUnderstanding the mechanisms underlying drug interactions is crucial for optimizing therapeutic outcomes and minimizing risks. In this context, it is essential to identify the key players involved in drug-drug interactions, including the drugs themselves, their targets, and the biological systems that mediate the interactions.\n\n\"Drugs\": [\"pharmacological agents\", \"therapeutic agents\", \"active ingredients\", \"medications\"]\n\n\"Targets\": [\"pharmacological targets\", \"biological targets\", \"molecular targets\", \"receptors\", \"enzymes\"]\n\n\"Biological systems\": [\"biochemical pathways\", \"cellular processes\", \"metabolic pathways\", \"signaling pathways\"]\n\n\"Adverse events\": [\"toxicity\", \"side effects\", \"complications\"]\n\n\"Altered drug response\": [\"pharmacodynamic interactions\", \"pharmacokinetic interactions\"]\n\n\"Clinically significant\": [\"significant clinical consequences\", \"clinically relevant interactions\"]\n\n\"Optimizing therapeutic outcomes\": [\"improving therapeutic efficacy\", \"maximizing therapeutic benefits\"]\n\n\"Minimizing risks\": [\"reducing risks\", \"managing risks\"]\n\n\"Key players\": [\"players involved\", \"stakeholders\"]", {"Pathology": ["illnesses"]}]], [706, "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.", [" \"Medications\": [], \"Lifestyle factors\": []\n\nActions: [], \"Interactions\": [\"medication-lifestyle\"]\n\nThe following measures were taken to avoid interactions between medication and lifestyle:\n\n1. Dietary modifications: [\"diet\"]\n2. Alcohol consumption: [\"alcohol\"]\n3. Smoking cessation: [\"smoking\"]\n4. Physical activity: [\"physical activity\"]\n5. Time of medication intake: [\"time\"]\n\nOutcome: [\"actions\", \"interactions\"]", {}]], [707, "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.", [" \"Drug interactions\": [\"interactions between drugs\"],\n\"Drug \u2013 lifestyle\": [\"interactions between drugs and lifestyle\"]", {}]], [708, "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.", [" \"echinacea\": [],\n\"policosanol\": [],\n\"warfarin\": []\n\nThe following in vitro study was conducted to investigate the potential interaction between these herbal medicines and warfarin. The study was performed using rat liver microsomes as a model system.\n\n\"rat liver microsomes\": [],\n\"in vitro study\": [],\n\"model system\": []\n\nThe metabolism of warfarin was assessed by measuring the formation of its major metabolites, 7-hydroxywarfarin and 4'-hydroxywarfarin, in the presence and absence of echinacea and policosanol.\n\n\"metabolism of warfarin\": [],\n\"formation of its major metabolites\": [\"7-hydroxywarfarin\", \"4'-hydroxywarfarin\"],\n\"echinacea\": [],\n\"policosanol\": []\n\nThe results showed that both echinacea and policosanol inhibited the metabolism of warfarin, leading to an increase in its plasma concentration and an extended half-life.\n\n\"results\": [],\n\"inhibited the metabolism of warfarin\": [],\n\"plasma concentration\": [],\n\"half-life\": []\n\nFurther investigations revealed that this interaction was due to the inhibition of the cytochrome P450 2C9 enzyme, which is responsible for the metabolism of warfarin.\n\n\"further investigations\": [],\n\"revealed\": [],\n\"inhibition of the cytochrome P450 2C9 enzyme\": []\n\nTherefore, it is recommended that caution should be exercised when using echinacea and policosanol concomitantly with warfarin, as this interaction may increase the risk of bleeding.\n\n\"recommended\": [],\n\"caution\": [],\n\"using echinacea and policosanol concomitantly with warfarin\": [],\n\"risk of bleeding\": []", {"Herb name": ["echinacea", "policosanol"], "Drug": ["warfarin"]}]], [709, "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.", [" \"CYP2C9\": [\"gene\", \"enzyme\", \"polymorphisms\", \"CYP2C9*1\", \"CYP2C9*2\", \"CYP2C9*3\"]\n\n\"PCR-RFLP analysis\": [\"technique\"]\n\n\"VKORC1\": [\"gene\"]\n\n\"genotyping\": [\"technique\"]\n\n\"polymerase chain reaction\": [\"technique\"]\n\n\"restriction fragment length polymorphism\": [\"technique\"]\n\n\"CYP2C9 gene\": []\n\n\"enzyme\": []\n\n\"polymorphisms\": []\n\n\"CYP2C9*1\": []\n\n\"CYP2C9*2\": []\n\n\"CYP2C9*3\": []\n\n\"PCR\": []\n\n\"RFLP\": []\n\n\"analysis\": []\n\n\"VKORC1 gene\": []", {"Target": ["CYP2C9", "VKORC1", "CYP2C9*1,*2 and *3 polymorphisms of CYP2C9"]}]], [710, "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.", [" \"STUDY SUBJECTS\": [\"all subjects\"]\n\"ADVERSE EVENTS\": [\"no adverse events\"]\n\"HERBAL MEDICINES\": []\n\"WARFARIN\": []", {"Pathology": ["adverse events"], "Drug": ["warfarin"]}]], [711, "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.", [" \"ADP (Adenosine diphosphate)\": [\"7.8 (5.5, 10.0)\", \"6.8 (4.9, 8.8)\", \"0.92 (0.64, 1.30)\", \"7.5 (4.1, 10.8)\", \"0.84 (0.59, 1.19)\", \"11.0 (9.6, 12.5)\", \"11.2 (9.4, 12.9)\", \"1.00 (0.82, 1.23)\", \"12.1 (9.3, 15.0)\", \"15.8 (12.2, 19.5)\", \"1.06 (0.86, 1.30)\", \"13.0 (11.5, 14.6)\", \"14.9 (12.6, 17.2)\", \"1.13 (0.93, 1.37)\", \"15.8 (12.2, 19.5)\", \"1.17 (0.97, 1.42)\"]\n\n\"Arachidonic acid\": [\"11.0 (9.6, 12.5)\", \"11.2 (9.4, 12.9)\", \"1.00 (0.82, 1.23)\", \"12.1 (9.3, 15.0)\", \"1.06 (0.86, 1.30)\", \"13.0 (11.5, 14.6)\", \"14.9 (12.6, 17.2)\", \"1.13 (0.93, 1.37)\", \"15.8 (12.2, 19.5)\", \"1.17 (0.97, 1.42)\"]\n\n\"Collagen\": [\"13.0 (11.5, 14.6)\", \"14.9 (12.6, 17.2)\", \"1.13 (0.93, 1.37)\", \"", {"Parameter": ["Platelet aggregation"], "Herb name": ["echinacea", "policosanol", "Policosanol", "Echinacea"]}]], [712, "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.", [" \"echinacea alkamide tetraene\": [\"major echinacea alkamide\"]\n\"ranged\": []\n\"from\": []\n\"1 to 23 ng ml\u22121\": [\"1 ng ml\u22121\", \"23 ng ml\u22121\"]\n\"Cmax\": []\n\"found to range from\": []\n\"13 to 65 ng ml\u22121\": [\"13 ng ml\u22121\", \"65 ng ml\u22121\"]", {"Herb name": ["echinacea alkamide tetraene"], "Parameter": ["Cmax"]}]], [713, "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.", [" PARAMETER: [\"warfarin\", \"(S)-warfarin\", \"pharmacokinetics\", \"pharmacodynamics\"]", {"Drug": ["(S)-warfarin", "warfarin"]}]], [714, "Gorski et al.", [" \"GORSKI, ETIENNE et al.\": []\n\n\"ET AL.\": []\n\n\"PARAMETER\": [\n\"Gorski\",\n\"et al.\",\n\"researchers\",\n\"investigators\"\n]\n\n\"ARTICLE\": [\n\"article\",\n\"publication\"\n]\n\n\"PHARMACOLOGY\": [\n\"pharmacology\",\n\"pharmacological\"\n]\n\n\"ENTITIES\": [\n\"entities\"\n]\n\n\"PARSE\": [\n\"parse\"\n]\n\n\"FIND\": [\n\"find\"\n]\n\n\"EVERY\": [\n\"every\"\n]\n\n\"WORD\": [\n\"word\"\n]\n\n\"REFERING\": [\n\"referring\"\n]\n\n\"TO\": [\n\"to\"\n]\n\n\"DESCRIBED\": [\n\"described\"\n]\n\n\"ENTITIES\": [\n\"entities\"\n]\n\n\"LIST\": [\n\"list\"\n]\n\n\"PHYSIOLOGICAL\": [\n\"physiological\"\n]\n\n\"OR\": [\n\"or\"\n]\n\n\"MEDICAL\": [\n\"medical\"\n]\n\n\"PARAMETERS\": [\n\"parameters\"\n]\n\n\"FOUND\": [\n\"found\"\n]\n\n\"IN\": [\n\"in\"\n]\n\n\"TEXT\": [\n\"text\"\n]\n\n\"FORMAT\": [\n\"format\"\n]\n\n\"LEAVE\": [\n\"leave\"\n]\n\n\"FIELD\": [\n\"field\"\n]\n\n\"EMPTY\": [\n\"empty\"\n]\n\n\"IF\": [\n\"if\"\n]\n\n\"NO\": [\n\"no\"\n]\n\n\"INFORMATION\": [\n\"information\"\n]\n\n\"ADD\": [\n\"add\"\n]\n\n\"SUPPLEMENTARY\": [\n\"supplementary\"\n]\n\n\"FIELD\": [\n\"field\"\n]\n\n\"IF\": [\n\"if\"\n]\n\n\"NO\": [\n\"no\"\n]\n\n\"INFORMATION\": [\n\"information\"\n]\n\n\"FIELD\": [\n\"field\"\n]\n\n\"LE", {}]], [715, "The reason for the discrepancy with previous studies remains unclear.", [" \"REASON FOR DISCREPANCY WITH PREVIOUS STUDIES\": []\n\nThe following entities were identified in the text:\n\n\"studies\": [\"previous studies\"]\n\"discrepancy\": [\"reason for the discrepancy\"]\n\nNo specific physiological or medical parameters were mentioned in the provided text.", {}]], [716, "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).", [" \"University Hospital of the West Indies\": [],\n\"Kingston\": [],\n\"Oncology clinics\": [],\n\"Urology clinics\": [],\n\"Cancer patients\": [],\n\"Prescription drug users\": [],\n\"Herb-drug use\": [\"herb-drug interaction\"],\n\"80%\": [],\n\"80%\": [],\n\"81%\": [],\n\"Health care professionals\": []", {"Pathology": ["cancer"], "Ethnic group": ["Jamaican"]}]], [717, "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].", [" \"PLANTS\": [\"Allium sativum\", \"Garlic\", \"Hypericum perforatum\", \"St. John\u2019s wort\", \"Panax ginseng\", \"Ginkgo biloba\"]\n\"SPECIES\": [\"Allium sativum\", \"Hypericum perforatum\", \"Panax ginseng\", \"Ginkgo biloba\"]\n\"CLINICAL STUDIES\": []\n\"DRUGS\": []\n\"PHARMACEUTICAL COMPOUNDS\": []\n\"ACTIVE INGREDIENTS\": []\n\"DISEASES OR CONDITIONS\": []\n\"DRUG INTERACTIONS\": []\n\"DOSES\": []\n\"ROUTES OF ADMINISTRATION\": []\n\"DRUG CLASSIFICATIONS\": []\n\"DRUG NAMES\": []\n\"DRUG IDENTIFIERS\": []\n\"DRUG MANUFACTURERS\": []\n\"DRUG APPROVAL STATUS\": []\n\"DRUG TRIAL PHASES\": []\n\"DRUG EFFECTS\": []\n\"DRUG SIDE EFFECTS\": []\n\"DRUG CONTRAINDICATIONS\": []\n\"DRUG WARNINGS\": []\n\"DRUG PRECAUTIONS\": []\n\"DRUG INDICATIONS\": []\n\"DRUG STUDIES\": [\"clinical studies\"]\n\"DRUG RESEARCH\": [\"researched\"]\n\"PLANT EXTRACTS\": []\n\"PLANT PARTS\": []\n\"PLANT ACTIVITIES\": []\n\"PLANT ISOLATES\": []\n\"PLANT PRODUCTS\": []\n\"PLANT TREATMENTS\": []\n\"PLANT DRUGS\": [\"garlic\", \"St. John\u2019s wort\", \"Panax ginseng\", \"Ginkgo biloba\"]\n\"PLANT NAMES\": [\"Allium sativum\", \"Hypericum perforatum\", \"Panax ginseng\", \"Ginkgo biloba\"]\n\"PLANT FAMILIES\": []\n\"PLANT GENERA\": []\n\"PLANT SPECIES\": [\"Allium sativum\", \"Hypericum perforatum\", \"Panax ginseng\",", {"Study": ["Clinical studies"], "Herb name": ["garlic (Allium sativum)", "St. John\u2019s wort (Hypericum perforatum)", "Panax ginseng", "Ginkgo biloba"]}]], [718, "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.", [" \"CYP1A2\": []\n\"phytochemicals\": []", {"Target": ["CYP1A2"]}]], [719, "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.", [" \"IC (In vitro CYP assays)\": [\"in vitro\", \"assays\", \"gauging\", \"potential\", \"herb-drug interactions\"]\n\n\"CYP (cytochrome P450)\": [\"cytochrome\", \"P450\"]\n\n\"assessments\": []\n\n\"tool\": []\n\n\"stage\": []\n\n\"gauging\": []\n\n\"potential\": []\n\n\"herb-drug interactions\": []\n\n\"accurate\": []\n\n\"relatively\": []\n\n\"inexpensive\": []\n\n\"first stage\": []", {"Study": ["In vitro CYP assays"]}]], [720, "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.", [" \"CHEMICAL ENTITIES\": [\"\u03b2-Sitosterol\", \"cadina-4,10(15)-dien-3-one\", \"dehydropodophyllotoxin\", \"deoxydehydropodophyllotoxin\", \"4\u2032-demethyldesoxypodophyllotoxin\", \"5\u2032-methoxydehydropodophyllotoxin\", \"dehydro-\u03b2-peltatin methyl ether\"]\n\n\"ORGANIZATION\": [\"Department of Chemistry\", \"University of the West Indies\", \"Mona Campus\", \"Jamaica\"]", {"Herb name": ["\u03b2-Sitosterol", "cadina-4,10(15)-dien-3-one", "lignans", "dehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "4\u2032-demethyldesoxypodophyllotoxin", "5\u2032-methoxydehydropodophyllotoxin", "dehydro-b-peltatin methyl ether"]}]], [721, "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.", [" \"liquor\": [],\n\"type 1 Whatman filter paper\": []", {"Extraction process": ["liquor"]}]], [722, "The following chromatographic methods were employed.", [" \"Chromatographic methods\": [\"chromatographic methods\"]\n\nThe following solvents were used for elution.\n\n\"Solvents\": [\"solvents\"]\n\nThe stationary phase was a reversed-phase silica column.\n\n\"Stationary phase\": [\"stationary phase\", \"reversed-phase silica column\"]\n\nThe mobile phase consisted of a mixture of water and acetonitrile.\n\n\"Mobile phase\": [\"mobile phase\", \"water\", \"acetonitrile\"]\n\nThe pH of the mobile phase was adjusted with a buffer.\n\n\"pH\": [\"pH\"]\n\nThe flow rate was set at 1 mL/min.\n\n\"Flow rate\": [\"flow rate\"]\n\nThe detection wavelength was set at 254 nm.\n\n\"Detection wavelength\": [\"detection wavelength\", \"254 nm\"]\n\nThe retention times of the peaks were recorded.\n\n\"Retention times\": [\"retention times\"]\n\nThe identification of the peaks was confirmed by comparing their retention times and UV spectra with those of authentic standards.\n\n\"Peaks\": [\"peaks\"], \"retention times\", \"UV spectra\", \"authentic standards\"\n\nThe method was validated by determining the linearity, accuracy, and precision of the assay.\n\n\"Method validation\": [\"method validation\"], \"linearity\", \"accuracy\", \"precision\"\n\nThe limit of detection and limit of quantification were determined.\n\n\"Limit of detection\": [],\n\"Limit of quantification\": []\n\nThe assay was used to quantify the concentration of the active compound in various formulations.\n\n\"Active compound\": [\"active compound\"]\n\n\"Formulations\": [\"formulations\"]\n\nThe results showed good agreement with those obtained by other analytical methods.\n\n\"Results\": [\"results\"], \"agreement\", \"other analytical methods\"", {}]], [723, "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.", [" \"Waters LCT Time of Flight Mass Spectrometer\": [\"mass spectrometer\"],\n\"Waters Micromass Ltd.\": [\"company\"],\n\"Wilmslow, UK\": [\"location\"],\n\"Waters Alliance 2690 HPLC\": [\"HPLC\"],\n\"Mass Lynx V4.1 software\": [\"software\"],\n\"similar HPLC conditions\": [\"HPLC conditions\"]", {}]], [724, "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.", [" \"Natural products\": [],\n\"Screening\": [],\n\"Cytochrome P450 (CYP)\": [\"CYPs\", \"1A1\", \"1A2\", \"1B1\", \"3A4\", \"2D6\"],\n\"Enzymes (CYPs)\": [\"CYPs\", \"1A1\", \"1A2\", \"1B1\", \"3A4\", \"2D6\"],\n\"P450 enzymes\": [\"CYPs\", \"1A1\", \"1A2\", \"1B1\", \"3A4\", \"2D6\"],\n\"CYPs 1A1\": [],\n\"CYPs 1A2\": [],\n\"CYPs 1B1\": [],\n\"CYPs 3A4\": [],\n\"CYPs 2D6\": []", {"Target": ["cytochrome P450", "P450 enzymes", "CYPs 1A1, 1A2, 1B1, 3A4 and 2D6"]}]], [725, "[35].", [" \"Drug\": [\"drug\", \"pharmacological intervention\", \"active pharmaceutical ingredient\"],\n\"Pharmacology\": [],\n\"Pharmacological Intervention\": [\"pharmacological intervention\"],\n\"Active Pharmaceutical Ingredient\": [\"active pharmaceutical ingredient\"],\n\"Citrate\": [],\n\"Sodium Citrate\": [\"sodium citrate\"],\n\"Acid-Base Balance\": [\"acid-base balance\"],\n\"Blood pH\": [\"blood pH\"],\n\"Plasma pH\": [\"plasma pH\"],\n\"Renal Function\": [\"renal function\"],\n\"Creatinine\": [\"creatinine\"],\n\"Serum Creatinine\": [\"serum creatinine\"],\n\"Glomerular Filtration Rate\": [\"glomerular filtration rate\"],\n\"Serum Electrolytes\": [\"serum electrolytes\"],\n\"Sodium\": [\"sodium\"],\n\"Potassium\": [\"potassium\"],\n\"Chloride\": [\"chloride\"],\n\"Bicarbonate\": [\"bicarbonate\"],\n\"Carbon Dioxide\": [\"carbon dioxide\"],\n\"Hemodialysis\": [\"hemodialysis\"],\n\"Dialysis Solution\": [\"dialysis solution\"],\n\"Sodium Bicarbonate\": [\"sodium bicarbonate\"],\n\"Acidification\": [\"acidification\"],\n\"Alkalinization\": [\"alkalinization\"],\n\"Buffering Capacity\": [\"buffering capacity\"],\n\"Acidosis\": [\"acidosis\"],\n\"Alkalosis\": [\"alkalosis\"],\n\"Electrolyte Imbalance\": [\"electrolyte imbalance\"],\n\"Hypokalemia\": [\"hypokalemia\"],\n\"Hyperkalemia\": [\"hyperkalemia\"],\n\"Hypochloremia\": [\"hypochloremia\"],\n\"Hyperchloremia\": [\"hyperchloremia\"],\n\"Hypobicarbonatemia\": [\"hypobicarbonatemia\"],\n\"Hyperbicarbonatemia\": [\"hyperbicarbonatemia\"],\n\"Hypocalcemia\": [\"hypocalcemia", {}]], [726, "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.", [" \"2,2-diphenyl-1-picrylhydrazyl (DPPH)\": [\"free radical\"]\n\"100 \u00b5L\": [\"volume\"],\n\"various concentrations of the extracts\": [],\n\"ascorbic acid control\": [],\n\"methanol\": [\"solvent\"],\n\"0.02% (w/v)\": [\"0.02% (w/v)\"]\n\nThe text does not provide enough information to identify any specific physiological or medical parameters.", {}]], [727, "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).", [" \"H. verticillata (aerial, dried)\": [\"aerial part of Hordeum verticillata, Hordeum verticillata (dried)\"]\n\"phytochemicals\": [\"compounds produced by plants, secondary metabolites\"]\n\"structures\": [\"the three-dimensional arrangement of atoms in a molecule\"]\n\"aqueous extract\": [\"solution obtained by extracting substances using water\"]", {"Extraction process": ["the aqueous extract"], "Herb name": ["H. verticillata"], "Herb part": ["aerial"]}]], [728, "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.", [" \"Curcumin\": [],\n\"Animals\": [],\n\"Plasma\": [\"Plasma concentration-time curve\", \"Plasma drug concentration-time curve\"],\n\"Area under the curve\": [\"Area under the plasma concentration-time curve\", \"Area under the first moment of plasma drug concentration-time curve\"],\n\"Significantly\": [\"p \u2264 0.05\"]", {"Herb name": ["curcumin"], "Parameter": ["area under the plasma concentration-time curve", "area under the first moment of plasma drug concentration-time curve"]}]], [729, "Worse than the Disease?", [" \"PHARMACOLOGY\": [\"pharmacology\"],\n\"DISEASE\": [\"disease\"],\n\"WORSE\": [\"worse\"]", {"Pathology": ["the Disease"]}]], [730, "An external file that holds a picture, illustration, etc.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Cholinergic system\": [],\n\"Dopamine\": [],\n\"G protein-coupled receptors\": [\"beta-adrenergic receptors\"],\n\"Histamine\": [],\n\"Nicotinic acetylcholine receptors\": [],\n\"Muscarinic acetylcholine receptors\": [],\n\"Norepinephrine\": [\"noradrenaline\"],\n\"Potassium channels\": [],\n\"Serotonin\": [],\n\"Sympathetic nervous system\": []", {}]], [731, "Five days after presentation, her symptoms had completely resolved.", [" PARAMETER: []\n\nFive days after presentation: [\"five days\", \"presentation\"]\n\nher symptoms had completely resolved: [\"her symptoms\", \"symptoms\", \"had completely resolved\"]", {}]], [732, "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.", [" \"Lomatium\": [],\n\"rashes\": [\"skin rashes\"],\n\"naturopathic literature\": [],\n\"most information\": [],\n\"treatment of the rash\": [],\n\"supportive care\": [],\n\"cessation of Lomatium ingestion\": []", {"Pathology": ["rashes", "the rash"], "Herb name": ["Lomatium", "Lomatium"]}]], [733, "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.", [" \"PATIENT\": [\"the patient\"],\n\"RASH\": [\"the rash\"],\n\"GLUCOCORTICOIDS\": [\"glucocorticoids\"],\n\"ANTIHISTAMINES\": [\"antihistamines\"],\n\"PRURITIS\": [\"pruritis\"]", {"Pathology": ["the rash", "pruritis"], "Drug": ["glucocorticoids", "antihistamines"]}]], [734, "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.", [" \"OS (Operating System)\": []\n\"SELECTED SINGLE HERBS\": [\"herbs\"]\n\"Wen Bing formulas\": []", {"Drug": ["OS"], "Herb name": ["Wen Bing formulas"]}]], [735, "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.", [" \"Radix Scutellariae (RS)\": [\"extract\", \"Shanghai U-sea Biotech Co., Ltd.\", \"batch number (110208)\", \"quality of control standard number (WS-10001-(HD-0989)-2002)\"]", {"Herb name": ["Radix Scutellariae extract (RS)"]}]], [736, "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.", [" \"Albuterol\": [\"Albuterol (as internal standard)\"]\n\nSigma-Aldrich Chem.: []", {}]], [737, "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.", [" \"Hygromycin B\": [\"chemical\", \"compound\", \"drug\"],\n\"glycyl-sarcosine (Gly-Sar)\": [\"chemical\", \"compound\"],\n\"thiazolyl blue tetrazolium bromide (MTT)\": [\"chemical\", \"compound\"],\n\"Sigma-Aldrich Chem.\": [\"company\"]", {}]], [738, "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.", [" \"5 \u03bcL\": [],\n\"8 mg/mL dichlorvos\": [\"dichlorvos\"],\n\"600 \u03bcL PBS\": [\"PBS\"]", {}]], [739, "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.", [" \"ANESTHETIZED RATS\": [],\n\"BLOOD\": [\"About 10 mL\"],\n\"INFERIOR VENA\": [],\n\"RATS\": []", {}]], [740, "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.", [" \"OS\": [\"1 \u03bcg/mL\"]\n\"rat plasma\": []\n\"incubation system\": []\n\nThe super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.\n\n\"100% rat plasma\": []\n\"reaction rate\": []\n\"discrimination\": []\n\"studied herb/herbal components\": []", {}]], [741, "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.", [" \"OSA (Obstructive Sleep Apnea)\": []\n\"formation rate\": [\"rate of formation\"]\n\"OSA (Obstructive Sleep Apnea)\": [\"Obstructive Sleep Apnea\"]\n\"herb/herbal components\": []", {"Drug": ["OSA"]}]], [742, "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.", [" \"RESULTS FROM RLM AND hCE1\": []\n\n\"TEN Marker Components\": [\"ten marker components\"]\n\n\"Figs\": []\n\nThe text does not provide enough information to identify specific physiological or medical parameters.", {}]], [743, "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.", [" \"OS\": [\"operating system\", \"\"],\n\"HDI\": [\"herb-drug interaction\", \"\"],\n\"absorption\": [],\n\"metabolism\": []", {"Study": ["in-vitro experiments"], "Drug": ["OS"]}]], [744, "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.", [" \"OS\": [\"systemic exposure\"],\n\"RS\": [\"co-administration\"],\n\"systemic exposure\": [],\n\"exposure\": [\"systemic\"],\n\"OSA\": [\"systemic exposure\"],\n\"decrease\": [\"that of OSA\"],\n\"fig\": []", {"Herb name": ["RS"], "Drug": ["OS", "OSA"]}]], [745, "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.", [" \"OSA/OS ratio\": [\"OSA ratio in rat urine samples\"]\n\"RS\": []\n\"co-administration\": []\n\"rat urine samples\": []\n\"fig\": []\n\n\"Pharmacokinetic parameters\": [\"OSA/OS ratio\"]\n\"rat\": []\n\"urine samples\": []\n\n\"RS\": [\"co-administration\"]\n\n\"Co-administration\": [\"RS\"]\n\n\"Fig\": [\"[\"]\n\"[\": [],\n\"]\": [],\n\"[\": [],\n\"]\": []\n\n\"Lowered\": [\"OSA/OS ratio\"]\n\"in rat urine samples\": []\n\"after co-administration\": []\n\"with RS\": []", {"Drug": ["OSA", "OS"], "Herb name": ["RS"]}]], [746, "S8).", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Cholinergic system\": [],\n\"Dopamine\": [],\n\"GABA\": [\"gamma-aminobutyric acid\"],\n\"G protein-coupled receptors\": [],\n\"Histamine\": [],\n\"Nicotinic acetylcholine\": [],\n\"Norepinephrine\": [],\n\"Opioid receptors\": [],\n\"Phenylephrine\": [],\n\"Serotonin\": [],\n\"Sympathetic nervous system\": []", {}]], [747, "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.", [" \"OS\": [\"operating system\", \"], \"anti-influenza herb/herbal components\": [\"herb\", \"herbal components\"]\n\n\"screening platform\": [],\n\"microsomes\": [],\n\"enzymes\": [],\n\"cells\": [],\n\"influenza viruses\": []", {"Drug": ["OS"]}]], [748, "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.", [" \"OS hydrolysis in rat plasma\": [\"OS\"]\n\"Herbal extracts\": [\"herbal extracts\"]\n\"Herbal components\": [\"herbal components\"]\n\"500 \u03bcg/mL\": []\n\"100 \u03bcg/mL\": []\n\"rat plasma\": []", {"Amount": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "Drug": ["OS"]}]], [749, "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.", [" \"hydrolyase activities\": [\"activities of hydrolyzing enzymes\"],\n\"rat plasma\": [],\n\"kind of enzymes\": [\"different kinds of hydrolyzing enzymes\"],\n\"hCE1\": [\"first type of hydrolyzing enzyme\"],\n\"herbal components\": [],\n\"inhibition activities\": [\"abilities to inhibit\"],\n\"each kind of hydrolysis enzymes\": [\"different types of hydrolyzing enzymes\"]", {"Target": ["hCE1"]}]], [750, "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.", [" \"HERB/HERBAL COMPONENT\": [],\n\"OS (Overall Survival)\": [\"overall survival\"],\n\"HDI (Healthy Days Gained)\": [\"Healthy Days Gained\"],\n\"effect\": [],\n\"level\": [],\n\"relevancy\": []", {"Drug": ["OS", "OS"]}]], [751, "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.", [" \"RS\": [\"potential herb\", \"co-administrated OS\"],\n\"OS\": [\"co-administrated OS\"],\n\"BIO\": [\"increased by 62%\"],\n\"k\": [],\n\"AUC\": [],\n\"pop-PK model\": [],\n\"interpretation\": [],\n\"contradictory phenomena\": [],\n\"co-administration of RS\": [],\n\"elimination rate\": [\"increased\"],\n\"systemic exposure (AUC)\": [],\n\"platform\": [],\n\"six-dimension in-vitro screening\": [],\n\"in-vivo pharmacokinetics in rats\": [],\n\"ex-vivo pharmacodynamic evaluation\": []", {"Herb name": ["RS", "RS", "RS"], "Parameter": ["BIO", "AUC"], "Drug": ["OS", "OS"], "Study": ["in-vitro screening", "in-vivo", "ex-vivo"]}]], [752, "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).", [" \"Radix Isatidis (Root of Isatis indigotica Fort., Banlangen)\": []\n\nIsatis indigotica Fort., Banlangen: [\"Plant species\"]\n\nRoot: [\"Anatomical part of a plant\"]\n\nFort.: [\"Person, usually used to refer to Carl Peter Thunberg, a Swedish botanist\"]\n\nIsatis indigotica: [\"Plant species\"]\n\nBanlangen: [\"Common name of a plant\"]\n\nThe active components of Radix Isatidis include indigo, isatan, isatidin, and isatidic acid.\n\n\"indigo\": []\n\nisatan: []\n\nisatidin: []\n\nisatidic acid: []\n\nThe pharmacological effects of Radix Isatidis are mainly attributed to its antiviral, antibacterial, antitumor, and anti-inflammatory properties.\n\n\"antiviral\": []\n\n\"antibacterial\": []\n\n\"antitumor\": []\n\n\"anti-inflammatory\": []\n\nThe antiviral activity of Radix Isatidis has been studied extensively against various viruses, including influenza A virus, human immunodeficiency virus (HIV), hepatitis B virus (HBV), and herpes simplex virus (HSV).\n\n\"influenza A virus\": []\n\n\"human immunodeficiency virus (HIV)\": []\n\n\"hepatitis B virus (HBV)\": []\n\n\"herpes simplex virus (HSV)\": []\n\nThe antibacterial activity of Radix Isatidis has been demonstrated against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.\n\n\"Staphylococcus aureus\": []\n\n\"Escherichia coli\": []\n\n\"Pseudomonas aeruginosa\": []\n\nThe antitumor activity of Radix Isatidis has been investigated in various cancer models, including liver cancer, breast cancer, and colon cancer.\n\n\"liver cancer\": []\n\n\"breast cancer\": []\n\n\"colon cancer\": []\n\nThe anti-inflammat", {"Herb name": ["Radix Isatidis", "Isatis indigotica Fort"], "Herb part": ["Root"]}]], [753, "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).", [" \"Fructus Arctii (Fruit of Arctium lappa L., Niubangzi)\": []\n\nArctium lappa L., Niubangzi: [\"Plant\", \"Species\"]\n\nFructus (Fruit): []\n\nLappa: []\n\nArctium: [\"Genus\"]\n\nlappa: [\"Species\"]\n\nNiubangzi: []", {"Herb name": ["Fructus Arctii", "Arctium lappa L."], "Herb part": ["Fruit"]}]], [754, "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.", [" \"CLINICAL BREAST CANCER PATIENTS\": [\"clinical breast cancer patients\"]\n\"PERCENTAGE\": [\"30%\u201370%\"]\n\n\"NATURAL PRODUCTS\": [\"natural products\"]\n\n\"LIKELIHOOD\": [\"likelihood\"]\n\"DRUG INTERACTIONS\": [\"drug interactions\"]", {"Pathology": ["breast cancer"]}]], [755, "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.", [" \"TAM (Tamoxifen)\": [\"antiestrogen\", \"selective estrogen receptor modulator (SERM)\", \"pharmacological agent\"]\n\n\"natural products\": [\"botanical compounds\", \"phytochemicals\", \"herbal remedies\"]\n\n\"pre-clinical studies\": [\"in vitro studies\", \"animal studies\"]\n\n\"clinical evidence\": []\n\n\"interactions\": []", {"Herb name": ["natural products"], "Drug": ["TAM"], "Study": ["pre-clinical studies"]}]], [756, "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).", [" \"BREAST CANCER PATIENTS, CANCER PATIENTS\": [\"patients with breast cancer, patients with cancer\"]\n\n\"COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM)\": []\n\n\"WANCHAI ET AL., 2010\": []", {"Pathology": ["cancer", "breast cancer"]}]], [757, "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.", [" \"Citrus aurantium L.\": [\"dried orange peel\"]\n\"Anemarrhena asphodeloides Bunge\": [\"Anemarrhena\"]\n\"Phellodendron amurense Rupr.\": [\"Phellodendron bark\"]", {"Herb name": ["dried orange peel (Citrus aurantium L.)", "Anemarrhena (Anemarrhena asphodeloides Bunge)", "Phellodendron bark (Phellodendron amurense Rupr."]}]], [758, "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)", [" \"Licorice (Glycyrrhiza glabra L)\": []\n\"Ginger (Zingiber officinale Roscoe)\": []\n\"Lilyturf (Ophiopogon japonicus (Thunb.))\": []\n\nParameters:\n\n\"\"\": []\n\"dose\": [\"doses\", \"500 mg/kg\", \"1 g/kg\", \"2 g/kg\", \"500 mg\", \"1 g\", \"2 g\"]\n\"extract\": [\"extracts\", \"ethanolic extracts\"]\n\"animals\": [\"rats\"]\n\"blood\": [\"blood samples\"]\n\"plasma\": [\"plasma samples\"]\n\"liver\": [\"liver homogenates\"]\n\"kidney\": [\"kidney homogenates\"]\n\"heart\": [\"heart homogenates\"]\n\"lungs\": [\"lung homogenates\"]\n\"intestines\": [\"intestinal homogenates\"]\n\"brain\": [\"brain homogenates\"]\n\"tissues\": [\"tissue homogenates\"]\n\"pharmacological\": []\n\"activity\": []\n\"inhibition\": [\"inhibited\", \"inhibiting\"]\n\"acetylcholinesterase\": [\"acetylcholinesterase enzyme\"]\n\"cholinesterase\": [\"cholinesterase enzymes\"]\n\"neuroprotective\": []\n\"antioxidant\": []\n\"hepatoprotective\": []\n\"nephroprotective\": []\n\"cardioprotective\": []\n\"anti-inflammatory\": []\n\"anticancer\": []\n\"cytotoxicity\": []\n\"apoptosis\": []\n\"oxidative stress\": []\n\"lipid peroxidase\": [\"lipid peroxidase enzyme\"]\n\"malondialdehyde\": [\"malondialdehyde levels\"]\n\"glutathione\": [\"glutathione levels\"]\n\"superoxide dismutase\": [\"superoxide dismutase enzyme\"]\n\"nitric oxide\": [\"nitric oxide levels\"]\n\"histamine\": [\"histamine levels\"]\n\"prostaglandin\": [\"prostaglandin E2 levels\"]\n", {"Herb name": ["Licorice (Glycyrrhiza glabra L.)", "Ginger (Zingiber officinale Roscoe)", "Lilyturf (Ophiopogon japonicus (Thunb.)"]}]], [759, "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).", [" \"ANTI-CANCER DRUGS\": [\"compounds used to treat cancer\"]\n\"APOPTOSIS\": [\"programmed cell death\"]\n\"AUTOPHAGY\": [\"process of self-digestion in cells\"]\n\"CELL CYCLE ARREST\": [\"halting of cell cycle progression\"]\n\"PHYSIOLOGICAL OR MEDICAL PARAMETERS\": []", {"Pathology": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"]}]], [760, "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).", [" \"HES (Hydroxyethyl starch)\": [\"hydroxyethyl starch\"],\n\"PIP (Pentasodium triphosphate)\": [\"pentasodium triphosphate\"],\n\"BV (Bovine serum)\": [\"bovine serum\"],\n\"TAM (Tamoxifen)\": [\"tamoxifen\"],\n\"MCF7\": [\"MCF7\"],\n\"T47D\": [\"T47D\"],\n\"cell apoptosis\": [\"cell apoptosis\"]", {"Herb name": ["HES", "PIP", "BV"], "Drug": ["TAM"], "Pathology": ["anti-proliferative effect", "apoptosis"]}]], [761, "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).", [" \"MCF-7 and T-47D cells\": [\"human breast cancer cell lines\"]\n\"it\": [\"unspecified compound or substance\"]\n\"when combined with TAM\": []\n\"exhibits\": [\"shows\"]\n\"significant synergistic inhibitory effect\": [\"enhanced inhibitory effect\"]\n\"on MCF-7 and T-47D cell growth\": [\"on the growth of MCF-7 and T-47D cells\"]\n\n\"Cho et al., 2010\": [\"authors of the study published in 2010\"]", {"Drug": ["TAM"], "Parameter": ["MCF-7 and T-47D cell growth"]}]], [762, "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.", [" \"Mistletoe (Viscum album L.)\": [\"botanical name\"]\n\"Medicinal preparations\": [\"pharmaceutical preparations\", \"drugs\"]\n\"European countries\": [\"geographical locations\"]", {"Herb name": ["Mistletoe (Viscum album L.)"], "Ethnic group": ["European"]}]], [763, "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).", [" \"TAM-resistant cell line MCF-7 tam-R\": [\"TAM-resistant\", \"MCF-7 tam-R\"]\n\"10 Evn-50\": []\n\"ethyl acetate extract\": []\n\"Vitex negundo L.\": [\"Vitex negundo\"]\n\"TAM\": [\"TAM\"]\n\"cell viability\": []\n\"cell growth\": []\n\"apoptosis\": []\n\"TAM resistance\": [\"TAM resistance\", \"MCF-7/TAM-R cells\"]", {"Drug": ["TAM", "TAM", "TAM", "TAM"], "Herb name": ["10 Evn-50", "Vitex negundo L."], "Extraction process": ["ethyl acetate extract"], "Parameter": ["cell viability", "cell growth"]}]], [764, "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).", [" \"Jaeumkanghwa soup (JEKHT)\": [\"compound\", \"12 traditional herbs\"]\n\n\"Jaeumkanghwa soup (JEKHT)\": [] (for other fields)\n\n\"12 traditional herbs\": []\n\n\"compound\": []\n\n\"Jaeumkanghwa soup\": []\n\n\"JEKHT\": []\n\n\"Jung et al., 2010\": [] (for other fields)\n\n\"2010\": []\n\n\"Jung\": []\n\n\"et al.\": []", {"Herb name": ["Jaeumkanghwa soup (JEKHT)"]}]], [765, "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).", [" \"Jiawei Xiaoyao San (JWXYS)\": [\"Chinese herbal formula\"]\n\"Chen et al., 2014\": []", {"Herb name": ["Jiawei Xiaoyao San (JWXYS)"], "Ethnic group": ["Chinese", "Chinese"], "Duration": ["for thousands of years"]}]], [766, "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).", [" \"DOSE-DEPENDENT\": [\"dose\"]\n\"RAHATE\": [],\n\"RAJASEKARAN\": []", {"Pathology": ["protective effect"]}]], [767, "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).", [" \"DDB (1)\": [],\n\"TAM (1)\": [],\n\"liver injury (1)\": [],\n\"rats (1)\": [],\n\"oxidative stress status (1)\": [],\n\"antioxidant enzymes (1)\": [],\n\"sGPT (1)\": [\"serum glutamate-oxalacetate transaminase\"],\n\"sGOT (1)\": [\"serum glutamate-oxalacetate transaminase\"],\n\"glutathione (1)\": [],\n\"reduction (1)\": [],\n\"TBARS (1)\": [\"thiobarbituric acid reactive substances\"],\n\"liver transaminases (1)\": []", {"Herb name": ["DDB"], "Pathology": ["the oxidative stress", "liver injury"], "Drug": ["TAM"], "Parameter": ["antioxidant enzymes", "the activity of sGPT and sGOT", "glutathione concomitant", "TBARS", "liver transaminases"]}]], [768, "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).", [" \"PROTEIN EXPRESSION LEVELS\": [\"protein expression\"]\n\"TRANSCRIPTION ACTIVITY\": [\"transcription activity\"]\n\nReferences:\n\"Gord\u00e2n, E., et al. (2009).\" [If the authors' names are not mentioned in the article, the reference should be left empty.]", {"Parameter": ["protein expression levels"]}]], [769, "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.", [" \"GA\": [\"compound\", \"inhibitor\"],\n\"PCA\": [\"compound\", \"inhibitor\"],\n\"OAT1/3\": [\"transporter\", \"organic anion transporter\"],\n\"MDR1\": [\"transporter\", \"multidrug resistance protein 1\"],\n\"BCRP\": [\"transporter\", \"breast cancer resistance protein\"]", {"Herb name": ["GA", "PCA"], "Target": ["OAT1/3", "MDR1", "BCRP"]}]], [770, "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).", [" \"COMMUNICABLE DISEASES\": [\"diseases\"],\n\"WHO'S Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020)\": []\n\nGlobally, the leading causes of death are ischemic heart disease, stroke, lower respiratory infections, and diarrheal diseases (GBD Diseases and Injuries, 2020).\n\n\"ISCHMIC HEART DISEASE\": [\"ischemic heart disease\"],\n\"STROKE\": [\"stroke\"],\n\"LOWER RESPIRATORY INFECTIONS\": [\"infections\", \"lower respiratory infections\"],\n\"DIARRHEAL DISEASES\": [\"diarrheal diseases\"]\n\nThe burden of these diseases is highest in low-income countries, particularly in sub-Saharan Africa and South-East Asia (GBD Diseases and Injuries, 2020).\n\n\"LOW-INCOME COUNTRIES\": [\"low-income countries\"],\n\"SUB-SAHARAN AFRICA\": [\"Sub-Saharan Africa\"],\n\"SOUTH-EAST ASIA\": [\"South-East Asia\"]\n\nAntimicrobial resistance (AMR) is a major threat to public health, contributing to increased morbidity and mortality from communicable diseases (WHO, 2019).\n\n\"ANTIMICROBIAL RESISTANCE (AMR)\": [\"antimicrobial resistance\"],\n\"MORBIDITY\": [],\n\"MORTALITY\": [],\n\"COMMUNICABLE DISEASES\": [\"communicable diseases\"]\n\nThe emergence and spread of AMR is driven by the misuse and overuse of antimicrobial agents in human and animal health (WHO, 2019).\n\n\"EMERGENCE\": [],\n\"SPREAD\": [],\n\"ANTIMICROBIAL AGENTS\": [\"antimicrobial agents\"],\n\"HUMAN HEALTH\": [\"human health\"],\n\"ANIMAL HEALTH\": [\"animal health\"]\n\nThe development of new antimicrobial agents is crucial to combat AMR, but the high cost and", {"Pathology": ["Communicable diseases"]}]], [771, "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).", [" \"Chinese herbal plant (D. Don)\": [\"D. Don\", \"Chinese herbal plant\"]\n\"Chinese Pharmacopoeia Commission\": [\"Chinese Pharmacopoeia Commission\"]\n\"P. capitatum\": [\"P. capitatum\"]\n\"antibacterial agents\": [\"antibacterial agents\"]\n\"urinary tract infections\": [\"urinary tract infections\"]\n\"pyelonephritis\": [\"pyelonephritis\"]\n\"prostatitis\": [\"prostatitis\"]\n\n\"in China\": []\n\n\"2010\": []\n\n\"Liao et al., 2011\": []", {"Herb name": ["ex D. Don (P. capitatum)"], "Ethnic group": ["Chinese", "Chinese"], "Drug": ["antibacterial agents"], "Pathology": ["urinary tract infections", "pyelonephritis", "prostatitis"]}]], [772, "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.", [" \"GA\": [\"GA (unspecified)\"],\n\"PCA\": [\"PCA (unspecified)\"],\n\"PCE\": [\"PCE (unspecified)\"],\n\"tracer components\": [],\n\"pharmacokinetic-based HDIs\": [],\n\"tissue distribution-based HDIs\": [],\n\"studies\": []", {"Herb name": ["GA", "PCA", "PCE"]}]], [773, "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).", [" \"CIP\": [\"compound\", \"drug\"]\n\"unchanged form\": [],\n\"into the urine\": [\"urine\"],\n\"approximately 60%\": [],\n\"CIP is\": [],\n\"excreted\": [],\n\"unchanged form into the urine\": [],\n\"Vance-Bryan et al.\": [],\n\"1990\": []", {"Drug": ["CIP"]}]], [774, "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).", [" \"ATP-binding cassette transporters\": [\"ABC transporters\"]\n\"CIP\": []\n\n\"intestinal secretion\": []\n\"biliary excretion\": []\n\"secretion into breast milk\": []\n\nVance-Bryan et al., 1990: []\nMerino et al., 2006: []\nAndo et al., 2007: []\nMulgaonkar et al., 2012: []", {"Drug": ["CIP"]}]], [775, "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.", [" PARAMETER: []\n\nThe gradient elution program was as follows:\n\n1. time: [0-8.5 min, 8.7-11 min, 11.5-13.5 min, 14-15 min]\n2. percentage of solvent A: [97% (0-8.5 min, 14-15 min), 60% (8.7-11 min), 10% (11.5-13.5 min)]", {}]], [776, "The supernate was utilized for the quantification of GA, PCA, and CIP.", [" \"GA (glucuronidated form of a drug or metabolite)\": [\"GA\"]\n\"PCA (paracetamol or acetaminophen)\": [\"paracetamol\", \"acetaminophen\"]\n\"CIP (cephalosporin antibiotic)\": [\"cephalosporin\"]\n\"supernate\": []", {"Herb name": ["GA", "PCA"], "Drug": ["CIP"]}]], [777, "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.", [" \"CIP (ciprofloxacin)\": [\"drug\"]\n\"ofloxacin\": [\"drug\"]\n\"precursor-product ion transitions\": [\"analytical technique\"]\n\"332.1\": [\"mass value\"]\n\"288.1\": [\"mass value\"]\n\"362.2\": [\"mass value\"]\n\"318.1\": [\"mass value\"]", {"Drug": ["CIP", "ofloxacin"]}]], [778, "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.", [" \"CIP (Ciprofloxacin)\": [],\n\"PCE (Phenylephrine)\": [],\n\"PK (Pharmacokinetics)\": [],\n\"GA (Gabapentin)\": [],\n\"PCA (Phenyleproclonidine)\": [],\n\"Figures 3, 4\": []", {"Drug": ["CIP"], "Herb name": ["PCE", "GA", "PCA"]}]], [779, "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.", [" \"PCE\": [\"distribution coefficients (K)\"],\n\"ciprofloxacin (CIP)\": [\"tissue to plasma distribution coefficients\"],\n\"GA\": [\"tissue distribution curves\"],\n\"rats\": []\n\nNote: No other specific physiological or medical parameters were mentioned in the given text.", {"Herb name": ["PCE", "PCE", "GA", "PCE"], "Drug": ["ciprofloxacin (CIP)", "CIP", "CIP"]}]], [780, "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.", [" \"CIP\": [\"ciprofloxacin\"],\n\"PCE\": [\"PCE (probencid)\"],\n\"GA\": [\"gallic acid\"],\n\"PCA\": [\"PCE-acetylated form (PCA)\"],\n\"K\": [\"tissue distribution coefficients\"]", {"Drug": ["CIP", "ciprofloxacin", "CIP"], "Herb name": ["gallic acid (GA)", "PCE", "PCA"]}]], [781, "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.", [" \"LIVER METABOLISM\": [\"approximately 10%\"],\n\"BILIARY EXCRETION\": [\"approximately 1%\"],\n\"DRUG\": [],\n\"CIRCULATING CIP\": [],\n\"HUMANS\": [],\n\"RENAL EPITHELIA\": [],\n\"INTESTINAL EPITHELIA\": []", {"Drug": ["CIP", "CIP"]}]], [782, "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.", [" PARAMETER: []\n\nThe present study was designed to investigate the protective effects of [Forsythia suspensa] extract against acetaminophen-induced hepatotoxicity in rats. [Forsythia suspensa]: [\"Forsythia suspensa\", \"extract\"]\n\nAcetaminophen-induced hepatotoxicity: [\"acetaminophen-induced hepatotoxicity\"]\n\nRats: [\"rats\"]\n\nThe acute oral toxicity of [Forsythia suspensa] extract was evaluated according to the Organization for Economic Co-operation and Development (OECD) 425 guideline. [Organization for Economic Co-operation and Development (OECD)]: [\"Organization for Economic Co-operation and Development\"]\n\nThe acute oral toxicity study was performed on male Wistar rats. [male Wistar rats]: [\"male Wistar rats\"]\n\nThe rats were fasted for 12 h before the administration of the extract. [rats, administration of the extract]: []\n\nThe extract was administered orally at a dose of 2000 mg/kg. [extract, dose of 2000 mg/kg]: []\n\nThe rats were sacrificed at 24 h after the administration of the extract. [rats, sacrifice, administration of the extract]: []\n\nThe liver and kidney tissues were collected for histopathological examination. [liver and kidney tissues, histopathological examination]: []\n\nThe serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin (TBil) levels were measured using an automatic biochemical analyzer. [serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin (TBil), automatic biochemical analyzer]: [\"serum alanine aminotransferase (ALT)\", \"aspartate aminotransferase (AST)\", \"alkaline phosphat", {"Ethnic group": ["Chinese"]}]], [783, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [" PARAMETER: []\n\nThe authors declare that:\n\n1. The research was conducted: [\"in the absence\", \"of any commercial or financial relationships\"]\n2. Potential conflict of interest: [\"was declared\", \"by the authors\"]\n\nThe following is the text of the article:\n\n[Article text]\n\nBackground:\nThe use of opioids for the management of chronic pain is a common practice in clinical settings. However, the long-term use of opioids is associated with several adverse effects, including the development of opioid-induced hyperalgesia (OIH). OIH is characterized by an increased sensitivity to painful stimuli and is thought to be mediated by various mechanisms, including changes in the expression of ion channels and receptors.\n\nMethods:\nIn this study, we investigated the role of the transient receptor potential vanilloid 1 (TRPV1) channel in the development of OIH using a rat model of chronic opioid administration. Rats were administered morphine (10 mg/kg, s.c.) daily for 14 days. Behavioral tests were performed before and after the morphine treatment to assess the development of hyperalgesia. Western blot analysis was used to determine the expression levels of TRPV1 and other related proteins in the dorsal root ganglia (DRG) and spinal cord.\n\nResults:\nOur results showed that chronic morphine administration led to a significant increase in TRPV1 expression in both the DRG and spinal cord. Furthermore, the behavioral tests revealed that morphine-treated rats exhibited increased sensitivity to thermal and mechanical stimuli, indicating the development of hyperalgesia. These findings suggest that TRPV1 plays a role in the development of OIH.\n\nConclusion:\nOur study provides new insights into the mechanisms underlying the development of OIH and highlights the potential of TRPV1 as a therapeutic target for the treatment of opioid-induced hyperalgesia.\n\nPARAMETER: [\"rats\", \"morphine\", \"daily\", \"14 days\", \"behavioral tests\", \"thermal stimuli\", \"mechanical stimuli\", \"TRPV1\", \"DRG\", \"spinal cord\", \"western blot analysis\"]", {}]], [784, "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", [" \"Diclofenac\": [], \"IBuprofen\": [], \"Non-steroidal anti-inflammatory drugs (NSAIDs)\": [], \"Prostaglandins\": [\"Prostaglandin E2\", \"Prostaglandin I2\"], \"Cyclooxygenase (COX)\": [], \"Lipoxygenase (LOX)\": [], \"Inflammation\": [], \"Pain\": [], \"Analgesic\": [], \"Fever\": [], \"Pyrexia\": [], \"Tumor necrosis factor-alpha (TNF-\u03b1)\": [], \"Interleukin-1 beta (IL-1\u03b2)\": [], \"Interleukin-6 (IL-6)\": [], \"Nitric oxide (NO)\": [], \"Cyclin-dependent kinase 1 (CDK1)\": [], \"Mitogen-activated protein kinase (MAPK)\": [], \"Adenosine monophosphate-activated protein kinase (AMPK)\": [], \"Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-\u03baB)\": [], \"Transcription factors\": [], \"Microglia\": [], \"Astrocytes\": [], \"Neurons\": [], \"Glial fibrillary acidic protein (GFAP)\": [], \"TNF-\u03b1 receptor\": [], \"IL-1\u03b2 receptor\": [], \"IL-6 receptor\": [], \"Toll-like receptors (TLRs)\": [], \"Lipopolysaccharides (LPS)\": [], \"Endothelial cells\": [], \"Platelets\": [], \"Thromboxane A2\": [], \"Leukotrienes\": [], \"Reactive oxygen species (ROS)\": [], \"Nitric oxide synthase (NOS)\": [], \"Cytochrome P450\": [], \"Glucuronidation\": [], \"Phase I metabolism\": [], \"Phase II metabolism\": [], \"Glutathione\": [], \"Hepatocytes\": [], \"Liver\": [], \"Renal clearance\": [], \"Pharmacokinetics\": [], \"Pharmacodynamics\": [], \"Bioavailability\": [], \"Plasma concentration\": [], \"Half-life\": [], \"", {}]], [785, "Click here for additional data file.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Cholinergic system\": [],\n\"Dopamine\": [],\n\"GABA\": [\"gamma-aminobutyric acid\"],\n\"G protein-coupled receptors\": [],\n\"Histamine\": [],\n\"Nicotinic acetylcholine\": [],\n\"Norepinephrine\": [],\n\"Opioid receptors\": [],\n\"Phenylephrine\": [],\n\"Serotonin\": [],\n\"Sympathetic nervous system\": []", {}]], [786, "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.", [" PARAMETER: []\n\nAll tests were performed at:\n- similar laboratory environmental conditions: []\n- controlling for:\n  - air temperature: []\n  - barometric pressure: []\n  - relative humidity: []", {}]], [787, "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).", [" \"Scale\": [\"measure used for data collection\"]\n\nThe following parameters were found in the text:\n\n\"labels\": [\"descriptions written on the ends of the scale\"]\n\"not at all (0 mm)\": [\"first label of the scale\"]\n\"extremely (100 mm)\": [\"second label of the scale\"]", {}]], [788, "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).", [" \"AUC (total area under the curve)\": [\"13.3\", \"15.00\"]\n\"CHO (carbonic hydroxyapatite)\": []\n\"PLC (porcine liver cells)\": []\n\"p\": [\"< 0.001\"]", {"Parameter": ["AUC", "CHO"], "Herb name": ["YM"]}]], [789, "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).", [" \"Total Energy Expenditure (TEE)\": []\n\n\"Treatment (YM vs. PLC)\": [\"YM\", \"PLC\"]\n\n\"Exercise time\": []\n\n\"Figure 3\": []", {"Parameter": ["Total Energy Expenditure (TEE)"], "Herb name": ["YM"], "Drug": ["PLC"]}]], [790, "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].", [" \"INCREASE\": [\"24%\", \"during low to moderate exercise intensities\"]\n\"STUDY [22]\": []\n\nThis increase is comparable with:\n- \"INCREASE\": []\n- \"24%\": []\n- \"during low to moderate exercise intensities\": []\n- \"study\": [\"[22]\"]\n\nfound during:\n- \"low to moderate exercise intensities\": []\n- \"study\": [\"[22]\"]\n\ndetermined using:\n- \"incremental protocol\": []\n- \"study\": [\"[22]\"]", {}]], [791, "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].", [" \"YM\": [\"ingestion\", \"metabolic rate\", \"RER\", \"acutely\", \"12 weeks\", \"healthy obese participants\"]\n\"metabolic rate\": []\n\"RER\": [\"acutely\"]\n\"blood lipid metabolites\": [\"after 12 weeks\", \"healthy obese participants\"]", {"Herb name": ["YM"], "Duration": ["12 weeks"], "Pathology": ["healthy"]}]], [792, "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].", [" \"ADRENGENIC EFFECTS\": [\"adrenergic effects\"]\n\"CENTRAL NERVOUS SYSTEM\": [\"central nervous system\"]\n\"CAFFEINE\": []\n\"CHLOROGENIC ACIDS\": [\"chlorogenic acids\", \"mono- and di-caffeolquinic acids\"]\n\"MONO- AND DI-CAFFEOLEQUINIC ACIDS\": [\"mono- and di-caffeolquinic acids\"]\n\"HYDROXYCINNAMIC ACIDS\": [\"hydroxycinnamic acids\", \"caffeic acid\", \"quinic acid\"]\n\"CAFFEIC ACID\": [\"caffeic acid\"]\n\"QUINIC ACID\": [\"quinic acid\"]\n\"TRITERPENIC SAPONINS\": [\"terpene saponins\", \"triterpenic saponins\"]\n\"MINERALS\": []\n\"VITAMINS\": []", {"Herb name": ["caffeine"]}]], [793, "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.", [" \"YM capsules\": []\n\nFurther research is required to assess:\n- active ingredients (of YM capsules) : []\n- bioavailability (of YM capsules' active ingredients) : []", {"Herb name": ["YM"], "Parameter": ["bioavailability"]}]], [794, "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.", [" \"Favorable psychomotor effects\": [],\n\"mood state\": [\"mood\"],\n\"satiety\": []\n\nThe mechanisms underlying these effects are multifaceted and include interactions with various neurotransmitter systems, such as dopamine, serotonin, and \u03b3-aminobutyric acid (GABA).\n\n\"dopamine\": [],\n\"serotonin\": [\"serotonin\"],\n\"\u03b3-aminobutyric acid (GABA)\": []\n\nMoreover, some supplements, such as caffeine and green tea extract, are known to stimulate the release of catecholamines, including dopamine and norepinephrine, which can contribute to improved mood and focus.\n\n\"caffeine\": [],\n\"green tea extract\": []\n\nAdditionally, certain nutrients, such as choline and inositol, have been shown to play a role in the synthesis and metabolism of neurotransmitters, potentially enhancing their effects.\n\n\"choline\": [],\n\"inositol\": []\n\nFurthermore, some supplements, such as 5-hydroxytryptophan (5-HTP) and L-tryptophan, are direct precursors to serotonin and can increase its levels in the brain, potentially leading to improved mood and reduced anxiety.\n\n\"5-hydroxytryptophan (5-HTP)\": [\"5-hydroxytryptophan\"],\n\"L-tryptophan\": [\"L-tryptophan\"]\n\nIt is important to note that the effects of these supplements can vary greatly from person to person, and some individuals may experience adverse reactions, such as increased heart rate or anxiety. Therefore, it is recommended that individuals consult with a healthcare professional before starting any new supplement regimen.\n\n\"adverse reactions\": [],\n\"heart rate\": [],\n\"anxiety\": []", {}]], [795, "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.", [" \"BF%\": [\"percentile of body fat\"]\n\n\"females\": []\n\n\"BF% percentile\": []\n\n\"lower BF% percentile\": []\n\n\"physically active\": []\n\n\"higher\" : []\n\n\"YM\": [\"YM treatment\"]\n\n\"fat-loss outcomes\": []\n\n\"during exercise\": []\n\n\"single trials\": []\n\n\"longitudinal YM effectiveness\": []\n\n\"regular exercise training\": []", {"Sex": ["females"], "Herb name": ["YM", "YM", "YM"]}]], [796, "R.A. collected the data and contributed to data analysis and manuscript writing.", [" \"R.A.\": [\"author\"]\n\n\"the following format\": [\"instruction\"],\n\"parse\": [\"action\"],\n\"all the cited entities\": [\"entities\"],\n\"find every word\": [\"action\"],\n\"referring to the described entities\": [\"instruction\"],\n\n\"PARAMETER\": {\n\n\"\": [],\n\"R.A.\": [\"author\"],\n\"collected\": [],\n\"the data\": [],\n\"contributed\": [],\n\"to data analysis\": [],\n\"and manuscript writing\": []\n}\n\n\"pharmacology\": [\"field_of_study\"],\n\"article\": [\"type_of_document\"],\n\"about\": [\"preposition\"],\n\"pharmacology\": [\"field_of_study\"]\n\n\"We\": [\"subject\"],\n\"need\": [\"verb\"],\n\"to parse\": [\"action\"],\n\"all\": [\"determiner\"],\n\"the cited\": [\"adjective\"],\n\"entities\": [\"entities\"]\n\n\"Find\": [\"verb\"],\n\"every word\": [\"action\"],\n\"referring\": [\"verb\"],\n\"to the described\": [\"preposition\"],\n\"entities\": [\"entities\"]\n\n\"The\": [\"determiner\"],\n\"following\": [\"adverb\"],\n\"format\": [\"instruction\"],\n\"must\": [\"modal_verb\"],\n\"be\": [\"linking_verb\"],\n\"followed\": [],\n\n\"Please\": [\"interjection\"],\n\"do\": [\"verb\"],\n\"not\": [\"determiner\"],\n\"add\": [\"verb\"],\n\"supplementary\": [\"adjective\"],\n\"information\": [\"noun\"],\n\n\"If\": [\"subordinating_conjunction\"],\n\"no\": [\"determiner\"],\n\"information\": [\"noun\"],\n\"is\": [\"linking_verb\"],\n\"found\": [\"verb\"],\n\"for\": [\"preposition\"],\n\"a field\": [\"noun_phrase\"],\n\"leave\": [\"verb\"],\n\"the field\": [\"noun_phrase\"],\n\"empty\": [\"adverb\"]\n}", {}]], [797, "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).", [" \"Prof. Yeong Bae Seo (specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea)\": [\"Prof. Yeong Bae Seo\", \"Seoul National University\", \"Natural Products Research Institute\"]\n\n\"(a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea)\": [\"specialist in plant classification\", \"Natural Products Research Institute\", \"Seoul National University\", \"Seoul\"]\n\n\"(Co., Seoul, Korea)\": [\"Co.\", \"Seoul\", \"Korea\"]", {}]], [798, "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).", [" \"HEK293 cells\": [],\n\"OAT1\": [\"OAT1 transporters\"],\n\"OAT3\": [\"OAT3 transporters\"],\n\"OCT1\": [\"OCT1 transporters\"],\n\"OCT2\": [\"OCT2 transporters\"],\n\"OATP1B1\": [\"OATP1B1 transporters\"],\n\"OATP1B3\": [\"OATP1B3 transporters\"],\n\"Corning-Gentest\": [],\n\"Tewksbury\": []", {"Parameter": ["OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"]}]], [799, "Food and water were supplied ad libitum.", [" PARAMETER: []\n\nThe following format must be followed for cited entities:\n\"ENTITY_NAME\": [\"Citation where the entity is mentioned\"]\n\nENTITY_1: [\"Food and water\", \"were supplied ad libitum\"]\n\nPlease note that according to the given instruction, no additional information will be added for the \"PARAMETER\" field, even if some information can be inferred from the text. In this case, since no specific parameters are mentioned in the text, an empty list is provided.", {}]], [800, "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.", [" \"Rats\": [],\n\"Cannulated\": [],\n\"Jugular vein\": [],\n\"PE-50\": [\"Polyethylene tubing\"],\n\"Natsume Co\": [],\n\"Tokyo, Japan\": []", {"Parameter": ["anesthesia"], "Drug": ["isoflurane"]}]], [801, "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.", [" \"Mass Hunter software\": [\"Mass Hunter\"]\n\n\"LC-MS/MS system\": []\n\n\"Agilent Technologies\": []", {}]], [802, "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].", [" \"Patient demographics\": [\"38% of respondents\"]\n\"Herbal co-medication\": []\n\"Prescription drugs\": []\n\nThe practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].", {}]], [803, "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].", [" \"grapefruit juice\": [],\n\"felodipine\": [\"drug\"],\n\"cytochrome P450 (CYP)\": [],\n\"P-glycoprotein (P-gp)\": [],\n\"pharmacokinetic profiles\": [\"drug metabolism\", \"drug absorption\", \"drug elimination\"],\n\"inhibition\": []\n\n[11]. Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI.\n\nTherefore, the following entities are mentioned in the text:\n- grapefruit juice\n- felodipine\n- cytochrome P450 (CYP)\n- P-glycoprotein (P-gp)\n- pharmacokinetic profiles\n- inhibition\n\nHowever, no specific parameters related to these entities are mentioned in the text.", {"Herb name": ["grapefruit juice"], "Drug": ["felodipine"], "Target": ["cytochrome P450 (CYP)", "P-glycoprotein (P-gp)"]}]], [804, "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.", [" \"celery\": [],\n\"echinacea\": [],\n\"ginkgo\": [],\n\"ginseng\": [],\n\"hydroxycut\": [],\n\"kava\": [],\n\"kratom\": [],\n\"moringa\": [],\n\"piperine\": [\"black pepper\"],\n\"rhodiola\": [],\n\"St. John\u2019s wort\": [],\n\"terminalia/commiphora ayurvedic mixture\": [],\n\"valerian\": []", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "hydroxycut", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic", "valerian"]}]], [805, "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.", [" \"Phytoestrogens\": [\"bioactive components of celery\", \"DMEs\", \"including\", \"those in the CYP450 family\"]\n\"Celery\": []\n\"Bioactive components\": [\"phytostrogens\"]\n\"DMEs\": [\"drug-metabolizing enzymes\"]\n\"CYP450 family\": [\"DMEs\", \"family\"]", {"Herb name": ["celery"], "Target": ["DMEs", "CYP450 family"]}]], [806, "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.", [" \"Anecdotal pieces of evidence\": []\n\n\"consequences of HDIs\": []\n\n\"importance of further studies\": [\"further studies\"]\n\n\"clinical decisions\": []\n\n\"HDIs (hepatic drug interactions)\": [\"hepatic drug interactions\"]\n\n\"reality and severity\": []", {}]], [807, "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].", [" \"CLINICAL STUDIES\": [\"controlled\", \"published data\", \"symptoms of cognition decline and memory loss\", \"anxiety and mood disorders\", \"fatigue and general well-being\", \"cardiovascular disorders\"]\n\"GINKGO\": []\n\n\"USE OF GINKGO\": []\n\n\"SYMPTOMS OF COGNITION DECLINE AND MEMORY LOSS\": []\n\"ANXIETY AND MOOD DISORDERS\": []\n\"FATIGUE\": []\n\"GENERAL WELL-BEING\": []\n\"CARDIOVASCULAR DISORDERS\": []\n\n\"REVIEW\": []\n\"META-ANALYSIS\": []\n\"PUBLISHED DATA\": []", {"Study": ["Several controlled clinical studies"], "Herb name": ["ginkgo"], "Pathology": ["cognition decline", "memory loss", "anxiety", "mood disorders", "fatigue", "cardiovascular disorders"]}]], [808, "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.", [" \"SEIZURE\": [\"seizure\"]\n\"DEATH\": []\n\"TOXICOLOGICAL AUTOPSY\": []\n\"SERUM LEVELS\": [\"serum levels\"]\n\"DRUGS\": [\"drugs\"]\n\nNo specific entities were mentioned for the following words: \"he\", \"reported\", \"revealed\", \"subtherapeutic\".", {"Pathology": ["seizure"]}]], [809, "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].", [" \"CYP3A4\": [\"enzyme\"],\n\"different phytochemicals in ginseng\": [],\n\"inhibitory effect\": [],\n\"inductive effect\": [],\n\"AUC\": [\"pharmacokinetic parameter\"],\n\"midazolam\": [\"drug\"],\n\"human studies\": []", {"Herb name": ["ginseng"], "Target": ["CYP3A4"], "Parameter": ["AUC"], "Drug": ["midazolam"], "Study": ["human studies"]}]], [810, "Chronic use of ginseng on its own has been associated with manic psychosis [90].", [" \"Chronic use of ginseng\": [\"chronic use\", \"ginseng\"]\n\"manic psychosis\": [\"manic psychosis\"]", {"Herb name": ["ginseng"], "Pathology": ["manic psychosis"]}]], [811, "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].", [" \"Kavalactones\": [\"chemical compounds\"]\n\"rhizomes\": [\"part of plant\"]", {"Herb name": ["kava", "kavalactones"], "Herb part": ["rhizomes"]}]], [812, "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.", [" \"Kava\": [\"plant\"],\n\"CNS (Central Nervous System)\": [\"\"]\n\nDespite the general concern about its safety, kava is still popularly consumed for Central Nervous System benefits.", {"Herb name": ["kava"]}]], [813, "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].", [" \"HEALTH VOLUNTEERS\": [\"18\"]\n\"KAVA\": []\n\"BROMAZEPAM\": []\n\"CLINically RELEVANT INTERACTION\": []", {"Cohort": ["18 health volunteers"], "Herb name": ["kava"], "Drug": ["bromazepam"]}]], [814, "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].", [" \"Kratom\": [\"complementary medicine\", \"diabetes\", \"diarrhea\", \"improve circulation\", \"enhance alertness and concentration\", \"increase libido\"]\n\"Diabetes\": []\n\"Diarrhea\": []\n\"Circulation\": [\"improve\"]\n\"Alertness and concentration\": []\n\"Libido\": []", {"Herb name": ["Kratom"], "Pathology": ["diabetes", "diarrhea"]}]], [815, "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.", [" \"SJW (Saw Palmetto or Sabja junzi)\": []\n\"serotonergic effects\": [\"serotonergic\"]\n\nPARAMETER: []", {"Herb name": ["SJW"]}]], [816, "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.", [" \"SJW (Saw Palmetto or Serenoa repens)\": []\n\"CYP3A4\": [\"cytochrome P450 3A4\"]\n\"2-way\": []\n\"open-label\": []\n\"crossover study\": []\n\"21\": []\n\"healthy subjects\": []\n\"midazolam\": []\n\"probe substrate\": []", {"Herb name": ["SJW"], "Target": ["CYP3A4"], "Study": ["open-label crossover study"], "Cohort": ["21 healthy subjects"], "Drug": ["midazolam"]}]], [817, "This is important because the vast majority of herbal products are orally administered.", [" \"Herbal products\": [\"herbal products\"]\n\"Orally administered\": [\"orally\"]\n\nPARAMETER: []\n\n\"vast majority\": []\n\n\"pharmacology\": [\"pharmacology\"]\n\n\"scientific article\": []\n\n\"cited entities\": [\"cited entities\"]\n\n\"find every word\": []\n\n\"referring to\": []\n\n\"described entities\": [\"described entities\"]\n\n\"following format\": []\n\n\"physiological or medical parameters\": []\n\n\"found in text\": []\n\n\"This is\": []\n\n\"important because\": []\n\n\"the vast majority\": []\n\n\"of herbal products\": []\n\n\"are orally administered\": []", {}]], [818, "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.", [" \"Marketed herbal products\": [\"marketed herbal products\"]\n\"different herbal species\": [\"different herbal species\"]\n\"dietary supplements\": [\"dietary supplements\"]\n\"biological disposition\": [\"biological disposition\"]\n\"humans\": []", {}]], [819, "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.", [" \"CYP3A4\": [\"human small intestinal enterocytes\"]\n\"P-gp\": [\"human small intestinal enterocytes\"]", {}]], [820, "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.", [" \"HERBAL PRODUCTS\": [\"celery\", \"echinacea\", \"ginkgo\", \"ginseng\", \"hydroxycut\", \"kava\", \"kratom\", \"moringa\", \"piperine\", \"rhodiola\", \"St. John\u2019s wort\", \"terminalia/commiphora ayurvedic mixture\", \"valerian\"]\n\n\"NEUROPSYCHIATRIC DRUGS\": []", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic mixture", "valerian"], "Herb part": ["hydroxycut"], "Drug": ["neuropsychiatric drugs"]}]], [821, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.", [" \"Medicinal herbs\": [\"botanical sources\", \"natural bioactive compounds\"]\n\"drugs\": []\n\nThe interaction between herbal medicines and drugs could lead to pharmacokinetic and pharmacodynamic interactions.\n\n\"herbal medicines\": [\"traditional medicines\", \"botanical remedies\"]\n\"interaction\": [\"pharmacological interaction\", \"drug-herb interaction\"]\n\"pharmacokinetic interactions\": [\"absorption\", \"distribution\", \"metabolism\", \"excretion\"]\n\"pharmacodynamic interactions\": [\"synergistic effect\", \"antagonistic effect\", \"potentiating effect\"]\n\nThe cytochrome P450 system plays a crucial role in drug metabolism.\n\n\"cytochrome P450 system\": [\"cytochrome P450 enzymes\", \"drug metabolism\"]\n\nSt. John's wort (Hypericum perforatum) is a well-known herbal medicine that interacts with several drugs through the cytochrome P450 system.\n\n\"St. John's wort (Hypericum perforatum)\": [\"herbal medicine\", \"Hypericum perforatum\"]\n\nGrapefruit juice is another common food item that can interact with drugs through the cytochrome P450 system.\n\n\"grapefruit juice\": [\"food item\", \"cytochrome P450 interaction\"]\n\nThe mechanism of interaction between St. John's wort and drugs involves the inhibition of cytochrome P450 enzymes, particularly CYP3A4.\n\n\"St. John's wort\": [\"herbal medicine\", \"Hypericum perforatum\", \"cytochrome P450 interaction\", \"CYP3A4 inhibition\"]\n\"cytochrome P450 enzymes\": [\"CYP3A4\"]\n\"inhibition\": [\"enzyme inhibition\"]\n\nThe interaction between St. John's wort and warfarin can lead to an increased risk of bleeding due to the decreased metabolism of warfarin.\n\n\"St. John's wort\": [\"herbal medicine\", \"Hypericum perforatum", {}]], [822, "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.", [" \"Sirolimus\": []\n\n\"calcineurin inhibitors\": [\"immunosuppressive agents\", \"kidney transplantation\"]\n\n\"synergistic action\": []\n\n\"distinctive mechanism of action\": []\n\n\"indispensable\": [\"immunosuppressive agents\", \"kidney transplantation\"]\n\n\"kidney transplantation\": []", {"Drug": ["Sirolimus", "calcineurin inhibitors", "calcineurin inhibitors"]}]], [823, "This is especially important for drugs with a narrow therapeutic window.", [" \"Acetaminophen\": [\"drug\"],\n\"analgesic\": [\"pharmacological property\"],\n\"antipyretic\": [\"pharmacological property\"],\n\"hepatic\": [\"organ\"],\n\"toxicity\": [\"adverse effect\"],\n\"overdose\": [\"adverse effect\"],\n\"N-acetylcysteine\": [\"drug\"],\n\"glutathione\": [\"molecule\"],\n\"cytochrome P450\": [\"enzyme\"],\n\"CYP3A4\": [\"enzyme\"],\n\"CYP2E1\": [\"enzyme\"],\n\"glucuronidation\": [\"metabolic pathway\"],\n\"conjugation\": [\"metabolic pathway\"],\n\"serum\": [\"body fluid\"],\n\"plasma\": [\"body fluid\"],\n\"liver\": [\"organ\"],\n\"kidney\": [\"organ\"],\n\"renal\": [\"organ or physiological process\"],\n\"excretion\": [\"physiological process\"],\n\"elimination\": [\"physiological process\"],\n\"half-life\": [\"pharmacokinetic parameter\"],\n\"dose\": [\"pharmacological parameter\"],\n\"therapeutic index\": [\"pharmacological parameter\"],\n\"narrow\": [\"adjective\"],\n\"toxic\": [\"adjective\"],\n\"drug-drug interactions\": [\"pharmacological concept\"],\n\"pharmacokinetics\": [\"pharmacological concept\"],\n\"pharmacodynamics\": [\"pharmacological concept\"],\n\"dosage\": [\"pharmacological parameter\"],\n\"overdose treatment\": [\"medical concept\"],\n\"acetylcysteine\": [\"drug\"],\n\"acetyl-CoA\": [\"molecule\"],\n\"glutathione synthesis\": [\"biological process\"],\n\"glutathione conjugation\": [\"metabolic pathway\"],\n\"glutathione S-transferase\": [\"enzyme\"],\n\"NADPH\": [\"molecule\"],\n\"oxidative stress\": [\"biological process\"],\n\"lipid peroxidation\": [\"biological process\"],\n\"protective effect\": [\"biological effect\"],\n\"hepatotoxicity\": [\"adverse effect\"],\n\"acetamin", {}]], [824, "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.", [" \"tacrolimus\": [\"immunosuppression treatment received by the patient until April 2016\"],\n\"sirolimus\": [\"immunosuppression treatment to which the patient switched from tacrolimus due to tremors\"],\n\"April 2016\": []", {"Drug": ["tacrolimus", "tacrolimus", "sirolimus"], "Pathology": ["tremors"]}]], [825, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" \"serum creatinine level\": [\"74.27 \u00b5mol/L\"]", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [826, "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.", [" \"Herb-drug interactions\": [\"interactions\"]\n\"Adverse effects\": []\n\"Serious adverse effects\": []", {"Pathology": ["adverse effects"]}]], [827, "Author contributions: MK drafted the initial and final versions of the manuscript.", [" PARAMETER: []\n\nTitle: \"Effect of a Novel Nitric Oxide Donor on Pulmonary Arterial Hypertension in Rats\"\n\nAbstract:\n1. rats\n2. pulmonary arterial hypertension (PAH)\n3. nitric oxide (NO) donor\n4. hypoxia\n5. right ventricular (RV) function\n6. left ventricular (LV) function\n7. mean arterial pressure (MAP)\n8. heart rate (HR)\n9. pulmonary artery (PA) pressure\n10. pulmonary artery (PA) resistance\n11. right atrial (RA) pressure\n12. left atrial (LA) pressure\n13. systemic arterial pressure (SAP)\n14. pulmonary capillary wedge pressure (PCWP)\n15. pulmonary vascular resistance (PVR)\n16. cardiac output (CO)\n17. stroke volume (SV)\n18. end-diastolic volume (EDV)\n19. end-systolic volume (ESV)\n20. ejection fraction (EF)\n21. fractional shortening (FS)\n22. pulmonary artery (PA) diameter\n23. right ventricular (RV) diameter\n24. left ventricular (LV) diameter\n25. wall thickness (WT)\n26. myocardial infarction (MI)\n27. isoproterenol\n28. sodium chloride\n29. saline\n30. hypoxia chamber\n31. anesthesia\n32. body temperature\n33. hemodynamic measurements\n34. histological analysis\n35. morphometric analysis\n36. nitrite\n37. nitrate\n38. nitric oxide synthase (NOS)\n39. endothelium\n40. smooth muscle cells\n41. vasodilation\n42. vasorelaxation\n43. pulmonary artery (PA) remodeling\n44. right ventricular (RV) hypertrophy\n45. left ventricular (LV) hypert", {}]], [828, "Sirolimus is an immunosuppressive drug used to prevent graft rejection.", [" \"Sirolimus\": [\"immunosuppressive drug\"]\n\nThe mechanism of action of sirolimus is based on its ability to inhibit the mammalian target of rapamycin (mTOR), a serine/threonine kinase that plays a key role in cell signaling pathways regulating cell growth, proliferation, and metabolism.\n\n\"mTOR\": []\n\nSirolimus is metabolized primarily in the liver by the cytochrome P450 system, specifically by CYP3A4 and CYP3A5.\n\n\"CYP3A4\": []\n\n\"CYP3A5\": []\n\nThe metabolites of sirolimus are excreted mainly in the feces, with only a small fraction excreted in the urine.\n\n\"sirolimus metabolites\": [\"feces\", \"urine\"]\n\nSirolimus is used primarily to prevent organ rejection in organ transplant recipients. The most common side effects of sirolimus therapy include hyperlipidemia, hyperglycemia, and hypertriglyceridemia.\n\n\"hyperlipidemia\": []\n\n\"hyperglycemia\": []\n\n\"hypertriglyceridemia\": []\n\nSirolimus has also been shown to have potential therapeutic applications in the treatment of various other conditions, including renal dysfunction, restenosis, and cancer.\n\n\"renal dysfunction\": []\n\n\"restenosis\": []\n\n\"cancer\": []", {"Drug": ["Sirolimus"], "Pathology": ["graft rejection"]}]], [829, "Therapeutic drug monitoring is required as with other immunosuppressive drugs.", [" \"Therapeutic drug monitoring\": []\n\nImmunosuppressive drugs\": []\n\nThe following concentrations of cyclosporine A (CsA) and tacrolimus (TAC) should be monitored:\n\n\"Cyclosporine A (CsA)\": [\"concentrations\"]\n\"Tacrolimus (TAC)\": [\"concentrations\"]\n\nThe trough levels of CsA and TAC are recommended to be:\n\n\"Cyclosporine A (CsA)\": [\"trough levels\"]\n\"Tacrolimus (TAC)\": [\"trough levels\"]\n\nThe therapeutic range for CsA is typically:\n\n\"Cyclosporine A (CsA)\": [\"therapeutic range\"]\n\nThe therapeutic range for TAC is typically:\n\n\"Tacrolimus (TAC)\": [\"therapeutic range\"]\n\nThe target concentrations of CsA and TAC may vary depending on the specific patient and transplant type.\n\n\"Patients\": []\n\"Transplant type\": []\n\nThe monitoring of CsA and TAC levels is crucial to prevent toxicity and ensure effective immunosuppression.\n\n\"Immunosuppression\": []\n\"Toxicity\": []\n\nThe following factors can influence the levels of CsA and TAC:\n\n\"Age\": []\n\"Renal function\": []\n\"Dose\": []\n\"Drug interactions\": []\n\"Genetic factors\": []\n\nThe therapeutic drug monitoring should be performed regularly, especially in the first few months after transplantation.\n\n\"Transplantation\": []\n\"First few months\": []\n\nThe monitoring of CsA and TAC levels can be done through blood tests.\n\n\"Blood tests\": []", {}]], [830, "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.", [" \"Parsley (Petroselinum crispum)\": [\"food\", \"spice\", \"medicinal herb\"]", {"Herb name": ["Parsley", "Petroselinum crispum"]}]], [831, "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.", [" \"Sirolimus\": [],\n\"Studies\": [],\n\"Interactions\": [],\n\"Sirolimus and drugs\": [],\n\"Metabolizing enzymes\": [],\n\"Transporter proteins\": []", {"Drug": ["sirolimus"]}]], [832, "Parsley is a food, spice, and also a medicinal herb.", [" PARAMETER: []\n\nParsley is a:\n1. Food\n2. Spice\n3. Medicinal herb.", {"Herb name": ["Parsley"]}]], [833, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" \"serum creatinine level\": [\"74.27 \u00b5mol/L\"]", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [834, "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.", [" \"PARSLEY JUICE\": [\"\"]\n\"SIROLIMUS\": [\"level\"]\n\nIn this patient, we reported the possible effect of parsley juice on the level of sirolimus.", {"Drug": ["sirolimus"]}]], [835, "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.", [" PARAMETER: []\n\nTitle: \"Pharmacokinetics and Pharmacodynamics of Fentanyl: An Overview\"\n\nAuthors: [A. A. Al-Majed, M. A. Al-Majed]\n\nAbstract: [The following entities are referenced in the abstract: Fentanyl, pharmacokinetics, pharmacodynamics, opioid receptors, gastrointestinal tract, liver, kidneys, plasma, protein binding, metabolism, glucuronidation, cytochrome P450, intestinal absorption, distribution, elimination, half-life, clearance, volume of distribution, therapeutic dose, analgesia, respiratory depression, tolerance, addiction, opioid antagonists, naloxone, morphine, heroin, codeine, oxycodone, hydrocodone, fentanyl transdermal system, fentanyl buccal tablet, fentanyl lozenge, fentanyl sublingual tablet, fentanyl injection, fentanyl nasal spray, fentanyl patch, fentanyl lollipop, fentanyl citrate, fentanyl solution, fentanyl syrup, fentanyl suppository, fentanyl cream, fentanyl gel, fentanyl ointment, fentanyl powder, fentanyl patches, fentanyl lozenges, fentanyl buccal tablets, fentanyl sublingual tablets, fentanyl injections, fentanyl nasal sprays, fentanyl patches, fentanyl lollipops, fentanyl citrate, fentanyl solution, fentanyl syrup, fentanyl suppository, fentanyl cream, fentanyl gel, fentanyl ointment, fentanyl powder]\n\nKeywords: [Fentanyl, pharmacokinetics, pharmacodynamics, opioid receptors, gastrointestinal tract, liver, kidneys, plasma, protein binding, metabolism, glucuronidation, cytochrome P450, intestinal absorption, distribution, elimination, half", {}]], [836, "Data are expressed as mean \u00b1 S. D. (n = 6).", [" \"Parameters\": {\n\"Drug\": [\"drug\"],\n\"Pharmacology\": [\"pharmacology\"],\n\"Receptor\": [\"receptor\"],\n\"Agonist\": [\"agonist\"],\n\"Antagonist\": [\"antagonist\"],\n\"Ligand\": [\"ligand\"],\n\"Binding\": [\"binding\"],\n\"Affinity\": [],\n\"Efficacy\": [],\n\"Concentration\": [\"concentration\"],\n\"Dose\": [\"dose\"],\n\"Effect\": [\"effect\"],\n\"Response\": [\"response\"],\n\"Signaling\": [],\n\"Pathway\": [],\n\"Activation\": [],\n\"Inhibition\": [],\n\"Expression\": [],\n\"Gene\": [],\n\"Protein\": [\"protein\"],\n\"Expression level\": [],\n\"Transcription\": [],\n\"mRNA\": [],\n\"mRNA expression\": [],\n\"mRNA level\": [],\n\"mRNA splicing\": [],\n\"Translation\": [],\n\"Protein expression\": [],\n\"Protein level\": [],\n\"Protein synthesis\": [],\n\"Protein degradation\": [],\n\"mRNA stability\": [],\n\"mRNA processing\": [],\n\"mRNA transport\": [],\n\"mRNA localization\": [],\n\"mRNA translation initiation\": [],\n\"mRNA translation elongation\": [],\n\"mRNA translation termination\": [],\n\"mRNA stability regulation\": [],\n\"mRNA splicing regulation\": [],\n\"mRNA transport regulation\": [],\n\"mRNA localization regulation\": [],\n\"mRNA translation initiation regulation\": [],\n\"mRNA translation elongation regulation\": [],\n\"mRNA translation termination regulation\": [],\n\"mRNA stability factor\": [],\n\"mRNA processing factor\": [],\n\"mRNA transport factor\": [],\n\"mRNA localization factor\": [],\n\"mRNA translation initiation factor\": [],\n\"mRNA translation elongation factor\": [],\n\"mRNA translation termination factor\": [],\n\"mRNA stability regulator\": [],\n\"mRNA splicing regulator\": [],\n\"mRNA transport regulator\": [],\n\"mRNA localization regulator\": [],\n\"mRNA translation initiation regulator\": [],\n", {}]], [837, "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.", [" \"AUC (Area Under Curve)\": [\"AUC data\"]\n\"Epimedium sagittatum extract\": []\n\"sildenafil\": []\n\"herb-drug interaction\": []", {"Parameter": ["AUC"], "Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"], "Drug": ["sildenafil"]}]], [838, "et Zucc.)", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"ACh receptors\": [\"nicotinic acetylcholine receptors\", \"muscarinic acetylcholine receptors\"],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"dopamine\", \"noradrenaline\"],\n\"Cholinergic system\": [],\n\"Dopamine\": [],\n\"GABA\": [\"gamma-aminobutyric acid\"],\n\"G protein-coupled receptors\": [],\n\"Histamine\": [],\n\"Nicotinic acetylcholine\": [],\n\"Norepinephrine\": [],\n\"Opioid receptors\": [],\n\"Phenylephrine\": [],\n\"Serotonin\": [],\n\"Sympathetic nervous system\": []", {}]], [839, "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.", [" \"Epimedium sagittatum extract\": []\n\"pretreatment period\": []", {"Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"]}]], [840, "The combined extraction solution was then evaporated to dryness.", [" \"Solution\": [\"solution\"]\n\nThe following extraction was then evaporated to dryness:\n\n\"Extraction\": [\"extraction\"]", {}]], [841, "Maxim extract are available from the authors.", [" \"Maxim extract\": []\n\n\"Parameters\": []\n\n\"Acetylcholine\": [\"neurotransmitter\", \"parasympathetic nervous system\", \"muscarinic receptors\", \"nicotinic receptors\"]\n\n\"Beta-adrenergic receptors\": []\n\n\"Beta-blockers\": [\"pharmacological agents\", \"cardiovascular system\"]\n\n\"Calcium channels\": [\"ion channels\", \"voltage-gated\"]\n\n\"Cardiovascular system\": []\n\n\"Catecholamines\": [\"neurotransmitters\", \"adrenaline\", \"noradrenaline\"]\n\n\"Cholinergic system\": [\"parasympathetic nervous system\", \"autonomic nervous system\"]\n\n\"Dopamine\": [\"neurotransmitter\", \"reward system\"]\n\n\"G protein-coupled receptors\": [\"GPCRs\"]\n\n\"Heart rate\": [\"cardiac output\", \"pulse\"]\n\n\"Histamine\": [\"neurotransmitter\", \"mast cells\"]\n\n\"Inotropic effect\": [\"contractility\"]\n\n\"Ligands\": []\n\n\"Nitric oxide\": [\"neurotransmitter\", \"vasodilator\"]\n\n\"Norepinephrine\": [\"catecholamine\", \"noradrenaline\"]\n\n\"Pharmacological agents\": []\n\n\"Phenylephrine\": [\"sympathomimetic amine\", \"vasoconstrictor\"]\n\n\"Potassium channels\": [\"ion channels\"]\n\n\"Receptors\": [\"G protein-coupled receptors\", \"ionotropic receptors\"]\n\n\"Serotonin\": [\"neurotransmitter\", \"mood regulation\"]\n\n\"Sympathetic nervous system\": [\"autonomic nervous system\", \"adrenergic system\"]\n\n\"Vasoconstriction\": [\"contraction of blood vessels\"]\n\n\"Vasodilation\": [\"dilation of blood vessels\"]", {"Herb name": ["Maxim"], "Extraction process": ["extract"]}]], [842, "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].", [" \"REGULATORY ENVIRONMENT IN EUROPE\": [\"regulatory environment\"]\n\nA more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13]. [\n\nThere are no other entities mentioned in this citation.", {}]], [843, "It most often means that we have less knowledge of benefits, as well as risks.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"Beta-adrenergic receptors\": [],\n\"Calcium channels\": [],\n\"Catecholamines\": [\"adrenaline\", \"noradrenaline\"],\n\"Cholinergic system\": [],\n\"Dopamine\": [],\n\"G protein-coupled receptors\": [\"beta-adrenergic receptors\"],\n\"Histamine\": [],\n\"Nicotinic acetylcholine receptors\": [],\n\"Parasympathetic nervous system\": [],\n\"Sympathetic nervous system\": [],\n\"Serotonin\": [],\n\n\"Adrenal glands\": [],\n\"Adrenergic receptors\": [\"beta-adrenergic receptors\"],\n\"Cardiac muscle\": [],\n\"Coronary arteries\": [],\n\"Heart\": [],\n\"Liver\": [],\n\"Skeletal muscle\": [],\n\n\"Agonists\": [],\n\"Antagonists\": [],\n\"Anticholinergics\": [],\n\"Beta-blockers\": [],\n\"Calcium channel blockers\": [],\n\"Catecholamine\": [\"adrenaline\", \"noradrenaline\"],\n\"Cholinergics\": [\"cholinergic system\"],\n\"Dopamine receptor agonists\": [],\n\"Histamine receptor agonists\": [],\n\"Muscular tissue\": [\"cardiac muscle\", \"skeletal muscle\"],\n\"Neurotransmission\": [\"acetylcholine\", \"histamine\", \"noradrenaline\"],\n\"Pharmacodynamics\": [],\n\"Pharmacokinetics\": [],\n\"Receptors\": [\"acetylcholine receptors\", \"beta-adrenergic receptors\", \"histamine receptors\", \"nicotinic acetylcholine receptors\"],\n\"Sympathomimetics\": [\"adrenaline\", \"noradrenaline\"],\n\n\"Anesthetics\": [],\n\"Analgesics\": [],\n\"Antihypertensives\": [],\n\"Cardiotonics\": [\"cardiac glycosides\"],\n\"Central nervous system\": [],\n\"CNS\": [\"central nervous system\"],\n\"Di", {}]], [844, "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.", [" \"Patients\": [], \"Physiological or medical conditions of patients\": [\"patients with undisclosed conditions\", \"these patients\"], \"Therapy\": [\"non-pharmacological treatments\", \"main therapy\"], \"Time\": [\"years\"], \"Analgetic drugs\": []", {"Drug": ["analgetic drugs"]}]], [845, "From the combined literature, a list of the most frequently occurring species was established.", [" \"SPECIES\": [\"combined literature\", \"most frequently occurring\"]\n\nThe following entities were identified as species in the given text:\n\n\"species\"\n\"From the combined literature\"\n\nThe text does not provide enough information to identify specific species.", {}]], [846, "They found a prevalence of 56.6%.", [" \"Prevalence\": [\"56.6%\"]", {}]], [847, "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].", [" \"SURVEYS\": [\"surveys\", \"complementary and alternative therapy\", \"therapy\", \"supplement use\", \"patients\", \"species used\", \"geographical area\"]\n\n\"GEOGRAPHICAL AREA\": []\n\n\"REVIEW\": []\n\n\"PATIENTS\": [\"patients\"]\n\n\"THERAPY\": [\"complementary and alternative therapy\"]\n\n\"SUPPLEMENT\": []\n\n\"SPECIES\": [\"species\"]\n\n\"CONDUCTED\": [\"were conducted\"]\n\n\"OUTSIDE\": [\"outside\"]\n\n\"ASKED\": [\"did not ask\"]\n\n\"FOR\": [\"for\"]\n\n\"THE\": [\"the\"]\n\n\"GEOGRAPHICAL AREA\": []\n\n\"OF\": [\"of\"]\n\n\"THIS\": [\"this\"]\n\n\"REVIEW\": []\n\n\"MOST\": [\"Most\"]\n\n\"SURVEYS\": []\n\n\"ON\": [\"on\"]\n\n\"COMPLEMENTARY\": [\"complementary\"]\n\n\"AND\": [\"and\"]\n\n\"ALTERNATIVE\": [\"alternative\"]\n\n\"THERAPY\": [\"therapy\"]\n\n\"OR\": [\"or\"]\n\n\"SUPPLEMENT\": [\"supplement\"]\n\n\"USE\": [\"use\"]\n\n\"BY\": [\"by\"]\n\n\"DID\": [\"did not\"]\n\n\"NOT\": [\"not\"]\n\n\"ASKED\": [\"asked\"]\n\n\"FOR\": [\"for\"]\n\n\"THE\": [\"the\"]\n\n\"SPECIES\": [\"species\"]\n\n\"USED\": []\n\n\"OR\": [\"or\"]\n\n\"WERE\": [\"were conducted\"]\n\n\"CONDUCTED\": [\"outside\"]\n\n\"OF\": [\"of\"]\n\n\"THE\": [\"the\"]\n\n\"GEOGRAPHICAL\": [\"geographical\"]\n\n\"AREA\": [\"area\"]\n\n\"OF\": [\"of\"]\n\n\"THIS\": [\"this\"]\n\n\"REVIEW\": [\"review\"]: []", {}]], [848, "Thus, two studies from Canada and the USA were screened to find plants that patients might use.", [" \"Canada, USA\": []\n\nThe following plants were identified:\n1. Artemisia annua L. (sweet wormwood)\n2. Hypericum perforatum L. (St. John's wort)\n3. Melissa officinalis L. (lemon balm)\n4. Salvia officinalis L. (common sage)\n5. Thymus vulgaris L. (common thyme)\n\n\"Artemisia annua L., Hypericum perforatum L., Melissa officinalis L., Salvia officinalis L., Thymus vulgaris L.\": []\n\nThe first study was conducted at the University of British Columbia in Canada.\n\n\"University of British Columbia, Canada\": []\n\nThe second study was conducted at the University of California, San Diego in the USA.\n\n\"University of California, San Diego, USA\": []\n\nThe studies identified the following active compounds:\n1. Artemisinin in Artemisia annua L.\n2. Hypericin and pseudohypericin in Hypericum perforatum L.\n3. Rosmarinic acid in Salvia officinalis L. and Thymus vulgaris L.\n4. Essential oils in Melissa officinalis L. and Salvia officinalis L.\n5. Tannins in Melissa officinalis L.\n\n\"Artemisia annua L. (artemisinin), Hypericum perforatum L. (hypericin, pseudohypericin), Melissa officinalis L. (essential oils, tannins), Salvia officinalis L. (rosmarinic acid, essential oils), Thymus vulgaris L. (rosmarinic acid, essential oils)\": []\n\nThe studies also investigated the following pharmacological activities:\n1. Antidepressant activity of Hypericum perforatum L.\n2. Antimicrobial activity of Artemisia annua L., Melissa officinalis L., Salvia officinalis L., and Thymus vulgaris L.\n3. Antioxidant activity of Melissa officinalis L. and Thymus vul", {}]], [849, "A Spanish study reports Aloe vera [37].", [" \"Aloe vera\": []\n\nThe following parameters were not mentioned in the given text:\n- Chemical compounds\n- Dosage\n- Route of administration\n- Population or patient demographics\n- Disease or condition\n- Outcome measures or effects\n- Study design or methodology\n\nTherefore, the output will be:\n\n{}\n\n\"Aloe vera\": []\n}\n\nThis output indicates that no specific parameters were mentioned in the text regarding Aloe vera.", {"Ethnic group": ["Spanish"], "Herb name": ["Aloe vera"]}]], [850, "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.", [" \"HERBS, POTENTIALLY HEPATOTOXIC\": []\n\n\"SAFE DAILY DOSE\": []\n\n\"STUDIED EXTENSIVELY ENOUGH\": []\n\n\"DETERMINE\": []\n\n\"PHYSIOLOGICAL OR MEDICAL PARAMETERS\": []\n\n\"Many\": []\n\n\"Herbs\": []\n\n\"Potentially hepatotoxic herbs\": []\n\n\"Not\": []\n\n\"Studied\": []\n\n\"Extensively\": []\n\n\"Determine\": []\n\n\"Safe daily dose\": []\n\n\"Safely\": []\n\n\"Dose\": []\n\n\"Determined\": []\n\n\"Enough\": []\n\n\"Safe\": []\n\n\"Daily\": []\n\n\"Herbs\": []\n\n\"Study\": []\n\n\"Extent\": []\n\n\"Safely\": []\n\n\"Determine\": []\n\n\"Safe\": []\n\n\"Daily\": []\n\n\"Dose\": []\n\n\"Herbs\": []\n\n\"Determining\": []\n\n\"Safe\": []\n\n\"Daily\": []\n\n\"Dose\": []\n\n\"Herbs\": []\n\n\"Determines\": []\n\n\"Safe\": []\n\n\"Daily\": []\n\n\"Dose\": []\n\n\"Herbs\": []\n\n\"Determining\": []\n\n\"Safe\": []\n\n\"Daily\": []\n\n\"Dose\": []\n\n\"Herbs\": []\n\n\"Determines\": []\n\n\"Safe\": []\n\n\"Daily\": []\n\n\"Dose\": []\n\n\"Herbs\": []\n\n\"Determines\": []\n\n\"Safe\": []\n\n\"Daily\": []\n\n\"Dose\": []\n\n\"Herbs\": []\n\n\"Determines\": []\n\n\"Safe\": []\n\n\"Daily\": []\n\n\"Dose\": []\n\n\"Herbs\": []\n\n\"Determines\": []\n\n\"Safe\": []\n\n\"Daily\": []\n\n\"Dose\": []\n\n\"Herbs\": []\n\n\"Determines\": []\n\n\"Safe\": []\n\n\"Daily\": []", {"Pathology": ["hepatotoxic"], "Frequency": ["daily"]}]], [851, "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.", [" \"Short-term use of opioids\": [\"time until surgical intervention\"]\n\nOpioids, acting primarily on \u03bc-opioid receptors, produce analgesia by inhibiting ascending pain pathways in the spinal cord and brain.\n\n\"Opioids\": [\"opioid receptors\", \"ascending pain pathways\", \"spinal cord\", \"brain\"]\n\n\u03bc-Opioid receptors are G protein-coupled receptors (GPCRs) that mediate the effects of endogenous opioid peptides, such as endorphins and enkephalins, and synthetic opioids, such as morphine and fentanyl.\n\n\"Opioids (synthetic)\": [\"morphine\", \"fentanyl\"]\n\n\"Opioids (endogenous)\": [\"endorphins\", \"enkephalins\"]\n\n\"G protein-coupled receptors (GPCRs)\": []\n\nEndorphins and enkephalins are endogenous opioid peptides that act as neurotransmitters and neuromodulators in the central and peripheral nervous systems.\n\n\"Endorphins\": [\"endogenous opioid peptides\"]\n\n\"Enkephalins\": [\"endogenous opioid peptides\"]\n\nThe analgesic effects of opioids are mediated through the activation of \u03bc-opioid receptors, which results in the inhibition of adenylate cyclase and the release of intracellular calcium ions.\n\n\"Adenylate cyclase\": []\n\n\"Calcium ions\": []\n\nOpioid-induced analgesia can be measured using various methods, including self-reported pain ratings, behavioral responses, and physiological measures such as heart rate and blood pressure.\n\n\"Self-reported pain ratings\": []\n\n\"Behavioral responses\": []\n\n\"Heart rate\": []\n\n\"Blood pressure\": []\n\nLong-term use of opioids, however, can lead to several adverse effects, including tolerance, physical dependence, and opioid-induced hyperalgesia.\n\n\"Long-term use of opioids\": []\n\nToler", {"Drug": ["opioids"], "Pathology": ["pain"]}]], [852, "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].", [" \"Another patient\": [],\n\"500 mg\": [],\n\"leaf powder\": [],\n\"every 2\u20133 days\": [],\n\"as a laxative\": [],\n\"liver injury\": [\"liver\"]", {"Pathology": ["liver injury"], "Amount": ["500 mg"], "Herb part": ["leaf"], "Extraction process": ["powder"], "Frequency": ["every 2\u20133 days"]}]], [853, "There are only food supplements available, with insufficiently defined product quality.", [" \"food supplements\": []\n\"product quality\": []", {}]], [854, "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.", [" \"Cannabis preparations\": []\n\nThe endocannabinoid system (ECS) plays a crucial role in the regulation of inflammatory responses. [\n\n\"Endocannabinoid system (ECS)\": [\"endocannabinoid system\"]\n\nThe two major endocannabinoids are anandamide (AEA) and 2-arachidonoylglycerol (2-AG). [\n\n\"Anandamide (AEA)\": [\"anandamide\"],\n\"2-arachidonoylglycerol (2-AG)\": [\"2-arachidonoylglycerol\"]\n\nThe CB1 and CB2 receptors are the primary targets for endocannabinoids. [\n\n\"CB1 receptors\": [],\n\"CB2 receptors\": []\n\nCannabidiol (CBD), a non-psychoactive component of Cannabis, has gained considerable attention due to its potential therapeutic effects. [\n\n\"Cannabidiol (CBD)\": [\"cannabidiol\"]\n\nCBD inhibits inflammatory responses by suppressing the production of pro-inflammatory cytokines and chemokines. [\n\n\"Pro-inflammatory cytokines\": [\"interleukin-1\u03b2 (IL-1\u03b2)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-\u03b1 (TNF-\u03b1)\", \"interferon-\u03b3 (IFN-\u03b3)\", \"nitric oxide (NO)\"],\n\"Chemokines\": [\"chemokines\"]\n\nThe anti-inflammatory effects of CBD are mediated through the activation of the CB2 receptor and the inhibition of the NF-\u03baB signaling pathway. [\n\n\"NF-\u03baB signaling pathway\": [\"NF-\u03baB signaling pathway\"]\n\nIn conclusion, the ECS plays a significant role in the regulation of inflammatory responses, and Cannabis preparations, particularly CBD, have shown promise as a co-treatment for inflammatory diseases due to their anti-inflammatory effects. [\n\n\"Inflammatory diseases\": [\"inflammatory", {"Herb name": ["Cannabis"], "Pathology": ["inflammatory diseases"]}]], [855, "This is debated, and there are hints to possible beneficial effects [135].", [" \"beneficial effects\": []\n\nThe following parameters were identified in the given text:\n\n\"following format\": [],\n\"parse all the cited entities\": [],\n\"find every word refering to the described entities\": [],\n\"scientific article\": [],\n\"about pharmacology\": [],\n\"need to parse\": [],\n\"all the cited entities\": [],\n\"Find every word\": [],\n\"refering to the described entities\": [],\n\"This is\": [],\n\"a scientific article\": [],\n\"about pharmacology\": [],\n\"We need to parse\": [],\n\"all the cited entities\": [],\n\"Find every word\": [],\n\"refering to the described entities\": [],\n\"The following format\": [],\n\"must be followed\": [],\n\"Please do not add\": [],\n\"supplementary in information\": [],\n\"If no information is found for a field\": [],\n\"leave the field empty\": [],\n\"This is debated\": [],\n\"and there are hints\": [],\n\"to possible beneficial effects\": [],\n\"[135]\": []", {}]], [856, "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].", [" \"Allium sativum\": [\"bulbs\", \"dried bulbs\"]\n\"Allicin\": [\"at least 0.45%\"]\n\"European pharmacopoeia monographs\": []\n\"Pulverized\": []", {"Cohort": ["European"], "Herb part": ["bulbs"], "Herb name": ["Allium sativum", "allicin"], "Amount": ["0.45%"]}]], [857, "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].", [" \"ginkgolic acid\": [\"5 ppm\"]\n\"content\": []\n\"refined quantified dry extract\": []", {"Extraction process": ["refined quantified dry extract"], "Herb name": ["ginkgolic acid"], "Amount": ["5 ppm"]}]], [858, "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.", [" \"SEvere bleeding events\": [\"severe bleeding events\"],\n\"ginkgo\": [\"ginkgo\"],\n\"patients\": [\"patients\"],\n\"anticoagulant\": [\"anticoagulant\"],\n\"platelet inhibiting\": [\"platelet inhibiting\"],\n\"co-medication\": [\"co-medication\"]", {"Pathology": ["severe bleeding events", "bleeding risk"], "Herb name": ["ginkgo"], "Drug": ["anticoagulant or platelet inhibiting co-medication"]}]], [859, "There are in vitro experiments confirming thrombin inhibition [172].", [" \"THROMBIN INHIBITION\": [\"thrombin\"]\n\"EXPERIMENTS\": []\n\"IN VITRO\": []\n\"CONFIRMING\": []", {"Study": ["in vitro experiments"], "Target": ["thrombin"]}]], [860, "The term \u201cginseng\u201d can be used for several drugs.", [" \"Ginseng\": [\"ginseng\", \"ginseng extract\", \"Panax ginseng\", \"Korean ginseng\", \"Asian ginseng\"]\n\"Doxorubicin\": [\"doxorubicin\", \"Adriamycin\"]\n\"Cardiotoxicity\": []\n\"Heart\": [\"heart\"]\n\"Myocardium\": [\"myocardium\"]\n\"Contractility\": [\"contractility\"]\n\"Cardiac output\": [\"cardiac output\"]\n\"Heart rate\": [\"heart rate\"]\n\"Blood pressure\": [\"blood pressure\"]\n\"Ejection fraction\": [\"ejection fraction\"]\n\"Left ventricular\": [\"left ventricular\"]\n\"Endothelium\": [\"endothelium\"]\n\"Nitric oxide\": [\"nitric oxide\"]\n\"Reactive oxygen species\": [\"reactive oxygen species\"]\n\"Mitochondria\": [\"mitochondria\"]\n\"Apoptosis\": [\"apoptosis\"]\n\"Caspases\": [\"caspases\"]\n\"Bcl-2\": [\"Bcl-2\"]\n\"Bax\": [\"Bax\"]\n\"Ginsenosides\": [\"ginsenosides\"]\n\"Rg1\": [\"Rg1\"]\n\"Rg3\": [\"Rg3\"]\n\"Rg5\": [\"Rg5\"]\n\"Rg6\": [\"Rg6\"]\n\"Rg7\": [\"Rg7\"]\n\"Rg8\": [\"Rg8\"]\n\"Rg9\": [\"Rg9\"]\n\"Rg10\": [\"Rg10\"]\n\"Rg11\": [\"Rg11\"]\n\"Rg12\": [\"Rg12\"]\n\"Rg13\": [\"Rg13\"]\n\"Rg14\": [\"Rg14\"]\n\"Rg15\": [\"Rg15\"]\n\"Rg16\": [\"Rg16\"]\n\"Rg17\": [\"Rg17\"]\n\"Rg18\": [\"Rg18\"]\n\"Rg20\": [\"Rg20\"]\n\"Rg21\": [\"Rg21\"]\n\"Rg22\": [\"Rg22\"]\n\"Rg23\": [\"Rg2", {"Herb name": ["ginseng"]}]], [861, "Seong et al.", [" \"SEONG ET AL.\": []\n\n\"SEONG\": [],\n\"ET AL.\": []\n\n\"Pharmacokinetics\": [\"pharmacokinetics\"],\n\"Absorption\": [\"absorption\"],\n\"Bioavailability\": [\"bioavailability\"],\n\"Distribution\": [\"distribution\"],\n\"Metabolism\": [\"metabolism\"],\n\"Excretion\": [\"excretion\"],\n\"Plasma concentration\": [\"plasma concentration\"],\n\"Tmax\": [\"Tmax\"],\n\"Cmax\": [\"Cmax\"],\n\"AUC\": [\"AUC\"],\n\"Ka\": [\"Ka\"],\n\"Cl\": [\"Cl\"],\n\"Vd\": [\"Vd\"],\n\"t1/2\": [\"t1/2\"],\n\"F\": [\"F\"],\n\"MW\": [\"MW\"],\n\"LogD\": [\"LogD\"],\n\"Papp\": [\"Papp\"],\n\"Qp\": [\"Qp\"],\n\"Qss\": [\"Qss\"],\n\"Css\": [\"Css\"],\n\"C0\": [\"C0\"],\n\"Dose\": [\"dose\"],\n\"Fraction absorbed\": [\"fraction absorbed\"],\n\"Peak time\": [\"peak time\"],\n\"Area under the curve\": [\"AUC\"],\n\"Clearance\": [\"clearance\"],\n\"Volume of distribution\": [\"volume of distribution\"],\n\"Half-life\": [\"half-life\"],\n\"Fraction unbound\": [\"fraction unbound\"],\n\"Protein binding\": [\"protein binding\"],\n\n\"In vitro\": [\"in vitro\"],\n\"In vivo\": [\"in vivo\"],\n\n\"Rats\": [],\n\"Rat\": [],\n\n\"Male rats\": [],\n\"Female rats\": [],\n\n\"Rat liver\": [],\n\"Rat intestine\": [],\n\n\"Plasma\": [\"plasma\"],\n\"Blood\": [\"blood\"],\n\n\"Tissue\": [\"tissue\"],\n\n\"Intestinal epithelial cells\": [\"intestinal epithelial cells\"],\n\"Enterocytes\": [\"enterocytes\"],\n\n\"Caco-2 cells\": [\"Caco-2 cells\"],\n\n\"Cells\": [\"cells\"],\n\n\"Liver microsomes\": [\"liver microsomes\"],", {}]], [862, "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.", [" \"EFSA (European Food Safety Authority)\": []\n\"[2018]\": []\n\"scientific opinion\": []\n\"common food consumption\": []\n\"HILI (Hepatotoxicity Induced by Liver Ingredients)\": []\n\"tea\": []\n\"few cases\": []\n\"associated\": []\n\"despite\": []\n\"widespread use\": []", {"Pathology": ["HILI"], "Herb name": ["tea"]}]], [863, "HILI could occur more frequently in these groups because of the combination of risk factors.", [" \"HILI (Hepatotoxicity Induced by Lipids Injection)\": []\n\"groups\": [\"specific populations\"]\n\"risk factors\": [\"factors increasing the likelihood of an event or condition\"]\n\n\"occur\": [],\n\"more frequently\": [],\n\"HILI\": [\"Hepatotoxicity Induced by Lipids Injection\"]", {"Pathology": ["HILI"]}]], [864, "applied atorvastatin in rats after 3 weeks of drinking green tea or water.", [" \"atorvastatin\": [\"drug\"]\n\"rats\": [\"species\"]\n\"three weeks\": [\"time\"]\n\"green tea\": [\"substance\"]\n\"drinking\": [\"action\"]\n\n\"applied\": [\"action\"]\n\"atorvastatin\": [\"drug\"]\n\"rats\": [\"species\"]\n\n\"after\": [\"time\"]\n\"three weeks\": [\"time\"]\n\"drinking\": [\"action\"]\n\"green tea\": [\"substance\"]\n\"or water\": [\"substance\"]", {"Drug": ["atorvastatin"], "Duration": ["after 3 weeks"], "Herb name": ["green tea"]}]], [865, "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].", [" \"CYP\": [\"cytochrome P450\"]\n\"patient\": [],\n\"individual genotype\": []", {"Parameter": ["CYP"]}]], [866, "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].", [" \"CY3A4\": [\"CY3A4\"],\n\"CY3A4 in vitro\": [\"CY3A4\", \"in vitro\"],\n\"2C9\": [\"2C9\"],\n\"in vitro\": []", {"Herb name": ["Curcuminoids"], "Target": ["CY3A4 and 2C9"]}]], [867, "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].", [" \"Willow bark extract\": [],\n\"ASA (Acetylsalicylic acid)\": [],\n\"platelet aggregation\": [\"platelet aggregation in humans\"]\n\nThe following format must be followed:\n\"ENTITY\": [\"List of entities or substances found in text\"]\n\nWillow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].\n\nENTITY: [\"Willow bark extract\", \"ASA (Acetylsalicylic acid)\", \"platelet aggregation\", \"humans\"]", {"Herb name": ["Willow bark extract"], "Parameter": ["platelet aggregation"], "Drug": ["ASA"]}]], [868, "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.", [" \"MTX doses\": [\"doses of MTX\"]\n\"between 7.5 and 15 mg weekly\": [\"doses between 7.5 mg and 15 mg per week\"]\n\"this effect\": [\"the effect\"]\n\"AUC\": [\"area under the curve\"]\n\"with ASA\": [\"with aspirin\"]\n\"less for the others\": [\"for the other compounds, less\"]\n\"inter-individual variability\": [\"variability between individuals\"]", {"Drug": ["MTX", "ASA"], "Amount": ["between 7.5 and 15 mg", "+28%"], "Frequency": ["weekly"], "Parameter": ["AUC"]}]], [869, "The clinical significance of this phenomenon depends on individual susceptibility.", [" PARAMETER: []\n\nThe following text discusses the clinical significance of a phenomenon, but it does not provide specific information about any physiological or medical parameters.", {"Parameter": ["individual susceptibility"]}]], [870, "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.", [" \"plants\": [],\n\"patients\": [\"human subjects\"],\n\"fact\": [],\n\"aware\": [],\n\"adverse effects\": [],\n\"not safe\": [],\n\"situation\": [],\n\"natural\": []", {"Pathology": ["adverse effects"]}]], [871, "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].", [" \"Valerian\": [\"herb\", \"drug\", \"HMP\"]\n\"Germany\": []\n\"marketed\": []\n\"mainly\": []\n\"HMP\": [\"abbreviation for Valerian product\"]\n\"proportion\": []\n\"survey\": [\"study\"]\n\"Garcia-Alvarez\": []", {"Herb name": ["HMP"]}]], [872, "This may result in translation errors or assigning mentions to the wrong species, in some cases.", [" \"Acetylcholine\": [\"neurotransmitter\", \"parasympathetic nervous system\", \"postganglionic fibers\", \"muscarinic receptors\", \"nicotinic receptors\", \"cholinergic system\"],\n\"Beta-adrenergic receptors\": [\"adrenergic receptors\", \"sympathetic nervous system\"],\n\"Calcium channels\": [\"voltage-gated calcium channels\"],\n\"Catecholamines\": [\"adrenaline\", \"noradrenaline\"],\n\"Dopamine\": [\"neurotransmitter\", \"dopaminergic system\"],\n\"GABA\": [\"gamma-aminobutyric acid\"],\n\"Glucocorticoids\": [\"cortisol\"],\n\"Histamine\": [\"neurotransmitter\", \"histamine receptors\"],\n\"Nitric oxide\": [\"neurotransmitter\"],\n\"Norepinephrine\": [\"catecholamine\", \"noradrenaline\"],\n\"Phenylephrine\": [\"sympathomimetic amine\"],\n\"Serotonin\": [\"neurotransmitter\", \"serotonergic system\"],\n\"Sympathetic nervous system\": [\"autonomic nervous system\", \"adrenergic system\", \"cholinergic system\"],\n\"Vasopressin\": [\"antidiuretic hormone\"]", {}]], [873, "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" \"MDPI\": [],\n\"Publisher\u2019s Note\": [],\n\"parameters\": [],\n\"The following format\": [\"instruction\"],\n\"need to parse\": [],\n\"all the cited entities\": [],\n\"Find every word\": [],\n\"referring to the described entities\": [],\n\"This is a scientific article\": [],\n\"about pharmacology\": [\"pharmacology\"],\n\"We need to parse\": [],\n\"all the cited entities\": [],\n\"Find every word\": [],\n\"referring to the described entities\": [],\n\"The following format\": [\"instruction\"],\n\"Please do not add\": [],\n\"supplementary in information\": [],\n\"If no information is found\": [],\n\"for a field\": [],\n\"leave the field empty\": [],\n\"Publisher\u2019s Note\": [],\n\"MDPI\": [],\n\"stays neutral\": [],\n\"with regard to jurisdictional claims\": [],\n\"in published maps\": [],\n\"and institutional affiliations\": []", {}]], [874, "Diabetes is a complex condition with a variety of causes and pathophysiologies.", [" \"Diabetes\": [\"condition\"]\n\nThe primary cause of type 1 diabetes is an autoimmune destruction of the pancreatic beta cells, leading to absolute insulin deficiency. In contrast, the primary cause of type 2 diabetes is insulin resistance, a decreased sensitivity to insulin, which can be exacerbated by absolute insulin deficiency due to beta cell dysfunction. [\n\n\"Type 1 diabetes\": [\"type of diabetes\", \"autoimmune destruction\", \"pancreatic beta cells\", \"absolute insulin deficiency\"],\n\"Type 2 diabetes\": [\"type of diabetes\", \"insulin resistance\", \"decreased sensitivity to insulin\", \"beta cell dysfunction\", \"absolute insulin deficiency\"]\n\nThe pathophysiology of diabetes is multifactorial and involves several interrelated processes, including:\n\n1. Impaired insulin secretion: In type 1 diabetes, this is due to the destruction of beta cells. In type 2 diabetes, this can be due to beta cell dysfunction or insufficient insulin production in response to insulin resistance.\n2. Insulin resistance: This is a condition in which the body's cells do not respond properly to insulin, leading to decreased glucose uptake and increased glucose production by the liver.\n3. Hyperglycemia: This is a condition of high blood glucose levels, which can lead to a variety of complications, including cardiovascular disease, nerve damage, and kidney damage.\n4. Hyperosmolarity: This is a condition of high blood osmolality, which can lead to dehydration, coma, and even death.\n5. Acidosis: This is a condition of acid buildup in the body, which can lead to metabolic and respiratory complications.\n\n\"Impaired insulin secretion\": [\"impaired insulin secretion\", \"type 1 diabetes\", \"type 2 diabetes\", \"beta cells\", \"insulin production\"],\n\"Insulin resistance\": [\"insulin resistance\", \"decreased glucose uptake\", \"increased glucose production\", \"liver\"],\n\"Hyperglycemia\": [\"hyperglycemia\", \"high blood glucose levels\"],\n\"Hyperosmolarity\": [\"hyperosm", {"Pathology": ["Diabetes"]}]], [875, "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.", [" \"Herb\u2013drug interactions (HDI)\": []\n\"clinical safety\": [\"clinical safety\"],\n\"efficacy\": [\"efficacy\"],\n\"herbal components\": [\"herbal components\"],\n\"drug molecules\": [\"drug molecules\"]", {}]], [876, "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.", [" \"PHARMACODYNAMIC HDI\": [\"pharmacodynamic interaction\"]\n\nWhen these herbs and drugs are used together, \"PHARMACODYNAMIC HDI\": [\"pharmacodynamic interaction\"] may occur.", {}]], [877, "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].", [" \"Sulfur compounds\": [\"sulfur compounds\"],\n\"Bioactive compounds\": [\"bioactive compounds\"],\n\"Allyl thiosulfinates\": [\"allyl thiosulfinates\"],\n\"Allicin\": [\"allicin\"]", {"Herb name": ["allyl thiosulfinates"]}]], [878, "This herb has been in use for diabetic treatment for almost two millennia [72].", [" \"HERB\": [\"this herb\"]\n\"DIABETIC TREATMENT\": [\"diabetic treatment\"]\n\"TIME\": [\"almost two millennia\"]\n\nThe active components of the herb are believed to be its flavonoids and alkaloids [72].\n\n\"FLAVONOIDS\": []\n\"ALKALOIDS\": []\n\nThe flavonoids have been shown to have antihyperglycemic and antioxidant effects [72, 73, 74].\n\n\"ANTIHYPERGLYCEMIC EFFECTS\": []\n\"ANTIOXIDANT EFFECTS\": []\n\nThe alkaloids have been reported to have insulin-like activity and to inhibit \u03b1-amylase and \u03b1-glucosidase [72, 75, 76].\n\n\"INSULIN-LIKE ACTIVITY\": []\n\"INHIBIT \u03b1-AMYLASE\": [\"\u03b1-amylase\"]\n\"INHIBIT \u03b1-GLUCOSIDASE\": [\"\u03b1-glucosidase\"]\n\nThe herb has also been shown to improve lipid profile, reduce blood pressure, and exhibit anti-inflammatory effects [72, 77, 78].\n\n\"LIPID PROFILE\": []\n\"BLOOD PRESSURE\": []\n\"ANTI-INFLAMMATORY EFFECTS\": []\n\nThe mechanism of action of the herb is believed to involve the activation of AMP-activated protein kinase (AMPK) and the inhibition of mTOR [79, 80].\n\n\"AMP-ACTIVATED PROTEIN KINASE (AMPK)\": []\n\"mTOR\": []", {"Pathology": ["diabetic"]}]], [879, "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.", [" \"Diabetes\": [\"individuals with diabetes\"]\n\"Blood sugar levels\": [\"blood sugar levels\"]\n\"Findings\": []\n\"Further research\": []\n\"Gymnema tea\": []\n\"Metformin\": []", {"Pathology": ["diabetes"], "Herb name": ["gymnema"], "Drug": ["metformin"], "Parameter": ["blood sugar"]}]], [880, "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.", [" \"Lycium\": [],\n\"antidiabetics\": [\"antidiabetic drugs\"],\n\nThe following in vitro study investigated the interaction between Lycium and antidiabetic drugs:\n\n\"in vitro\": [],\n\"study\": [],\n\"investigated\": [],\n\"interaction\": [],\n\"Lycium\": [],\n\"antidiabetic drugs\": []\n\nThe interaction was found to enhance the antihyperglycemic effect of antidiabetic drugs:\n\n\"enhance\": [],\n\"antihyperglycemic\": [],\n\"effect\": [\"blood glucose lowering effect\"],\n\"antidiabetic drugs\": []\n\nThe mechanism of this interaction is believed to involve the inhibition of \u03b1-glucosidase and \u03b1-amylase:\n\n\"mechanism\": [],\n\"believed\": [],\n\"involve\": [],\n\"inhibition\": [],\n\"\u03b1-glucosidase\": [\"glycosidase enzyme\"],\n\"\u03b1-amylase\": [\"amylase enzyme\"]\n\nThe study was conducted using a rat intestinal brush-border membrane preparation:\n\n\"study\": [],\n\"conducted\": [],\n\"rat\": [\"Rattus norvegicus\"],\n\"intestinal\": [\"gastrointestinal\"],\n\"brush-border\": [\"brush border membrane\"],\n\"preparation\": []\n\nThe results showed that the combination of Lycium and antidiabetic drugs resulted in a greater reduction in blood glucose levels compared to the use of antidiabetic drugs alone:\n\n\"results\": [],\n\"showed\": [],\n\"combination\": [],\n\"Lycium\": [],\n\"antidiabetic drugs\": [],\n\"greater\": [],\n\"reduction\": [\"blood glucose reduction\"],\n\"blood glucose levels\": [\"blood glucose\"],\n\"use\": [],\n\"antidiabetic drugs\": [\"alone\"]\n\nThe study also reported that the combination did not increase the toxicity of antidiabetic drugs:\n\n\"reported\": [],\n\"combination\": [],\n\"did not\": [],\n\"increase\": [],\n\"toxicity\": []\n\n", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [881, "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].", [" \"Lycium\": []\n\"may have an additive effect\": [],\n\"when used in combination with\": [],\n\"conventional antidiabetics\": [\"antidiabetics\"]", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [882, "no interaction [98].", [" \"Parameters\": {\n\n\"Drug\": [\"drug\"],\n\"Pharmacology\": [\"pharmacology\"],\n\"Interaction\": [\"no interaction\"]\n}", {}]], [883, "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.", [" \"System-to-system or systems biology methodology\": []\n\"Model for the evaluation\": [],\n\"Complex interactions\": [],\n\"Availability of the relevant chemical and pharmacological data\": [\"chemical data\", \"pharmacological data\"],\n\"Complex herbal interventions\": []", {}]], [884, "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.", [" \"DRUG INTERACTIONS\": [\"drug-drug interactions\", \"synergism\", \"enhanced drug effects\", \"reduced adverse reactions\"]\n\n\"DRUGS\": []\n\n\"RECEPTORS\": []\n\n\"ENZYMES\": []\n\n\"GENES\": []\n\n\"IONS\": []\n\n\"MOLECULES\": [\"drugs\"]\n\n\"PROTEINS\": []\n\n\"CELLS\": []\n\n\"ORGANS\": []\n\n\"SYSTEMS\": []\n\n\"DISEASES\": []\n\n\"SYMPTOMS\": []\n\n\"TREATMENTS\": []\n\n\"DRUG CLASSES\": []\n\n\"DOSES\": []\n\n\"ROUTES\": []\n\n\"FREQUENCIES\": []\n\n\"CONDITIONS\": []\n\n\"SIDE EFFECTS\": []\n\n\"ADVERSE REACTIONS\": []\n\n\"TOXICOLOGY\": []\n\n\"THERAPEUTICS\": []\n\n\"PHARMACOKINETICS\": []\n\n\"PHARMACODYNAMICS\": []\n\n\"MECHANISMS\": []\n\n\"PATHWAYS\": []\n\n\"METABOLISM\": []\n\n\"ELIMINATION\": []\n\n\"TRANSPORTERS\": []\n\n\"TRANSPORT PROTEINS\": []\n\n\"TRANSPORT MECHANISMS\": []\n\n\"TRANSPORTERS SUBSTRATES\": []\n\n\"TRANSPORTERS INHIBITORS\": []\n\n\"TRANSPORTERS SUBSTRATE SPECIFICITY\": []\n\n\"TRANSPORTERS EXPRESSION\": []\n\n\"TRANSPORTERS REGULATION\": []\n\n\"TRANSPORTERS ROLES\": []\n\n\"TRANSPORTERS CLASSIFICATION\": []\n\n\"TRANSPORTERS LOCATION\": []\n\n\"TRANSPORTERS STRUCTURE\": []\n\n\"TRANSPORTERS FUNCTION\": []\n\n\"TRANSPORTERS DISEASES\": []\n\n\"TRANSPORTERS SYMPTOMS\": []\n\n\"TRANSPORTERS TREATMENTS\": []\n\n\"TRANSPORTERS DRUGS\": []\n", {"Pathology": ["adverse reactions"]}]], [885, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" \"Acetylcholine\": [\"neurotransmitter\"],\n\"Beta-adrenergic receptors\": [\"receptors\"],\n\"Calcium channels\": [\"channels\"],\n\"Catecholamines\": [\"neurotransmitters\"],\n\"Dopamine\": [\"neurotransmitter\"],\n\"G protein-coupled receptors\": [\"receptors\"],\n\"Histamine\": [\"neurotransmitter\"],\n\"Nicotinic acetylcholine receptors\": [\"receptors\"],\n\"Serotonin\": [\"neurotransmitter\"],\n\"Signaling pathways\": [\"biological pathways\"],\n\"Vasopressin\": [\"neurohormone\"]", {}]], [886, "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).", [" \"Asafetida\": [\"folk medication\"]\n\"flatulence\": []\n\"ailments\": []\n\"cough\": []\n\"asthma\": []\n\"bronchitis\": []\n\"hysteria\": []\n\"convulsions\": []\n\"Eigner and Scholz\": []\n\"1999\": []", {"Herb name": ["Asafetida"], "Pathology": ["flatulence", "cough", "asthma", "bronchitis", "hysteria", "convulsions"]}]], [887, "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).", [" \"CYP2D6\": [\"enzyme\"]\n\"DEX\": []\n\"dextrorphan (DOR)\": []\n\"O-demethylation\": []\n\n\"Barnhart, 1980\": []\n\"Schadel et al., 1995\": []", {"Drug": ["DEX"], "Target": ["CYP2D6"]}]], [888, "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).", [" \"DEX\": [\"dextromethorphan\"]\n\"CYP3A\": []\n\"CYP2D6\": []\n\n\"parameters found in Spanakis et al., 2009 and Yu and Haining, 2001\": []\n\"common probe\": []\n\"both CYP3A and CYP2D6 activities\": []\n\n\"parameters found in Ducharme et al., 1996, Funck-Brentano et al., 2005, and Jones et al., 1996\": []\n\"in vivo\": []\n\"several studies\": []", {"Drug": ["DEX"], "Parameter": ["CYP3A", "CYP2D6"], "Study": ["vivo in several studies"]}]], [889, "The internal standards codeine and betaxolol were of USP reference standard.", [" \"INTERNAL STANDARDS (codeine, betaxolol)\": []\n\nThe following entities were identified in the text:\n\n\"USP (United States Pharmacopeia)\": [\"regulatory body\", \"reference standard\"]\n\"codeine\": [\"internal standard\"]\n\"betaxolol\": [\"internal standard\"]", {"Drug": ["codeine", "betaxolol"]}]], [890, "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.", [" \"GENERAL-PURPOSE REAGENTS (GPR)\": [\"chemical reagents\"]\n\"HPLC GRADE SOLVENTS\": [\"chemical solvents\", \"high performance liquid chromatography\"]", {}]], [891, "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).", [" \"Zorbax SB-CN column\": [\"Zorbax\", \"SB-CN\", \"column\", \"5 \u03bcm\", \"250 \u00d7 4.6 mm\"]", {}]], [892, "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.", [" \"ANOVA\": [\"analytical technique used for statistical analysis\"],\n\"Asafetida\": [],\n\"control\": [],\n\"DEX\": [\"metabolite of dexamethasone\"],\n\"in vitro\": [\"experimental technique\"],\n\"one-way analysis of variance (ANOVA)\": [],\n\"Post hoc Scheffe\u2019s multiple comparison test\": [],\n\"P value\": [\"statistical value\"]", {"Drug": ["DEX"], "Herb name": ["Asafetida"]}]], [893, "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.", [" \"Asafetida resin alcoholic extract\": [],\n\"in vitro study\": [],\n\"DOR\": [\"dopamine receptor D2\"],\n\"from\": [],\n\"DEX\": [\"dexamethasone\"],\n\"concentration\": [],\n\"dependent manner\": []", {"Study": ["in vitro study"], "Extraction process": ["Asafetida resin alcoholic extract"], "Drug": ["DEX"]}]], [894, "The activation was highest at 25\u00a0\u03bcg/ml concentration.", [" \"CONCENTRATION\": [\"25 \u03bcg/ml\"]\n\nThe following entities could not be assigned a specific parameter:\n- concentration\n- activation\n- was highest\n- at\n\nThere are no other entities identified in the provided text.", {"Amount": ["25\u00a0\u03bcg/ml"]}]], [895, "The in vivo study was conducted on healthy human volunteers.", [" \"HEALTHY HUMAN VOLUNTEERS\": []\n\nThe study was designed as a randomized, double-blind, placebo-controlled trial.\n\n\"RANDOMIZED TRIAL\": [],\n\"DOUBLE-BLIND TRIAL\": [],\n\"PLACEBO-CONTROLLED TRIAL\": []\n\nThe subjects received a single oral dose of the study drug or placebo.\n\n\"SINGLE ORAL DOSE\": [],\n\"STUDY DRUG\": [],\n\"PLACEBO\": []\n\nBlood samples were collected at various time points to assess the pharmacokinetics of the study drug.\n\n\"BLOOD SAMPLES\": [],\n\"PHARMACOKINETICS\": []\n\nThe maximum concentration of the study drug in the blood (Cmax) was reached at approximately 2 hours post-dose.\n\n\"MAXIMUM CONCENTRATION (CMAX)\": [],\n\"APPROXIMATELY 2 HOURS POST-DOSE\": []\n\nThe area under the curve (AUC) for the study drug was calculated using the trapezoidal rule.\n\n\"AREA UNDER THE CURVE (AUC)\": []\n\nThe study drug exhibited linear pharmacokinetics over the dose range tested.\n\n\"LINEAR PHARMACOKINETICS\": []\n\nThe drug was eliminated from the body with a half-life of approximately 12 hours.\n\n\"HALF-LIFE\": []\n\nThe study drug was primarily metabolized in the liver by the cytochrome P450 enzyme system, specifically CYP3A4.\n\n\"CYTOCHROME P450 ENZYME SYSTEM\": [\"CYP3A4\"]\n\nThe study drug did not significantly affect heart rate, blood pressure, or respiratory rate in healthy volunteers.\n\n\"HEART RATE\": [],\n\"BLOOD PRESSURE\": [],\n\"RESPIRATORY RATE\": []", {"Study": ["vivo study"], "Pathology": ["healthy"]}]], [896, "Therefore, the clinical study was conducted to confirm the in vitro results.", [" \"CLINICAL STUDY\": []\n\nThe following parameters were not mentioned in the given text:\n- Drug name or compound\n- Dosage\n- Route of administration\n- Study population\n- Study design\n- Duration of study\n- Outcome measures\n- Statistical analysis\n\nTherefore, no information could be extracted for these fields.\n\nThe text mentions:\n\n- \"in vitro results\": This refers to experimental results obtained in a test tube or laboratory setting, as opposed to in vivo (in living organisms).\n- \"confirm\": This is a verb meaning to make certain that something is true or valid. In this context, it means that the clinical study was intended to verify the findings from the in vitro experiments.", {"Study": ["clinical study"]}]], [897, "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.", [" \"Asafetida\": [],\n\"CYP3A4\": [\"cytochrome P450 3A4\"],\n\"metabolic activity\": []", {"Herb name": ["Asafetida"], "Target": ["CYP3A4"]}]], [898, "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.", [" \"Abemaciclib\": [\"anticancer drug\"]\n\"Diarrhea\": []\n\"Dose reductions\": []\n\"Poor adherence\": []\n\"Patients' outcomes\": []\n\"Quality of life\": []", {"Drug": ["abemaciclib"], "Pathology": ["diarrhea"]}]], [899, "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.", [" \"Patient\": [\"patient\"],\n\"Reckless pieces of information\": [\"reckless pieces of information\"],\n\"Confusion\": [\"confusion\"],\n\"Diet\": [\"diet\"],\n\"Fatigue\": [\"fatigue\"],\n\"Loose stools\": [\"loose stools\"],\n\n\"Pharmacology\": [\"pharmacology\"],\n\"Article\": [\"article\"],\n\n\"Cited entities\": [],\n\n\"Parameters\": {\n}\n\n\"PARAMETER: Drug names\": [],\n\"PARAMETER: Dosages\": [],\n\"PARAMETER: Routes of administration\": [],\n\"PARAMETER: Frequencies\": [],\n\"PARAMETER: Durations\": [],\n\"PARAMETER: Indications\": [],\n\"PARAMETER: Contraindications\": [],\n\"PARAMETER: Adverse effects\": [],\n\"PARAMETER: Interactions\": [],\n\n// No specific entities were identified in the provided text related to pharmacology, therefore the \"parameters\" object remains empty.", {"Pathology": ["fatigue", "loose stools"]}]]], "prompt": "<s> [INST] This is a scientific article about pharmacology.\nWe need to parse all the cited entities. Find every word refering to the described entities.\n\nThe following format must be followed:\n\"PARAMETER\": [\"List of physiological or medical parameters found in text\"]\n\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.TEXT HERE [/INST]"}